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Abstract 
Thesis Title: Methodology and Software for Joint Modelling of Time-to-Event Data and 
Longitudinal Outcomes Across Multiple Studies 
Author: Maria Sudell 
Introduction and Aims: Univariate joint models for longitudinal and time-to-event data 
simultaneously model one outcome that is repeatedly measured over time, with another 
outcome which measures the time until the occurrence of an event. They have been 
increasingly used in the literature to account for dropout in longitudinal studies, to include 
time-varying covariates in time-to-event analyses, or to investigate links between 
longitudinal and time-to-event outcomes.  Meta-analysis is the quantitative pooling of data 
from multiple studies.  Such analyses can provide increased sample size and so detect small 
covariate effects.   Modelling of multi-study data requires accounting for the clustering of 
individuals within studies and careful consideration of heterogeneity between studies. 
Research concerning methodology for modelling of joint longitudinal and time-to-event 
data in a multi-study or meta-analytic setting does not currently exist.  This thesis develops 
novel methodologies and software for the modelling of multi-study joint longitudinal and 
time-to-event data. 
Methods: A review of current reporting standards of analyses applying joint modelling 
methodology to single study datasets, with a view to future Aggregate Data Meta-Analyses 
(AD-MA) of joint data is undertaken.  Methodology for the one and two-stage Individual 
Participant Data Meta-Analyses (IPD-MA) are developed. A software package in the R 
language containing functionalities for various aspects of multi-study joint modelling 
analyses is built.  The methodology and software is implemented in a real hypertension 
dataset, and also is tested in extensive simulation studies. 
Results: Reporting of model structure was amongst the areas identified for improvement in 
the reporting of joint models employed in single study applied analyses.  Sufficient 
information was reported in the majority of studies for them to contribute to future AD-
MA.  Guidelines developed to ensure good quality two-stage IPD-MA of joint data were 
presented, designed to ensure only parameters with comparable interpretations are 
pooled.  A range of one-stage models, each accounting for between study heterogeneity in 
varying ways, were described and applied to real data and simulation analyses.  Models 
employing study level random effects were found unreliable for the investigated 
association structure, however fixed effect approaches or those that stratified baseline 
hazard by study were more reliable.  The benefit of using joint models over separate time-
to-event models in the presence of significant association between the longitudinal and 
time-to-event outcomes in both one and two-stage analyses was established. Novel 
software capable of one or two-stage analyses of large multi-study joint datasets was 
demonstrated in both the real data and simulation analyses. 
Conclusions: Reporting of joint modelling structure in single study applied analyses should 
be maintained and improved.  Two-stage meta-analyses of joint modelling results should 
take care to pool only parameters with comparable interpretations.  In meta-analyses, 
investigators should employ a joint modelling approach when association is known or 
suspected between the longitudinal and time-to-event outcomes.  Further work into meta-
analytic joint models is required to expand the range of available multi-study joint 
modelling structures, to allow for multivariate joint data, and to employ multivariate meta-
analytic techniques in a two-stage meta-analysis.
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Notation  
Note that parameters displayed in bold could indicate a vector containing multiple 
elements e.g. 𝜶 = (𝛼(2), 𝛼(3)), or a matrix e.g. 𝑨. 
TERM DESCRIPTION 
𝑨 Covariance matrix for study level (level 3) random effects 
𝒂 Abscissa for Gauss-Hermite quadrature generated by generic 
algorithm 
𝒂(𝟑)𝒌 Abscissa for Pseudo-adaptive Gauss-Hermite quadrature for study 
level random effects 
𝒂(𝟐)𝒌𝒊 Abscissa for Pseudo-adaptive Gauss-Hermite quadrature for 
individual level random effects 
𝜶 Collection of association parameters 
𝜶(𝟐) Association parameter linked to individual level (level 2) random 
effects 
𝜶(𝟑) Association parameter linked to study level (level 3) random effects 
𝑩 Choleski decomposition of negative second derivative of log 
likelihood 
𝜷 Collection of fixed effect coefficients 
𝜷𝟏 Fixed effect coefficients, with first element of subscript identifying 
as from longitudinal sub-model 
𝜷𝟐 Fixed effect coefficients, with first element of subscript identifying 
as from time-to-event sub-model 
𝒃 Zero mean normally distributed random effects 
𝒃𝒌𝒊
(𝟐) Individual level (level 2) random effects 
𝒃𝒌
(𝟑) Study level (level 3) random effects 
𝑫 Covariance matrix for individual level (level 2) random effects 
𝚫𝒌𝒊 Censoring indicator for individual 𝑖 in study 𝑘 
𝜺𝒌𝒊𝒋 Error term from longitudinal sub-model 
𝒇 Used to denote a function, e.g. a component of the likelihood 
𝒈 Generic counter used to count through e.g. the events when 
calculating the baseline hazard or through the score vector when 
updating the fixed effects from a sub-model 
𝒉 Generic counter used to count through e.g. the events when 
calculating the baseline hazard or through the score vector when 
updating the fixed effects from a sub-model 
𝑰 Information matrix 
𝒊 Character used to identify individuals within studies 
𝒋 Character used to identify measurements within individuals within 
studies 
𝒌 Character used to identify studies 
𝑲 Total number of studies included in meta-analysis  
𝜿 Scale parameter for Gompertz distribution used during simulation 
studies 
𝑳(𝛀) Likelihood based on complete data 
𝓵(𝛀) Log-likelihood based on complete data 
𝝀𝒌𝒊(𝒕) Hazard function for individual 𝑖 from study 𝑘 based on time 𝑡 
𝝀𝟎(𝒕) Baseline hazard function common across studies 
𝝀𝟎𝒌(𝒕) Baseline hazard function stratified by study 
𝑴 Used to represent a particular model in Section 3.3.3, calculation of 
the number of parameters present in a one-stage joint model. 
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𝒎𝒌𝒊 The number of longitudinal measurements recorded for individual 𝑖 
in study 𝑘 
𝒏𝒌 The number of individuals included in study 𝑘 
𝑷 The degrees of freedom of the 𝜒2 distribution used when 
comparing two nested models 
𝒑𝟏 The number of fixed effects included in the longitudinal sub-model 
𝒑𝟐 The number of fixed effects included in the time-to-event sub-
model 
𝒒 The number of individual level random effects 
𝒓 The number of study level random effects 
𝝔 The number of association parameters to be estimated 
𝑺 Score vector 
𝝈𝒆
𝟐 Variance for longitudinal error term 𝑘𝑖𝑗  
𝝈𝑨
𝟐  Variance of study level random effect if only a single study level 
random effect is included in the one stage meta-analytic joint 
model 
𝒕𝒌𝒊𝒋 Longitudinal time variable for individual 𝑖 in study 𝑘 at time point 𝑗 
𝝉𝟐 Term quantifying between study heterogeneity 
𝑻𝑪𝒌𝒊 Censoring time for individual 𝑖 in study 𝑘  
𝑻𝑬𝒌𝒊 Event time for individual 𝑖 in study 𝑘 
𝑻𝑺𝒌𝒊 Survival time (minimum of event and censoring time) for individual 
𝑖 in study 𝑘  
𝒗𝒌 Variance of treatment effect from study 𝑘 used in two stage MA 
𝝂 Iteration counter used in Newton-Raphson estimation of 𝛽2 
parameters in M-step 
𝝎 Shape parameter for Gompertz distribution used during simulation 
studies 
𝒘𝒌 Weight for study 𝑘 used in two stage MA 
𝑾𝟏𝒌𝒊(𝒕) Function of longitudinal sub-model involved in the association 
structure 
𝑾𝟐𝒌𝒊(𝒕) Term present in time-to-event sub-model as part of association 
structure 
𝑿𝟏 Design matrix for covariates included with fixed effects in the 
longitudinal sub-model 
𝑿𝟐 Design matrix for covariates included with fixed effects in the time-
to-event sub-model 
𝒀𝒌𝒊𝒋 Longitudinal outcomes recorded for individual 𝑖 in study 𝑘 at time 
point 𝑗 
𝒁𝒌𝒊
(𝟐) Design matrix for covariates assigned individual level (level 2) 
random effects 
𝒁𝒌
(𝟑) Design matrix for covariates assigned study level (level 3) random 
effects 
𝛀 Complete data, used in description of full likelihood in one stage 
model 
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Chapter 1 : Introduction 
This thesis aims to investigate the meta-analysis of joint longitudinal and time-to-event 
data. Joint models allow simultaneous assessment of longitudinal and time-to-event 
outcomes, and are useful in cases of informative dropout, or time-varying covariates for 
time-to-event data, or where a relationship is suspected between longitudinal and time-to-
event outcomes. Meta-analyses allow all available evidence from multiple studies to be 
used to answer a research question, whilst accounting for any between study variability. 
Linking these two areas would ensure that multi-study longitudinal and time-to-event data 
can be appropriately analysed, however currently methodology and software to permit 
such analyses to be conducted is lacking. This thesis will combine these areas, providing 
methodology and software for use in the meta-analysis of joint data.  
To accomplish this, the thesis will firstly assess the current reporting standards of joint 
models applied to single studies, with a view to pooling published results in future 
aggregate data meta-analyses. Following this, frequentist methods for both two and one-
stage meta-analysis of individual participant joint data will be proposed, and assessed 
through application to both real and simulated datasets. A novel software package 
developed to facilitate the application of the proposed methods is presented and 
discussed. Finally areas where future research would be beneficial are examined. 
In this chapter an introduction to the concepts of meta-analysis and joint modelling is 
given, in order to introduce the terminology and methodology that this thesis aims to 
extend. A review of current methodology for the meta-analysis of longitudinal or time-to-
event data is also presented. The chapter concludes with a statement of the aims and 
structure of the thesis. 
Throughout the thesis, reference to computer packages, functions or code is identified 
through a change in font e.g. the R package developed during this research is identified in 
the text by joineRmeta. 
1.1 Meta-analysis 
One of the main aims of medical research is patient wellbeing, both protecting patients 
(whether participating in clinical trials or undergoing general treatment) from potentially 
harmful or less effective treatments, but also identifying treatments that improve standard 
care (either by being more effective, or by causing fewer side effects).  A common practice 
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is to undertake a systematic review, possibly combined with a meta-analysis, to assess 
what investigations have already been conducted in an area, and to compile the available 
information in order to inform a clinical decision concerning a treatment, or to 
demonstrate the need for further clinical trials. 
A systematic review is a structured assessment of studies relating to the research question 
of interest (for example the benefits of a given treatment over the current standard for a 
specified disease and population). This process identifies published (and potentially 
unpublished) studies that address this research question, and collates their results into one 
report, thereby providing clinicians with a concise summary of the current information 
concerning a treatment. 
A meta-analysis (MA) is similar to a systematic review in that it collates available evidence 
on a subject, but it quantitatively collates this evidence rather than qualitatively evaluating 
it. Glass [1] defined a meta-analysis to be “the statistical analysis of a large collection of 
analysis results from individual studies for the purpose of integrating the findings”. The 
estimates of treatment effect sizes from different studies, for example, are pooled. An 
overall summary treatment effect is then calculated, based on the information from the 
available studies. Therefore whilst a systematic review presents the available evidence, a 
meta-analysis generates a numeric quantification of the available evidence, giving a 
stronger basis for clinical decisions [2]. 
Section 1.1 gives a general background to the area of meta-analyses, with details of meta-
analysis for longitudinal or time-to-event data given in Sections 1.3 and 1.5 respectively. 
Further information concerning meta-analytic methods is available in Whitehead [2]. 
1.1.1 Individual Patient Data and Aggregate Data 
A meta-analysis can be based on Aggregate Data (AD), Individual Participant or Patient Data 
(IPD) or a mix of the two (see Riley et al [3], Sutton et al [4] and Donegan et al [5]). Some 
studies have noted the increased power in an IPD regression analysis compared to an AD 
regression analysis [6]. These two data types will now be defined and discussed. 
1.1.1.1 Aggregate Data Meta-Analysis 
An Aggregate Data Meta-Analysis (AD-MA) can be performed using study level summary 
statistics provided in study reports, or by study authors through direct communication. 
Information is not available for each individual, only for each study, for example the exact 
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characteristics of each study participant would not be known, however the proportions of 
the study population falling into each group of a categorical variable may be known. 
One advantage of an AD-MA is that it can be completed with less resource expenditure 
than an IPD-MA, as there is no lengthy data collection process. Additionally an AD-MA does 
not require as high a level of statistical knowledge as an IPD-MA, in which data specific 
methods such as time-to-event analysis may be required. Straightforward computer 
software is available to aid researchers to easily complete AD-MA without a high level of 
statistical programming, for example the RevMan software provided by the Cochrane 
group [7].  
A major drawback of AD-MA is that summary statistics may not be uniformly reported over 
studies. Also some studies may report unadjusted estimates, whilst others report only 
adjusted, or a mix of the two. There may be differences across the scales used to report 
results (for example differing depression scales between studies), or the measures used 
(one study reporting risk differences, another reporting odds ratios), or the scales used (log 
versus unlogged results [8]). Sufficient information to complete the meta-analysis may not 
always be included, for example 𝑝 values may be reported in place of odds ratios, or 
sample sizes may not be stated in the text of the report. This may result in clarification of 
data being required from study authors, which may extend the time taken to complete the 
meta-analysis. 
Another limitation of AD-MA is that inference concerning patient level covariate effects (for 
example effect of age of the patient on treatment effect) cannot be made. Only the effect 
of study level covariates (such as median patient age in each study) can be examined. Any 
attempt to interpret study level covariates at the patient level can result in ecological bias 
[9].  
Additionally if interest lies in a particular subgroup of patients, for example those over a 
certain age or with a particular characteristic, only studies reporting the relevant subgroup 
summary statistics can contribute to the analyses (unless study authors can provide 
additional information). Consequently subgroup analyses can be hard to perform, or may 
only contain a subset of the identified studies. Furthermore an investigation into the 
reasons for any heterogeneity between included studies may be hampered by having 
access only to aggregate data. AD-MA can account for heterogeneity by using a random 
effects model [2, 10] or study level meta-regression [11], but cannot fully investigate the 
 4   
 
causes of the heterogeneity as only study level covariates can be used in an attempt to 
explain the presence of heterogeneity.  
Some of these problems can be overcome, through additional communication with the 
study authors, or standardisation of scales or measures used. However, sometimes 
sufficient information to complete the required analyses cannot be obtained, and so the 
researcher has to choose between a restricted analysis or the possibly lengthy process of 
obtaining IPD. 
1.1.1.2 Individual Participant Data Meta-Analysis 
Individual Participant Data Meta-Analyses (IPD-MA) are considered the gold standard of 
meta-analysis [12]. Stewart and Parmar [13] suggest that if possible an IPD meta-analysis 
should be  performed in preference to an AD meta-analysis, as it reduces bias and allows 
further investigation into additional research questions (for example differing treatment 
effects between subgroups). Additionally IPD-MA allow investigations into the reasons 
behind heterogeneity between studies, including examination of interaction effects 
between covariates. Furthermore, having access to the original data allows more in-depth 
data checking, and replication of the results given in the study report, which gives more 
credibility to the data and so the final output. Finally, obtaining IPD allows those designing 
the meta-analysis to have full choice of methods used. If only aggregate data is obtained, 
the meta-analysis investigators cannot change the methods used to obtain the study level 
results.  
However, seeking IPD for a meta-analysis is often time consuming and resource intensive. 
For example, older datasets may no longer be available or may only exist in hard copy 
format, or there may be issues sharing the data. Nevitt et al [14] provide a review of 
retrieval of IPD for systematic reviews. In addition to issues obtaining data, IPD-MA may 
require more complex data analysis methods (for example for longitudinal or time-to-event 
data), resulting in a higher necessary level of statistical expertise, and knowledge of 
statistical software in the team conducting the MA [15]. A discussion of the benefits and 
problems of seeking IPD is given in Chapter 18 of the Cochrane handbook [16], and the 
benefits of an IPD analysis over an AD analysis are discussed by Stewart [17]. Additionally 
Tudur Smith et al [18] compared the results of IPD and AD meta-analyses, concluding that 
IPD-MA allow additional investigations to be conducted, but as the results are often similar 
it may be beneficial to conduct an AD-MA initially, and assess what benefit would be gained 
by conducting an IPD-MA. 
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1.1.1.3 IPD and AD during this research 
Methods developed during this research assume availability of IPD from each study 
included in the meta-analysis. This is due to the fact that joint models are complex, and so 
IPD is necessary to ensure that the model structure is correctly estimated. In any case 
where the methodology presented has applications to AD-MA, these are highlighted and 
discussed. 
1.1.2 Heterogeneity 
An important issue in meta-analysis is heterogeneity. Heterogeneity is defined to be any 
variability between studies included in the meta-analysis [19], and can be divided into 
clinical heterogeneity (differences in study populations, interventions and outcomes), and 
methodological or statistical heterogeneity (differences in risks of bias between studies and 
differences in study design). Heterogeneity is quantified using various statistics including 
the 𝐼2 statistics and Cochrane’s 𝑄 (see Higgins and Thompson [20] for more detail). It is 
important to account for heterogeneity in a meta-analysis, as otherwise conclusions drawn 
could be misleading. If there is no evidence of heterogeneity between included studies, 
data from the studies can be pooled without difficulty. However, if there is heterogeneity 
between studies, this needs to be accounted for in the analysis, for example by using a 
meta-regression (Thompson et al [11]) or random effects model (DerSimonian and Laird 
[10]).  If there is a large amount of heterogeneity between studies (for example significant 
estimates of treatment effect in opposite directions reported by included studies), it may 
not be appropriate to pool results from different studies, and so only a narrative summary 
of the results should be given. A benefit of using IPD over AD is that any heterogeneity 
present can be investigated using variables in the data. 
1.1.3 Bias 
Bias is defined as some systematic error [21] that can cause the results of a study to be 
under or overestimated. Bias is not the same as random error, as bias is a systematic 
deviation from the true value within a study rather than a varying deviation. Generally 
meta-analyses asses the risk of bias for included studies rather than attempting to quantify 
the amount of bias. Including studies at more risk of bias could lead to more erroneous 
conclusions being drawn: a meta-analysis of more rigorous studies which are at less risk of 
bias is generally more reliable.  
As bias is not a focus of this thesis, it will not be discussed further. More details concerning 
bias can be found in Whitehead [2] and in Chapter 8 of the Cochrane Handbook [21]. 
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1.1.4 Models for Meta-Analysis 
In the coming section, models commonly encountered in meta-analysis are discussed, 
including one-stage and two-stage models, as well as fixed and random effects meta-
analyses. Models are discussed in general terms, with meta-analytic models specific to joint 
longitudinal and time-to-event data presented in Chapter 3. 
1.1.4.1 One-stage models 
A one-stage model is where data from different studies are held in one large meta-dataset, 
and a single model is fitted to the dataset. The study that the data originated from is 
identified in some way in the model, such as by stratifying by study, or including a fixed or 
random effect study indicator in the model. Therefore, the model fitted is a hierarchical 
model, with individuals in the dataset nested within the included studies. To fit a one-stage 
model, IPD must be obtained from the included studies. One-stage MA models for joint 
data are discussed further in Section 3.3. 
1.1.4.2 Two-stage models 
A two-stage model is where separate models are fitted to data from each study, and then 
the study level results from these separate models are pooled using general meta-analytic 
methods. As with a one-stage model, a two-stage model requires the IPD to be obtained 
from the included studies. However, the second stage of a two-stage model, where the 
study level treatment estimates are pooled, is comparable to performing a meta-analysis 
on aggregate data (AD-MA). Two-stage joint MA models are discussed further in Section 
3.2. 
1.1.4.2.1 Fixed effect and random effects models 
In the second stage of a two-stage model, or an AD-MA, fixed effect meta-analyses assume 
that the true treatment effect is constant across all included studies, and that any variation 
can be attributed to study specific measurement error. These models are straightforward 
to implement and most meta-analytic software provide functions to fit them. However, as 
the treatment effect estimate is based solely on the included trials, it may not be 
generalizable to a wider population. Also, as the treatment effect is considered to be the 
same across studies, fixed effect models do not account for possible heterogeneity 
between studies.  
Random effects MA assume that the treatment effect in each included study is a realisation 
from a common random variable [10]. If there is no heterogeneity between the included 
studies, the fixed effect and random effect models should produce the same results. 
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Random effects models can account for heterogeneity between studies and so are often 
used if the included studies appear heterogeneous in nature. Their use is disputed as a 
random effects MA assumes the included studies are a random sample of all studies that 
address the research question. However, a meta-analysis expects that all available studies 
are included in the meta-analysis. In addition, a random effects MA assign more weight to 
smaller studies than a fixed effect MA when heterogeneity is present, which can be an 
invalid assumption. Further discussion of fixed versus random effects MA is given in 
Whitehead [2]. 
1.1.4.3 Extensions to basic meta-analysis 
For more complex data types (including longitudinal data, time-to-event data or multiple 
correlated outcomes) more advanced methods are needed, because these data types 
inherently have additional structure that needs to be accounted for in the models. For 
example, in longitudinal data, measurements recorded from the same individual are 
correlated. An overview of current methodology for longitudinal and time-to-event MA are 
given in Sections 1.3 and 1.5. Many papers have been published dealing with data types 
other than longitudinal or time-to-event, such as cross-sectional data. These include 
methods for ordinal data [22] for continuous outcomes [23], and methods to combine 
parallel and cross over trials [24-26]. 
1.2 Longitudinal Data 
Longitudinal data (sometimes referred to as repeated measures data) is data repeatedly 
collected from study participants over time, and unlike crossover trials, study participants 
generally undertake only one treatment regimen during the study period. By collecting 
longitudinal data, researchers can investigate differences between groups with particular 
demographics at a given time, as well as trends over time. Additionally, collection of 
longitudinal data can be more cost effective than other data types, as it is cheaper to 
repeatedly measure an individual already included in the study than expending resources in 
finding and recruiting new individuals [27].  
Longitudinal data can be balanced or unbalanced. Balanced data results from studies that 
plan to measure individuals a predefined number of times, for example a study that takes 
measurements at baseline, 3 months, 6 months and 1 year. If a set number of 
measurements was planned, but some individuals have missed measurements, the data is 
referred to as balanced with missing data. Unbalanced data refers to a dataset where the 
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number of measurements and the timing of measurements between individuals can vary 
considerably, and generally there are not specified measurement times. Some methods to 
analyse longitudinal data rely on having balanced data (for example repeated measures 
ANOVA), whereas others can incorporate unbalanced data (for example multilevel models, 
including random effects models), see Diggle et al [28] for further information. 
Variables in longitudinal data can be thought of as constant (such as gender), or variable 
(such as blood pressure) across the study period, denoted time stationary and time varying 
covariates respectively. Time varying covariates can be split into two groups: Endogeneous 
and exogeneous (also referred to as internal and external covariates). These are further 
discussed in Section 1.6. 
It is important when modelling longitudinal data to ensure that the structure of the data is 
correctly accounted for. As measures are repeatedly recorded from each individual, within 
individual measurements will be more similar than measurements between different 
individuals. Individual specific random effects can model the correlation between 
measurements within individuals, as such the mixed effect model accounts for the nested 
structure of the data. 
Various models currently exist for longitudinal data, such as growth curves, Generalised 
Estimating Equations and mixed effect models. Mixed effect models were described by 
Laird and Ware [29], and have structure as displayed in equation (1).  
 𝒀𝒊 = 𝑿𝒊𝜷𝟏 + 𝒁𝒊𝒃𝒊 + 𝜺𝒊   
  
(1) 
In the above equation, the longitudinal measurements recorded for individual 𝑖 are 
represented by 𝒀𝒊. This model type contains both fixed and random effects, which are 
separated out in the model. Fixed effects (represented by 𝜷𝟏 terms) are parameters that 
have a constant value across the study population, and so are sometimes termed 
population effects. Covariates assigned fixed effects are held in design matrix 𝑿𝒊. Random 
effects (represented by 𝒃𝒊 terms) are random variables that follow a zero mean distribution 
that act on a particular level of the data, e.g. individuals, and quantify how a unit at that 
level differs from the population average. Covariates assigned random effects are held in 
design matrix 𝒁𝒊, which is generally a subset of the 𝑿𝒊 matrix. The final term 𝜺𝒊 is a vector 
of error terms for each time point. 
Mixed effects models allow population effects and trends to be modelled, but can also 
estimate through random effects how much individuals differ from these estimates. The 
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exact specification of models used for longitudinal data are discussed where appropriate in 
later chapters. 
Other models for analysis of longitudinal data exist, for example Generalised Estimating 
Equations (GEE), or growth curves. However, in this thesis only mixed models will be 
considered, as mixed models are commonly used to represent the longitudinal component 
in joint model formulation discussed below. The reader is referred to Weiss [27] or Diggle 
et al [28] for a comprehensive introduction to longitudinal data analysis. 
An issue often present in longitudinal datasets is dropout, which can occur in time-to-event 
studies or in longitudinal studies. Dropout is when an individual provides measurements up 
to a certain time point, and then leaves the study and so provides no further information. 
Dropout can occur for reasons unrelated to the study, in which case it is referred to as non-
informative dropout, or for reasons of interest to the study, referred to as informative 
dropout. An example of informative dropout discussed by  Henderson et al [30] in a study 
concerning schizophrenia patients that measured a PANSS (Positive And Negative Symptom 
Scale) score over time, where researchers were concerned that patients with higher 
(worse) PANSS scores were less likely to complete the study (i.e. dropout for reasons of 
interest to the study outcomes before the end of the study period). Informative dropout is 
one of the motivations for using the joint modelling structure, introduced in Section 1.6. 
1.3 Meta-Analysis of Longitudinal Data 
The benefits of longitudinal data, such as modelling trends and cost effectiveness, have 
naturally prompted researchers to pool longitudinal data or the results from longitudinal 
model fits in meta-analyses. This section describes some of the issues often encountered 
during a longitudinal MA, followed by a description of current methodology for AD-MA and 
IPD-MA of longitudinal data. 
1.3.1 Issues surrounding Longitudinal Data Meta-Analysis 
As longitudinal data consists of multiple measurements recorded from the same individual, 
measurements on the same individual will be inherently correlated. As with single trial 
longitudinal analyses, meta-analytic methods (AD or IPD) that ignore this correlation may 
be considered inappropriate. When Jones et al [31] examined the methods commonly used 
in meta-analyses of longitudinal studies, they identified that there seemed to be no 
universally adopted approach to longitudinal meta-analysis, and that the most common 
 10   
 
approach was to perform multiple independent meta-analyses at various time points, thus 
ignoring the correlation between time points. 
Another difficulty in longitudinal meta-analyses is that the time at which measurements are 
taken may differ considerably between studies. For example, one study may assess 
individuals only at pre-specified follow-up meetings, whereas others could additionally 
record data from unscheduled GP appointments.  In addition, some studies may record 
observations over a much shorter time period than other studies, resulting in different 
maximum follow-up times between included studies. Therefore if separate independent 
meta-analyses are performed at specific time points, the studies contributing to each meta-
analysis is likely to vary, as studies can only contribute to a meta-analysis if they have 
measured patients at that particular time point. This may lead to a form of publication bias 
[32]. 
In addition to these longitudinal specific issues, longitudinal meta-analyses also fall prey to 
the more common meta-analysis problems, for example differences in sample populations, 
study design and study measures. These issues may all introduce bias into the meta-
analysis. Additional issues may arise if the longitudinal data stems from observational 
studies rather than randomised control trials, however this thesis assumes data from 
randomised controlled trials. Approaches for dealing with bias arising from longitudinal 
observational studies in a meta-analysis are given in Thompson et al [33]. 
1.3.2 IPD meta-analysis of longitudinal data 
The Cochrane Handbook [19], Section 9.3.4 “Repeated observations on participants”, 
suggests that if longitudinal data is to be meta-analysed using IPD, a suitable model that 
uses the entire follow-up should be fitted (they suggest a time-to-event analysis), or a 
single summary measure be calculated for each individual that utilises all the available data 
(for example one value that represents a trend over time of the longitudinal measure). 
However, it does not give further guidance concerning what a suitable model for 
longitudinal IPD would be. 
Jones et al [31] propose both one and two-stage models for longitudinal IPD-MA (discussed 
in the following text). They provide methods for when time is considered continuous (e.g. 
number of days from randomisation) or as a factor (visit number 1, 2…). They assume an 
overall set of all possible measurement times (where a measurement time is included if it 
has occurred in any of the studies to be included in the meta-analysis) on the 
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understanding that any given study will have only recorded a subset of this set of possible 
measurement times. 
One-stage approaches 
Methods presented in the literature that consider time as a factor (e.g. visit number) are 
firstly discussed, starting with the methods presented by Jones et al [31]. In their model, 
𝑗 counts longitudinal measurements (with 𝑗 = 1, … , 𝑚, where 𝑚 is the maximum possible 
number of measurements),  ℎ the treatment indicator (for example, ℎ = 0, … , 𝑔 − 1 where 
𝑔 is the number of treatment groups),  𝑘 be the study indicator (for 𝑘 = 1, … , 𝐾), and 𝑖 be 
the patient indicator (for 𝑖 = 1, … , 𝑛ℎ𝑘 where 𝑛ℎ𝑘 is the number of individuals in the ℎth 
treatment group in the 𝑘th study). Also, let ℎ𝑘𝑖𝑗 be the residual error term and 𝑦ℎ𝑘𝑖𝑗 the 
longitudinal response for individual 𝑖 in treatment group h in study 𝑘 at the 𝑗th 
measurement. Note that Jones et al allowed for multiple separate treatments, but this 
thesis concerns randomisation only to a control (ℎ = 0) or an experimental (ℎ = 1) 
treatment. Then the one-stage model is given by equation (2).  
 𝑦ℎ𝑘𝑖𝑗  =  𝛼𝑘𝑗  +  𝛽ℎ𝑗  +  ℎ𝑘𝑖𝑗  
 
(2) 
In this equation, the 𝛼𝑘𝑗 is the effect of the control treatment at measurement 𝑗 in study 𝑘, 
and 𝛽ℎ𝑗 is the additional effect of the experimental treatment ℎ compared to the control 
treatment at measurement 𝑗. If baseline measurements are to be included (𝑗 = 0) the 𝛽ℎ0 
term would be restricted to equal zero as there is expected to be no difference in 
treatment groups at baseline. 
Gurrin and Turkovic [34] mention a similar model to Jones et al for meta-analysing studies 
with factor time points. They discuss a regression model with study specific intercept, and 
explanatory variable coefficients stratified by trial for non-longitudinal data, and then 
briefly show how the model can be extended to allow for repeated measures data, by 
including a participant specific random effect (random intercept) into the model.  
If time is a continuous variable (e.g. days since randomisation) the proposed formulation of 
the one-stage model in Jones et al [31] changes to that shown in equation (3): 
 𝑦ℎ𝑘𝑖𝑗  =  𝜆𝑘 + 𝜐ℎ +  𝛼𝑘𝑡𝑗  +  𝛽ℎ𝑡𝑗  +  ℎ𝑘𝑖𝑗  
 
(3) 
In this model, 𝜆𝑘 is the intercept term for the control treatment, and 𝜐ℎ is the difference in 
intercepts between the experimental treatment ℎ and control treatment. Additionally, 𝛼𝑘 
is the study specific slope over time for the control treatment, and 𝛽ℎ is the difference in 
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slope between the experimental treatment ℎ and the control treatment. As before, 𝑦ℎ𝑘𝑖𝑗 
represents the longitudinal response and ℎ𝑘𝑖𝑗 the residual error of the 𝑖th individual in 
study 𝑘 assigned to treatment ℎ at the 𝑡𝑗 time point. As before this formulation assumes no 
baseline measurements – if baseline measurements were to be included then the  𝜐ℎ term 
would be removed from the model, as the intercepts would then be calculated at baseline, 
where they are not expected to differ between treatment groups. 
In these models, each study is allowed to exhibit a study specific treatment effect over 
time. In the discrete time model this is achieved through the study specific 𝛼𝑘𝑗 term, which 
can take a different value for each included study at each time point. In the continuous 
time model, this is achieved through the study specific intercept term 𝜆𝑘 and the study 
specific slope term 𝛼𝑘. These terms allow each included study to have differing initial 
measurements at the earliest time point, and each included study to display differing 
treatment effects over time. However, across all studies, these models assume that the 
difference between the effect of the control and experimental treatment ℎ is fixed across 
the included studies (neither the 𝛽ℎ𝑗 term in the discrete time model, nor the 𝛽ℎ term in 
the continuous time model contain the 𝑘 subscript, indicating that they remain constant 
across included studies). 
1.3.2.1 Two-stage approaches 
Two-stage methods for longitudinal MA may be more straightforward than one-stage 
methods. Jones et al [31] describe fitting a separate longitudinal model to each included 
study and then combining the relevant study level treatment estimates using a multivariate 
meta-analysis framework [35-41]. 
If time is supplied as a factor, they suggest that the model in equation (2) would be fitted to 
the data from each study 𝑘 separately and an estimate of the value of the mean difference 
between treatments ℎ (for ℎ = 0, … , 𝑔 − 1) at each time point 𝑗 (for 𝑗 = 1, … , 𝑚) in that 
study are calculated, denoted by ?̂?ℎ𝑘𝑗 . The values of ?̂?ℎ𝑘𝑗 from each study 𝑘 for 𝑘 =
1, … , 𝐾 are then combined using a multivariate meta-analysis framework.  
If time has been supplied as a continuous variable, Jones et al [31] suggest that the model 
in equation (3) is fitted to each included study 𝑘 separately, and the estimates of the 
differences in intercepts between the treatment groups (?̂?ℎ𝑘), and the differences in slopes 
between the treatment groups (?̂?ℎ𝑘) are extracted. The study level estimates are then 
combined again using a multivariate meta-analysis framework 
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For both time as a factor and time as a continuous variable, the study level estimates are 
weighted using a function of the variance of the estimates themselves, and the covariance 
with the other estimates stemming from the same study. A more detailed description is 
given by Jones et al [31]. 
1.3.2.1.1 Limitations for longitudinal IPD-MA 
For any IPD analysis, the issue of additional resource expenditure compared to an AD 
analysis exists. In addition the research team must have sufficient statistical knowledge to 
handle the data appropriately. This issue is exacerbated for longitudinal data, when the 
nested structure of the data (measurements within individuals) must be accounted for. 
Correctly modelling the data structure is necessary to reduce bias in the analysis, as such, a 
longitudinal IPD-MA requires even greater statistical knowledge than a normal IPD-MA. 
In addition, modelling of trend over time provides an additional consideration. Jones et al 
[31] note that their model assumes a linear treatment effect over time, which is potentially 
not suitable for all datasets. To suitably model the trend over time in longitudinal data, 
complex methods such as splines may be required, again requiring a high level of statistical 
expertise.  
Furthermore the methods discussed by Jones et al [31] here include only fixed treatment 
effects across studies. They note the issues involved in introducing random effects into 
longitudinal IPD-MA models, namely that assumptions need to be made whether random 
effects should be time specific , and whether there should be between study correlation 
parameters (random correlation parameters). They note the need for future research in 
this area. Ishak et al [32] discussed random effect models for AD-MA of longitudinal data 
(see Section 1.3.3) but experienced issues estimating the relevant correlation parameters, 
potentially due to the relative shortage of reporting of such parameters in study reports.  
1.3.3 Aggregate data meta-analysis of longitudinal data 
Whilst AD-MA methods are not the main focus of the thesis, in the following section a brief 
summary is given, highlighting some key references. 
Longitudinal AD-MA can be divided into two main groups: namely meta-analyses where the 
treatment effect is allowed to vary over time, and meta-analyses with a constant treatment 
effect. Ishak et al [32] noted that for aggregate data cases, if each included study 
contributes one overall estimate of treatment effect to the meta-analysis (i.e. the 
treatment effect does not vary over time, for example the slopes of fitted regression 
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models), these estimates can be combined using basic meta-analytic methods, as 
correlation between time points in the data should have already been accounted for. The 
report continues by identifying that if a treatment effect is reported at different time 
intervals within a study, standard methods cannot be used as they do not account for the 
correlation between the estimates at different time points. Contrary to this fact, many AD-
MA that involve longitudinal studies currently do not account for the correlation between 
the treatment effects reported at different time points [31].  
The Cochrane Handbook [19], in Section 9.3.4 “Repeated observations on participants”, 
suggests that if aggregate longitudinal data is to be meta-analysed, one of the following 
three methods should be employed (i) Several outcomes should be defined for different 
follow-ups, for example a shorter term and a longer term analysis be performed, (ii) one 
time point should be selected at which to perform a meta-analysis (for either a clinical 
reason or to maximise the amount of data used), (iii) use the longest follow-up data 
available from each study (i.e. meta-analyse data from the final reported time-point).  
However, various issues exist with these methods, for example selecting one time point 
could increase the possibility of reporting bias (as if a study does not report treatment 
effect at that time point, it is excluded from analysis), or selecting the longest follow-up 
could lead to increased heterogeneity (as included studies may vary considerably in 
maximum follow-up time) [19]. Many of these methods, whilst simple to follow, do not use 
all the available information and may produce biased results [32].  
Ishak et al [32] suggest using mixed effect models, where the responses are the treatment 
effects from each study at each time point, i.e. a mixed effect model, where measurements 
from each time point are nested within studies. The basic formulation of this model is given 
in equation (4). It is assumed that there are 𝐾 studies in the meta-analysis, with 𝑚 possible 
measurement times across all studies. In the equation, 𝑌𝑘 is the vector of length 𝑚 of the 
treatment effect estimates from study 𝑘 (so 𝑌𝑘 is a vector of study level summaries of 
information at each time point from 𝑡1 to 𝑡𝑚, without outcome missing where a timepoint 
was not recorded in the study). 𝑋𝑘 is the 𝑚 × 𝑝 design matrix for the fixed effects for study 
𝑘, 𝑍𝑘  is the 𝑚 × 𝑟 design matrix for the random effects for study 𝑘, 𝛽 is the vector of 
length 𝑝 of fixed effects, 𝑏𝑘 is the vector of length 𝑟 of random effects and 𝑘 is the vector 
of length 𝑚 of measurement errors.  
 𝒀𝑘  =  𝑿𝒌𝜷 + 𝒁𝒌𝒃𝒌 + 𝜺𝒌 (4) 
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Observations from different studies are assumed independent, and within a study the 
random effects and measurement errors are also assumed independent. The measurement 
errors are assumed to follow a multivariate normal distribution of dimension 𝑚, namely 
𝑘~𝑀𝑉𝑁𝑚(0, 𝑺𝒌), where 𝑺𝒌 is a 𝑚 × 𝑚 covariance matrix. The random effects are 
assumed to follow a multivariate normal distribution of dimension 𝑟 with 𝑏𝑘~𝑀𝑉𝑁𝑟(0, 𝑨), 
where 𝑨 is a 𝑟 × 𝑟 covariance matrix. Note that the covariance matrix for the measurement 
errors 𝑺𝒌 is study specific (and so accounts for the within study correlation), and the 
covariance matrix for the random effects 𝑨 is common across the included studies (and so 
represents the variability between data from different studies). The structure assigned to 𝑨 
defines how the random effects influence each other, options for this matrix include 
unstructured, autoregressive and compound symmetry amongst others. Ishak et al [32] 
note that ideally 𝑨 would be unstructured, however that as data is often limited in AD 
meta-analyses, this may lead to problems with estimating parameters correctly. 
Ishak et al [32] discuss cases of equation (4) with a random intercept and a random slope. 
In these models they assumed that the study specific covariance matrix 𝑺𝒌 for the 
measurement errors 𝜺𝒌 was diagonal. Where 𝑺𝒌 was assumed diagonal, Ishak et al note 
that 𝑨 must not be diagonal (e.g. allowing 𝑨 to be unstructured, or following an auto-
regressive or compound symmetrical structure), as if both 𝑨 and 𝑺𝒌 were diagonal, 
measurements made a different time-points would be treated as independent. In the last 
model Ishak et al discuss, they do not restrict 𝑺𝒌 to be diagonal (although they recommend 
various approaches to simplify the estimation of 𝑺𝒌 such as using measures stated in the 
study report for the variances, keeping the correlations constant across studies or assuming 
a correlation structure that only requires one parameter to be estimated, such as an 
autoregressive or compound symmetry structure).  
Ishak et al [32] note that the models that account for correlation between the observations 
in the studies provide better fits to the data than models that assume the observations are 
independent. Another benefit of this model is that as included studies are unlikely to be 
measured at exactly the same time points, modelling the correlation between observations 
allows these missing values to be treated as missing at random (see Rubin [42], and Little 
and Rubin [43] for definitions of missing data mechanisms). 
However, these methods still have drawbacks. Ishak et al [32] noted that as they did not 
know the true values of the covariance parameters (as they used Aggregate Data only) they 
could not confirm how accurate the methods they proposed were. Jones et al [31] 
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presented methods for AD-MA as well as for IPD-MA, for cases were correlations within 
studies were reported or were missing. If sufficient information is available, they suggest 
using the second stage of two-stage IPD-MA of longitudinal data. If covariances between 
parameter estimates are not available, they recommend a sensitivity study to assess the 
robustness of conclusions to different correlation levels. 
Similarly to Ishak et al [32], Maas et al [44] used multi-level modelling to perform meta-
analysis of AD from longitudinal studies. They highlighted the benefits of modelling 
aggregate data using the model, such as inclusion of explanatory variables at different 
levels and exclusion of fewer studies from the analysis. 
Peters and Mengersen [45] approach the issue of AD-MA of longitudinal studies from a 
slightly different direction. They argued that the aim of the meta-analysis, and the type of 
data available in the study reports, dictated the type of information required from included 
studies. The report defined five types of longitudinal AD-MA; (i) relevant time point MA 
where all available data at one time point is analysed (the time point being chosen for 
clinical relevance or to maximise available data), (ii) first/final time point MA (which uses 
only data from the first or final time point of included studies), (iii) all time points MA 
(where data at all time points are analysed, and data from different time points are 
considered independent, regardless of the fact that the same study can contribute to 
multiple meta-analyses), (iv) trend meta-analysis (where regression is used to model trend 
over time), (v) change in time point meta-analysis (where either the change from baseline 
to each time-point is analysed or the change between successive time-points is analysed).  
The fourth method (trend meta-analysis) mentioned by Peters and Mengersen [45] 
requires either a slope estimates with variance to be supplied by the included studies, or 
the mean slope estimates with their variances at each time point. They suggest combining 
the study specific slope estimate using a random effects meta-analysis model, or if means 
and variances are reported at each time point within a study, to fit a regression model to 
each study and then combine the study specific slope estimates. The fifth method (change 
in time point meta-analysis) requires some summary estimate (for example the mean slope 
estimate) and a variance to be reported at each time point. The differences between the 
summary estimates at successive time points are then calculated and these differences are 
pooled between studies for each time point. Both the trend meta-analysis and change in 
time point meta-analysis account for the correlation inherent to longitudinal data by either 
by pooling slopes (which account for the trend over time) or by assessing changes over 
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time. However, the other three methods suggested by Peters and Mengersen [45] treat 
each time point as independent, ignoring the correlation between time points.  
Ahn et al [46] focused on providing methods to model the correlations between data in 
longitudinal AD-MA, focusing on dose response models in the software NONMEM. The 
report states multiple levels of random effects (at either the study level or patient level) or 
correlated residual errors or both as possible methods to account for correlation. This is in 
line with the previous suggestions for longitudinal AD-MA [32].  
1.3.3.1 Limitations for longitudinal AD-MA 
For AD-MA, longitudinal studies often do not consistently report the summary measures 
needed for a particular method. For example, variances and covariances are not commonly 
reported [31], or may only be reported for specific time points. The lack of information can 
lead to issues with fitting models, for example Ishak et al [32] noted issues with 
convergence when estimating the covariance matrix, especially for structures that required 
multiple parameters to be estimated (for example unstructured covariance matrices). 
Methods for the imputation of missing variance data are described by Dakin et al [47] for 
Bayesian network AD-MA of longitudinal studies, and more generally by Boucher [48] for 
MA who focussed on modelling standard deviations over time for pain measurement. Jones 
et al [31] note that use of IPD solves the problem of non-reporting of covariance 
parameters,  however this then requires a more costly IPD-MA rather than a less resource 
intensive AD-MA. 
Additionally if longitudinal MA methods are used that only conduct a meta-analysis at 
specific time points, studies are excluded if they do not supply information at these 
specified time points – this can bias the conclusions drawn from the meta-analysis. 
Therefore, it is better to use AD methods that allow information across all possible time 
points to be used (as in equation (4), [32]), or to seek IPD from all studies concerned. 
1.3.4 Comparison of IPD-MA and AD-MA of longitudinal data  
Across the reports dealing with methods for longitudinal MA, there is a general consensus 
that the best approach is to obtain IPD, but that this is not always possible. Since ignoring 
correlation in longitudinal data can lead to unreliable parameter estimates and bias,  IPD is 
preferred over AD to allow the correlation in the data to be properly modelled [31, 45], 
especially as relevant study reports often do not report the AD necessary to correctly 
model the correlation structure [32]. However, the time and resource expenditure 
problems of obtaining IPD datasets remain for longitudinal MA. 
 18   
 
Overall, IPD methods for longitudinal MA can be considered a straightforward extension of 
the models generally used to model single study longitudinal data. A wide range of AD 
methods have been presented, however issues with them include a lack of reporting of 
variance and covariance parameters, ignoring correlation inherent to longitudinal data and 
differences between studies in measurement and follow-up times. Random effects, a 
common part of longitudinal data analysis, present a potential problem for meta-analysis 
due to the lack of data to estimate them, and the decisions that must be made as to what 
random effects to include. In general, for IPD versus AD meta-analyses, using IPD allows 
more flexible techniques to be used, as well as giving the potential for further investigation 
of specific subgroups and modelling structures (random effects and differing correlation 
structures).  
1.3.5 Conclusions 
A range of methods are presented in the literature both for AD-MA or IPD-MA. As IPD 
methods allow a wider choice of modelling methods as well as the opportunity to 
investigate the effect of individual level covariates on treatment effect, this thesis assumes 
the availability of IPD for studies included in the meta-analysis. In addition, the thesis will 
focus on the use of linear mixed effect models to represent the longitudinal data. 
1.4 Time-to-event data 
Time-to-event (or survival) data results from studies that aim to investigate the time 
between an individual entering the study, and experiencing a specific event (e.g. treatment 
withdrawal or death). Whilst some individuals may experience the event, others may reach 
the end of the study without experiencing the event, or may exit the study early for 
reasons unrelated to the event (e.g. moving away from the study location). Therefore, 
time-to-event data typically consists of two recorded values per study participant – a time 
(sometimes called a survival time, the minimum of the individual’s event and censoring 
times) and a censoring indicator. The censoring indicator records a value of 1 if the 
individual experienced the event of interest, or a value of 0 if the individual was censored 
(dropped out for reasons unrelated to the event, or did not experience the event during 
the study period). An overview of time-to-event analysis is given in Collett [49]. 
There are three main types of censoring; left censoring, right censoring and interval 
censoring. Right censoring is defined as when it is known that the event occurs at some 
point after a certain measurement time (such as the event occurring after the end of the 
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study). Left censoring is defined as the event occurring before a certain time, but again it is 
unknown at what point before this recorded time the event occurs (such as the act of 
contracting a disease). Finally interval censoring is where the event is known to have 
occurred between two time points, for example between two follow-up times. The data 
considered in this thesis is right censored. 
As time-to-event data is often skewed, and it has the unique property that both a time and 
a censoring variable is recorded, special methods are required to model the data. 
Throughout a time-to-event analysis, interest lies in the risk or hazard of individuals 
experiencing the event at a given time. A hazard function (also known as the hazard rate, 
instantaneous death rate or intensity rate) is calculated, represented by 𝜆𝑖(𝑡), which is 
interpreted as the risk of the individual in question experiencing the defined event in the 
next time interval, given that they have survived thus far (the formal definition is given in 
equation (5), where 𝑇𝑖 is the survival time of the individual 𝑖, 𝑡 is a given time in the study, 










Various models for the hazard function have been suggested to link the covariate values 
observed for an individual to their hazard of an event. A commonly used model in time-to-
event analysis is the Cox Proportional Hazard (PH) model [50]. This is a semi-parametric 
model as no particular distribution is assumed for the survival times (a parametric model 
would be one that assumes the survival times are for example realisations from a Weibull 
distribution). This property of the model is often referred to as having an unspecified 
baseline hazard. The proportional hazards assumption of this model is that the hazard of 
experiencing the event in one group is proportional to the hazard of experiencing the event 
for a similar individual in a different group. This assumption can be checked by plotting the 
hazards of the two groups – if the hazard functions do not cross then the proportional 
hazards assumption is valid.  
The equation for the hazard function for an individual 𝑖 for a Cox PH model is given in 
equation (6). 




In equation (6), 𝜆0(𝑡) is the unspecified baseline hazard function (the function for the 
underlying risk of an event for all study participants), and the exponential function contains 
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covariates (𝒙𝟐𝒊(𝒕)
′) and their coefficients (𝜷𝟐) that adjust the baseline hazard function to 
the value of that individual’s hazard at time 𝑡. The baseline hazard function is defined as 
the hazard function for an individual for whom all the values of the covariates held in the 
exponential function are zero [49].  
To investigate the effect of different explanatory covariates on the hazard function for an 
individual, these explanatory variables can be included inside the exponential function of 
equation (6). If these explanatory variables are time stationary, there is no issue with 
inclusion of these variables in the equation. However, if these covariates are time variable, 
depending their type of variability over time, issues can arrive with their inclusion in the 
model. 
There are two types of time dependent variables, namely exogenous (external) variables, 
and endogenous (internal) variables (see Kalbfleisch and Prentice [51] for formal 
definitions). Briefly, an exogenous variable may be considered predictable, for example the 
season of the year. Another type of exogenous variable may be described using a stochastic 
process independent to the individuals included in the study (such as air pollution count). 
In all cases, exogenous variables are independent of the time the event of interest occurs, 
and so can be included in the time-to-event model without issues.  
However, endogenous variables rely on the existence of the study individuals to be 
measured. Examples include clinical measures and biomarkers. Various issues arise with 
endogenous variables with their inclusion in time-to-event models [52]. Endogenous 
variables are generally recorded with measurement error (for example when measuring 
blood pressure of an individual, measurements may vary due to biological and 
measurement factors, although exogenous variables can also be subject to measurement 
error). Secondly, as the endogenous variable relies on the existence of the individual the 
occurrence of the event implies that the endogenous variable can no longer be measured. 
Finally the endogenous variables are only measured at specific intervals across the study 
period – their values between the measurements cannot be stated with absolute certainty, 
unlike the exogenous variables whose values are predictable. Whilst exogenous variables 
can be included in the analysis of time-to-event outcomes through use of the extended Cox 
models (see Andersen and Gill [53], Fleming and Harrington [54] , and Andersen et al [55]), 
including endogenous variables in a Cox model is not generally appropriate as doing so 
assumes that the values of the time dependent variable remain constant between 
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measurements (i.e. a step function). Therefore other methods are required, such as those 
described in Section 1.6. 
Another type of term that may be included in the exponential function of equation (6) are 
frailty terms (the name given to random effects included in time-to-event analyses). These 
allow the population hazard model to be adjusted for each individual, and for the 
researcher to assess how much variation there is within the population for certain 
characteristics. Inclusion of frailty terms in time-to-event models is extended through the 
joint modelling framework, discussed in Section 1.6. 
Two other important areas of time-to-event analyses are the extensions to allow for 
recurrent events and competing risks. Under certain conditions the event of interest in a 
time-to-event analysis may not be terminating; the individual may continue to survive after 
the event, such as time until treatment withdrawal. An extension of this is the case where 
the event is not terminating and can occur multiple times, for example asthma attacks. An 
individual could record multiple times until asthma attacks in one study, with time set to 
zero after each attack. Methods exist to account for this, however during this investigation 
it is assumed that events can only occur once in the study of interest, and additional data is 
not available for the study participant in question for any time point after they have 
experienced the event of interest.  
The second extension (competing risks) involves single events rather than recurrent events, 
but allows for the fact that there may be multiple reasons that the event could occur. For 
example, when testing a new treatment if the outcome of interest is time until death, there 
are many causes of death that an individual could experience (such as cancer, cardiac 
arrest, etc.). It may be of interest to compare the hazards for the event of interest due to 
these separate reasons between the two treatment groups. This has led to competing risks 
models, where a separate hazard function is calculated for each event reason. 
Apart from the Cox PH model, various other modelling approaches exist for time-to-event 
data, such as the Accelerated Failure Time (AFT) model. Unlike the Cox PH model (which 
assumes that the baseline hazard functions of the two treatment groups for example are 
proportional), the AFT model assumes that the hazard functions for both treatment groups 
(for example) are identical in shape but scaled differently over time. Different groups 
progress at different speeds along the graph of the hazard function, making the AFT model 
a suitable choice where progression through stages of a disease is of interest. One of the 
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joint modelling techniques described in Section 1.6 allows either Cox PH models or AFT 
models, although interest in this thesis centres on the Cox PH model. 
In conclusion, the unique structure of time-to-event data requires specific methods to be 
used to analyse it. However, issues arise with time-to-event investigations when time 
dependent variables generated by internal processes of the study participant are 
potentially relevant explanatory variables. Joint modelling methods that allow the 
researcher to analyse time-to-event data including time dependent variables as 
explanatory variables are discussed in Section 1.6. 
1.5 Meta-Analysis of Time-to-Event Data 
The unique structure of time-to-event data has led to the development of methods specific 
to the data type. A range of references have extended these single study methods to a 
meta-analytic setting. This section details some of the issues encountered during the MA of 
time-to-event data, as well as a description of methodology for AD-MA and IPD-MA of 
time-to-event data. 
1.5.1 Issues surrounding Time-to-Event Data Meta-Analysis 
A range of issues surround the meta-analysis of time-to-event data. For example, for AD-
MA, hazard ratios may not be reported at the same time points across different studies, 
meaning that only a subset of studies could contribute to a meta-analysis. Time-to-event 
data is complex with a unique structure, and so to ensure it is correctly modelled, it is often 
better to seek IPD. Again, however, this can lead to a range of issues including obtaining 
data, and the statistical expertise necessary to analyse it. However, a range of methods for 
both IPD and AD-MA of time-to-event data have been presented in the literature, some of 
which are now discussed. 
1.5.2 Individual participant data meta-analysis of time-to-event data 
1.5.2.1 One-stage methods for Time-to-Event Data MA 
Various modifications of the Cox PH model have been suggested to allow its use in a time-
to-event meta-analysis. A key reference for the one-stage frequentist meta-analysis of 
time-to-event data is Tudur Smith et al [56] (also Tudur Smith [57]). Tudur Smith et al 
examine a range of 5 one-stage models applied to IPD time-to-event data. These models 
have the following formulations: 
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           𝜆𝑘𝑖(t) = 𝜆0(t)exp (𝛽0𝑘 + 𝛽1𝑥1𝑘𝑖)   (7) 
 𝜆𝑘𝑖(𝑡) = 𝜆0𝑘(𝑡)exp (𝛽1𝑥1𝑘𝑖)  
  
(8) 
             𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝛽0𝑘 + 𝛽1𝑘𝑥1𝑘𝑖) 
                 𝛽1𝑘 = 𝛽1 + 𝑏1𝑘  




   𝜆𝑘𝑖(𝑡) = 𝜆0𝑘(𝑡)exp (𝛽1𝑘𝑥1𝑘𝑖) 
𝛽1𝑘 = 𝛽1 + 𝑏1𝑘  
         𝑏1𝑘~𝑁(0, 𝜏
2)  
(10) 
            𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝑏0𝑘 + 𝛽1𝑖𝑥1𝑘𝑖) 
                𝛽1𝑘 = 𝛽1 + 𝑏1𝑘 
                 𝑏0𝑘~𝑁(0, 𝜎
2) 
                                                    𝑏1𝑘~𝑁(0, 𝜏
2)       
 
(11) 
In the above equations, the hazard function for the 𝑖th individual in the 𝑘th study is given 
by 𝜆𝑘𝑖(𝑡), with 𝑘 ranging from 1 to 𝐾 (the number of included studies), and 𝑖 ranging from 
1 to 𝑛𝑘 (the number of individuals in the 𝑘th study). Treatment allocation is given by the 
𝑥1𝑘𝑖 variable (as in the longitudinal MA section only a control and experimental treatment 
are considered, taking values 0 and 1 respectively).  
The models presented provide a range of ways to account for between study heterogeneity 
in a time-to-event MA. For example, Equations (7) and (9) identify study membership using 
the fixed parameter 𝛽0𝑘, treating the first included study as the baseline (𝛽01 = 0). This 
term quantifies the difference in log hazard ratio between the baseline study and study 𝑘. 
The parameter 𝛽1 quantifies the difference in log hazard ratio for experiencing an event for 
those assigned to the experimental treatment compared to the control treatment. 
Between study heterogeneity can be tested for by estimating study specific treatment 
parameters, and comparing the two models. The models shown in equation (8) and (10) 
demonstrate a baseline hazard stratified by study, rather than common across studies. This 
method accounts the log hazard ratio for risk of an event to completely differ in shape 
across time between studies. Models shown in equations (9) and (11) introduce random 
effects for the treatment effect, and the model in equation (11) includes a random effect 
𝑏0𝑘 that adjusts the baseline hazard between studies. 
Various advantages and disadvantages are attached to the models shown in equations (7)- 
(11). The models with common baseline hazard across studies assume proportional hazards 
across all studies included in the meta-analysis, an assumption that may not be reasonable 
especially if the demographics or design of the included studies vary. The models with 
baseline hazards stratified by study assume proportional hazards only within studies, 
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potentially a more reasonable assumption. Models that rely on fixed effects to account for 
differences in the log hazard ratio for different groups between studies could become 
cumbersome as the number of studies increases, but they provide study specific parameter 
estimates. Inclusion of random effects allows the variation between studies attributable to 
treatment effect or from other sources to be quantified, by parameters 𝜏2 and 𝜎2 
respectively. However, random effects do not automatically produce study specific 
estimates of the parameters, although meta-analyses aim to provide overall rather than 
study specific estimates. 
After comparisons of the models, Tudur Smith et al [56] noted that of these five models, 
the models that stratify baseline hazard by trial are more suited for meta-analyses as they 
preserve the multiple study structure. However, they note that with larger numbers of 
included trials, estimates from models with fixed trial effects or with stratification by trial 
could be unreliable. Random effect models are stated to be beneficial compared to a 
stratification by study approach if the meta-analysis consists of many included studies, 
each with a small sample size, but stratification is preferable to random effects modelling 
when there are few included studies with larger sample sizes.  
Various other references also discussed IPD-MA of time-to-event data. Crowther et al [58] 
examine multilevel parametric time-to-event models for application to clustered time-to-
event data (such as multi-centre or meta-analytic data), which use random effects to 
account for between cluster variation. An alternative to Cox PH models is presented by 
Crowther et al [59], who describe the one-stage IPD-MA of time-to-event data using 
Poisson regression models. 
A summary of available methods for the IPD-MA of time-to-event data is provided by 
Katsahian et al [60]. Both Katsahian et al [60], and Michels et al [61] argue that inclusion of 
random effects is a valuable method to account for between study heterogeneity in time-
to-event IPD-MA, an area also discussed by Rondeau et al [62]. 
1.5.2.2 Two-stage methods for Time-to-Event Data MA 
For two-stage MA of time-to-event data, Thompson et al [63] used a two-stage method 
where Cox PH models were fitted separately to each included study. The model fitted to 
each included study was stratified by gender and randomised group, but included exposure 
and other covariates as model terms rather than additional stratification factors. They 
extracted log hazard ratio of the effect of a unit increase in exposure on the response, 
adjusted for the included covariates, and suggested combining these log(HR)s using a 
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random effects meta-analysis or a fixed effect meta-analysis. However, Thompson et al[63] 
report that one-stage and two-stage methods often present similar results.  
Thompson et al [63] noted that whilst they utilised a two-stage model, a one-stage model 
similar to those discussed in Tudur Smith et al [56] (Cox PH models with random effects to 
account for between study heterogeneity) would be preferable. The main reason stated for 
not employing this approach was computational problems given the large size of the 
dataset (1.2 million participants over 116 included studies). However, they additionally 
note that use of two-stage models allows adjustment for different covariates between the 
included studies (which is beneficial if the covariates reported differ between included 
studies). 
1.5.3 Aggregate data meta-analysis of time-to-event data 
As with other data types, the use of AD-MA methods for time-to-event data can be 
valuable when IPD-MA is cannot be obtained from all studies. However, care must be taken 
to ensure that the methods used to analyse the time-to-event data in each study were 
appropriate (e.g. taking into account censoring). 
Parmar et al [64] describe a range of methods available to extract hazard ratios (HR) from 
trials, (including methods for if the log(HR) and variance are reported, if log(HR) are 
reported along with a confidence interval, if the log(HR) are reported along with the 𝑝 
value of a log rank test under certain conditions) for use when estimating the log(HR) and 
variance from survival curves, or to estimate log(HR) and variance from survival curves 
whilst incorporating numbers at risk. These methods were then applied and investigated by 
Tudur Smith et al [65] . The methods for AD-MA of time-to-event data are also described by 
Tierney et al [66] in a manner accessible to non-statisticians. 
Various other papers make key contributions to the AD-MA of time-to-event data. 
Williamson et al [67] describe methods to improve the estimation of log(HR) from survival 
curves or life tables, note that different approaches to extract data may be required across 
studies identified in the meta-analysis. Duchateau et al [68] state that the number of 
events should not be estimated from Kaplan-Meier curves unless the number of patients 
lost to follow up or censored is very small, and the number of patients at risk in the groups 
at the time at which the number of events is to be estimated is large. Arends et al [69] 
describe a method to perform AD-MA of survival proportions measured at multiple time 
points through a multivariate random effects model. In addition, Bennett et al [70] 
compare frequentist and Bayesian approaches to the AD-MA of time-to-event data. 
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However, the data available to conduct a time-to-event MA with aggregate data can often 
be limited, and drawing conclusions about treatment effects at the patient level on the 
basis of inferences based on aggregate data can be misleading [56]. 
1.5.4 Comparison of IPD and AD MA of time-to-event data  
Duchateau et al [71] compare IPD-MA and AD-MA and note that the results can differ, 
potentially due to the fact that IPD-MA will include all follow up in the analysis, whereas 
AD-MA will be based on information at only a subset of time points. In addition, an IPD-MA 
of time-to-event data allows a more effective investigation into the causes of heterogeneity 
than an AD-MA [56], which reduces the chances of conclusions drawn from the 
investigation being misleading. 
1.5.5 Conclusions 
The methodology discussing the meta-analysis of time-to-event data is extensive. This 
thesis focuses on methods that rely on estimating hazard ratios from the data, although 
other methods also exist. For example, Barrett et al [72] suggests use of percentile ratios in 
place of hazard ratios in the second stage of a two-stage MA of time-to-event data, whilst 
Siannis et al [73] examine their use in a one-stage model. However, as these methods are 
not the focus of this thesis, they are not considered further. 
Whilst many methods exist to meta-analyse time-to-event data, there is a trend towards 
the principle that availability of IPD time-to-event data is beneficial, as data at all time 
points rather than a subset can be analysed. A range of methods exist for IPD-MA of time-
to-event data, including one-stage and two-stage models. Between study heterogeneity in 
one-stage models exist can be modelled in various including fixed or random terms, or 
stratification of the baseline hazard by study. The methods in this thesis will extend those 
for multi-study time-to-event data to multi-study joint data. 
1.6 Joint models for longitudinal and time-to-event data 
Joint models for longitudinal and time-to-event data (also referred to as joint models) 
simultaneously model longitudinal and time-to-event outcomes. Models of this type are 
typically used for one of three reasons; to account for informative dropout in a longitudinal 
study, to include a time dependent (longitudinally measured) explanatory variable in a 
time-to-event analysis, or to investigate possible association between a longitudinal and a 
time-to-event outcome where both are of equal interest [30]. Throughout this thesis, data 
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that contains both a longitudinal component and a time-to-event component of interest is 
referred to as joint longitudinal and time-to-event data, or more concisely joint data.  
The use of joint models is increasing [74-76], with a growing number of methodology 
papers available in the literature describing joint model formulations for a range of 
scenarios. Joint models fall into two main groups, shared parameter models [74, 75] (which 
link models for the longitudinal and time-to-event outcomes by sharing parameters 
between them), and latent class models [76] (where the population being modelled are 
assumed to fall into a set of latent classes). This thesis concerns only shared parameter 
joint models, and any joint model discussed, unless otherwise stated, is a shared parameter 
joint model. 
During this section an overview is given of various areas of single study joint modelling 
methodology including the general structure of the joint model, association structures 
within the joint model, software and model fitting, and finally the benefits and limitations 
of joint models. 
1.6.1 General Structure of a Joint Model 
A simple joint model contains a longitudinal sub-model and a time-to-event sub-model, 
which are linked through an association structure.  The association structure quantifies the 
dependence between the longitudinal and the time-to-event outcomes.  
A wide range of joint models have been presented in the literature. Proposed longitudinal 
sub-models include mixed effects models, use of splines, and non-linear models. Suggested 
time-to-event sub-models include proportional hazards (PH) models, AFT models, or 
parametric models. An overview of joint modelling methodologies is given by Gould et al 
[75] and Davidian et al [74], with useful textbooks by Rizopoulos [52] and Elashoff et al [77]. 
Other key references of joint models include Wulfsohn and Tsiatis [78] (generally regarded 
as the first joint modelling paper) and Henderson et al [30]. 
During the thesis, the joint models take following structure: 
 𝒀𝒊 = 𝑿𝟏𝒊𝜷𝟏 + 𝒁𝒊𝒃𝒊 + 𝜺𝒊 
𝜆𝑖(𝑡) = 𝜆0(𝑡) exp(𝑿𝟐𝒊𝜷𝟐 + 𝑊2𝑖(𝑡)) 
𝑊2𝑖(𝑡) = 𝑔(𝑿𝟏𝒊, 𝜷𝟏, 𝒁𝒊, 𝒃𝒊) 
  
(12) 
In equation (12), the longitudinal outcome is modelled using a mixed effects model (first 
line), and the time-to-event outcome through a PH model with an unspecified baseline 
hazard (second line). The longitudinal and time-to-event sub-models are linked using term 
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𝑊2𝑖(𝑡), which takes some function 𝑔 of the longitudinal sub-model and inserts it into the 
time-to-event sub-model (third line in equation (12)). Exact model formulae used in this 
thesis are stated as required.  
1.6.2 Association Structures 
A range of association structures (also called sharing structures) for joint models have been 
proposed in the literature, each of which allows different patterns of dependence. A good 
overview is given by Gould et al [75]. 
This thesis investigates models that employ a proportional association structure. In this 
structure, the random effects from the longitudinal sub-model are correlated with the 
frailty term in the time-to-event sub-model. As such, the 𝑊2𝑖(𝑡) has the following format: 
𝑊2𝑖(𝑡) ∝ 𝑊1𝑖(𝑡) 
= 𝜶𝑊1𝑖(𝑡) 
= 𝜶𝒁𝒊𝒃𝒊 
In the above equations, it is stated that the 𝑊2𝑖(𝑡) is proportional to 𝑊1𝑖(𝑡) (which consists 
of the random effects of the longitudinal sub-model). The zero mean random effects are 
represented by 𝒃𝒊, with design matrix 𝒁𝒊, and association parameter(s) 𝜶. In a single study 
case, there is a single 𝜶 parameter, however during the extension to a multi-study case, 
which permit random effects at multiple levels, separate association or 𝜶 parameters are 
permitted for each level of random effects (see Section 3.3).  
The proportional random effects only association structure can also include separate 
random effects only structure, where separate association parameters 𝛼1, 𝛼2, … are 
permitted for each shared random effect. Other association structures involving both the 
fixed and the random effects are discussed in Rizopoulos [52]. The current value structure 
inserts the longitudinal sub-model (apart from the error term) with coefficient into the 
time-to-event sub-model, giving 𝑊2𝑖(𝑡) = 𝛼𝑚𝑖(𝑡) = 𝛼(𝑿𝟏𝒊𝜷𝟏 + 𝒁𝒊𝒃𝒊). The current slope 
structure inserts the first derivative of the longitudinal trajectory (apart from the error 
term) with respect to time into the time-to-event sub-model with coefficient, giving 
𝑊2𝑖(𝑡) = 𝛼𝑚𝑖′(𝑡) = 𝛼 (
𝑑
𝑑𝑡
(𝑿𝟏𝒊𝜷𝟏 + 𝒁𝒊𝒃𝒊)). Association structures modelling the 
cumulative effect of the longitudinal trajectory integrate under the longitudinal trajectory 
utilise 𝑊2𝑖(𝑡) = 𝛼 ∫ 𝑚𝑖(𝑡) = 𝛼 ∫(𝑿𝒊𝜷𝟏 + 𝒁𝒊𝒃𝒊). A weighting function can also be included 
in the cumulative effect, to allow recent longitudinal measurements to have a greater 
effect on the risk of an event than older measurements. 
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These association structures each give association parameters with different 
interpretations [52, 75]. For the proportional random effects only association structure, the 
association parameter 𝛼 quantifies the effect of individual deviation from the population 
mean value at a given time point on their risk of an event. The separate random effects 
only structure has association parameters that quantify the effect of individual deviation 
from the population effect of the covariate assigned the random effect on the risk of an 
event. The current value structure quantifies the risk of an event for an individual based on 
their true current value of their longitudinal outcome. The current slope structure gives the 
risk of an event for an individual based on the current rate of change of their longitudinal 
outcome. The cumulative structure details how the history of an individual’s longitudinal 
outcome up to a given time point affects their risk of an event.  
The difference in interpretation of association parameters could affect the meta-analysis of 
results from joint models, an issue discussed in Chapter 2 and Chapter 3. 
1.6.3 Currently available software 
A range of software is currently available to fit single study joint models. In the statistical 
software R [79], there are two main frequentist packages to fit single study joint data, 
namely joineR [80] and JM [81]. These software packages differ in the models that they 
provide, this is further discussed in Section 5.1.1. The package JMBayes [82] provides a 
Bayesian approach to joint modelling in R. Whilst this thesis focusses on the R software, 
joint modelling is also possible in other software. The stjm function [83] in STATA [84] is 
well established, and in the SAS software [85] various options exist including the PROC 
NLMIXED function, as well as other specifically designed macros (see Chapter 2 for a review 
of current use of joint modelling software). However, there did not appear to be readily 
available software designed to handle multi-study joint data. 
1.6.4 Discussion 
One major benefit of joint modelling is that for a longitudinal study, it allows the 
investigator to model informative dropout, which if ignored could lead to biased results 
[86]. Additionally for a study where a time-to-event outcome is of interest, joint modelling 
allows the investigator to include a longitudinal covariate (that may not be continuously 
measured or may be recorded with error) in the time-to-event model. Additionally, Ibrahim 
et al [87] also notes that joint modelling of available longitudinal and time-to-event data 
leads to more efficient estimates of the treatment effects in both the time-to-event and 
the longitudinal sub-models, and gives a larger power for a smaller sample size in a study.  
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However, there are limitations to joint models due to their complexity. Expectation-
Maximisation (EM) algorithms are commonly used during model fitting, but can be slow to 
converge, and does not automatically produce estimates of the standard errors [88]. Due 
to use of the unspecified baseline hazard, it is necessary to use bootstrap re-samples to 
obtain standard errors, as relying on the profile likelihood could lead to underestimation 
[89]. Whilst joint models reduce bias in certain cases, and allow inclusion of endogenous 
variables in time-to-event models, their complexity may cause some investigators to opt for 
more naïve but more straightforward methods such as the extended Cox model [53-55]. 
1.7 Meta-Analysis of Joint Data 
The benefits of both subject areas of meta-analysis and joint models for longitudinal and 
time-to-event data are clear. Meta-analysis allows currently existing data to be pooled, 
allowing smaller effects to be identified, potentially reducing the number of trials required 
in the future, and thus reducing the number of patients exposed to experimental, 
potentially detrimental treatments. Joint models allow more efficient and in-depth 
investigation of data involving both longitudinal and time-to-event variables, whilst 
accounting for issues such as informative dropout in longitudinal data, or time varying 
covariates in time-to-event models. The meta-analysis of joint models would therefore 
provide a useful tool to both the statistical and medical research communities. 
A review of the available methodology for separate meta-analysis of time-to-event data or 
longitudinal data identifies a range of considerations. For time-to-event data, it is 
preferable to have IPD for each study to allow the full follow-up of the data to contribute to 
the analysis. For longitudinal data, the multilevel nested structure of the data must be 
accounted for. Again IPD is preferred, but given sufficient reporting in available studies, AD-
MA are feasible.  However, given the issues that joint data MA may inherit from 
longitudinal MA, time-to-event MA or single study joint models, IPD is likely to be 
preferable. 
A review of current literature on the meta-analysis of joint longitudinal and time-to-event 
data did not reveal literature or software specific to the area of meta-analysis. Brombin et 
al [90] provided an analysis of multi-centre joint data, however they did not present 
methods designed to deal with the meta-analysis of joint data, such as a comparison of 
methods to deal with between study heterogeneity. The methods are comparable, as both 
involve three level joint data, however meta-analytic and multi-study analyses differ in the 
number of units at each level. Meta-analyses involve few studies at the top level, each 
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including many individuals. Multi-centre studies involve many centres at the top level, 
typically each containing few individuals. As such, suitability of methods to account for 
differences between top level units may differ between multi-centre and meta-analytic 
analyses. In addition, generalisable software designed for joint data meta-analysis did not 
appear available in the literature. As such, there is a gap in methodology linking the 
important areas of meta-analysis and joint models for longitudinal and time-to-event data. 
1.8 Thesis Aims and Structure 
1.8.1 Motivation for research 
In summary, this chapter introduced the basics of meta-analysis, and the two types of data 
of interest in this thesis (longitudinal and time-to-event). The joint model formulation for a 
single study case including various model structures and association types were outlined. 
An overview of the literature underpinning meta-analysis of longitudinal data and time-to-
event data was given. The single reference that implemented a three level joint model was 
identified. The large gap in the methodology linking the important areas of longitudinal 
data, time-to-event data and meta-analysis was noted, which provides the motivation for 
this thesis. Methodology and software to ensure that longitudinal and event-time 
outcomes from multiple studies can be appropriately modelled is an under-developed area 
of research, especially given the increasing popularity of joint modelling. 
 
1.8.2 Aims of Thesis 
This thesis aims to extend current meta-analytic and joint modelling research in the 
following ways: 
1. Develop methods for the two-stage IPD-MA of joint longitudinal and time-to-event 
data comparing separate and joint models through real data application, and a 
simulation study investigating  the behaviour of methods under a range of different 
event rates, association parameters and levels of between study heterogeneity. 
2. Develop methods for the one-stage IPD-MA of joint longitudinal and time-to-event 
data investigating methods to account for between study heterogeneity as well as 
comparing use of joint and separate models, through a real data application and a 
simulation study investigation varying association levels, number of included 
studies and levels of between study heterogeneity 
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3. Develop software in the R programming language [79] to aid researchers 
conducting MA of joint longitudinal and time-to-event data. 
4. Assess current reporting standards of joint modelling investigations of single study 
medical or biostatistical data with a view to future AD-MA of published analyses. 
1.8.3 Thesis structure.  
In this first chapter of the thesis, I have discussed the background of the methodologies 
developed in this thesis and outlined the thesis aims. I now conclude the chapter with a 
discussion of the structure of the thesis. 
Chapter 2 contains the results of a review of current reporting standards in the literature of 
joint modelling analyses of medical or biostatistical data, with an aim to assess the current 
feasibility of extracting sufficient information to conduct an AD-MA of the published 
results. A range of aspects of the identified studies including disease area, joint model type, 
and software employed were recorded, as well as an assessment of how many of the 
identified studies provided sufficient information to contribute to future AD-MA. 
I develop and present methodology for the meta-analysis of joint longitudinal and time-to-
event data in Chapter 3. Methods are separated into two-stage and one-stage methods. 
The two-stage methods present guidelines designed to describe the process that should be 
undertaken in a two-stage MA. The one-stage methods describe various groups of models 
designed to account for between study heterogeneity in several ways, including fixed 
parameters for study membership and interaction between study membership and other 
covariates of interest, study level random effects, and stratification of the baseline hazard 
by study.  
The R software package that I have developed during this thesis to implement the 
methodology discussed in Chapter 3 is presented in Chapter 4. This package includes 
methods for the preparation and visualisation of multi-study joint data, functions to aid the 
second stage of a two-stage MA, and functions to fit one-stage meta-analytic joint models. 
The software is designed to be flexible for use in future multi-study investigations, and is 
freely available. The theory used by the functions in the package (e.g. to fit models) is 
discussed in Chapter 5. 
A real data application of the one-stage and two-stage methods is presented in Chapter 6. 
This chapter involves the analysis of the INDANA [91] dataset, a multi-study dataset of 
hypertensive patients which contains the longitudinal outcome Systolic Blood Pressure 
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(SBP), and time-to-event outcomes time to death, time to myocardial infarction and time to 
stroke. I compare meta-analyses based on joint methods to meta-analyses based solely on 
longitudinal or on time-to-event methods, in order to assess for this real dataset whether a 
benefit to joint models exists. This analysis is designed to test the methodology developed 
in a real data setting, rather than influence clinical practice. 
A simulation study is presented in Chapter 7. Separate simulation studies are undertaken 
for two-stage methods and one-stage methods. In both cases, meta-analyses using joint 
models are compared to meta-analyses using longitudinal or time-to-event models to 
assess any benefit in using the more complex joint modelling methodology. During the two-
stage MA simulation study, a range of scenarios including varying association level, event 
rate and between study heterogeneity in treatment effect are investigated. During the one-
stage MA simulation study, a range of associations are tested for a single event rate. The 
effect of varying between study heterogeneity, and varying numbers of available studies on 
the estimation of one-stage model parameters are also assessed. 
A discussion of the work presented as well as an assessment of its impact on future 
research is given in Chapter 8. This chapter also includes a concise statements of 
conclusions drawn from the research, as well as a presentation of planned future work. 
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Chapter 2 : Review of reporting of joint models in the 
literature 
Joint modelling of longitudinal and time-to-event data is an area of increasing research [75, 
76, 92].  As such, results of joint longitudinal and time-to-event analyses could be expected 
to be increasingly published in the literature.  Aggregate Data Meta-Analyses (AD-MA) 
numerically pool study level results to obtain an overall estimate of, for example, 
treatment effects.  These study level results can be extracted from publications, or 
obtained through direct contact with publication authors.  Whilst not the gold standard for 
meta-analyses, AD-MA are commonly performed in place of Individual Participant Data 
Meta-Analyses (IPD-MA), as they can be less resource intensive to complete.  However, 
they are reliant on sufficient information being available from publications or authors to 
conduct the meta-analyses.  This chapter describes a review conducted of the published 
results of joint longitudinal and time-to-event analyses of medical and biostatistical data, 
which aims to assess whether AD-MA of joint models is feasible given current reporting 
practices.  This review has been published in Sudell et al [93]. 
The chapter starts with an examination of the issues to be considered when assessing the 
current feasibility of AD-MA of joint model results.  The structure of the conducted review 
is then stated, followed by the results.  The chapter concludes with a discussion of AD-MA 
of joint data and recommendations for future reporting of joint longitudinal and time-to-
event models in the literature. 
2.1 Motivation for the review 
An AD-MA using published data would only be successful if the studies identified during the 
meta-analysis search state results in a way that is useable in a meta-analysis.  It is assumed 
that for an AD-MA of joint longitudinal and time-to-event models, separate meta-analyses 
using standard methods would be performed for the parameters from the longitudinal sub-
model, from the time-to-event sub-model and from the association structure.   
The association parameters are assigned a separate class to the time-to-event sub-model 
fixed effect parameters as their interpretation differs. The association parameters quantify 
the effect of some component or function of the longitudinal sub-model on the risk of an 
event.  They communicate both the effect of the function of the longitudinal outcome on 
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risk of an event, but also the relationship between the longitudinal and time-to-event 
outcomes, an important aspect as if the relationship is non-significant, the difference 
between results from separate longitudinal or time-to-event models, and from joint 
models, may be small. The time-to-event sub-model fixed effect parameters quantify the 
direct effect of variables that do not change over time on the risk of an event.  As such, 
separating the MA for the time-to-event fixed effect coefficients and the association 
parameters highlights their difference in interpretation.  Additionally, performing MA for 
the association parameters communicates whether a significant relationship between the 
longitudinal and time-to-event outcomes exists. 
To perform the meta-analyses, the sample size of the study must be reported, as well as 
the parameter estimates with some representation of their precision (standard error, or 
confidence intervals with stated significance level).  If interest also lies in results from 
particular sub-groups, this same information must be available for each sub-group of 
interest.   
A wide range of types and structures of joint models are currently available to researchers.  
Section 3.2.4, discusses that pooling results from different types of joint models may not 
have meaningful interpretations.  For example, a joint model that uses a random effects 
only proportional association structure has an association parameter that is interpreted as 
the effect of individual deviation from the population mean trajectory on the risk of an 
event [75]. However, a joint model that uses a current value association structure has an 
association parameter that quantifies the effect of the current recorded value of the 
longitudinal outcome on the risk of an event [52].  Pooling the association parameters from 
such different joint modelling structures would not be interpretable, and so care needs to 
be taken during AD-MA not to make this mistake.   
An additional consideration stems from the choice of association structure.  If a random 
effects association structure is used, then fixed effect parameter estimates can be directly 
read from each sub-model.  However, if an association structure that involves both fixed 
and random effects is used, then direct, indirect and overall effects for covariates can be 
extracted from the time-to-event sub-model (see Ibrahim et al [87] and Section 5.1.1).  
Consider a joint model that includes treatment assignment as a fixed covariate in both the 
time-to-event and the longitudinal sub-models, and that utilises a fixed and random effects 
current value association structure.  The time-to-event sub-model will contain a direct 
effect of treatment assignment by inclusion of the variable as a fixed effect in the time-to-
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event sub-model.  It will also include an indirect effect, resulting from the inclusion of the 
treatment effect covariate as a fixed effect in the longitudinal sub-model, present in the 
time-to-event sub-model as a result of the association structure linking the sub-models.  
The indirect effect will be a product of the association parameter and the longitudinal 
treatment effect coefficient.  An overall effect of the treatment assignment in the time-to-
event sub-model is then the sum of the direct and indirect effects.  In joint models of this 
or similar format, this overall effect is generally the quantity of interest as it fully describes 
the effect of the covariate on the risk of an event.  As overall effects from joint models 
utilising association structures involving both fixed and random effects consist of both a 
direct and indirect effect, whereas the effects extracted from joint models utilising random 
effects only association structures are direct effects only, it may not be interpretable to 
combine parameter estimates from joint model analyses that used different joint modelling 
structures. 
Consequently, as it may not be meaningful to pool estimates from joint models with 
different structures, it is important for the joint modelling structure (parameters included 
in the sub-models, and association structure) to be discernible from the study report. 
An AD-MA may be difficult or impossible to perform if information such as the joint model 
structure is not provided for the contributing study in question, without either seeking 
additional information or full IPD datasets from the study authors.  In order to assess the 
current standard of reporting of joint models, a review was conducted of papers published 
in the literature using joint modelling methods. 
2.2 Review Methods  
2.2.1 Identification of Papers 
Medline, Pubmed and Scopus datasets were searched for studies using joint models for 
longitudinal and time-to-event data to analyse medical data (search strategies available in 
Appendix 1).   
Any papers that mentioned joint models for longitudinal (or repeated measures over time) 
data and time-to-event (or survival, event time or event history) data were identified.  The 
citations were downloaded and duplicates identified and removed.  The abstracts and 
keywords of the remaining papers were then examined and any irrelevant papers were 
removed. Examples of disregarded papers include papers modelling body joints, those 
discussing joint models as a future extension or alternative to methods used, or papers 
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using two-stage approaches rather than simultaneous estimation of the longitudinal and 
time-to-event sub-models.  Papers not relating to a medical or biostatistical dataset were 
also disregarded (for example application of joint models to data from plant or animal 
subjects except from those modelling human diseases input into animal hosts). In addition, 
papers involving repeated measures over space rather than time (e.g. repeated measures 
across different tumour sites recorded at the same time point) were removed.  If the 
relevancy of identified papers was unclear from the abstract, the full text was obtained and 
examined after which the study was included or discarded. 
Retained papers were sorted into an applied and methodological group.  Whilst many 
papers from the methodology group presented application of methods to example 
datasets, these were considered re-analyses of data or demonstration of methodology 
rather than primary analyses aimed to influence future medical practice.  Additionally, 
methodological papers could be expected to better report results than applied papers, as 
their authors tend to be joint modelling experts.  This review aimed to assess the reporting 
of joint modelling analyses in the general medical literature, so the review focussed only on 
the applied group. 
2.2.2 Data extraction 
Throughout this chapter, references identified as relevant to the review are referred to as 
studies.  Other publications (such as those cited by the identified studies) are termed 
papers.   
The year of publication, author, journal, joint model type, association structure between 
the longitudinal and time-to-event sub-models, types of sub-models, Bayesian or 
frequentist methods, and software used were recorded from the identified studies.  
Additionally disease area was recorded with respect to the type of longitudinal and time-
to-event data, for example studies modelling biomarkers in heart disease patients after a 
transplant operation were classed as transplant data. 
Also the source of the methods used in the study was recorded.  If the study developed 
methods specific to their dataset or research objectives, a value of “own methods 
developed” was recorded.  If the study referenced a particular paper or papers as the 
source of the methods used in their investigation, the papers referenced were recorded. 
The availability of each piece of information necessary for an AD-MA to be performed was 
recorded.  Specifically, the number of participants, significance level, and the presence of 
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the parameters from the longitudinal and time-to-event sub-models, and the association 
structure along with estimates of their precisions were searched for in each study.  The 
significance level was identified either through its direct statement in the study text, or in a 
statement of a confidence interval of a particular size on tables, graphs or footnotes 
specifically relating to the joint models fitted in the analysis.  Feasibility of meta-analyses 
was assessed separately for the longitudinal, the time-to-event and the association 
parameters.  For each group of MAs to be considered possible, the number of participants 
contributing to the analysis, the relevant parameter estimates and an estimate of their 
precision (their standard errors or a confidence intervals with accompanying significance 
level) had to be reported. 
As noted earlier, it is assumed that an AD-MA of results from joint longitudinal and time-to-
event models will involve separate MA for each parameter from each of three groups – 
namely the parameters from the longitudinal sub-model, the parameters from the time-to-
event sub-model and the association parameters.  Ideally MA should be possible for each 
of these three groups.  However, if insufficient information is reported in a study, MA may 
only be possible for a subset of these three groups. 
Joint models in single study cases may be utilised for a variety of reasons, for example to 
account for study dropout in a longitudinal study, to include a longitudinal covariate 
measured with error in a time-to-event analysis, or simultaneously analysing a longitudinal 
and a time-to-event outcome both of which are of interest [30].  If joint models were 
utilised in order to account for informative dropout in a longitudinal study, the study might 
not report the time-to-event sub-model parameters as the sub-model exists to account for 
a structural issue in the data rather than to model an outcome of interest.  If a joint model 
was employed in order to include a longitudinal covariate measure with error as a time 
variable covariate in a time-to-event model, again the parameters of the longitudinal sub-
model may not be clearly reported.   Therefore the reason reported in the study for using 
joint modelling methods was recorded, to assess whether it affected the proportion of 
possible MA for each of the three groups (longitudinal, time-to-event, and association 
parameters). 
The aim of this review was not to perform MA of the study level results of joint modelling 
analyses reported in the literature, it was solely to assess if such an MA were undertaken, 
what proportion of identified studies could currently contribute.  It should be emphasised 
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that methods for AD-MA of study level results are comparable to the second stage of two-
stage methods for IPD data, which are discussed in Chapter 3. 
2.3 Results 
Searches were conducted on the 15th September 2015.  A flowchart depicting the process 
the review followed is shown in Figure 1.  Once duplicate references and an erratum paper 
that corrected an author’s name were removed there were 618 remaining references.  Of 
these, 210 were classed as methodological papers, and 343 were disregarded for reasons 
mentioned above.  In total, 65 studies remained [90, 94-157] that applied joint models for 
longitudinal and time-to-event data to medical or biostatistical datasets with the aim of 
influencing healthcare rather than demonstrating new modelling methods. 
 
Figure 1: Flowchart of review of reporting of joint modelling of longitudinal and time-to-event medical or 
biostatistical data in the literature 
2.3.1 Characteristics of identified studies 
2.3.1.1 Year of Publication 
A plot of the years of publication of the identified studies is shown in Figure 2.  The 
distribution of year of publication of the identified studies appears skewed towards more 
recent dates.  The median year of publication was 2014, with interquartile range 2011 to 
2014, range 2001 to 2015.  An overall trend is noticeable of increasing numbers of 
publications of applied joint models per year, although there is some variation between the 
years and the maximum number of publications published in a year is only 20.   
Numbered lines (1-6) are included on Figure 2 to indicate years when events or 
publications that could have influenced the rate of publication of applied joint modelling 
papers occurred.  Line 1 indicates the publishing of the seminal paper by Wulfsohn and 
Tsiatis [78] commonly cited as one of the first joint modelling papers.  Their methodology 
was extended by Henderson et al [30] in 2000 (line 2).  Line 3 represents two papers of 
 40   
 
interest, firstly by Tsiatis and Davidian [92] who published a review of joint modelling 
methodology, and secondly by Guo and Carlin [158], who published a paper giving 
examples of implementation of joint models in current software.  In 2010 (line 4), 
Rizopoulos published a paper detailing the R joint modelling package JM [81].  Line 5 
highlights 2012, which saw the publication of a joint modelling textbook [52], and papers 
describing joint modelling options in Stata (Crowther et al [159]) and the joineR package 
in R (Philipson et al [80]).  Further papers were published by Crowther et al concerning joint 
modelling in Stata in 2013 (line 6, [83, 160]).  In addition to these events, the number of 




accessed 10th February 2016).  Although it is unclear by how these events or publications 
influenced the use of joint modelling methods, there is an apparent increase in the use of 
the methods after 2012. 
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Figure 2: Year of publication of identified studies.  Line numbers identify possibly influential publications (see 
main text) 
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 N (%) 
Full text or abstract available  
Full text 63 (96.9) 
Abstract 2(3.1) 
Disease Area  
Cancer related data 10 (15.4) 
HIV/AIDS 9 (13.8) 
Patient status after transplants 8 (12.3) 
Cognitive decline 7 (10.8) 
Glaucoma 4 (6.2) 
Renal disease 4 (6.2) 
Disability in the elderly 3 (4.6) 
Heart related data 3 (4.6) 
Schizophrenia 3 (4.6) 
Sclerosis 3 (4.6) 
Other 11 (16.9) 
Journal  
Statistics in Medicine 5 (7.7) 
Journal of the Royal Statistical Society. Series C: Applied Statistics 4 (6.2) 
Ophthalmology 3 (4.6) 
Quality of Life Research 3 (4.6) 
Journal of the American Geriatrics Society 2 (3.1) 
Journal of the American Statistical Association 2 (3.1) 
Journals of Gerontology - Series B Psychological Sciences and Social 
Sciences 
2 (3.1) 
Statistical Methods in Medical Research 2 (3.1) 
Other (only one study per journal) 45 (64.6) 
Reason for joint modelling use* 
 
To investigate the link between longitudinal and time-to-event 
outcomes 43 (66.2) 
To account for dropout 22 (33.8) 
To include longitudinally measured variable in time-to-event model 4 (6.2) 
To increase efficiency 3 (4.6) 
To reduce bias 2 (3.1) 
Easier to interpret 1 (1.5) 
To use all of available data 1 (1.5) 
Table 1: Characteristics of Identified Studies (*Note for “disease area” and “journal” only one value was 
recorded per included study giving total N=65, however for “reason for joint modelling use” multiple reasons 
could be recorded per included study giving total N≥65 
2.3.1.2 Full text or Abstract 
Full texts were obtainable for 63 of the identified studies (96.9%) [90, 94-105, 107-138, 
140-157], with only abstracts available for 2 studies (3.1%) [106, 139], see Table 1.  Some 
individuals were listed as authors on multiple studies, suggesting that the group of 
individuals applying joint models may currently be limited. 
2.3.1.3 Disease Area 
A wide range of disease areas were reported in the identified studies (see Table 1).  The 
most commonly reported types were Cancer (10, 15.4%), HIV/AIDS (9, 13.8%), transplant 
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data (8, 12.3%) and cognitive decline (7, 10.8%).  The wide range of disease areas identified 
by this review demonstrates the applicability of joint modelling methods to a variety of 
areas of medicine.  However, this also highlights the issue that currently identifying 
multiple studies utilising joint modelling methods in the same disease area for use in an AD-
MA could be difficult. 
2.3.1.4 Journal 
The studies identified in this review were published in a range of journals, with 8 journals 
providing more than one identified study (see Table 1).  This could indicate that currently 
there may not be a preferred journal to present joint modelling studies for medical or 
biostatistical datasets in.   
2.3.1.5 Reason for use of joint model 
Some studies identified in the review provided multiple reasons for using joint modelling 
methods.  All reasons given by a study were recorded (see Table 1), giving a total number 
of reported reasons greater than the number of identified studies.  The two most 
commonly reported reasons for joint model use were to investigate a link between the 
longitudinal and time-to-event outcomes, or to account for dropout in the study.  Of the 
identified studies, only 4 stated that they used joint models in order to include a time 
varying covariate measured with error in a time-to-event analysis. 
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 N (%) 
Source of joint modelling methods used  
Own methods developed 18 (27.7) 
Guo-Carlin 2004 [158] 13 (20.0) 
Rizopoulos 2010 (JM R package) [81] 10 (15.4) 
Henderson et al 2000 [30] 7 (10.8) 
Tsiatis and Davidian 2004 [92] 7 (10.8) 
Rizopoulos 2012 [52] 6 (9.2) 
Wulfsohn and Tsiatis 1997 [78] 6 (9.2) 
Diggle et al 2008 [161] 3 (4.6) 
Crowther et al 2013 [160] 2 (3.1) 
Proust-Lima et al 2009 [162] 2 (3.1) 
Rizopoulos 2011 [163] 2 (3.1) 
Approach  
Frequentist 45 (69.2) 
Bayesian 17 (26.2) 
Both 1 (1.5) 
Unclear 2 (3.1) 
Association structure  
Fixed and Random Effects 33 (50.8) 
Current Value of Fixed and Random Effects 24 (36.9) 
Current Slope (first derivative) of Fixed and Random Effects 3 (4.6) 
Current Value of Fixed and Random Effects and Current 
Slope (first derivative) of Fixed and Random Effects 
5 (7.7) 
Fixed and random effects without covariates 1 (1.5) 
Random Effects only 27 (41.5) 
Intercept only 5 (7.7) 
Random Effects with covariates 7 (10.8) 
Random Effects without covariates 9 (13.8) 
Random Effects unclear with or without covariates 6 (9.2) 
Latent Class 3 (4.6) 
Specialist association structure 4 (6.2) 
Unclear 4 (6.2) 
Table 2: Methods used in identified studies (Note for “Approach” only one value was recorded per included study 
giving total N=65, however for “Source of joint modelling methods used” and “Association structure” multiple 
values could be recorded per included study giving total N≥65) 
2.3.1.6 Source of methods used 
In total, 18 (27.7%) of the identified studies used modelling methods specific to their study.  
The remaining identified studies used methods described in other papers, of which a total 
of 38 unique papers were cited.  Ten of these papers were referenced by more than one of 
the identified studies (see Table 2).  Some of these commonly cited papers were software 
specific.  For example the papers of Rizopoulos 2010 [81] and 2012 [52] are R related, 
whilst Crowther et al 2013 [160] is Stata related.  Other commonly cited papers provided 
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overviews of the methodology and implementation of joint models, such as Proust-Lima et 
al [162] and Guo-Carlin [158]. 
2.3.1.7 Modelling approach 
For each included study it was recorded whether a Bayesian or Frequentist approach was 
undertaken (see Table 2).  Of the 65 identified studies, a total of 45 (69.2%) undertook a 
frequentist approach, 17 (26.2%) a Bayesian approach, 1 (1.5%) used both approaches (in 
separate model fits) and in 2 (3.1%) studies the approach was unclear (these were the two 
abstracts).  The larger proportion of studies taking frequentist approaches could be 
attributable to the fact that a larger number of papers and packages are based on 
frequentist methods.  In addition, the original joint modelling textbook [52] deals with 
frequentist methods. 
The type of model used for each of the longitudinal and the time-to-event sub-models was 
recorded.  Overall, there were 21 unique model types recorded for the longitudinal sub-
model, with unclear model type recorded for 1 study.  The most common type of 
longitudinal sub-model specified was the linear mixed effects model (35 studies, 53.8%), 
followed by mixed effect models that used splines (6 studies, 9.2%), or mixed models with 
an unspecified structure (5 studies, 7.7%).  Other modelling methods recorded included use 
of different mixed models dependent on latent class membership, non-linear models with 
or without splines, and models using change points. 
A wide range of models were reported for the time-to-event sub-models, with 4 studies 
recorded as unclear.  The most commonly reported time-to-event sub-model type was the 
Cox PH model (8 studies, 12.3%).  However, other methods were also reported across the 
studies, including models with a parametric baseline (e.g. a Weibull PH model which was 
reported by 5 studies, 7.7%), PH models with piecewise constant baseline hazard (4 studies, 
6.3%) or spline based baseline hazard (2 studies, 3.1%).  Additionally there was mention of 
fully parametric models, including the Weibull (5 studies, 7.7%), and the exponential model 
(1 study, 1.5%).  Additionally 1 study (1.5%) examined both Weibull and exponential 
models for the time-to-event sub-model. 
2.3.1.8 Association structure between longitudinal and time-to-event sub-models 
The association structure links the longitudinal and the time-to-event sub-models in a joint 
model.  A variety of options are currently available to researchers, each with slightly 
different interpretations.  The association structures reported in the studies identified by 
the review are reported in Table 2.  Some identified studies fitted more than one joint 
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model in their analyses, with varying association structures, allowing a total of more than 
65 (the number of identified studies) recorded association structures. 
An association structure that involves some function of both the fixed and random effects 
of the longitudinal sub-model as a “Fixed and Random effects” association structure, 
whereas those that only involve random effect but no fixed effects are designated 
“Random effects only”.  The association parameter for association structures that involve 
both fixed and random effects quantifies the effect of the recorded longitudinal value for 
an individual on their risk of an event.  Alternatively the association parameter for 
association structures that involve only random effects quantifies the effect of an 
individual’s deviation away from the population mean on their risk of an event.  As such 
these association structures have different interpretations.  A description of fixed and 
random effects association structures is given in Rizopoulos [52], whilst Henderson et al 
[30] discuss random effects only association structures. Additionally Rizopoulos and Ghosh 
[164] and Gould et al [75] discuss a range of association structures. 
In total 33 studies (50.8%) reported at least one joint model that used a fixed and random 
effect association structure.  A range of fixed and random effect association structures was 
reported (see Table 2).  The current value association structure (24 studies, 36.9%) refers to 
models that inserted the value of the longitudinal trajectory at the current time point for 
the individual into their time-to-event sub-model, and is used when the effect of the 
current value of the longitudinal trajectory on the risk of an event is of interest.  The 
current slope or first derivative of the fixed and random effects (3 studies, 4.6%) is when 
the first derivative of the longitudinal trajectory at the current time point is calculated.  This 
association structure is used if the effect of the rate of change of the value of the 
longitudinal trajectory of an individual on the risk of an event is of interest.  The current 
value and the current slope can be inserted into the model in tandem (5 studies, 7.7%), if 
both the effect of the current value and its current rate of change of the longitudinal 
trajectory are of interest.  Finally 1 study (1.5%) reported a fixed and random effect 
association structure that inserted the coefficients of the fixed and random effects but not 
their covariates into the time-to-event sub-model. 
Overall, 27 studies (41.5%) reported at least one joint model that used a random effects 
only association structure.  The random effects only association structures also fall into 
distinct groups.  Here, a random effects only association structure is defined to contain 
covariates if it is of a format such as (𝑏0 + 𝑏1𝑡) or 𝛼1𝑏0 + 𝛼2𝑏1 + 𝛼3(𝑏0 + 𝑏1𝑡) where the 
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𝛼 terms are association parameters, the 𝑏 terms are random effects, and 𝑡 represents a 
covariate such as time.  Alternatively, the random effects only association structure is 
defined to not contain covariates if no covariates are present in the association structure, 
and it takes a format similar to 𝛼(𝑏0 + 𝑏1), where the random effect 𝑏1 had a covariate 𝑡 in 
the longitudinal sub-model (see Henderson et al [30] for further examples).  Of the 
identified studies, 5 (7.7%) shared only a random intercept between the longitudinal and 
time-to-event sub-models.  A total of 7 studies (10.8%) shared random effects with 
covariates, whilst 9 (13.8%) state that they shared only random effects, but without 
covariates, and in 6 studies (9.2%) it was unclear if the random effects were shared with or 
without their covariates. 
Four studies (6.2%) were classed as falling into a specialist association structure group.  This 
group contained less common association structures, such as linking the time-to-event and 
longitudinal sub-models through a multivariate normal distribution.  Another notable group 
was the latent class structure [76, 162], used in at least one joint model in 3 studies (4.6%).  
Latent class joint models are a different joint model formulation to those that use the 
above association structures (which are termed shared parameter joint models).  This 
thesis focuses only on the shared parameter joint models.   
Finally there were 4 studies (6.2%), including the two studies only available as abstracts, for 
which the association structures were unclear. 
2.3.1.9 Software 
The software and packages used to fit joint models are listed in Table 3.  Packages or 
methods have been stated even if no studies identified in the review currently used them.   
The software and packages used to fit the joint model can often give information about the 
structure of the joint model.  For example the joineR package in R only allows random 
effects only association structures, whilst the JM package in R only allows fixed and random 
effect association structures.  However, the software used was not always stated by the 
identified studies, a potential issue for future MA when attempting to determine the 
structure of the joint model used. 
The most commonly mentioned software was R, although SAS and Stata were also 
commonly stated.   A possible reason for the preference of these software could be the 
availability of dedicated joint modelling packages in each. Some of the other software 
mentioned in the identified studies could require more coding input from the user (such as 
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C++ or Winbugs).  Such software was used less frequently in the identified studies than the 
software with dedicated joint modelling packages, again adding credibility to the 
suggestion that software was picked for ease of use. 
Several packages in R currently provide options for joint models.  The current preference 
indicated by this review is for the JM package [81], which implements frequentist joint 
models that insert both the fixed and random effects of the longitudinal trajectory into the 
time-to-event sub-model. This preference could be attributable to the wide range of 
options available in the package, including range of baseline hazards and random effects 
specifications. Additionally, Rizopoulos’ joint modelling textbook [52] provides detailed 
examples of implementation and interpretation of joint models using the package.  Also of 
note is that the majority of analyses using SAS (10 of the 13 studies that fitted models using 
SAS) used the PROC NLMIXED function, although dedicated joint modelling macros for the 
software are now available. 
In four studies (6.2%) more than one software was stated, it was unclear which 
implemented the joint model fit, and so these studies were grouped into a separate 
category. 
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Software N (%) 
R [79] 21 (32.3) 
R (JM) [81] 15 (23.1) 
R (JMBayes) [82] 0 (0) 
R (joineR) [80] 1 (1.5) 
R (frailtypack) [165] 0 (0) 
R (JM and joineR) [80, 81] 1 (1.5) 
R (unspecified package) 2 (3.1) 
R (own code developed, unclear if available) 2 (3.1) 
SAS [85] 13 (20.0) 
SAS (PROC NLMIXED)  10 (15.4) 
SAS (own code available) 1 (1.5) 
SAS (unspecified) 2 (3.1) 
JM Macro [166] 0 (0) 
JMFit Macro [167] 0 (0) 
Stata [84] 5 (7.7) 
Stata (stjm) [83] 2 (3.1) 
Stata (unspecified) 3 (4.6) 
WinBUGS [168] 4 (6.2) 
WinBUGS (own code available) 2 (3.1) 
WinBUGS (no available code) 1 (1.5) 
WinBUGS (unspecified) 1 (1.5) 
OpenBUGS (no available code) 1 (1.5) 
Fortran  3 (4.6) 
Fortran (code available, not study specific) 1 (1.5) 
Fortran (own code developed) 1 (1.5) 
Fortran (study states code available) 1 (1.5) 
NONMEM (unspecified) [169] 2 (3.1) 
C++ (own code unclear if available) [170] 1 (1.5) 
Mplus (unspecified) [171] 1 (1.5) 
More than one software listed/potentially used 4 (6.2) 
R (JM) or SAS (unspecified) 1 (1.5) 
R or SAS (unspecified) 1 (1.5) 
WinBUGS and R (Directed Acyclic Graph provided) 1 (1.5) 
WinBUGS and R (own code available) 1 (1.5) 
Unclear 10 (15.4) 
Table 3: Software used in joint model fits in included studies (note that studies could report multiple joint fits 
using different software, so total N≥65.  For Mclain [128] R code is stated as available in supplementary 
material, which was missing when accessed. Lawson [122] may have used WinBUGS but without seeking 
confirmation from the authors this was classed as unclear software.  For Fortran see http://www.fortran.com/, 
accessed 10th February 2016) 
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2.3.2 Did studies report sufficient information to contribute to AD-MA? 
The main aim of this review was to assess to what extent the current reporting practice of 
joint models for longitudinal and time-to-event medical or biostatistical data would allow 
AD-MA to be performed.  As noted earlier, the feasibility of meta-analyses are considered 
separately for three separate groups: for the longitudinal sub-model parameters, for the 
time-to-event sub-model parameters and for the association parameters.  For each of 
these groups, for an identified study to contain enough information for a MA to be 
possible, it must report a sample size and the relevant parameter estimate along with a 
precision estimate (which could be a standard error, or a confidence interval with a  
specified significance level).  A summary of the proportions of studies reporting this 
information is given in Table 4, along with, for each of the three groups of interest, the 









Coefficients reported (%) 45 (69.2) 46 (70.8) 51 (78.5) 
Precision reported (%) 44 (67.7) 45 (69.2) 50 (76.9) 
     Standard Errors reported (%) 22 (33.8) 23 (35.4) 25 (38.5) 
     Confidence Intervals (CI) reported (%) 30 (46.2) 32 (49.2) 36 (55.4) 
     Significance level reported (%) 57 (87.7) 57 (87.7) 57 (87.7) 
Sample size reported (%) 64 (98.5) 64 (98.5) 64 (98.5) 
MA possible given reported information (%)    
All identified studies (N=65) 44 (67.7) 45 (69.2) 50 (76.9) 
Studies using joint models to account for 
dropout (N=22) 
18 (81.8) 14 (63.6) 15 (68.2) 
Studies using joint models to include time 
varying covariate in time-to-event sub-model 
(N=4) 
2 (50.0) 3 (75.0) 3 (75.0) 
Table 4: Summary of information available to contribute to meta-analysis 
The sample size was reported in the majority (98.5%) of the identified studies, with median 
sample size of 514 (IQR 277 to 1054.5, range 46 to 3814). 
The association parameters were more commonly reported (51 studies (78.5%)) than those 
of the longitudinal and time-to-event sub-models (45 (69.2%) and 46 (70.8%) respectively).  
This could be attributable to the high proportion of identified studies that stated that joint 
models were used to investigate the link between longitudinal and time-to-event 
outcomes, which is quantified by the association parameter (Table 1).   
The number of studies where a precision measure was available was comparable to the 
number of studies that reported coefficients, across the three MA categories.  Whilst a MA 
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would be possible for each category if the parameter, the standard error and the sample 
size were reported, if the only available precision estimate was the confidence interval then 
the significance level was also required.  In the studies identified, the significance level was 
unclear for 8 (12.3%) studies, was 0.05 for 53 (81.5%) studies, 0.01 for 3 (4.6%) studies, 0.1 
for 1 (1.5%) study.   
Overall, a MA would be possible for the association parameter group in 50 (76.9%) studies, 
for the longitudinal parameter group in 44 (67.7%) studies, and for time-to-event 
parameter group in 45 (69.2%) studies.   
Ideally, enough information would be available to perform MA in all three groups of 
interest. Sufficient information to allow MA to be undertaken in all three groups was 
available from 38 (58.5%) of the studies.  MA were possible in only two groups in 6 studies 
(9.2%), and only 1 in 13 studies (20.0%).  In 8 studies (12.3%) there was insufficient 
information to complete any MA. 
As noted earlier, the reasons for joint model use could affect what information is reported.  
The feasibility of each of the MA groups was re-examined dependent on the reasons stated 
for joint model use (Table 1). 
For the 22 studies which stated “accounting for dropout” as a reason for joint model use, 
there was a higher percentage (81.8%) for which MA of longitudinal sub-model parameters 
was possible, compared to for all studies (67.7%).  However, the percentage of MA that 
were possible for the time-to-event coefficients or association parameters was smaller.  
This could be explained by studies using joint models to account for dropout being mainly 
interested in the parameters from the longitudinal sub-model.  
Only 4 studies stated inclusion of a time varying covariate in a time-to-event model as one 
of their reasons for using joint models.  There was a slight indication that the longitudinal 
coefficients for studies using joint models to include time varying covariates in time-to-
event models are worse reported than for all identified studies, possibly because the 
longitudinal component of the joint model is of interest as a covariate rather than an 
outcome in these cases, however more information is needed before this relationship can 
be fully investigated. 
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2.4 Discussion 
Joint models for longitudinal and time-to-event data are often stated as beneficial 
compared to separate longitudinal or time-to-event analyses, as they can reduce bias and 
increase efficiency in model estimation (see Ibrahim et al [87] for example).  Additionally, 
Powney et al [172] discuss a study where joint models showed a significant difference 
between treatment groups that was not identified by separate analyses [173, 174]. These 
benefits of joint models reinforce the suggestion that in certain circumstances MA of joint 
models may be more appropriate than MA of separate models. The review conducted in 
this chapter assessed the current use of joint modelling methods in single study analyses, 
with a view to their use in future meta-analyses.   
2.4.1 Recommendations for reporting of future single study joint analyses 
This review highlighted that single study joint analyses are currently implemented in a 
range of clinical areas, using a variety of modelling structures, implemented with an 
assortment of software.  Whilst reporting of single study joint analyses was good, steps 
could be taken to ensure the information necessary to conduct a meta-analysis is included 
in publications.  These recommendations are discussed below, and summarised in Figure 3. 
The search strategy aimed to identify all studies that implemented joint models to 
influence future healthcare, and it is believed that the studies identified are representative 
of the current literature.  However, if studies did not state the key search terms used in this 
review (see Appendix 1 for search strategies) in text accessible to the search, the study may 
not have been identified.  For example, from Powney et al [172] it is known that the 
MAGNETIC trial [173, 174] utilised joint models, however this is not mentioned in the 
abstract.  When joint models are not used as part of the primary analyses, their use may be 
unclear from the abstract or keywords.  Therefore this research suggests that statement of 
statistical methods should be made in text accessible to search engines (see Figure 3). 
With the increasing use of joint models in the literature, ensuring they are well reported is 
vital so that the analyses can be interpreted fully and that the published data can be used 
in future evidence synthesis.  For the scenario of AD-MA of the results of joint models 
published in the literature, it was determined that it was possible to perform MA for a high 
proportion of, but not all, studies.  For future practice it is recommended that regardless of 
the reason for joint model use, full model covariates with precision estimates be reported 
either in the study report or supplementary materials (Figure 3) not only to aid 
interpretation within the study itself, but to ensure that future MA would be possible.  
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Furthermore, it is important that model structure (both sub-models and the association 
structures that link them) are clearly reported (Figure 3).  In some studies identified in this 
review, model formulae were not reported (a particular issue for association parameters).  
A wide range of association structures are available to researchers.  Due to the different 
interpretation of each, it may not make sense to pool association parameters from radically 
different association structures (see Section 3.2.4).  Without clear statement of the model 
structure it may be difficult to reliably conduct future MA.  It would be beneficial if studies 
applying joint models included statement of the model structure as standard to give clarity 
to the methods used. 
Additionally, details of the demographic of the population should be reported, as results 
could differ between different study populations.  For example, a treatment may have a 
different effect in an older compared to a younger population.  It is generally accepted in 
meta-analyses that if populations are too dissimilar, information from them should not be 
pooled.  If populations are comparable, but differ in certain demographic characteristics 
that could affect the analysis (e.g. treatment effect differing across age groups), sub-group 
analyses can be performed in AD-MA (grouping studies included in the meta-analysis, e.g. 
by a categorical variable, and pooling effects within sub-groups).  Whilst this may show 
differing treatment effect between different sub-populations, sub-grouping requires 
simplifications of data, such as categorisation of continuous treatment effect modifiers 
(such as age ≤50, age >50).  As such, if it is thought that treatment is affected in a complex 
way by covariates, or that detail more than that supplied by basic sub-group analyses in an 
AD-MA is needed, IPD may have to be sought, and analyses conducted that include the 
demographic covariates that could affect treatment (see Section 3.4.3). This is not an issue 
specific to the meta-analysis of joint data, and so has not been included in our 
recommendations for reporting of joint models, as it is good practice for any analysis of 
data to give description of the demographics of the study population. 
In analyses of time-to-event data, the baseline hazard is not commonly reported.  However 
it can communicate useful information about the progression of an illness [175].  
Additionally, comparison of baseline hazards between study populations can indicate 
potential heterogeneity in the data, for example differences in populations may cause the 
disease to progress at different rates. Baseline hazards that differ significantly between 
studies (such as one study reporting a constant baseline hazard, and another reporting 
non-linear, non-constant baseline hazard) should motivate the researcher to examine 
whether it is appropriate to pool results from the two studies (this can be assessed ideally 
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through provided estimates of the baseline hazard, or if this is not available a comparison 
of chosen modelling method for the baseline hazard could be made). As such, it is 
beneficial if the baseline hazard estimates are reported for a joint modelling analysis, so 
that the shape of the baseline hazard can be viewed and compared between studies.  
However, as baseline hazard is often viewed as a nuisance parameter, provided it has been 
adequately modelled, non-reporting of baseline hazard estimates would not exempt a 
study from contributing to a meta-analysis (resulting in reporting of baseline hazard not 
being included in recommendations for reporting of joint models, which aim to describe 
the minimum information that should be reported to a joint model to be able to contribute 
to AD-MA).  Analyses utilising different (but appropriate) methods to model the baseline 
hazard can be pooled.  If methods to model baseline hazards differ between studies, and 
estimates of baseline hazards are not supplied, sensitivity analyses can be undertaken to 
assess whether MA conclusions differ dependent on the method used to model the 
baseline hazard.  
As it is useful if baseline hazard estimates are reported, the code produced during this 
research (which can fit joint models to both single study and multi-study data) returns 
estimates of the baseline hazard (see Section 4.3.2.2). A future extension to the package 
which may be beneficial are functions to plot the baseline hazard, and also alternatives to 
modelling the baseline hazard including spline approaches. 
Also, it is important especially in joint modelling to state the software, packages or 
functions used to fit the joint models. In any investigation, statement of the software used 
to conduct the analysis is vital to ensure reproducibility and transparency of the research.  
However. the software used could indicate the joint model structure, as well as methods 
used to obtain the parameter estimations (Figure 3), as, for example, some packages only 
support certain types of association structures.  Consequently, the software used to fit the 
model can also indirectly inform researchers as to the joint modelling methods used.  
Consistently, the proportion of studies where association parameter MA was possible was 
higher than the proportion where MA was possible for longitudinal or time-to-event 
parameters.  The association information may have been more commonly reported than 
the longitudinal or time-to-event information because the association parameters in shared 
random effect models quantify the link between the sub-models.  It can be expected 
therefore that studies aiming to quantify the link between the sub-models report the 
association information more prominently than other model parameters.  
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Figure 3: Recommendations for future reporting of joint models 
2.4.2 Concluding Remarks 
Overall, this chapter has reported the results of a review of current reporting of joint 
models in the literature.  It has highlighted the importance of fully reporting the 
coefficients and precision estimates of applied joint models in publications, as well as a 
clear statement of the structure of the joint model used and the software employed.  
Whilst the review identified a limited number of studies that reported sufficient 
information to contribute to a meta-analysis, there was great variation in the disease area 
and joint modelling structures.  It may not be currently possible to identify sufficient 
studies in an area to conduct a published data AD-MA of joint model fits. Nevertheless this 
review has indicated that joint model publications are increasing in number, and the 
increasing availability and flexibility of joint modelling software is likely to facilitate their 
application further. 
This chapter prompted many point of discussion for the two-stage IPD-MA of joint data.  
The methods of two-stage IPD-MA are closely linked to those of AD-MA: the second stage 
in such a two-stage process is the same as an AD-MA.  Points of interest included the 
suitability of pooling association parameters from different joint models, the interpretation 
of parameters from different model structures and the process of selecting the methods to 
use in a joint modelling analysis. These and other points are discussed in Section 3.2. 
In the future, this investigation recommends that reporting standards of joint model fits 
should be maintained and improved on, following the recommendations given here and in 
Sudell et al 2016 [93], in order that published applied joint models can contribute to future 
AD-MA. 
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Chapter 3 : Methods for Meta-Analysis of Joint 
Longitudinal and Time-to-Event Data  
In this chapter, I propose a range of methods to meta-analyse joint data generated by 
multiple studies. The chapter commences with a description of the structure of the data 
assumed available. Two-stage methods for the meta-analysis of multi-study joint data are 
then presented, and discussed. One-stage methods are then described, including a range of 
model groups each of which account for between study heterogeneity in different ways. 
The model groups are discussed and evaluated in turn. The chapter concludes with a 
discussion of meta-analytic joint modelling methodology.  
3.1 Description of assumed data type 
Throughout this chapter it is assumed that Individual Patient or Participant Data (IPD) is 
available. The methods described assume constant treatment effect over time and that 
time is reported as a continuous measure, measured from the same time point (e.g. time 
from randomisation into study) for each individual. Exact times at which longitudinal 
measurements are taken and the number of recorded measurements can differ between 
individuals. Only univariate joint models (those involving a single time-to-event and a single 
longitudinal outcome) are considered. 
3.1.1 General notation 
The multi-study joint longitudinal and time-to-event IPD is considered to have three nested 
levels: longitudinal measurements at level 1, nested within individuals at level 2, nested 
within studies at level 3. 
Study membership is identified by 𝑘 = 1 … 𝐾 where 𝐾 represents the total number of 
studies in the meta-dataset.  
Individuals within each study are represented by 𝑖 = 1 … 𝑛𝑘 where 𝑛𝑘 denotes the total 
number of individuals in study 𝑘.  
The longitudinal time points are identified using 𝑗 = 1 … 𝑚𝑘𝑖 where 𝑚𝑘𝑖 represents the 
total number of longitudinal measurements recorded for individual 𝑖 in study 𝑘. 
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The longitudinal outcome for individual 𝑖 in study 𝑘 at the 𝑗th time point is represented by 
𝑌𝑘𝑖𝑗, whilst the survival time for individual 𝑖 in study 𝑘 is denoted by 𝑇𝑆𝑘𝑖 (where 𝑇𝑆𝑘𝑖 is the 
minimum of the individual’s event time 𝑇𝐸𝑘𝑖 and their censoring time 𝑇𝐶𝑘𝑖). 
Fixed effects are represented using 𝜷 terms, with the first element of the subscript 
identifying the sub-model they belong to (such that 𝜷𝟏 = 𝛽11, 𝛽12, 𝛽13, … are the 
longitudinal fixed effects, and 𝜷𝟐 = 𝛽21, 𝛽22, 𝛽23, … are the time-to-event fixed effects). 
Random effects are represented by 𝒃, with the level at which the random effects act 
identifiable through the bracketed superscript, such that individual level (level 2) random 
effects are represented by 𝒃𝒌𝒊
(𝟐)
 and study level (level 3) random effects by 𝒃𝒌
(𝟑)
.  
Design matrices (matrices containing the covariates included in the model) are represented 
by 𝑿 for the fixed effects and 𝒁 for the random. As with the fixed effect coefficients, 𝑿𝟏 
represents the longitudinal fixed effects design matrix, and 𝑿𝟐 represents the time-to-
event fixed effects design matrix. Additionally, 𝒁𝒌𝒊
(𝟐) represents the design matrix for the 
individual level (level 2) random effects, and 𝒁𝒌
(𝟑) represents the design matrix for the study 
level (level 3) random effects. 
Association parameters are represented by 𝜶, with association parameters linked to 
individual level (level 2) random effects labelled 𝛼(2), and those linked to study level (level 
3) random effects as 𝛼(3). 
Finally, error terms are represented by . Additional notation will be defined as required. A 
table of notation used in the thesis is provided for reference at the start of the document 
on pages ix-x. 
3.2 Methods for Two-stage IPD Meta-Analyses 
In this section, methods for the two-stage meta-analysis of joint longitudinal and time-to-
event IPD are discussed. The second stage of the methods could be used to perform an AD-
MA of joint data, for example of published study level results, given that sufficient 
information was available to ensure that only parameters with comparable interpretations 
were pooled. 
This section describes the process of a two-stage MA, starting with preliminary steps to 
assess the structure of the joint model, followed by a description of the first and second 
stages of the analysis. A set of guidelines is then presented, designed to ensure that 
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researchers conducting two-stage IPD-MA only pool parameters with comparable 
interpretations. The section concludes with a discussion of the two-stage methods. 
The methodology covered in this section has been published as part of Sudell et al [176], 
including concise guidelines for the stages of a two-stage MA of joint data (presented here 
in detail).  
3.2.1 Preliminaries  
Before modelling the joint data available within each study, the most appropriate 
modelling structure must be selected. This includes choice of longitudinal and time-to-
event sub-models, association structure, and a consideration as to the fixed and random 
effects to include. A variety of joint models are currently employed in the literature in 
analyses of medical data [93], see Chapter 2. Many choices exist for the longitudinal sub-
model (including linear mixed effects models, or use of splines), or for the time-to-event 
sub-model (including PH or AFT models). To appropriately model the data, the most 
suitable family of sub-models for each of the longitudinal and time-to-event outcome must 
be selected. A useful method in this assessment is to produce plots of the study specific 
data. 
Firstly, plots of the individual specific longitudinal trajectories panelled by event type 
(censored or experienced the event) should be generated. The time (displayed on the x-axis 
of the plot) can be the recorded longitudinal time-point, or can be adjusted by subtracting 
the survival time of each individual from their measurement times. This approach highlights 
changes in the longitudinal trajectories as time approaches the survival time. If the 
longitudinal trajectories show evidence of change (e.g. change in slope) immediately before 
survival time, there is evidence of an association or relationship between the longitudinal 
outcome and the time-to-event outcome.  
Examination of the trajectories could indicate an appropriate random effects structure. For 
example, if variation in the trajectory intercept is apparent between individuals, an 
individual specific random intercept could be included in the study specific model. If the 
trend over time differs between individuals, an individual specific random time term may 
be beneficial. Through examination of these plots, the most appropriate sub-model family 
(random effects specification, linear or non-linear model) for the longitudinal outcome can 
be selected. 
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If the sample size within a study is large, inclusion of a “smoother” over the longitudinal 
trajectories can aid the assessment of the shape of trajectories (e.g. linear, non-linear, 
changes in trajectory shape before survival time). Another option is to colour each 
individual’s trajectory separately, allowing different individual’s longitudinal measurements 
over time to be distinguished in the plot containing all individuals within a study.  
Alternatively, samples of individuals from each study can be taken, and individual 
trajectories plotted side by side for each individual in trellis plots.  This allows the 
behaviour of individual’s longitudinal trajectories to be clearly assessed. 
If the measurement error in the longitudinal outcome is high, significant variability may be 
seen within the longitudinal measurements, even from the same individual.  In this case, 
rather than producing trajectory plots that plot trajectory lines that join the longitudinal 
measurements recorded at each time point for the individual, a smoother can be produced 
for the measurements from each individual.  This method would plot the general trend for 
an individual, allowing variation in measurements caused by larger measurement errors 
around this general trend. 
Secondly the time-to-event data should be examined, to enable the family of time-to-event 
sub-models to be selected. This can be achieved by plotting the Kaplan-Meier [177] curves 
for each study. Examination of these curves, stratified by covariates of interest (for 
example treatment assignment), would help the most appropriate sub-model family for the 
time-to-event data to be determined (for example a PH or AFT model).   
Additionally a choice for the modelling of the baseline hazard should be made.  Options 
include flexible methods (including unspecified, piecewise constant or spline based) or 
parametric (including exponential or Weibull). As the baseline hazard itself is not of 
interest, just ensuring that it has been modelled appropriately, choice of methods can 
differ between studies.  However, serious discrepancies between studies (such as one 
study having a constant risk of event over time, and another having a non-linear non-
constant baseline hazard) should be motivation for further examination of the studies, to 
ensure that the study populations are comparable, and the results from the two studies 
appropriate to pool. 
Finally, the association structure linking the sub-models must be selected. This is often 
chosen based on the aims of the investigation, and the clinical background of the data. 
Each association structure has a different interpretation [52, 75], and pooling parameters 
from different types of structure might be inappropriate (Section 3.2.4). Care should be 
 60   
 
taken to select an association structure that has a meaningful interpretation to the 
investigation. 
As the longitudinal and time-to-event outcomes are the same across the studies, the 
general behaviour of each outcome (e.g. nonlinear longitudinal trajectories), and so the 
most appropriate family of sub-models for each of the longitudinal and the time-to-event 
outcomes is likely to be similar across studies. If this is not the case, the reason for such 
disparity between studies in behaviour of outcomes should be investigated. 
If there is uncertainty about the most appropriate model specification to employ in a joint 
modelling analysis, for example if there is uncertainty what random effects structure to 
use, multiple joint models representing differing potential specifications can be fitted. 
Models including different parameters can be compared, for example information criteria 
could be used [52, 77] such as Akaike’s Information Criterion (AIC) [178], or the Bayesian 
Information Criterion (BIC) [179]. For these values, the smaller values of the AIC/BIC 
identify the better model.  Alternatively, procedures such as forward or backward variable 
selection can be employed.  In this way, the different potential model specifications 
suggested by the study specific plots can be compared, and an appropriate model 
specification selected. In practice, the choice of sub-models and association structures may 
be somewhat dictated by the availability of software to fit the required model, unless the 
researcher is willing to write their own code. For example, the two main frequentist 
univariate joint modelling packages in R (joineR [80] and JM [81]) permit different types 
of models. The joineR package allows random effects only association structures, with a 
Cox PH time-to-event sub-model with unspecified baseline hazard, and a linear mixed 
effects longitudinal sub-model. The JM package allows association structures involving both 
the fixed and random effects of the longitudinal sub-model (namely the current value or 
current slope structures). A variety of baseline hazards for the time-to-event sub-model are 
permitted, and either a parametric, a PH or an AFT model can be selected. The longitudinal 
sub-model can be a linear mixed effects model or can also contain splines. The 
joineRmeta package (discussed further in Chapter 4) extends the joineR package to the 
multi-study data case, however is still restricted to the same association structures and 
model types as the joineR package. Other modelling options also exist in other software, 
for example the stjm [83] function in Stata. Consequently, researchers are faced with a 
choice between one of the modelling options currently available in pre-existing packages, 
or to invest time in writing code specifically for their project. 
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3.2.2 Stage 1 – Modelling of joint data within studies 
In the first stage of a two-stage IPD-MA of joint data, joint models would be fitted to the 
IPD within each study. Studies identified in the meta-analysis should be grouped so that the 
chosen model structure within each group (sub-model types, association structure, and 
specification of any terms fixed or random that are involved in the association structure) 
are identical. Models of the same structure should then be fitted to each of the study 
specific datasets within each group. The recommendation of grouping studies, and fitting 
identical models within each group, is discussed in Section 3.2.4. 
During this investigation of the two-stage MA of joint data, only joint models of the 
following format are considered. The longitudinal sub-model is a linear mixed effect model 
of specification: 




+ 𝑘𝑖𝑗  (13) 
In equation (13), the longitudinal outcome is represented by 𝑌𝑘𝑖𝑗, and the design matrix for 
the fixed effects (containing the covariate values for individual 𝑖 in study 𝑘 at time point 𝑗) 
is represented by 𝐗𝟏𝒌𝒊𝒋 with corresponding population coefficients 𝜷1𝑘, which are 
estimated for each separate study 𝑘. The individual level random effects are represented 
by 𝒃𝑘𝑖
(2)
, with corresponding design matrix 𝒁𝒌𝒊𝒋
(𝟐)
. The random effects are assumed to follow 
a zero mean multivariate normal distribution 𝑁(0, 𝑫𝒌). The error term is represented by  
𝑘𝑖𝑗, and is assumed to follow a 𝑁(0, 𝜎𝑘
2) distribution, with error terms at each time point 
identically but independently distributed (IID). Within and across studies, the error terms 
and the random effects are considered independent of each other. 
The time-to-event sub-model of the joint model assumes the specification in equation (14). 
 𝜆𝑘𝑖(𝑡)  =  𝜆0(𝑡)exp (𝑿𝟐𝒌𝒊𝜷2𝑘 + 𝑊2𝑘𝑖(𝑡))   (14) 
In equation (14), 𝜆0(𝑡) represents an unspecified baseline hazard, 𝑿𝟐𝒌𝒊 represents fixed 
time stationary population covariates with associated coefficients 𝜷2𝑘, which again are 
estimated for each separate study. 𝑊2𝑘𝑖(t) is the association structure linking the time-to-
event and longitudinal sub-models. A shared zero mean random effects proportional 
association structure is assumed, specifically,   
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 are the zero mean random effects of the longitudinal sub-model, 
and 𝛼𝑘
(2)
 quantifies the association between the longitudinal and the time-to-event 
outcomes. This association parameter can be interpreted as the effect of the individual 
deviation from the population mean trajectory value at a given time point on the 
individual’s risk of an event. 
3.2.3 Stage 2 – Pooling of results between studies 
In the second stage, estimates of parameters of interest are extracted from the study 
specific model fits and pooled using standard meta-analytic techniques. During this thesis, 
both fixed and random effect MA are conducted and the results compared. The Inverse 
Variance approach is employed in both cases (using the DerSimonian and Laird [10] 
approach for random MA, see Whitehead [2] for a MA overview).  
A fixed effect MA assumes that each study is estimating a common underlying effect 
denoted by 𝜃. Any variability between studies is attributed to sampling variability. Study 











In equation (16), 𝜃𝑘 is the effect estimate from the 𝑘th study, 𝜃 is the overall pooled effect 
estimate, and 𝑤𝑘 is the weight for study 𝑘. For the inverse variance method this specified 
as 𝑤𝑘 = 1 𝑣𝑘⁄  where 𝑣𝑘 = var(𝜃𝑘). 
A random effects MA assumes that the observed study specific effect estimates are a 
random sample from a distribution of possible effect estimates, and pooled results 
estimate the mean effect and its variance for the population. If the between study 
variability in effect estimates is represented by 𝜏2, then the variance of the effect estimate 
is var(𝜃𝑘) = 𝑣𝑘 + 𝜏
2. Results are then pooled using equation (16), but with the weight 
term now equal to 𝑤𝑘 = 1 (𝑣𝑘 + 𝜏
2)⁄ . 
As mentioned, parameters should only be pooled within groups, not across groups.  This 
ensures that the parameters have comparable interpretations, as joint models fitted to 
studies within the same group employ the same model structure (sub-model types, 
association structure, and specification of any terms fixed or random that are involved in 
the association structure).  As stated, the methodology employed in this chapter assumes 
availability of IPD, allowing similar models (provided they are appropriate) to be fitted to 
the data from each study.  However, the second stage of this process can be applied to AD-
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MA.  In this case, it may be anticipated (given the variability in joint model structure 
observed in Chapter 2) that there are not many analyses that fall within the same group.  If 
this is the case, in order to ensure comparable interpretation of pooled parameters, it is 
recommended to seek IPD from each study included in the meta-analysis. 
3.2.4 Recommendations for a two-stage IPD-MA of joint data 
Whilst this thesis is concerned only with joint models that employ an association structure 
that shares zero mean random effects with a common association parameter, a variety of 
random effect and association specifications exist for joint models [75]. However, 
dependent on the model specified, association parameters can have very different 
interpretations.  
For example, consider a joint model that employs an association structure that shares only 
zero mean random effects between the longitudinal and time-to-event sub-models with a 






quantifies how the deviation of individual 𝑖 in study 𝑘 from the population mean 
longitudinal trajectory at a given time affects their risk of an event [75]. An example could 
be a case where individuals with higher blood pressure than the population average at a 
given time are at higher risk of a cardiac event.  
Alternatively, a joint model that employs an association structure involving the true 
complete longitudinal trajectory with a common association parameter (such that 




)) has a different interpretation. Here, 𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡 
quantifies how the value of the longitudinal outcome for individual 𝑖 in study 𝑘 at a given 
time point affects their risk of an event [52, 75]. An example could be where the risk of a 
cardiac event for an individual increases as their recorded blood pressure increases.  
The above two association parameters are modelling different types of links between the 
sub-models. Pooling the two association parameters described in the example above would 
assume that the risk of an event at a given time point due to the difference in the 
individual’s recorded longitudinal value and the population mean, and the risk of an event 
due to individual’s recorded longitudinal value, are the same.  
The size of the difference in association parameter estimates between the current value 
and random effects only examples mentioned above (assuming the same random effects 
structure) depends on the scale of the longitudinal measurements, and their variability 
between individuals.  Longitudinal outcomes that take large values on a scale (e.g. values of 
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several hundred) but show little variability between individuals, could result in the 
expression 𝐗𝒌𝒊𝜷𝟏𝒌 + 𝒁𝒌𝒊𝒋
(𝟐)𝒃𝒌𝒊
(𝟐)
 having larger values, whilst 𝒁𝒌𝒊𝒋
(𝟐)𝒃𝒌𝒊
(𝟐)
 taking smaller values. 
Alternatively, longitudinal outcomes that take smaller values on a scale, but display clear 








 for a given individual.  The significance of the association parameter informs the 
researcher whether the association structure represents an existing relationship between 
the longitudinal and time-to-event outcomes.  The effect of the association structure on 
risk of an event is found by the product of the association parameter and the sum of the 





large), then the association parameter estimate might be small in magnitude, but 
significant.  To summarise, the interpretation of the association structure is separated into 
whether the association structure represents a true relationship between the longitudinal 
and time-to-even outcomes (as judged by the significance of the association parameter) 
and the effect the association parameter has on risk of an event (as judged by the value of 
𝑊2𝑘𝑖(𝑡), the product of the association parameter and the sum of the shared terms). 
If the specification of the longitudinal sub-model differs between joint models fitted, the 
terms linking the sub-models in the association structure may differ, again leading to 
association parameters with differing interpretations. For example, consider two joint 
models each linking the sub-models using 𝑊2𝑘𝑖(𝑡) = 𝛼𝑘
(2) (𝒁𝒌𝒊
(𝟐)𝒃𝒌𝒊
(𝟐)), one with random 






) and the other 




(2)𝑡𝑖𝑚𝑒𝑘𝑖). In the first case, 
the 𝛼𝑘
(2) parameter quantifies the difference in risk of an event due to the difference 
between the population and individual specific intercept of the longitudinal trajectory. In 
the second, 𝛼𝑘
(2) quantifies the risk of an event due to differences between the individual 
and the population both in the intercept and the slope of the longitudinal trajectory.  
As such, differences in interpretation of association parameters can stem from the type of 
association structure used, or differences in terms included in the joint model. Pooling 
association parameters with different interpretations assumes that these differences are 
unimportant, potentially a strong assumption. To avoid this, it is recommended to pool 
association parameters from joint models with identical association structures (family of 
association structure, and the terms it involves). If differing joint models are appropriate 
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between studies identified in a meta-analysis, studies could be sub-grouped, with joint 
models of identical specification within but not across sub-groups. This is reiterated in the 
recommendations for two-stage meta-analysis of joint data, see Sections 3.2.4.2-3.2.4.3. 
In addition, a variety of options for the longitudinal and time-to-event sub-models have 
been employed in the literature [93]. Pooling fixed effect coefficients from different types 
of sub-model again assumes their interpretation is comparable, which may not always be 
the case (such as for coefficients from PH models and AFT models). Again, care should be 
taken when employing joint models in a two-stage analysis to only pool parameters with 
comparable interpretations. The recommendation of sub-grouping studies such that the 
specification of joint models applied to each study within each group ensures that only 
parameters with comparable interpretations are pooled. 
To ensure only appropriate pooling of parameters from joint model fits, the following 
recommendations are proposed for researchers to consider when conducting a two-stage 
MA of joint longitudinal and time-to-event IPD. 
3.2.4.1 Preliminary Work 
 For each study in the meta-analysis produce the following plots: 
o Longitudinal trajectories plots panelled by event type such that the 
behaviour of trajectories of those experiencing an event and those 
censored is clearly visible 
o Kaplan Meier plots, with curves stratified by covariates of interest for 
example treatment assignment.  
 Using these plots:  
o Assess if an association might be present between the longitudinal and 
time-to-event outcomes (indicated for example by differences in the 
longitudinal trajectories for those experiencing an event and those 
censored). 
o For each study, identify an appropriate longitudinal sub-model family. 
Additionally consider what types of random effects structures (random 
intercept, random slope (time) term etc.) are appropriate 
o For each study, identify an appropriate time-to-event sub-model family 
 Determine the type of association structure that best suits the aims of the analysis 
e.g. if clinically the amount of deviation between an individual’s and the population 
average longitudinal trajectory at a given time is thought to affect the risk of an 
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event, then a zero mean random effects only sharing structure should be 
employed. Alternatively, if there is clinical evidence to suggest that the rate of 
change of the longitudinal trajectory affects the risk of an event, then the first 
derivative of the longitudinal trajectory should be shared between sub-models.  
3.2.4.2 First Stage 
 Group the studies identified in the meta-analysis so that the chosen model 
structure within each group (type of longitudinal sub-model, type of time-to-event 
sub-model, association structure, random effect specification, and if both fixed and 
random effects are shared between sub-models specification of fixed effects in the 
longitudinal sub-model) is identical. 
 Within each sub-group, fit identical joint models to data from each study. Model 
structures can differ between groups. 
3.2.4.3 Second Stage 
 For each study 𝑘 extract parameters of interest (subsets of the fixed effects from 
the longitudinal sub-model 𝜷𝟏𝒌, of the fixed effects from the time-to-event sub-
model 𝜷𝟐𝒌 and the association parameter(s) 𝛼𝑘
(2)) from the model fit, along with 
estimates of their precisions, and the sample size of the study.  
 Pool estimates within each group using the inverse variance methods described in 
Section 3.2.3. Perform MA separately for each longitudinal coefficient, time-to-
event coefficient and association parameter of interest. 
 Results between groups with different joint model specifications can be 
qualitatively compared in discussion of the meta-analysis. 
3.3 Methods for One-stage IPD Meta-Analyses 
In this section, methods for the one-stage meta-analysis of joint longitudinal and time-to-
event IPD are discussed. The clustering of data within studies must be accounted for in 
some way in the model. A variety of methods exist to accomplish this, including fixed 
interaction terms between covariates of interest and the study membership variable, study 
level random effects, or baseline hazard stratified by study.  
Whilst joint models accounting for clustering using fixed interaction terms with study 
membership variables were possible to implement at the start of this PhD using currently 
available software, no general software was available that designed specifically to model 
multi-study joint data. Some papers fitted multi-centre joint models (e.g. Brombin et al 
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[90]), however they did not provide generalisable code. As such, as part of this thesis, I 
aimed to develop an R package joineRmeta to allow joint models to be fitted to multi-
study joint data accounting for clustering using either fixed interaction terms, using study 
level random effects, stratifying baseline hazard or by using a combination of these 
methods. Although not the focus of this thesis, it is possible to model multi-centre joint 
data using this software. Descriptions of the software produced are available in Chapter 4, 
while theory behind the model fitting performed by the package is discussed in Chapter 5. 
3.3.1 Preliminaries 
The notation already defined in this chapter is adopted, but extended to account for study 
level as well as individual level random effects.  
As the models investigated in this section have exact specifications of included fixed and 
random effects, individual covariates are identified by name rather than labelling 𝑥1, 𝑥2, … . 
Covariates additional to those mentioned can be included in the models fitted by the 
joineRmeta package.  
During the discussion of one-stage methods, again the investigation is restricted to 
proportional random effects only association structures. However, some of the models 
considered allow random effects both at the individual and at the study level, with 
separate association parameters for each level of random effects. Separate association 
parameters are permitted for each level of random effects as the level of association 
between the longitudinal and the time-to-event outcomes may differ between the 
individual and the study level.  
Consider a case where higher values of the longitudinal outcome results in increased risk of 
an event. At an individual level, an individual who reports longitudinal outcome larger than 
the study population average at a given time point would have an increased risk of an 
event. But at a study level, a study that has a higher study level average longitudinal 
outcome at a given time point than other studies, will contain a population of individuals at 
higher risk of an event. The differences between study populations may be much greater 
than the differences between individuals within a study. As such, distinguishing between 
association based on individual level and on study level random effects was appropriate. 
As a real example, imagine a joint model with individual level random intercept and slope, 
and study level random intercept and treatment effect applied to data with longitudinally 
measured blood pressure and time until death. If the association parameters for both levels 
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are positive and significant, then study populations  with average study blood pressure 
higher than the overall population average at a given time are at higher risk of death. In 
addition, individuals within a study with recorded blood pressure higher than the study 
mean at a given time are at higher risk of death.  
In some cases, it may not be appropriate to separate the association parameter in this way. 
A future area of research beyond this thesis is to extend the software developed to allow 
for a range of association structures, such as those discussed in Gould et al [75]. Future 
research aims are discussed fully in Chapter 8.  
3.3.2 Methods to account for between study heterogeneity 
As noted earlier, the clustering of data within studies must be accounted for in the model. 
If differences exist between the data stemming from different studies, termed between 
study heterogeneity, this can be estimated or accounted for in the model. Various options 
exist, including fixed interaction terms between covariates thought to have differing effects 
between studies and study membership, study level random effects, or (in the case of the 
time-to-event sub-model) stratification of the baseline hazard by study. As discussed in 
Chapter 1, a considerable amount of work exists for separate IPD one-stage meta-analysis 
of longitudinal outcomes [31] and time-to-event outcomes [56, 180]. Drawing on the 
existing literature for these two areas, during this section a selection of potential modelling 
structures for one-stage meta-analytic models for joint longitudinal and time-to-event data 
containing a single longitudinal and a single time-to-event outcome are explored.  
Six main groups of models are examined, detailed in Table 5. The models presented are 
restricted to involve only longitudinal time, treatment assignment and study membership 
as covariates of interest.  Each of the 6 groups accounts for between study heterogeneity in 
a different way. Comparisons of the different methods will be made, and their advantages 
and disadvantages discussed.  
If variables other than study membership, treatment assignment and longitudinal time are 
of interest to the investigation, they could also be included in the model in various formats 
(i.e. with interaction terms or with study level random effects), making the one-stage multi-
study joint models a flexible method to investigate the effect of covariates on between 
study heterogeneity. However, during this thesis only the effect of treatment assignment 
on between study heterogeneity is examined. Software to enable the flexible modelling of 
multi-study joint data, allowing flexibility for future investigations, is discussed in Chapter 4. 
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The choice of what model group to use in a one-stage meta-analysis should be made on a 
case by case basis.  For example, if it is important for the investigation to produce study 
specific estimates of the treatment effect for both the longitudinal and the time-to-event 
outcomes, then a model from group 1, which estimates interaction terms between the 
study membership and the treatment assignment covariates, should be chosen. However, 
if the meta-analysis contains a large number of studies, a model that accounts for between 
study heterogeneity using study level random effects (e.g. model groups 2, 3, or 5), may be 
more appropriate. Model groups are discussed and contrasted in the following sections. 
As with the methods for two-stage analysis of multi-study joint data (Section 3.2), before 
fitting joint models to the data, it is recommended to produce study specific plots of the 
data.  These plots have been described and discussed in Sections 3.2.1 and 3.2.4.1, and 
include study specific Kaplan-Meier plots and study specific longitudinal trajectory plots 
(plotting longitudinal outcome both against measurement times, and against measurement 
times minus each individual’s survival time). Using these plots, as for the two-stage 
procedures, appropriate longitudinal sub-model and time-to-event sub-model can be 
examined.  For example, the longitudinal trajectory plots could indicate that functions of 
time need to be included in the model, or the Kaplan-Meier plots could indicate that a 
proportional hazards assumption is reasonable.  Comparisons of the plots between studies 
would also help to indicate the level of between study heterogeneity; if the plots between 
studies are similar, the level of between study heterogeneity is likely to be low.
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3.3.2.1 Group 0: Naïve model 
The first group of models (referred to as group 0, Table 5) is a naïve group of models, which 
does not account for between study heterogeneity in any way. It is not recommended to use 
such a model where heterogeneity exists between studies, and is presented in this 
investigation for comparison to the models which do account for differences between studies. 
This model represents the base model to which alterations are made to account for the multi-
study nature of the data.  In an analysis, between study heterogeneity would be tested for by 
comparing models from groups that accounted for between study heterogeneity in some way 
(e.g. through fixed or random effects, or stratification of baseline hazard by study) and this 
model group that ignores between study heterogeneity. This can be done for example by using 
information criteria such as the AIC/BIC [52, 77, 178, 179], where smaller values of the 
information criteria indicate better model fit. If the model accounting for between study 
heterogeneity gives a better fit, there is an indication that between study heterogeneity is 
present.   
The longitudinal sub-model contains a population fixed intercept, longitudinal time (𝑡𝑘𝑖𝑗), and 
treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖), as well as individual specific random intercept (𝑏0𝑘𝑖
(2)) and time 
(𝑏1𝑘𝑖
(2)
) terms and an error term ( 𝑘𝑖𝑗). The error terms are independently and identically 
distributed at each time point following 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). The random effects follow a zero mean 
multivariate normal distribution 𝒃𝑘𝑖
(2)
~𝑁(𝟎, 𝑫), where 𝑫 is a 2 by 2 covariance matrix with on 
diagonals giving the variance of the random effects and the off-diagonal giving the covariance 
between the random effects. 
The time-to-event sub-model contains a fixed treatment assignment term (𝑡𝑟𝑒𝑎𝑡𝑘𝑖), and the 
association structure term 𝑊2𝑘𝑖(𝑡) = 𝛼
(2) (𝑏0𝑘𝑖
(2) + 𝑏1𝑘𝑖
(2)𝑇𝑆𝑘𝑖), which involves the zero mean 
individual level random effects between the sub-models with common association parameter.  
3.3.2.2 Group 1: Fixed interaction term with study membership variable 
The group of models labelled group 1 (Table 5) accounts for between study heterogeneity 
through the inclusion of the study membership covariate, and the interaction between study 
membership and treatment assignment, as fixed or population effects.  
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The longitudinal sub-model contains a fixed intercept, time (𝑡𝑘𝑖𝑗), treatment assignment 
(𝑡𝑟𝑒𝑎𝑡𝑘𝑖), study membership (𝑠𝑡𝑢𝑑𝑦𝑘𝑖) and interaction between treatment assignment and 
study membership (with corresponding coefficients 𝛽10 to 𝛽14), as well as individual specific 
random intercept and slope (time) terms (𝑏0𝑘𝑖
(2)  and 𝑏1𝑘𝑖
(2)), and an error term 𝑘𝑖𝑗. The random 
effects and the error term are considered to be independent. The individual level random 
effects follow distribution 𝒃𝑘𝑖
(2)~𝑁(𝟎, 𝑫), where 𝑫 is a 2 by 2 covariance matrix, whilst the 
error terms each follow distribution 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). The time-to-event sub-model contains 
treatment assignment, study membership and an interaction between treatment assignment 
and study membership as fixed effects (with corresponding coefficients 𝛽21 through 𝛽23), as 
well as an unspecified baseline hazard common across included studies. Again, the association 
structure shares the zero mean individual level random effects between the sub-models with 
common association parameter. 
This model group yields study specific estimates for the treatment effect for both sub-models. 
These are calculated, for the longitudinal outcome, by the sum of the 𝛽12 coefficient and each 
study’s 𝛽14 parameter (a 𝛽14 coefficient will be produced for each study apart from that 
considered to be the baseline study due to the factor being transformed into dummy variables, 
so if for example there are 𝐾 studies, there will be 𝐾 − 1 unique study specific 𝛽14 
parameters). The study’s estimate of 𝛽14 quantifies the difference in treatment effect between 
a particular study and the study specified as the baseline study. For the time-to-event 
outcome, the study specific coefficient is calculated by the sum of the 𝛽21 and each study’s 𝛽23 
parameter, and this represents the study specific log hazard ratio of risk of an event between 
the treatment groups. Consequently, for this model group, exact estimates of the treatment 
effect in each study are available for each sub-model, and so the between study heterogeneity 
is not just accounted for, the exact differences between treatment effect in each study can be 
examined.  
The model also includes fixed study membership terms in each sub-model. For the longitudinal 
sub-model, this results in study specific estimates of trajectory intercepts being obtained from 
the sum of the intercept 𝛽10 and the coefficient for the relevant study dummy variable 𝛽13 
coefficient. The study’s estimate of 𝛽13 quantifies the difference in intercept between a 
particular study and the baseline study. In the time-to-event sub-model, the 𝛽22 parameter 
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represents the difference in log hazard ratio of risk of an event between the study in question, 
and the baseline study. 
A comparison of the deviance (−2 ∗ ℓ(𝜃), where ℓ(𝜃) is the log-likelihood) between a model 
including the fixed study membership and interaction terms, and one without can identify if 
between study heterogeneity exists. The difference in the deviances will follow a 𝜒2 
distribution with 𝑃 degrees of freedom, where 𝑃 is the difference in number of parameters 
between the two models. This comparison can only be used for nested models.  
There are important considerations for this model group. For example, the choice of baseline 
study is important as it should be representative of the overall population of interest. In 
addition, the treatment effect estimates from this group of models are study specific, whereas 
the aim of a meta-analysis is generally to provide an overall pooled parameter estimate for the 
entire population.    
Also, this model assumes that the baseline hazard in each study is proportional to a common 
baseline hazard. This may not be a suitable assumption given the differing populations and 
designs of the studies included in the meta-analysis. Assuming proportional hazards within 
studies rather than across all studies can be achieved by stratifying the baseline hazard by 
study, as examined in model groups 4 and 5 (Sections 3.3.2.5 and 3.3.2.6).  
Finally, as the interaction terms result in a parameter per study for treatment effect in both 
sub-models, as the number of studies in the meta-analysis increases, the number of 
parameters estimated will also increase. There may be a cut-off point over which the number 
of studies makes this model unwieldy. This issue is investigated during the simulation study 
presented in Chapter 7. 
3.3.2.3 Group 2:  Fixed study indicator, study level random treatment effect 
The second group of models introduces study level random effects to the multi-study joint 
model (Table 5). This group contains a longitudinal sub-model with population fixed intercept, 
time (𝑡𝑘𝑖𝑗), treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖), and study membership (𝑠𝑡𝑢𝑑𝑦𝑘𝑖) terms, with 
coefficients 𝛽10 to 𝛽13, along with two groups of random effects (𝒃𝑘𝑖
(2), 𝒃𝑘
(3)), and error term 
( 𝑘𝑖𝑗).  
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The individual level (level 2) random effects (𝒃𝑘𝑖
(2)), as before, consist of an individual level 
random intercept (𝑏0𝑘𝑖
(2)
) and a random time term (𝑏1𝑘𝑖
(2)
), following distribution 𝒃𝑘𝑖
(2)
~𝑁(𝟎, 𝑫). 
The study level (level 3) random effects (𝒃𝑘
(3)) consists of a study level random treatment effect 
(𝑏1𝑘
(3)
) following normal distribution 𝒃𝑘
(3)
~𝑁(0, 𝜎𝐴
2), where in this case 𝜎𝐴
2 is a single value giving 
the variance of the single study level random effect. The random effects acting at different 
levels are considered independent of each other, and independent of the error terms. The 
error terms at each time point are independently and identically distribution following 
𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). 
The time-to-event sub-model contains a population fixed treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖) and 
study membership terms (𝑠𝑡𝑢𝑑𝑦𝑘𝑖) with coefficients 𝛽21 and 𝛽22, with an unspecified baseline 
hazard common across the studies in the meta-analysis. 
The association structure (given in Table 5) involves all random effects included in the model, 
with common association parameter 𝛼(2) for the shared individual level random intercept and 
slope, and common association parameter 𝛼(3) for the shared study level random treatment 
effect. Occurrences of the longitudinal time variable 𝑡𝑘𝑖𝑗 in the association structure are 
replaced with the individual’s survival time 𝑇𝑆𝑘𝑖. 
In this group of models, between study heterogeneity is accounted for in two ways. Firstly, a 
fixed study membership variable is included in both sub-models. In the longitudinal sub-model 
this adjusts the intercept for the baseline study for the longitudinal trajectory 𝛽10 by a study 
specific amount quantified by the 𝛽13 parameters (one of which will be calculated for each 
study apart from the baseline study in the meta-analysis). So (apart from the baseline study) 
for study 𝑘 for the longitudinal outcome there is a study specific intercept of 𝛽10 + 𝛽13𝑘  where 
𝛽13𝑘 represents the coefficient for the dummy variable for membership to study 𝑘. Inclusion of 
the fixed study membership variable in the time-to-event sub-model adjusts the log hazard 
ratio of risk of an event in the baseline study by a set amount for each study, quantified 
through the coefficient for the dummy variable for membership to study 𝑘.  
Between study heterogeneity in treatment effect is quantified using a random effect, through 
inclusion of the 𝑏1𝑘
(3) term. The interpretation of treatment effect is more complex in joint one-
stage MA models for separate longitudinal or time-to-event one-stage MA models due to its 
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presence in both sub-models. In the longitudinal sub-model, the 𝑏1𝑘
(3) term adjusts the overall 
population treatment effect coefficient 𝛽12 to give the observed treatment effect in study 𝑘 
through expression 𝛽12 + 𝑏1𝑘
(3). Through the association structure, the study level random 
treatment effect 𝑏1𝑘
(3)
 is also present in the time-to-event sub-model. As such, the population 
effect of treatment group 𝛽21 is altered to give a study specific estimate of the deviation in log 




As a result, between study heterogeneity is assessed in two ways. Between study 
heterogeneity due to treatment effect is assessed through the variance of the study level 
random effect 𝜎𝐴
2. The presence of between study heterogeneity due to treatment effect can 
be assessed by comparing models with and without the study level random treatment effect 
using information criteria such as the AIC/BIC [52, 77, 178, 179], where smaller values of the 
information criteria indicate better model fit. If the model including the study level random 
treatment effect is preferred, then study level heterogeneity in the treatment is indicated, with 
large values of 𝜎𝐴
2 indicating greater levels of between study heterogeneity.   
Once the model has converged, values of the potential study specific treatment effect 
parameter estimates can be obtained by generating realisations from normal distributions.  Let 
the estimated distribution of the study level random treatment effect 𝑏1𝑘
(3)
 be 𝑁(0, ?̂?𝐴
2).  
Therefore, to assess possible study specific longitudinal treatment effect estimates from 
hypothetical studies under this model, realisations from a 𝑁(?̂?12, ?̂?𝐴
2) distribution must be 
generated. To assess possible study specific time-to-event treatment effect estimates under 




2) distribution must be generated. These 
realisations (their mean, range, spread etc.) can be visualised e.g. by producing a histogram of 
the realisations.  The more spread out the values, the greater the between study 
heterogeneity.   
 Residual heterogeneity other than that in the treatment effect is tested for by comparison of 
the deviance of models with and without study membership included in the sub-models, which 
will follow a 𝜒2 distribution with 𝑃 degrees of freedom, where 𝑃 is the difference in number of 
parameters between the two models. 
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One advantage of group 2 models compared to group 1 models is that as the number of 
studies increases in the meta-analysis, the number of parameters to be estimated does not 
increase as severely (although there is  still an increase due to the presence of the fixed study 
membership covariate in each sub-model). Contrastingly, the model includes a study level 
random treatment effect, whose distribution might be poorly estimated if there are few 
studies included in the meta-analysis. As such, for this model, a balance between enough 
studies to reliably estimate the study level random effects, but not so many that the model 
becomes unwieldy due to the fixed effects, may be difficult to obtain. The issue of number of 
contributing studies is investigated further through simulation study in Chapter 7. 
As with group 1, this group produced study specific estimates of the longitudinal intercept, and 
of the log hazard ratio for each study. However, it does not provide fixed study specific 
estimates of the treatment effect. Rather, it adjusts for between study heterogeneity using 
study level random effects, and quantifies the level of between study heterogeneity through 
the estimate of the variance of the study level random effects. As meta-analyses aim to 
produce an overall pooled estimate of the parameter of interest (in this case treatment effect), 
not outputting study specific fixed estimates of treatment effect may not be an issue.  
In addition, this model group employs a common baseline hazard across studies, and so still 
assumes that hazards are proportional across studies. As noted earlier, this may be an 
unreasonable assumption if the study demographics differ significantly. 
3.3.2.4 Group 3: Study level random intercept and treatment effect 
The third group of models relies completely on study level random effects to model between 
study heterogeneity (Table 5). This group of models involves a longitudinal sub-model 
containing a fixed or population intercept, longitudinal time term (𝑡𝑘𝑖𝑗) and treatment 
assignment covariate (𝑡𝑟𝑒𝑎𝑡𝑘𝑖), with coefficients 𝛽10 through 𝛽12, as well as two sets of 
random effects (𝒃𝑘𝑖
(2), 𝒃𝑘
(3)) and an error term ( 𝑘𝑖𝑗).  
The first set of random effects act at the individual level (level 2), and include an individual 
level random intercept (𝑏0𝑘𝑖
(2)
) and a random slope (𝑏1𝑘𝑖
(2)
). The individual level random effects 
follow distribution 𝒃𝑘𝑖
(2)~𝑁(𝟎, 𝑫), where 𝑫 is a 2 by 2 covariance matrix. The second set act at 
the study level (level 3), and include a study level random intercept (𝑏0𝑘
(3)) and random 
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treatment effect (𝑏1𝑘
(3)). The study level random effects follow distribution 𝒃𝑘
(3)~𝑁(𝟎, 𝑨), 
where 𝑨 is a 2 by 2 covariance matrix. For both 𝑨 and 𝑫, the on-diagonals of the covariance 
matrix are the variances of the random effects at the respective levels, and the off-diagonals 
contain the covariance between the random effects at each level. The error terms are 
independently and identically distribution at each longitudinal time point, following 
𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). 
The time-to-event sub-model contains a fixed population treatment assignment covariate 
(𝑡𝑟𝑒𝑎𝑡𝑘𝑖) with coefficient 𝛽21, with an unspecified baseline hazard common across studies. The 
association structure (see Table 5 for full expression) involves both the individual level and the 
study level random effects, with common association parameter 𝛼(2) for the shared individual 
level random effects, and common association parameter 𝛼(3) for the study level random 
effects.   
As mentioned, 𝑨 is the covariance matrix for the study level random effects, and so quantifies 
the between study heterogeneity. As such the first on diagonal element of 𝑨 (termed 𝑨𝟏𝟏) is 
the variance of the study level random intercept, and quantifies the between study variability 
in the intercept. The second on-diagonal element 𝑨𝟐𝟐 is the variance of the study level random 
treatment effect, and quantifies the between study variability in treatment effect. The larger 
these values, the more variability between studies in the intercept and the treatment effect 
respectively. 
The presence of between study heterogeneity in model group 3 can be assessed by comparing 
models with and without the study level random effects using information criteria such as the 
AIC/BIC [52, 77, 178, 179], where smaller values of the information criteria indicate better 
model fit. If the model including the study level random effects are preferred, then study level 
heterogeneity indicated, with large on-diagonal values of 𝑨 indicating greater levels of 
between study heterogeneity.   
The effect of the adjustments of different parameters due to study level random effects can be 
examined again by producing realisations from the relevant normal distributions.  Specifically, 
once the model has converged, potential hypothetical study parameter estimates can be 
generated from normal distributions based on the estimated model parameters.  Let the 
estimated distribution of the study level random treatment effect 𝒃𝒌
(𝟑) be 𝑁(𝟎, 𝑨).  To assess 
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possible longitudinal intercept and treatment effect estimates for hypothetical studies under 




) , ?̂?) 
To assess possible time-to-event intercept and treatment effect estimates for hypothetical 







Histograms of the realisations can help to visualise the mean, range and spread of potential 
study specific estimates from hypothetic generated studies; the more spread out the values, 
the greater the between study heterogeneity. The interpretation of the study level random 
effects in the one stage joint MA model is more complex than for separate one-stage 
longitudinal or time-to-event MA models. The study level random effects are present in both 
the longitudinal and the time-to-event sub-model due to their involvement in the association 
structure. As such, the study level random intercept 𝑏0𝑘
(3) causes the longitudinal intercept for 
study 𝑘 to equal 𝛽10+𝑏0𝑘
(3)
, but also 𝛼(3)𝑏0𝑘
(3)
 represents the deviation in log hazard ratio for risk 
of an event in the 𝑘th trial from the population average taken across all studies in the meta-
analysis.    
The study level random treatment effect 𝑏1𝑘
(3)
 estimated for study 𝑘 adjusts the population 
fixed treatment effect in the longitudinal sub-model 𝛽21 to give the treatment effect observed 
in study 𝑘, 𝛽21 + 𝑏1𝑘
(3). However, its presence in the time-to-event model through the 
association structure adjusts the population effect of treatment group assignment 𝛽21 to give a 
study specific estimate of deviation in log hazard ratio due to treatment assignment 𝛽21 +
𝛼(3)𝑏1𝑘
(3).  
An advantage of this model is that as the number of studies included in the meta-analysis 
increases, the model does not become unwieldy, as the number of parameters that control the 
distribution of the study level random effects remains constant. However, the distribution of 
the study level random effects is based effectively on a sample size equal to the number of 
studies in the meta-analysis. The estimation of covariance matrix 𝑨 could be based on little 
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information if few studies contribute to the meta-analysis. As such, unless over a given number 
of studies is included in the meta-analysis, it may not be sensible to consider the estimated 
distribution of the study level random effects to be reliable. This could be an issue in the joint 
modelling case, as the study level random effect do not just account for between study 
heterogeneity, they act as part of the function linking the longitudinal and the time-to-event 
sub-models.  Additionally, many meta-analyses contain less than 10 studies, which may not be 
sufficient to estimate these study level random effects. It is important to establish how reliably 
the distribution of the study level random effects is estimated during model fitting, an issue 
investigated further through simulations in Chapter 7. 
Another consideration with this modelling group, as with group 2, is that study specific 
treatment coefficients are not directly estimated. However, when meta-analysing the data, the 
overall aim is to estimate a pooled treatment effect estimate based on data from all studies. 
This is accomplished in this model group through the estimation of 𝛽12 in the longitudinal sub-
model and 𝛽21 in the time-to-event sub-model. The lack of study specific covariate estimates is 
generally not an issue in a meta-analytic investigation, and if they are required, a model group 
that uses fixed interaction terms should be employed. In addition, this model still assigns a 
common baseline hazard to all studies, thus assuming proportional hazards across all studies 
(an assumption identified to be potentially unreasonable). 
3.3.2.5 Group 4: Unspecified baseline hazard stratified by study, fixed interaction term with 
study membership variable in longitudinal sub-model 
The fourth group of models displayed in Table 5 introduces stratification of baseline hazard by 
study. The longitudinal sub-model of this group contains population fixed intercept, time (𝑡𝑘𝑖𝑗), 
treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖), study membership (𝑠𝑡𝑢𝑑𝑦𝑘𝑖) and interaction between 
treatment assignment and study membership terms (with coefficients 𝛽10 to 𝛽14), as well as 
individual level random intercept (𝑏0𝑘𝑖
(2)) and random time (𝑏1𝑘𝑖
(2)) terms and an error term ( 𝑘𝑖𝑗).  
As before, the individual level random effects follow distribution 𝒃𝑘𝑖
(2)~𝑁(𝟎, 𝑫), where 𝑫 is a 2 
by 2 covariance matrix with on-diagonals equal to the variance of each random effect, and off-
diagonal equal to their covariance. The random effects and the error terms are independently 
distributed. The error terms at each time point follow 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). 
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The time-to-event sub-model contains a population fixed treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖) term 
with coefficient 𝛽21, as well as an unspecified baseline stratified by study 𝜆0𝑘. The association 
structure (fully stated in Table 5), involves just the individual level random effects.  
As such, between study heterogeneity is accounted for in the longitudinal sub-model through 
the fixed study membership variable and the fixed interaction term between study 
membership and treatment assignment. Study specific estimates of the treatment effect can 
be generated through the sum of the treatment assignment coefficient for the baseline study 
(𝛽12) and the study specific 𝛽14 variables resulting from the interaction between study 
membership and treatment effect. This study specific 𝛽14 coefficient quantifies the difference 
between the treatment effect in the baseline study and a given study in the meta-analysis for 
the longitudinal outcome. In this model, the presence of between study heterogeneity 
attributable to differences in treatment effect between studies can be tested for by comparing 
the differences in deviances between models containing and not containing interaction 
between study membership and treatment assignment. The difference in deviances will follow 
a 𝜒2 distribution with 𝑃 degrees of freedom, where 𝑃 is the difference in number of 
parameters between the two models. 
Study specific longitudinal intercepts are obtained through the sum of the baseline study 
intercept 𝛽10 and the estimated study specific 𝛽13 variable linked to the dummy variable for 
the appropriate study. The study specific 𝛽13 coefficient quantifies the difference in the 
intercept of the longitudinal trajectory between the baseline study, and a given study in the 
meta-analysis. The residual between study heterogeneity in the longitudinal outcome not 
accounted for through the treatment assignment variable can be tested for by comparing the 
deviance between a model with and without study specific fixed intercepts.  
In the time-to-event sub-model, between study heterogeneity is captured by the unspecified 
baseline, which is stratified by study. As such, between study heterogeneity is captured, but it 
is not estimated. As the aim of the meta-analysis is to provide a pooled coefficient estimate 
based on data from all studies, this may not be an issue unless it is necessary to explain existing 
heterogeneity. In this case, further covariates etc. could be included in the model. 
Unlike previous models, by stratifying baseline hazard by study, proportional hazards are 
assumed within studies rather across all studies included in the meta-analysis. This may be a 
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more reasonable assumption than a common baseline hazard across studies especially if the 
demographics of the studies differ considerably.  
Using study specific baseline hazards rather than a common baseline hazard may also reduce 
computation time, as the baseline hazard will take weight only at event times observed in each 
study rather than those observed in all studies, and so the length of the vector for baseline 
hazard will be shorter (and study specific). However, if use of a stratified baseline hazard does 
not fulfil the needs of the investigation, for example if the variability of a coefficient between 
studies is of interest, a stratified baseline hazard should not be employed just on the basis of 
computation time. Additionally, as number of studies increases, the computational burden of 
calculating a baseline hazard for each study may become relevant. 
3.3.2.6 Group 5:  Unspecified baseline hazard stratified by study, study membership variable in 
longitudinal sub-model, study level random treatment effect. 
The fifth group of models described in Table 5 include a variety of methods to account for 
between study heterogeneity. The longitudinal sub-model contains a fixed intercept, 
longitudinal time term (𝑡𝑘𝑖𝑗), treatment assignment (𝑡𝑟𝑒𝑎𝑡𝑘𝑖) and study membership variable 
(𝑠𝑡𝑢𝑑𝑦𝑘𝑖), as well as two sets of random effects (𝒃𝑘𝑖
(2), 𝒃𝑘
(3)), and an error term ( 𝑘𝑖𝑗). 
The individual level (level 2) random effects 𝒃𝑘𝑖
(2) contain a random intercept 𝑏0𝑘𝑖
(2)  and a random 
time term 𝑏1𝑘𝑖
(2), which again follow distribution 𝒃𝑘𝑖
(2)~𝑁(𝟎, 𝑫). The study term with coefficient 
(level 3) random effects 𝒃𝑘
(3) only involves a random treatment effect 𝑏1𝑘




2 is a single value giving the variance of the study level 
random effect. The random effects at each level are considered independent, and are also 
independent of the error terms. The error terms are identically and independently distributed 
at each time point with 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). 
The time-to-event sub-model contains a fixed treatment assignment with coefficient 𝛽21, as 
well as a baseline hazard stratified by study. The association structure (shown in Table 5) 
involves both individual and study level random effects, with common association parameter 
𝛼(2) for the shared individual level random effects, and common association parameter 𝛼(3) 
for the study level random effects. As before, longitudinal time in the association structure is 
replaced with individuals’ survival time.  
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In this group of models, between study heterogeneity is accounted for in a range of ways. In 
the longitudinal sub-model, the fixed study membership variable generates fixed study specific 
longitudinal intercepts, through the sum of the intercept for the baseline study 𝛽10 and the 
study specific coefficient for the relevant study’s dummy membership variable 𝛽13𝑘. 
Additionally between study heterogeneity due to treatment assignment is quantified through 
the study level random treatment effect 𝑏1𝑘
(3). The level of between study heterogeneity in the 
treatment effect can be assessed by examining the variance of the random effect 𝜎𝐴
2 (which in 
this case is a single value) in the same way as for model group 2 (comparing models with and 
without study level random effects: if the model with study level random effects displays lower 
information criteria values then there is evidence of between study heterogeneity in treatment 
effect).  The residual between study heterogeneity not accounted for by variation in treatment 
effect can be assessed by the difference in the deviance between joint models with and 
without a fixed study membership variable in the longitudinal sub-model. 
Between study heterogeneity is accounted for in two ways in the time-to-event sub-model. 
Firstly, as for group 4, the baseline hazard is stratified by study. As such, by allowing the 
baseline hazard to vary between studies, the between study heterogeneity is accounted for but 
not quantified. Through the association structure, the term 𝛼(3)𝑏1𝑘
(3) occurs in the time-to-
event model. This term adjusts the log ratio hazard of risk of an event dependent on treatment 
assignment from the population estimate 𝛽21 by an amount specific to each included study.  
The magnitude of the adjustment due to study level random effects can be examined in the 
same way as for model group 2.  Specifically, once the model has converged, potential study 
specific treatment effect parameter estimates can be generated from normal distributions 
based on the estimated model parameters.  Let the estimated distribution of the study level 
random treatment effect 𝑏1𝑘
(3) be 𝑁(0, ?̂?𝐴
2).  To assess possible study specific longitudinal 
treatment effect estimates under this model, generate realisations from a 𝑁(?̂?12, ?̂?𝐴
2). To 





2). Histograms of the realisations can help to visualise the mean, range and 
spread of potential study specific estimates from hypothetic generated studies; the more 
spread out the values, the greater the between study heterogeneity.   
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Between study heterogeneity in this model may be more difficult to interpret than the other 
models, because it is accounted for in a variety of ways. In addition, as number of studies 
increases, this model may experience issues due to the necessity to calculate a separate 
baseline hazard for each included study, and also the separate coefficients for study 
membership estimated for all but the baseline study. However, as with group 4, model fitting 
times are likely to be improved by the smaller vector lengths of the baseline hazard, as it will 
take weight only at event times observed in each study rather than those observed in all 
studies. 
3.3.3 Number of parameters in one-stage joint MA models 
In the descriptions of model groups 0 through 5, it was mentioned when fixed effects are used 
to account for between study heterogeneity, presence of between study heterogeneity can be 
tested by comparing the differences in deviances between models containing and not 
containing the relevant fixed effects (for example comparing the deviances of a model 
containing fixed interaction terms between study membership and treatment assignment, and 
a model without these interaction terms, to test for between study heterogeneity in treatment 
effect). The difference in deviances has been noted to follow a 𝜒2 distribution with 𝑃 degrees 
of freedom, where 𝑃 is the difference in number of parameters between the two models.  To 
calculate 𝑃, the number of parameters estimated in each model must be obtained.  This is 
easily calculated as follows: 
Classing baseline hazard as a nuisance parameter (and so not counting it towards parameters 
to be estimated), let 𝑃𝑀 be the number of parameters in a given model 𝑀.  𝑃𝑀 can be 
expressed: 
𝑃𝑀 = 𝑝1 + 𝑝2 + 𝜚 +
1
2
𝑞(𝑞 + 1) +
1
2
𝑟(𝑟 + 1) + 1 
In the above expression, 𝑝1 is the number of fixed effects in the longitudinal sub-model, and 𝑝2 
is the number of fixed effects in the time-to-event sub-model.  In each sub-model, the number 
of fixed effects includes any interaction terms present, and assumes factors have been 
decomposed into dummy variables.  The number of association parameters to be estimated is 
given by 𝜚.  Under the joint models examined in this chapter, if the model only contains 
individual level random effects, 𝜚 = 1, and if the model contains both individual level and 
study level random effects, 𝜚 = 2.  The number of individual level random effects is denoted 
 84   
 
by 𝑞, and the number of study level random effects is denoted by 𝑟.  The number of 
parameters to be estimated for each set of random effects is the number of unique values in 
the symmetric covariance matrix for the relevant random effect distribution.  This is equal to 
the total of the number of on-diagonal parameters and the number of unique off-diagonal 
parameters, i.e. the 𝑛th triangular number where 𝑛 is equal to the number of random effects 
at the given level.  Note, if no random effects are included at a given level (e.g.if no study level 
random effects are present in the model meaning 𝑟 = 0) then the corresponding term in the 
expression for 𝑃𝑀 also equals zero (i.e. 
1
2
𝑟(𝑟 + 1) = 0).  Finally, the plus one at the end of the 
expression represents the parameter quantifying the variance of the measurement error 
(namely 𝜎𝑒
2).  The difference in number of parameters between two models 𝑀1 and 𝑀2 can 
then be calculated as: 
𝑃 = 𝑃𝑀1 − 𝑃𝑀2  
Here, model 𝑀1 contains the larger number of parameters.  𝑃 then gives the degrees of 
freedom for the 𝜒2 distribution, which the differences in deviance between model 𝑀1 and 
model 𝑀2 should be compared to, in order to assess the presence of between study 
heterogeneity as accounted for using the fixed terms present in model 𝑀1 but not model 𝑀2. 
In the future, if alternative formulations for the baseline hazard are used (e.g. parametric or 
spline based) the number of parameters required for their estimation should contribute to the 
calculation of 𝑃 (see Chapter 8 for planned future work). 
3.4 Discussion of meta-analytic joint modelling methods 
During this chapter a range of methods for the one-stage or the two-stage meta-analysis of 
multi-study joint longitudinal and time-to-event data have been presented and discussed. It 
was assumed that IPD is available to the researcher, with a note that the second stage of the 
two-stage methods could be used if performing an AD-MA of joint data.  
3.4.1 Discussion of methods for two-stage joint IPD-MA 
During Section 3.2, the procedure of fitting joint models to each identified study, extracting the 
parameters and quantities of interest, and pooling the results using standard meta-analytic 
techniques has been described. In addition, guidelines for the conduct of the meta-analysis 
were presented, highlighting procedures to ensure that parameters with differing 
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interpretations are not quantitatively pooled, thus ensuring that pooled parameters have 
meaningful interpretations.  
A two-stage MA of joint models was possible at the start of this thesis using currently available 
software. In R [79], for the first stage, various packages exist to fit frequentist single study joint 
models, including the joineR package [80], and the JM package [81]. Whilst not directly 
designed to model single study univariate models, the joineRML package [181], and the 
joineRmeta package (which I have written during this thesis, available on github at 
https://github.com/mesudell/joineRmeta, and for download from the R CRAN mirror), both 
can also fit single study univariate joint models. In the second stage a range of packages exists 
to perform meta-analyses, including the meta [182] and metafor [183] packages. Software 
also exists in other packages (such as Stata [84] or SAS software [85]). However, the process to 
extract the values necessary for a meta-analysis from a joint model fit in R, and feed them into 
a meta-analysis package is convoluted, especially for those with limited programming 
experience. To address this, in the joineRmeta package, I have included a function that, when 
supplied with joint model fits from joineR or JM, along with names of parameters of interest, 
extracts and performs the second stage of the two-stage MA process (see Chapter 4). 
During the investigation of methods for the two-stage MA of joint data, it was assumed that 
separate MA would be performed for each parameter of interest. However, this could be a 
naïve approach. In a joint model, a core concept is that the longitudinal and time-to-event sub-
models are linked and so affect each other. As such, given a significant estimated association 
between the longitudinal and the time-to-event outcome, there would be correlation between 
parameters from various parts of the joint model. Performing separate MA for each parameter 
of interest ignores this correlation. A solution to this could be to perform multivariate meta-
analyses. This extension is further discussed in Chapter 8. 
The difference in interpretation of different association structures in joint models available to 
researchers leads to an important concept to consider in both two-stage IPD-MA, and in 
aggregate data meta-analyses (AD-MA, where study level results are obtained from published 
information or other sources, and pooled).  During a meta-analysis involving joint models this 
research recommends that the association structure should be kept consistent across included 
studies, in order to be able to pool the association estimates.  If the most appropriate joint 
modelling structure (random effect specification, association structure, longitudinal fixed 
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effects if both fixed and random effects are shared between sub-models) differs between 
identified studies, studies should be grouped by joint model structure, and only results from 
identical joint models (within group results) should be pooled. Pooled estimates from different 
groups (different joint modelling structures) can then be qualitatively compared in the 
discussion of the meta-analysis, whilst bearing in mind their potentially different 
interpretation.  Recommendations for the two-stage MA of joint longitudinal and time-to-
event data have been succinctly stated in Section 3.2.4. 
The recommendations for two-stage MA of joint longitudinal and time-to-event IPD (Section 
3.2.4, second stage applicable to AD) do not state that results should not be pooled from joint 
models employing different methods to model baseline hazard.  The recommendations have 
been produced to aid researchers in avoiding pooling parameters with non-comparable 
interpretations.  Generally in meta-analyses of time-to-event data, coefficients quantifying the 
difference in risk between patients with different characteristics are of interest, for instance 
treatment assignment coefficients. A proportional hazards time-to-event sub-model (for 
example) that uses an unspecified baseline hazard will produce fixed effect coefficients with 
comparable interpretations to one that employs a spline based or parametric baseline hazard.  
The method chosen to model the baseline hazard should be able to account for any 
characteristics of the baseline hazard.  For instance, if the baseline hazard initially increases, 
plateaus, then decreases, the method used to represent the baseline hazard must be able to 
represent this shape; modelling the baseline hazard using a constant function in this case 
would be inappropriate.  However, unless the baseline hazard itself is of interest to the 
analysis, provided it is appropriately modelled, and the fixed effect coefficients themselves 
have comparable interpretations, the coefficients can be pooled. 
The review detailed in Chapter 2 identified that joint modelling analyses employed a mix of 
frequentist and Bayesian approaches (Section 2.3.1.7).  It should be highlighted that the 
modelling assumptions of Bayesian and frequentist approaches are inherently different (see 
Section 16.8.1, Cochrane Handbook [184]).  As such, it is not appropriate to pool parameters 
from a mix of Bayesian and frequentist analyses.  The choice of Bayesian or Frequentist 
modelling approach should be made before the first stage of analysis for a two-stage IPD-MA.  
For an AD-MA, Bayesian and Frequentist analysis results should be pooled separately.  The 
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conclusions based on these two sets of analyses can then be qualitatively compared and 
discussed. 
The methods discussed in this chapter assume availability of IPD. It is possible that in practice, 
IPD could be obtained only for a subset of studies eligible for inclusion in the meta-analysis, 
with AD available for the remaining references.  The review conducted by Riley et al [3] 
identifies three approaches to pooling IPD and AD, namely using multi-level modelling, using 
Bayesian hierarchical related regression, and using a two-stage approach similar to that 
described in this chapter.  Under this approach, in the first stage, study level estimates would 
be obtained from any IPD data, and in the second stage these estimates would be combined, 
along with any AD extracted, to generate a pooled result.  In the context of a joint data MA, 
care would need to be taken to ensure that the joint modelling methods used to reduce the 
IPD to study specific AD were comparable to the methods stated as used to produce the AD 
extracted from studies, in line with the recommendations for conduct of two-stage MA of joint 
data (see Section 3.2.4). 
It is possible that the data supplied by each study in a meta-analysis could contain different 
subsets of potential treatment effect modifiers. In this circumstance, for a two-stage joint IPD-
MA, covariates should be selected separately for each study, using forward or backward 
selection methods, and an estimate of treatment effect after adjustment for covariates that 
significantly affect the longitudinal or the time-to-event outcomes should be output for each 
study.  Sensitivity analyses can then be performed, removing studies that did not adjust for 
certain covariates, to assess the robustness of the pooled result. Information on the covariates 
adjusted for in each study could be stated on forest plots summarising the conducted meta-
analyses.   
As an aside, in the case of AD-MA, where the results are comparable, study level results could 
be pooled, and the reported adjustment covariates noted e.g. on the forest plot displaying the 
pooled data.  Again, sensitivity analyses could be performed for AD-MA, removing studies that 
do not adjust for potential treatment effect modifiers, or removing studies that only adjust for 
a subset of the potential treatment effect modifiers, to test the robustness of the conclusion. 
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3.4.2 Discussion of methods for one-stage joint IPD-MA 
During Section 3.3, a range of model groups to model multi-study joint longitudinal and time-
to-event data were presented. Each of these model groups accounted for between study 
heterogeneity in different ways, through varying combinations of fixed terms (including study 
membership and its interaction with covariates of interest), study level random effects, and 
stratification of the baseline hazard in the time-to-event sub-model. The different methods to 
account for between study heterogeneity between model groups have been discussed, along 
with their advantages and drawbacks. Functions to fit the models described in this section have 
been included in the joineRmeta package, discussed in Chapter 4.  
As for the two-stage joint data MA (Section 3.2.1), in a one-stage joint MA it would be 
advisable before conducting the analysis to produce plots of the longitudinal outcome 
trajectories panelled by event.  These trajectory plots could also be panelled by other 
covariates of interest, e.g. treatment group, to provide an initial representation of whether the 
behaviour of the longitudinal outcome differs between different groups.  Plotting the 
longitudinal outcome against the longitudinal time variable can help to identify aspects of the 
trajectory shape that need to be accounted for (e.g. non-linear behaviour).  Plotting the 
longitudinal outcome against time adjusted by survival time can identify whether the 
longitudinal outcome changes immediately before experiencing an event– this would provide 
evidence that the longitudinal and time-to-event outcomes may be linked, implying joint 
modelling techniques are required.  Additionally, producing Kaplan-Meier plots for the time-to-
event outcome is advised, e.g. so that assumptions of proportional hazards within or across 
studies could be checked.  The longitudinal trajectory and the Kaplan-Meier plots would inform 
the choice of model specification for the longitudinal sub-model, time-to-event sub-model and 
the association structure.  
One issue identified is the suitability of different methods dependent on the number of studies 
included in the meta-analysis. As stated, if a large number of studies is available, a model using 
fixed terms such as the study membership variable and its interactions with other covariates 
will contain a large number of parameters to be estimated, potentially leading to an unwieldy 
model. However, if only a few studies are available, the distribution of any study level random 
effects could be poorly estimated. Consequently, effect of the number of studies on estimation 
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of model parameters in different model groups is investigated during the one-stage simulation 
study (Chapter 7). 
In addition to considerations about the actual estimation of the model parameters, models 
that employ fixed study membership and its interaction with covariates of interest terms 
provide parameter estimates specific to the studies included in the meta-analysis. As such, 
generalisation of the results to a wider population outside the included studies could be 
problematic. Alternatively, model group 3 relies completely on study level random effects to 
account for between study heterogeneity. The distribution of study level random effects, which 
quantifies the level of between study heterogeneity, is estimated during model fitting. As long 
as the studies included in the meta-analysis are representative of the wider population, results 
can be easily generalised given this distribution. However, study level random effects, whilst 
accounting for study heterogeneity, do not automatically provide estimates for study specific 
effects; this is not generally a main aim of meta-analyses and so is not a major drawback. 
Whilst joint modelling has been an area of increasing research [74-76, 93], the development of 
model diagnostics or procedures to choose the most appropriate model has been somewhat 
slower. Recently, publications have started to appear dealing with this area, including 
Rizopoulos et al [185] who discuss using residuals as a joint model diagnostic tool. However, 
their methods exclude joint models that involve a time-to-event sub-model with an unspecified 
baseline hazard. In addition, Park et al [186] discuss model selection and diagnostics for joint 
models, but again restrict themselves to the case where there are crossing hazard functions. 
Dobson and Henderson [187] present a range of graphical methods to assess joint models, 
however note that they are informal assessments rather than formal tests. 
Rizopoulos [52] describes a range of methods to test the inclusion of various parameters in a 
joint model, including the Likelihood Ratio Test, the score test and the Wald test. However, 
these tests are appropriate only when the models are nested (and as discussed earlier can be 
used to test for between study heterogeneity when accounted for using fixed effects).  
As stated, to compare non-nested models (e.g. those from different groups),  information 
criteria such as Akaike’s Information Criterion (AIC) [178], or the Bayesian Information Criterion 
(BIC) [179] could be used [52, 77]. For these values, the smaller values of the AIC/BIC identify 
the better model. Calculation of the AIC value has been programmed into the output from the 
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one-stage modelling function included in the joineRmeta package, to facilitate comparison of 
different one-stage joint MA models. This is further discussed in Chapter 4. 
If potential treatment effect modifiers are supplied in the dataset, these should be examined in 
the model, and retained where significant.  Covariates can be assessed through forward or 
backward selection processes.  Ideally, the same treatment effect modifiers would be 
measured in all studies.  This may not always be the case, and so inclusion of certain treatment 
effect modifiers may remove some individuals, or even entire studies, from the meta-analyses.  
A range of methods to account for this exist, such as performing sensitivity analyses where 
multiple imputation techniques are used to impute missing covariates for individual or studies, 
based on the observed data, and comparing the analyses based on imputed data to those 
based on the recorded dataset.  There has been a recent movement towards developing core 
outcome sets for different conditions, led by the COMET initiative [188]. This initiative aims to 
produce sets of outcomes that should be measured as standard in each study.  This may result 
in lower amounts of missing data for covariates of interest for individuals and studies in future 
meta-analyses.  
3.4.3 Concluding Remarks 
This chapter has presented and discussed methodology to conduct both one and two-stage 
meta-analyses.  These two approaches have differing characteristics.  One-stage approaches 
employ more accurate likelihood specifications than two-stage approaches [189-191], but care 
must be taken to separate within and between study effects [180].  Two-stage methods 
automatically account for the issue of ecological bias as they only pool within study 
information [63, 180, 192], but they assume that the study specific estimates are normally 
distributed with known variances (a potential issue for studies with small sample sizes or 
applications to rare events) [191, 193].  One-stage methods are known to be computationally 
intensive [63, 189, 191]; one-stage analyses involve fitting models to ∑ 𝑛𝑘
𝐾=1
𝑘  individuals, 
whereas two-stage analyses involve fitting 𝐾 models, each of which involves 𝑛𝑘 individuals.  
The results of a one and two-stage meta-analysis are often similar, but differences between 
results can occur for a variety of reasons [189]. Debray et al [194] and Burke et al [189] 
recommend that if researchers are unsure which approach to employ, both a one and a two-
stage analyses should be planned, conducted and reported. 
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This chapter has proposed methods to model multi-study joint data in meta-analyses.  In 
practice, there may be many covariates that modify the treatment effect parameter, which 
should be included in the model.  Investigation of patient level treatment effect modifiers is 
only possible when IPD is available, without results being subject to ecological bias [9], and so 
may be a motivation for AD rather than IPD-MA if treatment modifiers are known or 
suspected.  In two-stage IPD analyses, modifiers can be included in the study specific joint 
models, however they will only represent the effect of the covariate on treatment effect based 
on the range of covariate values reported in that study. If demographics of included studies 
differ significantly between studies, sub-group analyses may be required in the second stage 
that group studies into specified categories (e.g. age ≤ 50, age >50) and pool results only within 
these sub-groups.  In one-stage analyses, data from all comparable studies can be analysed 
under the same model, with differences in demographics accounted for by inclusions of 
relevant covariates in the model.  Accounting for differences in the demographics between 
included studies is established across meta-analysis methodology, not limited to joint data 
meta-analyses.  Analyses conducted with an aim to influencing future healthcare should firstly 
assess the demographics of the identified studies, and if the populations are not too disparate, 
should employ modelling approaches that account for differences in population demographics. 
In the literature, meta-analyses may be expected to be updated over the years, as new studies 
relevant to the meta-analysis become available.  In this case, the meta-analysis would have to 
be updated with respect to the new data (a process observable in Cochrane Reviews).  If a two 
stage approach to the MA had been undertaken, and the study level results for the currently 
included studies preserved, the analysis could be quickly updated by re-performing the second 
or pooling stage of the meta-analysis.  However, the process of updating a one-stage analysis 
would be more involved, as for the frequentist approach described in this chapter, the entire 
analysis would have to be redone.  An alternative to this (not investigated in this thesis) would 
be a Bayesian approach, where the information from currently included studies would be 
preserved in the prior of the new analysis, and the newly available data then included in the 
likelihood.  However, as mentioned in the Cochrane Handbook [184] (section 16.8.1), 
methodology for Bayesian meta-analysis is still being developed and is not yet widely 
implemented. 
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Having presented methods for the meta-analysis of multi-study joint data, Chapter 4 presents 
and discusses the software developed during this thesis to aid the meta-analysis of joint data. 
Over the chapters that follow, an analysis of a real dataset is presented, examining the 
feasibility of the methods proposed in this chapter in a real dataset (Chapter 6). This is 
followed by an in depth analysis of the behaviour of the proposed methods (both one and two-
stage) under a range of different scenarios such as varying levels of association and 



















Chapter 4 : R Software package for Meta-Analysis of Joint 
Longitudinal and Time-To-Event Data 
This chapter presents and discusses the R package joineRmeta that I have developed to 
facilitate researchers when conducting meta-analyses of joint longitudinal and time-to-event 
data. The current developmental version is available at  
https://github.com/mesudell/joineRmeta/ (where updates to the package will be loaded and 
tested before being included in the CRAN version of the package).  The current tested version 
of the package is available for download from CRAN in R [79] directly through R software 
interfaces. I am listed as the maintainer of the package. The chapter begins with a discussion of 
the simulated data and pre-run model fits available in the package for demonstration 
purposes, and is followed by details of the various functions contained in the package. This 
discussion is split into Analysis Functions (including the functions for one-stage or two-stage 
MA of joint data), followed by Exploratory Functions (including data simulation, preparation 
and visualisation). The chapter concludes with a discussion of the R package, and its use in the 
remainder of the thesis. 
During the chapter, reference will be made to R functions or code which can be run in the 
console in R. Code is clearly marked during text by a change in font e.g. jointmeta1 or is 
displayed in blocks between paragraphs, e.g. 
jointmeta1() 
Throughout, example code is used to demonstrate the functionality of the package, and the 
output is presented as it would appear when code is run in the R console.  As such, graphs in 
this chapter are presented as they would appear in the output and have not been assigned 
captions. 
In the text, when a function is introduced, the function call is printed. The default values for 
arguments, or the possible values the argument can take (if these are limited), are displayed in 
the function call or discussed in the main text. After the function call, brief definitions of the 
arguments involved in the function are given, with further discussion of function options after 
the argument definitions where appropriate. 
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It is expected that names of data variables are supplied as character strings.  For example, if 
the name of an individual identification or ID variable named IDVAR were being supplied to 
argument id in a function, the phrase id = "IDVAR" should be included in the function call. 
Using phrase id = IDVAR would cause R to search for an object named IDVAR to supply to 
the function. 
A range of models have been fitted to example data to demonstrate the functions in this 
package. These models may not necessarily represent the most appropriate model for the 
data. 
4.1 Installing the joineRmeta package 









Information concerning the functions and their usage is available in the help files and the user-
friendly vignette (tutorial file) of the joineRmeta package (available at the mentioned web 
address and by downloading the R package). When the package is loaded in R, the help file for 
any function can be accessed by typing ?functionname into the R console,  e.g. 
?jointmeta1.  Additionally, the help files overall for the package can be accessed using: 
help(package="joineRmeta") 
4.2 Data 
For demonstration purposes, the joineRmeta package contains simulated datasets and pre-
run joint model fits to allow the user to explore the package’s functionality without having to 
wait for lengthy model fitting processes such as bootstrapping to complete. These datasets and 
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fits are used in the examples throughout this chapter, but play no part in other chapters. A 
brief description of the examples used follows. 
4.2.1 Simulated data 
The joineRmeta package contains three simulated example datasets, named simdat, 
simdat2 and simdat3, generated using the simjointmeta function contained in the 
package (see Section 4.4.1). These datasets contain a single continuous longitudinal outcome 
and a single time-to-event outcome. Datasets simdat and simdat3 contain 5 studies, and 
simdat2 contains data from 3 studies. The datasets are supplied as a list of 3 list objects; a list 
of study specific longitudinal datasets longitudinal, a list of study specific time-to-event 
datasets survival, and a list of the event rates in each study percentevent. 
The simdat2 dataset is a subset of simdat included to provide datasets containing different 
numbers of studies for use with example code. Both the simdat and simdat2 datasets were 
generated such that longitudinal measurements made after the individuals survival time are 
not present in the dataset, however simdat3 contains longitudinal measurements recorded 
after an individual's event time. Real datasets may contain longitudinal measurements 
recorded after the event if the event is not terminal, and so a function has been included in the 
joineRmeta package to remove longitudinal data recorded after an individual's event time 
(see Section 4.4.2.2). The simdat3 dataset is included in the package in order to demonstrate 
this function. 
Further information concerning these datasets is available by loading the joineRmeta 
package into R, and typing ?simdat, ?simdat2 or ?simdat3 into the console.  
4.2.2 Single study joint model fits 
The function jointmeta2 is written to aid with the second stage of two-stage MA of joint 
data. This function is described fully in Section 4.3.1. The function can take a list of study 
specific joint model fits, and meta-analyse model parameters. The function can take fits from 
either the joineR or the JM packages.  Example fits from each package are supplied in objects 
joineRfits, joineRfits2, JMfits and JMfits2. As with the simulated datasets, more 
information can be obtained by loading the joineRmeta package in R, and typing e.g. 
?joineRfits into the console.  The model fits represent differing options for random effects 
 96   
 
or fixed effects specifications, as well as different choices of association structure.   As the 
model fits produced by joineR contain both the model fits, and the results of the 
bootstrapping procedure to obtain standard errors, these need to be extracted before 
conducting the meta-analysis, using the following code:  
joineRmodels <- joineRfits[c("joineRfit1", "joineRfit2", "joineRfit3")] 
joineRmodelsSE <- joineRfits[c("joineRfit1SE", "joineRfit2SE", "joineRfit3SE")] 
joineRmodels2 <- joineRfits2[c("joineRfit6", "joineRfit7", "joineRfit8")] 
joineRmodels2SE <- joineRfits2[c("joineRfit6SE", "joineRfit7SE", "joineRfit8SE")] 
4.2.3 One-stage fits to multi-study joint data 
The function jointmeta1 is written to allow the one-stage analysis of multi-study joint data. 
As this function requires bootstrapping to obtain standard errors, example model fits and 
bootstrapping results are available in the package, in objects onestage0, onestage1, 
onestage2, onestage3, and onestage4. The provided one-stage fits display a range of the 
modelling options available, including study level random effects, baseline hazard stratified by 
study, or fixed study membership terms and interactions between study membership and 
covariates of interest. Again, as these objects are not directly used in the thesis, but are 
present in the package to aid future users to familiarise themselves with the available 
functions, they are not discussed any further here. Additional information can be obtained by 
loading the joineRmeta package in R, and typing, e.g.?onestage0 into the console. 
4.3 Analysis Functions 
The functions discussed in this section relate to the meta-analysis of multi-study joint data. The 
section is split two sections, the first presenting functions to implement two-stage MA of joint 
data, and the second describing functions to implement one-stage MA of joint data. For details 
of proposed methods to conduct one or two-stage MA of joint data, see Chapter 3. 
4.3.1 Methods for Two-stage Meta-Analyses 
The function jointmeta2 can take the results of joint model fits from the joineR [80] and 
the JM [81] packages, extract the specified parameters of interest and perform separate meta-
analyses for each parameter. This function simplifies the process of a two-stage MA for joint 
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longitudinal and time-to-event data by reducing the level of programming required to perform 
the meta-analysis. The jointmeta2 function has the following syntax: 
jointmeta2(fits, SE = NULL, longpar = NULL, survpar = NULL, 
  assoc = TRUE, studynames = NULL) 
The arguments of the function have the following definitions: 
• fits - a list of joint modelling fits. These fits should all be of the same type (i.e. all fitted 
using joint function from the joineR package or all fitted using the jointModel 
function from the JM package), with the same model specification. 
• SE - a list of the results from the jointSE function from the joineR package (only to be 
supplied if the model fits supplied to argument fits are all fitted using the joineR 
package) 
• longpar - a vector of names of parameters from the longitudinal sub-model for which 
meta-analyses should be performed 
• survpar - a vector of names of parameters from the survival sub-model for which meta-
analyses should be performed 
• assoc - a TRUE/FALSE indicating whether a meta-analysis should be performed for the 
association parameter(s) 
• studynames - a vector of the names of the studies present in the dataset that the joint 
models were fitted to. These are used to label the meta-analyses performed by the 
function 
This function will perform both a fixed and a random effects MA. Meta-analyses are performed 
using the meta package [182] in R, and so the results of the function can be fed into the 
forest function in the meta package to produce forest plots of the analyses. 
The jointmeta2 function will return a list containing lists of meta-analyses, whose elements 
depend on the package used to produce the original joint model fits. This is due to the differing 
association structures employed by the joineR and the JM packages. The joineR package 
employs random effects only association structures, i.e. zero mean random effects are shared 
between the longitudinal and time-to-event sub-models to link them. In comparison, the JM 
package employs association structures that rely on some function of both the fixed and the 
random effects included in the longitudinal sub-model to link the sub-models.  As discussed in 
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Chapter 3, pooling of parameters from joint models of different specifications is not advised as 
the parameters have different interpretations. To prevent this from happening, the function 
does not allow results from a mix of JM and joineR fits to be pooled, and code has been 
included in the function to check the specifications of the joint model fits supplied. 
If the models supplied to the jointmeta2 function all had the same specification, the function 
would proceed with the meta-analysis. In the example below, the supplied joint models all 
employ a joint model whose longitudinal sub-model contains a fixed intercept, time and 
treatment terms and random intercept and time terms, and whose time-to-event sub-model 
contains a fixed treatment effect. The sub-models are linked through shared random effects 
with common association parameter. The function call (printed below) specifies that meta-
analyses are performed for the time and treatment terms in the longitudinal sub-model (using 
argument longpar = c("time", "treat1")), for the treatment effect in the time-to-
event sub-model (with argument survpar = "treat1"), and for the association parameter 
(through assoc = TRUE). Labels are also supplied to identify the studies contributing data to 
the analysis. 
MAjoineRfits <- jointmeta2(fits = joineRmodels, SE = joineRmodelsSE,  
                           longpar = c("time", "treat1"),  
                           survpar = "treat1", assoc = TRUE,  
                           studynames = c("Study 1", "Study 2", "Study 3")) 
The structure of the output is examined using the following code: 
names(MAjoineRfits) 
## [1] "longMA"   "survMA.direct"  "assocMA" 
The output is a list containing three elements, each of which is a list of the results of meta-
analyses performed using the meta packages for the parameters of interest for the longitudinal 
sub-model, the time-to-event sub-model and the association structure respectively. For 
example, the meta-analyses conducted for each of the longitudinal parameters of interest can 
be extracted using the code MAjoineRfits$longMA, or by using 
MAjoineRfits$longMA$treat1, just the meta-analysis for the longitudinal treatment effect 
can be extracted: 
MAjoineRfits$longMA$treat1 
##             MD           95%-CI %W(fixed) %W(random) 
## Study 1 2.0558 [1.6810; 2.4305]      29.8       33.3 
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## Study 2 2.4411 [2.0552; 2.8270]      28.1       33.2 
## Study 3 0.3452 [0.0296; 0.6607]      42.1       33.5 
##  
## Number of studies combined: k = 3 
##  
##                          MD           95%-CI     z  p-value 
## Fixed effect model   1.4447 [1.2400; 1.6493] 13.84 < 0.0001 
## Random effects model 1.6103 [0.2845; 2.9361]  2.38   0.0173 
##  
## Quantifying heterogeneity: 
##  tau^2 = 1.3390; H = 6.42 [4.63; 8.91]; I^2 = 97.6% [95.3%; 98.7%] 
##  
## Test of heterogeneity: 
##      Q d.f.  p-value 
##  82.46    2 < 0.0001 
##  
## Details on meta-analytical method: 
## - Inverse variance method 
## - DerSimonian-Laird estimator for tau^2 




In the meta-analyses of fits from the joineR package, the meta-analyses of the time-to-event 
parameters are held in a list labelled survMA.direct while from the JM package these are 
held in survMA.direct and survMA.overall.  This is due to the difference in available 
association structures between the two packages: the JM package allows association structures 
involving both fixed and random effects, whereas the joineR package shares only the random 
effects between the sub-models.  As a result, in joint model fits from the JM package, 
covariates included in the time-to-event sub-model have an overall effect on risk of an event 
consisting of the direct effect of including the covariate in the time-to-event sub-model, and 
the indirect effect of fixed effects present due to the association structure.  The theory behind 
this concept is described in Section 5.1.1.  
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Due to the presence of direct, indirect and overall effects in joint models that employ fixed and 
random effects association structures, when such joint modelling fits are supplied to the 
jointmeta2 function, meta-analyses are performed for both the direct effect, and the overall 
effect of specified parameters from the time-to-event sub-model: 
MAJMfits <- jointmeta2(fits = JMfits, longpar = c("time", "treat1"),  
                       survpar = "treat1", assoc = TRUE, 
                       studynames = c("Study 1", "Study 2", "Study 3")) 
names(MAJMfits) 
## [1] "longMA"   "survMA.direct"   "survMA.overall"   "assocMA" 
As before, forest plots of the results can be examined, allowing clear comparison of the direct 





As well as being able to calculate the overall effects for models that use just a current value 
association structure, the function can also handle the case where the association structure of 
the joint model involves both the current value and current slope (first derivative with respect 
to time) of the longitudinal trajectory. The models included in object JMfits2 use an 
association structure that involves both the current value and slope of the longitudinal 
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trajectory, and the longitudinal sub-model contains both a treatment assignment fixed effect 
and an interaction between time and treatment. As such the overall effect of the covariate 
treatment assignment on the risk of an event has format consisting of a direct effect resulting 
from inclusion of treatment as a fixed effect in the time-to-event sub-model, and one indirect 
effect from each of the current value and the current slope association structures (see Section 
5.1.1 for in-depth discussion of the theory of indirect and direct effects in joint models). Meta-
analyses can be performed by supplying the joint modelling fits to the jointmeta2 function, 
and specifying the parameters of interest. The function will identify any coefficient estimates 
that should contribute to overall effects of specified time-to-event parameters of interest, and 
will calculate the overall value. This is demonstrated through the following code: 
MAJMfits2 <- jointmeta2(fits = JMfits2, longpar = c("time", "treat1"),  
                        survpar = "treat1", assoc = TRUE, 
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As mentioned, based on the guidelines given for two-stage MA in Section 3.2.4, the function 
checks if the specifications of the joint models are identical.  Various differences in supplied 
joint model specifications can cause error messages to be returned by the jointmeta2 
function.  
Firstly, if the jointmeta2 function is supplied with a mixture of models that link sub-models 
through shared random effects, and models that link sub-models through shared fixed and 
random effects, the following message is returned: 
MAtest <- jointmeta2(fits = c(JMfits2[1:3], joineRmodels[1:2]),  
                     longpar = c("time", "treat1"),  
                     survpar = "treat1", assoc = TRUE,  
                     studynames =c("Study 1","Study 2","Study 3","Study 4","Study 5")) 
## Error in jointmeta2(fits = c(JMfits2[1:3], joineRmodels[1:2]), longpar = c 
## ("time", : Some of the joint modelling fits are different classes - 
##          consider subgrouping 
Secondly, pooling model fits from the joineR package whose random effects specification 
differ will cause the following message: 
MAtest <- jointmeta2(fits = c(joineRmodels[1:3], joineRmodels2[1:2]),  
                     SE = c(joineRmodelsSE[1:3],joineRmodels2SE[1:2]),                
            longpar = c("time", "treat1"), survpar = "treat1",  
                     assoc = TRUE,  
                     studynames =c("Study 1","Study 2","Study 3","Study 4","Study 5")) 
## Error in jointmeta2(fits = c(joineRmodels[1:3], joineRmodels2[1:2]), SE =  
## c(joineRmodelsSE[1:3], : Some of the joint model fits have differing  
##           random effects structures 
Additionally, pooling model fits from the JM package whose parameter specifications differ 
results in the following: 
MAtest <- jointmeta2(fits = c(JMfits2[1:3], JMfits[1:2]),  
                     longpar = c("time", "treat1"),  
                     survpar = "treat1", assoc = TRUE,  
                     studynames =c("Study 1","Study 2","Study 3","Study 4","Study 5")) 
## Error in jointmeta2(fits = c(JMfits2[1:3], JMfits[1:2]),                   
## longpar = c("time ", : Some of the joint model fits have differing         
## association structures 
The programmed error messages in the jointmeta2 function are designed to help the user 
pool only parameters with comparable interpretations. In addition to flagging differing 
association structures, the function will also return an error if a mix of PH and AFT models have 
been used in the time-to-event sub-model of fits using the JM package.  This functionality 
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should not replace the user considering what model fits are appropriate to pool, but aims to 
guard against the most common routes to pooling dissimilar parameters. 
Currently, the jointmeta2 function can only take fits produced by either the joineR or the 
JM packages. However, plans for future extensions of the R package include extending the 
function to take fits from additional packages such as single study univariate analyses 
conducted using the joineRML[181] and joineRmeta packages. Proposed further work on 
this package is discussed in Section 8.3.2. 
4.3.2 Methods for One-Stage Meta-Analyses 
4.3.2.1 Function to fit One-Stage Models 
The function jointmeta1 fits a one-stage model to a multi-study joint data object in R of 
formats discussed in Chapter 3. The function has the following syntax: 
jointmeta1(data, long.formula, long.rand.ind, long.rand.stud = NULL,  
           sharingstrct = c("randprop", "randsep", "value", "slope", 
                            "valandslope"), surv.formula, gpt, lgpt, max.it,  
           tol, study.name, strat = F, longsep = F, survsep = F, bootrun = F  
           print.detail = F)  
The arguments of this function are as follows: 
• data - a jointdata object containing the variables named in the model formulae. 
• long.formula - the formula for the longitudinal sub-model 
• long.rand.ind - the names of variables to assign individual level random effects to 
• long.rand.stud - the names of variables to assign study level random effects to 
• sharingstrct - association structure - currently must be set to "randprop" 
• surv.formula - the formula for the time-to-event sub-model 
• gpt - the number of quadrature points across which the integration with respect to the 
random effects will be performed. This defaults to gpt = 5 
• lgpt - the number of quadrature points which the log-likelihood is evaluated over 
following a model fit. This defaults to lgpt = 7 
• max.it - the maximum number of iterations of the EM algorithm that the function will 
perform. Defaults to max.it = 350, however more iterations could be required for 
large complex datasets. 
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• tol - the tolerance level used to determine convergence in the EM algorithm. Defaults to 
tol = 0.001. 
• study.name - name of the variable in the baseline dataset in the specified jointdata 
object giving study membership 
• strat - if TRUE then the survival sub-model contains a baseline hazard stratified by 
study. If FALSE, the baseline is common across studies 
• longsep - if TRUE, the results from a separate longitudinal model with the same 
specification as the joint model's longitudinal sub-model are returned, FALSE otherwise 
• survsep - if TRUE, the results from a separate time-to-event model with the same 
specification as the joint model's time-to-event sub-model (excluding the association 
structure) are returned, FALSE otherwise 
• bootrun - if TRUE, the log-likelihood for the model is not calculated 
• print.detail - if TRUE details of the parameters at each EM algorithm iteration are 
printed to the console 
The formulas for the longitudinal sub-model and the time-to-event sub-model, supplied to 
arguments long.formula and surv.formula respectively, are expressed in the same way 
as definition of the sub-models in the joineR package. Specifically, the longitudinal formula 
should be expressed as the name of the longitudinal outcome, followed by the specification for 
the model to fit to the longitudinal outcome, for example long.formula = Y ~ 1 + time 
+ treat. Interaction terms or functions can be specified, for example (as used in the real data 
analysis in Chapter 6) a specification of long.formula = Y ~ 1 + time + treat*study 
+ exp(-3*time) is permitted, to give a sub-model with an exponential of three times the 
longitudinal time term as well as an interaction term between treatment assignment and study 
membership. The function currently does not automatically support the inclusion of splines in 
the longitudinal sub-model, and only allows models that can be expressed as a linear 
combination of terms. 
The time-to-event sub-model should be expressed using the Surv function (see the survival 
[195] package). As an example, surv.formula = Surv(survtime, cens) ~ treat 
would fit a time-to-event sub-model containing a single fixed effect of treatment assignment to 
time-to-event data with survival time survtime and censoring variable cens. The time-to-
event sub-model, as with the longitudinal sub-model, can contain fixed interaction terms, for 
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example Surv(survtime, cens) ~ treat*study. Currently, the function only allows a 
proportional hazards model with an unspecified baseline hazard to be fitted. However, the 
baseline hazard can be common across studies (by setting argument strat = FALSE), or it 
can be stratified by study allowing a different baseline hazard for each study in the meta-
analysis (by setting strat = TRUE). 
Zero mean normally distributed random effects can be included at either the individual level 
(level 2), or at both the study level (level 3) and the individual level. The number of random 
effects at each level is capped at three in the current package, both for ease of programming 
when writing the model fitting function, and also to prevent the joint model from becoming 
overly complex. Random effects at any level should only be assigned to variables that are also 
assigned fixed effects in the model. This is because the study level random effects quantify the 
difference between overall population effects (quantified by the fixed terms) and the effect 
observed in each study, and the individual level random effects quantify the difference 
between the study effect and the individual effect (given that between study variation is 
accounted for, if not they quantify the difference between the overall population effect and 
the effect observed in the individual). Note, fixed effects do not have to be assigned random 
effects. 
Unlike Wulfsohn and Tsiatis [78], who absorb the fixed effects in their joint model into the 
mean of their random effects distribution, the models proposed in this research separate fixed 
and random effects, resulting in individual and study level random effects with zero means, 
and the necessity to only assign random effects to coefficients that have been assigned fixed 
effects in the model (an approach reminiscent of the mixed effect models proposed by Laird 
and Ware [29]).  The aim of this research is the meta-analysis of multi-study joint data, as such 
the parameters of interest are the population or overall effects of covariates (as quantified by 
the fixed effects).  As such, separation of parameters into fixed effects, and zero mean random 
effects, simplifies the reporting of the parameters of interest to MA in the output from this 
model fitting function, facilitating the researcher in extraction of the required results.    
If random effects were permitted non-zero means, as in Wulfsohn and Tsiatis [78], then the 
association structure would be closer to the current value than the random effects only 
parameterization.  The value shared between sub-models would quantify how the recorded 
value(s) for an individual for any covariates assigned random effects effect their risk of an 
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event. However, fixed effects not assigned random effects would not be shared between sub-
models (in Wulfsohn and Tsiatis [78], no standalone fixed effects are included in their model, 
so this does not occur).  Future work for this software package aims to allow the user to fit a 
joint MA models with current value association structures (see Chapter 8). 
Individual level random effects are specified by supplying the name or names of variables to be 
assigned individual level random effects to argument rand_ind. If a random intercept is to be 
included in the model, then the character string "int" should be included to argument 
rand_ind. As an example, to specify a model with an individual level random intercept and 
slope, then rand_ind = c("int","time"), where time would be the name of the 
longitudinal time variable. If an individual level random intercept is not to be included in the 
model, then "noint" should be included in the argument, e.g. rand_ind = c("noint", 
"time"). At least one individual level random effect must be included in the model to ensure 
that the sub-models are linked. If no individual level random effects, or more than three, are 
specified, then the function returns an error message. 
Study level random effects are specified in a way similar to the individual level random effects, 
in that the name or names of variables to be assigned study level random effects are supplied 
to argument rand_stud. If a study level random intercept is to be included in the model, then 
the name of the study membership variable should be supplied to rand_stud, e.g. 
rand_stud = c("study", "treat"), otherwise the study membership variable name 
should not be present in rand_stud. Study level random effects do not have to be included in 
the model, this can be achieved by not including the argument in the function call, or setting 
rand_stud = NULL. An error message will be returned if more than three study level 
random effects are specified. 
Currently, the jointmeta1 function only allows the sub-models to be linked through the 
proportional random effects only structure [30, 75] (see Section 5.1.2.1 for methodology 
behind code, and Section 3.3.2 for examples of the types of models it is possible to fit using this 
function). As such, argument sharingstrct must be set to "randprop", otherwise an error 
message will be encountered. It is planned to expand the function to permit additional 
association structures to be permitted (see Section 8.3.2.2), as such the argument 
sharingstrct has been included in the function call to facilitate this future work 
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Integration across the random effects included in the model is accomplished through pseudo-
adaptive Gaussian quadrature [196]; this is further discussed in Section 5.1.2.2. Arguments gpt 
and lgpt control the number of quadrature points for joint model fitting and estimation of the 
log-likelihood respectively. 
The joint model is fitted using an EM algorithm [197], which requires starting values for 
parameters to be supplied. These starting values are generated by fitting initial separate 
longitudinal and time-to-event models, with the same specification as the corresponding sub-
models in the joint model (apart from the association structure in the time-to-event sub-
model). By setting longsep and survsep to TRUE, the initial longitudinal and time-to-event 
model fits respectively are returned. This is useful if the user wishes to compare the results 
from the joint model and separate longitudinal and time-to-event models. 
The argument tol specifies the tolerance level used when testing if the EM algorithm has 
converged. If the maximum difference between parameters estimated at two consecutive 
iterations is less than the value of tol, convergence is declared and the parameter estimates 
are returned. The default tolerance value is tol = 0.001. The argument max.it specifies 
the maximum number of iterations that the EM algorithm will perform before non-
convergence is declared (the default value is 350 iterations, more iterations may be required 
for complex data). 
The bootrun argument is included for use by the jointmetaSE function (described below). 
When fitting models at each bootstrap iteration, calculating the log-likelihood of the model fit 
is of no interest; it is only necessary to generate the parameter estimates. As such, setting 
bootrun to TRUE means that the model will not calculate the log-likelihood during the model 
fit (speeding up the bootstrapping process). In addition messages will not be printed from the 
function during each bootstrap’s model fit. In general, when a model is fitted using 
jointmeta1, a message is printed when the EM algorithm commences the joint model fit, and 
also when calculation of the log-likelihood begins. In addition, during calculation of the log-
likelihood, a progress bar is printed showing the percentage progress of the calculation. This 
was implemented as with a multi-study joint dataset, the log-likelihood calculation can take 
some time, and a moving progress bar provides reassurance that the function has not halted. 
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The print.detail argument, if set to TRUE, causes the estimates of the model parameters 
to be printed at each iteration of the EM algorithm. This is beneficial if the user wishes to see 
the process of each parameter's convergence during the model fitting process. 
4.3.2.2 Output from jointmeta1 
The jointmeta1 function generates a jointmeta1.object. The help file describing the 
output can be accessed once the joineRmeta package is loaded by typing 
?jointmeta1.object into the R console. In brief, the object contains an element 
coefficient which contains the coefficient estimates from the model. These are split into 
fixed, random and latent. The fixed coefficients are themselves split into those from the 
longitudinal and those from the time-to-event sub-model. The random portion contains 
components random_ind and random_stud, which provide estimates of the random effect 
nodes for each individual for each individual level random effect (in random_ind), and for 
each study for each study level random effect (in random_stud) respectively.  If study level 
random effects have not been specified, random_stud will not be present. The component 
latent contains estimates of any association parameters. 
The object also contains the variance of the measurement errors in element sigma.e and the 
covariance matrices for the random effects in rand_cov (split into elements D for the 
individual level random effects and, if present, A for the study level random effects). The 
estimated baseline hazard function is provided in element hazard, which is a single vector if 
argument strat was set to FALSE, a list of vectors (one for each study) if strat = TRUE.  
The log-likelihood is provided in element loglik (with components jointlhood for the 
overall log-likelihood, jointy for log-likelihood attributable to the longitudinal process, and 
jointn for log-likelihood attributable to the time-to-event process). The number of completed 
iterations is returned in numIter, whether convergence was achieved (TRUE/FALSE) in 
element convergence, and the specified association structure in sharingstrct. Element 
sepests contains the separate longitudinal and time-to-event model fits if requested, 
otherwise it contains a message stating the results were not requested, and element 
sep.loglik contains the log-likelihood from the separate model fits. The data supplied to the 
one-stage function is returned in element data and the original function call is held in element 
Call. Finally the number of studies present in the data is reported in element numstudies, 
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the number of individuals within each study is staged in element n.bystudy, the number of 
longitudinal measurements in each study is stated in nobs, and the ids of any individuals 
excluded from analysis due to insufficient data to include them in the joint model are given in 
missingids.  
4.3.2.3 Example of one-stage MA model fit 
An example of a one-stage MA model fit is discussed below. This one-stage fit involves a fixed 
intercept, time, treatment and study membership terms in the longitudinal sub-model, along 
with an individual level random intercept and time term, and a study level random treatment 
effect. The association structure is set to "randprop" (currently this is the only association 
structure option). The time-to-event sub-model contains a fixed treatment effect only, as well 
as a baseline hazard stratified by study. The study membership variable is identified as the 
variable named "study".  The example involves the data held in simdat, which has been 
transformed into the jointdata format giving object jointdat (see Section 4.4.2.1). 
onestagefit <- jointmeta1(data = jointdat, long.formula = Y ~ 1 + time +  
                            treat + study, long.rand.ind = c("int", "time"),  
                          long.rand.stud = c("treat"),  
                          sharingstrct = "randprop",  
                          surv.formula = Surv(survtime, cens) ~ treat,  
                          study.name = "study", strat = TRUE) 
This example will be used during the rest of the chapter to demonstrate the functions 
applicable to one-stage model fits in the package. 
4.3.2.4 Functions to extract information and perform bootstraps 
Various functions have been included in the package to allow users to extract information from 
the model fit. These are discussed and demonstrated below, using the above example 
onestagefit.  The functions include package specific versions of core functions expected to 
be available in any model fitting packages (fixef, formula, print, ranef, summary, 
confint, vcov), as well as some not found in other packages (jointmetaSE and rancov).  
Some of these functions are applied to the results of the jointmeta1 function (i.e. they 
expect a multi-study joint model fit to be supplied); these are identified by the presence of 
.jointmeta1 in their names.  Others act on the results of the bootstrapping function 
jointmetaSE; these are identified by the presence of .jointmeta1SE in their names. These 
portions of function names (.jointmeta1, .jointmeta1SE) identify that the function is 
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written for use with jointmeta1 and jointmeta1SE objects, produced by functions 
contained in the joineRmeta package. Functions specific to the joineRmeta package do not 
contain the suffix .jointmeta1 or .jointmeta1SE.  
4.3.2.4.1 The fixef.jointmeta1 function 
The fixef.jointmeta1 function extracts fixed effects from the one-stage multi-study joint 
model fit. The function can be applied to the model fit simply through the code 
fixef(modelfit). R automatically identifies the class of model fit (jointmeta1.object) 
and finds the correct version of fixef to use. This structure of code applies to various other 
functions described below. The function call of the fixef function is as follows: 
fixef(object, type = c("Longitudinal", "Survival", "Latent"), ...) 
In the above function call, a jointmeta1.object should be supplied to argument object. 
The fixef function allows the user to extract the fixed effect coefficients from the 
longitudinal sub-model, by specifying argument type = "Longitudinal", or to extract the 
coefficients from the time-to-event sub-model by specifying type = "Survival". The 
association parameter(s) can be extracted by setting type = "Latent": 
fixef(object = onestagefit, type = "Longitudinal") 
## (Intercept)        time      treat1      study2      study3      study4  
##  0.28666444  2.84428399  1.56430760  0.60266225  0.09199601 -0.65413670  
##      study5  
## -1.38384289 
fixef(object = onestagefit, type = "Survival") 
##   treat1  
## 1.969607 
fixef(object = onestagefit, type = "Latent") 
##  gamma_ind_0 gamma_stud_0  
##   0.98582075  -0.07625637 
4.3.2.4.2 The formula.jointmeta1 function 
The formula.jointmeta1 function allows the model formulae defining various parts of the 
fitted joint model to be extracted. This function has the following format: 
formula(x, type = c("Longitudinal", "Survival","Rand_ind", "Rand_stud"), ...) 
In this function, a jointmeta1.object should be supplied to argument x. The component of 
the joint model to display the formula for should be supplied to argument type, i.e. to extract 
 111   
 
the formula for the fixed portion of the longitudinal sub-model set type = 
"Longitudinal", for the time-to-event sub-model set type = "Survival", for the 
individual level random effects set type = "Rand_ind", and for the study level random 
effects set type = "Rand_stud". The outputs of applying this function to the example 
model fit are shown below: 
formula(x = onestagefit, type = "Longitudinal") 
## Y ~ 1 + time + treat + study 
formula(x = onestagefit, type = "Survival") 
## Surv(survtime, cens) ~ treat 
formula(x = onestagefit, type = "Rand_ind") 
## ~1 + time 
formula(x = onestagefit, type = "Rand_stud") 
## ~ treat1 
4.3.2.4.3 The print.jointmeta1 function 
The print.jointmeta1 function prints basic information about the one-stage joint model 
fit supplied to argument x. The function takes the following format: 
print(x, ...) 
Applying the function to a model fit gives: 
print(x = onestagefit) 
##  
## Call: 
## jointmeta1(data = jointdat, long.formula = Y ~ 1 + time + treat +  
##     study, long.rand.ind = c("int", "time"), long.rand.stud = c("treat"),  
##     sharingstrct = "randprop", surv.formula = Surv(survtime,  
##         cens) ~ treat, study.name = "study", strat = TRUE) 
##  
## Random effects joint meta model 
##  Data: jointdat  
##  
## Longitudinal sub-model fixed effects: Y ~ 1 + time + treat + study                 
       
## (Intercept)  0.28666444 
## time         2.84428399 
## treat1       1.56430760 
## study2       0.60266225 
## study3       0.09199601 
## study4      -0.65413670 
## study5      -1.38384289 
##  
## Time-to-event sub-model fixed effects: Surv(survtime, cens) ~ treat 
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## Strat: TRUE 
##   treat1  
## 1.969607  
##  
##  
## Latent association:                         
## gamma_ind_0   0.98582075 
## gamma_stud_0 -0.07625637 
##  
## Variance components: 
##               Type        Name     Value 
## 1 Individual level (Intercept) 0.9909671 
## 2                         time  1.240652 
## 3      Study level      treat1 0.9171312 
## 4         Residual             0.0041291 
##  
## Number of studies: 5 
##  
## Number of individuals per study: 
##   1   2   3   4   5  
## 500 500 500 500 500  
##  
## Number of longitudinal observations: 
##    1    2    3    4    5  
## 1422 1296 1346 1595 1752 
The output of the function contains statements of the function call, the type of model fitted (a 
random effects joint meta model), the name of the data the function is fitted to, followed by a 
summary of the formulae and parameter estimates from each of the longitudinal and time-to-
event sub-models. The association parameters are displayed under the "Latent Association" 
section. The "Variance Components" section shows the variance of each of the random effects 
at the individual and the study levels as well as the residual variance. Reports of the number of 
studies in the data, number of individuals per study, and number of longitudinal observations 
per study are then printed. 
4.3.2.4.4 The rancov function 
The rancov function is a way for users to easily extract the estimated covariance matrices for 
the random effects at each level. The syntax of the function call is shown below: 
rancov(fitted, type = c("individual", "study")) 
The function expects a one-stage joint model fit of class jointmeta1.object to be supplied 
to argument fitted, whilst the level of the random effects for which to extract the covariance 
matrix needs to be supplied to argument type, (type = "individual" requests the 
covariance matrix for the individual level random effects, whilst type = "study" prints the 
covariance matrix for the study level random effects). 
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rancov(fitted = onestagefit, type = "individual") 
##             (Intercept)      time 
## (Intercept)   0.9909671 0.4800569 
## time          0.4800569 1.2406520 
rancov(fitted = onestagefit, type = "study") 
##           treat1 
## treat1 0.9171312 
4.3.2.4.5 The ranef.jointmeta1 function 
The ranef.jointmeta1 function extracts the estimated nodes of the random effects at each 
level. The function call has syntax: 
ranef(object, type = c("individual", "study"), ...) 
In the function, a jointmeta1.object is to be supplied to argument object, whilst the 
level of random effects to display the estimated nodes for should be supplied to argument 
type. Setting type = "individual" returns a list with number of elements equal to the 
number of studies in the dataset. Each element of the returned list is a matrix with number of 
columns equal to the number of individual level random effects (two in the example), and 
number of rows equal to the number of individuals in the study. Setting type = "study" 
returns a matrix with number of columns equal to the number of study level random effects, 
and number of rows equal to the number of studies in the dataset.  
An example is provided in the code below (with output requested for just the first five 
individuals in the first study; to print all results use ranef(object = onestagefit, type 
= "individual")). 
ranef(object = onestagefit, type = "individual")[[1]][1:5,] 
##     b2_(Intercept)    b2_time 
## 464     -0.4541902 -0.2101875 
## 104      2.1659179  1.0059201 
## 479      2.2555976  1.0493788 
## 448      1.0146335  0.4695370 
## 319      0.6621034  0.3358462 
ranef(object = onestagefit, type = "study") 
##    b3_treat1 
## 1  0.3515943 
## 2  0.8482005 
## 3 -1.4389932 
## 4  1.0234457 
## 5 -0.7843412 
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In the above example output, the results have columns labelled as random effects (with those 
acting at the individual level or level 2 of the data labelled b2_ followed by the name of the 
respective individual level random effect, and those acting at the study level or level 3 of the 
data labelled b3_ followed by the name of the respective study level random effect). The rows 
are labelled with the identifications of the units the random effect estimates relate to (if type 
= "study" the rows are labelled with the names of the studies in the dataset, whilst if type 
= "individual" the rows are labelled with the individual specific IDs). 
4.3.2.4.6 The summary.jointmeta1 function 
The summary.jointmeta1 function is similar to the print function, and has format: 
summary(object, variance = TRUE, ...) 
In the above function, a one-stage joint model fit of class jointmeta1.object is supplied to 
argument object. The argument variance specifies whether the values for the variances 
(variance = TRUE) or for the standard deviations are shown (variance = FALSE). The 
result of applying summary to the example fit is shown below: 
summary(object = onestagefit) 
##  
## Call: 
## jointmeta1(data = jointdat, long.formula = Y ~ 1 + time + treat +  
##     study, long.rand.ind = c("int", "time"), long.rand.stud = c("treat"),  
##     sharingstrct = "randprop", surv.formula = Surv(survtime,  
##         cens) ~ treat, study.name = "study", strat = TRUE) 
##  
## Random effects joint meta model 
##  Data: jointdat  
##  Log-likelihood: -14722.25  
##  AIC: 29472.49  
##  
## Longitudinal sub-model fixed effects: Y ~ 1 + time + treat + study                 
## (Intercept)  0.28666444 
## time         2.84428399 
## treat1       1.56430760 
## study2       0.60266225 
## study3       0.09199601 
## study4      -0.65413670 
## study5      -1.38384289 
##  
## Time-to-event sub-model fixed effects: Surv(survtime, cens) ~ treat 
## Strat: TRUE 
##   treat1  
## 1.969607  
##  
##  
## Latent association:                         
## gamma_ind_0   0.98582075 
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## gamma_stud_0 -0.07625637 
##  
## Variance components: 
##               Type        Name     Value 
## 1 Individual level (Intercept) 0.9909671 
## 2                         time  1.240652 
## 3      Study level      treat1 0.9171312 
## 4         Residual             0.0041291 
##  
## Convergence at iteration: 13  
##  
## Number of studies: 5 
##  
## Number of individuals per study: 
##   1   2   3   4   5  
## 500 500 500 500 500  
##  
## Number of longitudinal observations: 
##    1    2    3    4    5  
## 1422 1296 1346 1595 1752 
The output of the function is similar to that obtained by print(onestagefit), but slightly 
more information is returned. For example, a statement of the log-likelihood and the AIC is 
included along with the number of EM algorithm iterations conducted before convergence was 
achieved. 
4.3.2.4.7 The jointmetaSE function 
The model fitted using the jointmeta1 function includes an unspecified baseline hazard in 
the time-to-event sub-model. Hsieh et al [89] recommend that standard errors should be 
calculated through a bootstrapping procedure to avoid underestimation. A bootstrapping 
procedure is provided in the jointmetaSE function, which has the following function call: 
jointmetaSE(fitted, n.boot, gpt, max.it, tol, print.detail = FALSE, 
  overalleffects = NULL) 
Here, a one-stage joint model fit of class jointmeta1.object should be supplied to 
argument fitted. The number of bootstraps to complete should be supplied to n.boot, and 
the number of quadrature points to integrate the random effects over during model fitting 
should be supplied to gpt (this will default to 5). The maximum number of iterations to 
complete would be supplied to max.it (this defaults to 500), and the tolerance used to test 
convergence should be supplied to tol (this defaults to 0.001). If argument print.detail is 
set to TRUE, the parameter estimates at each iteration of each bootstrap will be printed. If this 
is set to FALSE then instead a progress bar showing completion of all bootstraps will be 
printed.  
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The code to apply the bootstrapping function to a multi-study joint model fit is: 
onestagefitSE <- jointmetaSE(fitted = onestagefit, n.boot = 200) 
The jointmetaSE function outputs a jointmeta1SE.object. The help file for this class of 
object can be displayed by typing ?jointmetaSE.object into the R console when the 
joineRmeta package is loaded.  
The structure of a jointmeta1SE object can be viewed using code such as 
str(onestagefitSE), which shows a list of three objects, labelled results, covmat, and 
bootstraps. The object bootstraps contains the parameter estimates from every model fit 
performed during the bootstrap process, and can be accessed by typing 
onestagefitSE$bootstraps. The object results gives the parameter estimates, standard 
errors and confidence intervals in a neatly arranged table, and can be obtained by typing 
onestagefitSE$results into the console. The covariance matrix for the model parameters 
is accessible by running code onestagefitSE$covmat. The bootstrapping procedure will 
only return confidence intervals if at least 100 bootstraps have been completed. 
A range of functions to work with an object of class jointmeta1SE are included in the 
package, to allow easy extraction of information, these are discussed in the following sections. 
4.3.2.4.8 The print.jointmeta1SE function 
The print function print.jointmeta1SE has function syntax: 
print(x, ...) 
The results of the jointmeta1SE function, i.e. a jointmetaSE.object should be supplied 
to argument x. This will extract and return the results element of a jointmetaSE.object. 
When applied to the example, the results of the bootstrapping procedure are returned: 
print(onestagefitSE) 
##       Component      Parameter Estimate     SE 95%Lower 95%Upper 
## 1  Longitudinal    (Intercept)   0.2867 0.0654   0.1578   0.4073 
## 2                         time   2.8443 0.0288    2.787   2.9034 
## 3                       treat1   1.5643 0.0379   1.4882   1.6386 
## 4                       study2   0.6027 0.0831   0.4409   0.7623 
## 5                       study3    0.092 0.0865  -0.0621   0.2503 
## 6                       study4  -0.6541  0.089  -0.8352  -0.4991 
## 7                       study5  -1.3838 0.0874  -1.5591  -1.2188 
## 8      Survival         treat1   1.9696 0.0727   1.8322    2.134 
## 9   Association    gamma_ind_0   0.9858 0.0227   0.9413   1.0299 
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## 10                gamma_stud_0  -0.0763 0.0868  -0.2533   0.0646 
## 11     Variance b2_(Intercept)    0.991 0.0295    0.924    1.036 
## 12                     b2_time   1.2407 0.0405   1.1603   1.3139 
## 13                   b3_treat1   0.9171 0.0718   0.7855   1.0634 
## 14                    Residual   0.0041  1e-04   0.0039   0.0044 
4.3.2.4.9 The confint.jointmeta1SE function 
The package also contains confint.jointmeta1SE which extracts only the confidence 
intervals from the results of the bootstrapping process, and has the following formulation. 
confint(object, parm = NULL, level = 0.95, ...) 
In the above function, a jointmetaSE.object should be supplied to argument object, 
parm is a vector giving the parameter names or locations in the list of model parameters for 
which confidence intervals should be returned, and the level of the confidence intervals should 
be supplied to argument level (this defaults to 0.95 for 95% confidence intervals).  This 
function was included to mirror the common practice of model fitting packages to include a 
function to extract only parameter estimates and confidence intervals from model fitting 
results, and also to allow the user to calculate confidence intervals at a level other than 95%.   
This function can be demonstrated using the example bootstraps object onestagefitSE. The 
first example requests 95% confidence intervals for all the parameters included in the model 
(as argument parm is not specified, all results are returned, and as level is not specified it 
defaults to 0.95). 
confint(object = onestagefitSE) 
##       Component      Parameter Estimate 95%Lower 95%Upper 
## 1  Longitudinal    (Intercept)   0.2867   0.1578   0.4073 
## 2                         time   2.8443    2.787   2.9034 
## 3                       treat1   1.5643   1.4882   1.6386 
## 4                       study2   0.6027   0.4409   0.7623 
## 5                       study3    0.092  -0.0621   0.2503 
## 6                       study4  -0.6541  -0.8352  -0.4991 
## 7                       study5  -1.3838  -1.5591  -1.2188 
## 8      Survival         treat1   1.9696   1.8322    2.134 
## 9   Association    gamma_ind_0   0.9858   0.9413   1.0299 
## 10                gamma_stud_0  -0.0763  -0.2533   0.0646 
## 11     Variance b2_(Intercept)    0.991    0.924    1.036 
## 12                     b2_time   1.2407   1.1603   1.3139 
## 13                   b3_treat1   0.9171   0.7855   1.0634 
## 14                    Residual   0.0041   0.0039   0.0044 
Confidence intervals can be requested just for one set of parameters (e.g. just the treatment 
effects), and can be requested at a different level (e.g. 99%) using the following code: 
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confint(object = onestagefitSE, parm = "treat1", level = 0.99) 
##      Component Parameter Estimate 99%Lower 99%Upper 
## 3 Longitudinal    treat1   1.5643   1.4510   1.6509 
## 8     Survival    treat1   1.9696   1.7931   2.1694 
4.3.2.4.10 The vcov.jointmeta1SE function 
Finally, the vcov.jointmeta1SE function automatically extracts the covariance matrix from 
an object of class jointmeta1SE when it is supplied to argument object, and has syntax: 
vcov(object, ...) 
As an example, running the code vcov(object = onestagefitSE) will extract the 
covariance matrix for the model parameters. 
4.4 Exploratory Functions 
A range of tools designed for the exploratory analysis of multi-study joint data are available in 
the joineRmeta package. These are divided into three main sections; functions for Data 
Simulation (Section 4.4.1), for Data Preparation (Section 4.4.2), and for Data Visualisation 
(Section 4.4.3). Functions described in this section are designed to be used prior to models 
being fitted to the data, and aim to help the users generate multi-study joint data to 
investigate models under controlled conditions, to prepare data into the format required by 
the model fitting functions, or to produce visual summaries of the data to aid with model 
choice (e.g. for use in Preliminary work before a two-stage MA, see Section 3.2.1). 
4.4.1 Data Simulation 
Simulation studies are a powerful tool to investigate model behavior under specified 
conditions. At the start of this thesis, functions to simulate joint data in a single study case 
were available, however multi-study data simulation functions for joint longitudinal and time-
to-event data that allowed control over study level variation through study level random 
effects were not available. As such, the data simulation function included in the joineR 
package [80] has been expanded to permit simulation of such data.  
The data simulation function simjointmeta allows the user to generate joint longitudinal and 
time-to-event data for multiple studies simultaneously. The function and its arguments are 
shown below, with the default settings for the arguments described: 
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simjointmeta(k = 5, n = rep(500, 5), sepassoc = FALSE, ntms = 5,  
             longmeasuretimes = c(0, 1, 2, 3, 4), beta1 = c(1, 1, 1),  
             beta2 = 1,rand_ind = c("intslope", "int"),  
             rand_stud = c("int", "inttreat", "treat", NULL), gamma_ind = 1,  
             gamma_stud = NULL, sigb_ind, sigb_stud = NULL, vare = 0.01,  
             theta0 = -3, theta1 = 1, censoring = TRUE, censlam = exp(-3), 
             truncation = FALSE, trunctime = max(longmeasuretimes))  
The function contains a range of arguments which are defined below.  
• k - the number of studies to be simulated 
• n - a vector (of length equal to k) specifying the number of individuals to be simulated per 
study 
• sepassoc - a TRUE/FALSE value specifying whether the data should be generated using 
separate association parameters per random effect (TRUE), or whether the association 
parameter is common across random effects acting at the same level (FALSE), see 
Section 1.6.2 for an introduction to association structures. 
• ntms - the number of longitudinal time-points at which a measurement is possible (this 
should be equal to the number of longmeasuretimes specified, see next argument). 
• longmeasuretimes - a vector of longitudinal measurement times. If this is not specified 
in the function call, longmeasuretimes will be set to equal integer values from 0 to 
ntms-1. 
• beta1 - a vector containing the longitudinal fixed effect coefficients in order intercept, 
treatment effect, time 
• beta2 - a vector containing the time-to-event fixed effect coefficient for treatment effect 
• rand_ind - the specification of individual level (level 2) random effects (individual level 
random effects must be present in the model the data is simulated under, to ensure 
random effects are present to link the sub-models). This argument can take the following 
values: 
– "intslope"- a model with individual level random intercept and slope (time) 
terms 
– "int"- a model with individual level random intercept 
• rand_stud - the specification of study level (level 3) random effects. Inclusion of study 
level random effects in the model the data is simulated under is optional. This argument 
can take the following values: 
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– NULL - no study level random effects (equivalent to not specifying the argument 
in the function call) 
– "int" - a model with study level random intercept 
– "treat"- a model with study level random treatment effect 
– "inttreat" - a model with study level random intercept and random treatment 
effect terms. 
• gamma_ind - the association parameter(s) linked to the individual level random effects. 
• gamma_stud - the association parameter(s) linked to the study level random effects (if 
included) 
• sigb_ind - the covariance matrix for the individual level random effects 
• sigb_stud - the covariance matrix for the study level random effects (if included) 
• vare - the variance of the longitudinal measurement error term 
• theta0 - a parameter used to control the distribution of the event times (the 
specification of the individual level random effects dictates the distribution of the event 
times) 
• theta1 – a parameter used to control the distribution of the event times  
• censoring - an argument indicating whether the event times should be subject to 
censoring (TRUE) or not (FALSE) 
• censlam - a parameter controlling the exponentially distributed censoring times 
• truncation - an argument indicating if the simulated survival times (the minimum of 
the event and censoring time if censoring is possible, the event time otherwise) are 
truncated at a certain value (TRUE) or not (FALSE) 
• trunctime - if truncation is true, the time at which the survival times are to be 
truncated 
As mentioned, study level random effects are specified through argument rand_stud. Under 
this function, it is possible to simulate data with variation between studies in treatment effect, 
or in the intercept, or both, or with no variation between studies due to study level random 
effects. As discussed in Section 3.3.2, inclusion of a study level random intercept introduces 
between study variation in the longitudinal trajectory intercept and in the log hazard ratio for 
risk of an event between data from two studies. Inclusion of a study level random treatment 
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effect introduces between study variation in the differences in the longitudinal trajectories 
between treatment groups, and in the log hazard ratio for risk of an event between treatment 
groups. If no study level random effects are specified, data simulated will be more similar 
between studies; however data will not be identical due to the use of realizations from random 
variables during the simulation process e.g. when generating error terms or the survival times. 
The function allows data to be generated with either separate association (sepassoc = 
TRUE) or common association (sepassoc = FALSE) parameters for the random effects at a 
given level.   For example, if an individual level random intercept and time term, and a study 
level random intercept and treatment term were specified, setting sepassoc = TRUE causes 









(3)𝑡𝑟𝑒𝑎𝑡𝑘𝑖.  However, setting sepassoc = FALSE 







If sepassoc is set to TRUE, then the number of association parameters supplied to 
gamma_ind should be the same as the specified number of individual level random effects in 
the model the data is generated under. For example, if rand_ind is set to "intslope", then 
the function would expect two association parameters be supplied to gamma_ind. Similarly, if 
study level random effects are specified, then the number of association parameters supplied 
to gamma_stud and the number of study level random effects should be equal. 
Between study heterogeneity can also be introduced to the data through the association 
parameters. If the user wishes to specify different association parameters for each study, then 
the association parameter arguments gamma_ind and gamma_stud can be supplied as lists of 
length equal to the number of studies. Each element of the list would be either a single value if 
sepassoc = FALSE or a vector of values equal in length to the number of random effects 
acting at the relevant level if sepassoc = TRUE. 
The arguments theta0 and theta1 control the distribution of the event times for individuals 
in the dataset. As with the association parameters, between study heterogeneity can be 
introduced by specifying different values for the arguments for each simulated study. If the 
parameters defining the distribution of the event times is to be identical between studies, 
theta0 and theta1 should be defined as single values in the function call. Otherwise, 
theta0 and theta1 should each be specified as a vector of values equal in length to the 
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number of studies to be simulated.  Further details concerning the effect of arguments theta0 
and theta1 are given in Section 5.2. 
The argument censlam controls the distribution of the censoring times (if censoring is 
permitted in the data by setting censoring = TRUE). As with the parameters controlling the 
distribution of event times, the censlam argument can be supplied as a single value, or as a 
vector of value of length equal to the number of studies to be simulated. This allows the 
distribution of censoring times to be the same or varying across studies, allowing another way 
for users to introduce between study heterogeneity to their data. 
The methodology used by this function to simulate multi-study joint data is detailed in Section 
5.2. 
An example of the data simulation function and its output is presented below. When the data 
is simulated, the percentage event rate is printed to the R console, but it is also saved as part of 
the output. To simulate 5 studies each containing 500 individuals the following code could be 
run: 
exampledat1 <- simjointmeta(k = 5, n = rep(500, 5), sepassoc = FALSE,  
                            ntms = 5,longmeasuretimes = c(0, 1, 2, 3, 4),  
                            beta1 = c(1, 2, 3), beta2 = 1, 
                            rand_ind = "intslope", rand_stud = NULL,  
                            gamma_ind = 1,  
                            sigb_ind = matrix(c(1, 0.5, 0.5, 1.5),nrow = 2),  
                            vare = 0.01, theta0 = -3, theta1 = 1,  
                            censoring = TRUE, censlam = exp(-3),  
                            truncation = FALSE, 
                            trunctime = max(longmeasuretimes)) 
## 72.2 % experienced event 
## 75 % experienced event 
## 75.8 % experienced event 
## 71.6 % experienced event 
## 79.2 % experienced event 
The exact structure of the simulated data can be checked by running the code 
str(exampledat1) in the R console. The data produced by the simulation function is a list of 
3 elements, longitudinal which is a list of study specific long format datasets, survival 
which is a list of study specific event datasets, and percentevent which is a list of values 
stating the event rate in each simulated study. This simulated data can be changed into a 
jointdata object using the function tojointdata. 
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In each case, for each study, the longitudinal dataset contains an identification variable id for 
each individual, the continuous longitudinal outcome Y, the continuous longitudinal time 
variable time, a study membership variable study, an intercept (which always takes value 1) 
intercept, a binary (0/1) treatment variable treat, and a duplicate of the longitudinal time 
variable ltime (this variable is duplicated due to the data simulation function, and could be 
discarded). 
The survival datasets each contain an identification variable id, the survival time for each 
individual survtime, a censoring indicator cens (with 1 indicating an event, and 0 otherwise), 
a study membership variable study, and a binary treatment group indicator treat. Identical 
values in the id variables between the longitudinal and time-to-event datasets for a particular 
study identify the same individual. 
The final element of the list, percentevent, contains a list of the event rate in each study, 
with the first element of the list giving the event rate in the first study included in the dataset, 
and so on. 
4.4.2 Data Preparation 
4.4.2.1 Data formatting 
Like the joineR package, joineRmeta expects joint data to be supplied as an object of class 
jointdata. This object is defined in the joineR package [80], and contains a list of six 
elements: namely a vector of the individual identification or id variable, a longitudinal dataset, 
a time-to-event or survival dataset, a baseline dataset, the name of the longitudinal time 
variable, and the name of the individual identification or id variable. The object has to contain 
at least either a longitudinal or a survival dataset. Given the expected multi-study nature of the 
data, the package contains function tojointdata to aid users reshape data into the required 
jointdata format. 
Multi-study joint modelling data can be made available to researchers in a range of formats. 
Separate datasets could be provided for each study in the meta-analysis. Longitudinal and 
time-to-event data could be supplied in the same dataset, in either long format (one line per 
longitudinal measurement, potentially multiple lines per individual), or wide format (one line 
per individual, longitudinal measurements supplied in multiple columns). Longitudinal and 
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time-to-event data could also be provided in separate datasets. Additional datasets containing 
baseline information could also be available. The tojointdata function is designed to take 
data in various formats, and output a jointdata object. It has the following syntax: 
tojointdata(dataset = NULL, longitudinal = NULL, survival = NULL, 
  baseline = NULL, id, longoutcome, timevarying = NULL, survtime, cens, 
  time = NULL, longtimes = NULL) 
The arguments of the tojointdata function are defined as follows: 
• dataset - a dataset or list of datasets 
• longitudinal - a dataset or list of datasets in long format containing the longitudinal 
outcome and any time varying covariates (baseline information can also be included) 
• survival - a dataset or list of datasets in wide format containing the survival time and 
censoring variable (baseline information can also be included) 
• baseline - a dataset or list of datasets in wide format containing any baseline 
information. This does not have to be supplied 
• id - the name of the identification variable 
• longoutcome - the name of the longitudinal outcome variable 
• timevarying - a vector of the names of any time varying covariates in the dataset 
• survtime - the name of the survival time variable 
• cens - the name of the censoring indicator variable 
• time - if data is supplied in wide format, the name to assign to the longitudinal time 
variable produced by transforming the longitudinal data from wide to long format. If data 
is supplied in long format, the name of the longitudinal time variable 
• longtimes - if wide data, labels identifying the time points that the time varying 
variables relate to 
It is assumed that data from different studies can be supplied to the tojointdata function in 
the same format, e.g. all studies provide datasets in wide format containing both longitudinal 
and time-to-event data. If this is not the case, reformatting the data is straightforward using 
packages such as reshape2 [198], tidyr [199], or using functions available in the base R code 
such as reshape. 
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The argument dataset can be supplied as a single dataset containing all longitudinal and 
time-to-event data from all studies, or can be supplied as a list of study specific datasets 
containing both longitudinal and time-to-event information. These datasets can be in wide or 
long format. It is expected that either the argument dataset is specified, or the arguments 
longitudinal and survival (with baseline if additional baseline data is available) are 
specified. 
If data is supplied in wide format, the argument longtimes should be supplied as a vector of 
labels identifying the time points that the time-varying variables relate to. For example if there 
are four time points, and a time varying variable x in the wide dataset labelled x_1, x_2, x_3, 
and x_4, then  longtimes=c(1,2,3,4) would be supplied to the function. 
An example of using the tojointdata function applied to simulated dataset simdat to 
obtain a jointdata object (with the structure of the resulting output printed) is displayed 
below:  
jointdat<-tojointdata(longitudinal = simdat$longitudinal,  
  survival = simdat$survival, id = "id", longoutcome = "Y",  
  timevarying = c("time","ltime"), survtime = "survtime", cens = "cens", 




## List of 6 
##  $ subject     : num [1:2500] 1 2 3 4 5 6 7 8 9 10 ... 
##  $ longitudinal:'data.frame':    7411 obs. of  4 variables: 
##   ..$ id   : num [1:7411] 1 2 3 4 5 5 5 5 5 6 ... 
##   ..$ Y    : num [1:7411] 0.847 3.04 -0.252 1.976 -1.23 ... 
##   ..$ time : num [1:7411] 0 0 0 0 0 1 2 3 4 0 ... 
##   ..$ ltime: num [1:7411] 0 0 0 0 0 1 2 3 4 0 ... 
##  $ survival    :'data.frame':    2500 obs. of  3 variables: 
##   ..$ id      : num [1:2500] 1 2 3 4 5 6 7 8 9 10 ... 
##   ..$ survtime: num [1:2500] 0.346 0.595 0.489 0.323 6 ... 
##   ..$ cens    : num [1:2500] 1 0 0 1 0 0 0 1 1 1 ... 
##  $ baseline    :'data.frame':    2500 obs. of  4 variables: 
##   ..$ id       : num [1:2500] 1 2 3 4 5 6 7 8 9 10 ... 
##   ..$ study    : Factor w/ 5 levels "1","2","3","4",..: 1 1 1 1 1 1 1 1 1 1 ... 
##   ..$ treat    : Factor w/ 2 levels "0","1": 1 2 1 2 1 1 2 2 1 2 ... 
##   ..$ intercept: num [1:2500] 1 1 1 1 1 1 1 1 1 1 ... 
##  $ time.col    : chr "time" 
##  $ subj.col    : chr "id" 
##  - attr(*, "class")= chr "jointdata" 
4.4.2.2 Data cleaning 
It is possible that longitudinal measurements are available for individuals after their survival 
time, if the event in question is non-terminal, such as time to next exacerbation in asthma 
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datasets. However, longitudinal data measured after the event of interest are not included in 
the joint model. As such, a function removeafter is included in the joineRmeta package, 
designed to remove any longitudinal measurements measured after the individual's survival 
time. This function has the following syntax: 
removeafter(data, longitudinal, survival, id, time) 
• data - a jointdata object 
• longitudinal - the name of the longitudinal variable 
• survival - the name of the survival time variable 
• id - the name of the individual identification or id variable for the data 
• time - the name of the longitudinal time variable 
The removeafter function must be supplied with data in the jointdata format, and also 
returns output in jointdata format. The removeafter function is demonstrated using the 
example dataset simdat3 from the package, which contains longitudinal measurements 
recorded after the survival time. Firstly the dataset is reformatted into a jointdata object. 
jointdat3<-tojointdata(longitudinal = simdat3$longitudinal,  
  survival = simdat3$survival, id = "id", longoutcome = "Y",  
  timevarying = c("time","ltime"), survtime = "survtime", cens = "cens", 
  time = "time") 
Once simdat3 is in jointdata format, the removeafter function can be used to remove 
any longitudinal information recorded after an individual's event. When this function is run in 
the R console, a progress bar is printed to display the progress of the function. 
jointdat3.1<-removeafter(data = jointdat3, longitudinal = "Y",  
                         survival = "survtime", id = "id", time = "time") 
If the structures of the original jointdata object containing all longitudinal measurements 
(jointdat3) and the jointdata object with longitudinal measurements recorded after the 
survival time removed (jointdat3.1) are compared, the removal of some longitudinal data 
(any measurements recorded after the individual in question's survival time) can be observed 
(12500 measurements versus 5846 measurements). 
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4.4.3 Data Visualization 
Two data visualization functions are currently included in the joineRmeta package. These 
functions produce study specific plots of the longitudinal and the time-to-event data, and 
arrange them neatly to display all studies on the same plot. These plotting functions use the 
flexible ggplot2 package [200] to create plots tailored to multi-study joint data.  
4.4.3.1 Study specific plotting function 
The jointmetaplot function is designed to produce the plots described in Chapter 3, to 
enable an assessment of the potential correlation between the longitudinal and time-to-event 
outcomes, and the suitability of different models for the longitudinal and time-to-event sub-
model. The function produces study specific graphs, and has the following function call: 
jointmetaplot(dataset, study, longoutcome, longtime, survtime, cens, id, 
  smoother = FALSE, studynames = NULL, type = c("Longitudinal", "Event", 
  "Both"), eventby = NULL, eventconfint = FALSE) 
• dataset - a jointdata object 
• study - the name of the study membership variable 
• longoutcome - the name of the longitudinal outcome variable 
• longtime - the name of the longitudinal time variable 
• survtime - the name of the survival time variable 
• cens - the name of the censoring indicator variable 
• id - the name of the ID variable 
• smoother - if TRUE a smoother is included over the longitudinal trajectory plots for each 
study, FALSE otherwise 
• studynames - a vector of labels for the study specific plots, e.g. the first element will be 
the label for any plot produced from data from the first study listed in the dataset 
• type - argument to select the type of plot to produce 
• eventby - optional argument giving the name of a grouping variable to stratify the 
Kaplan-Meier curves by if plots of the time-to-event data are requested 
• eventconfint - if TRUE, confidence intervals will be displayed for the time-to-event 
plots, defaults to FALSE 
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This function is designed to easily permit users to create identical plots of the longitudinal and 
or the time-to-event data in a multi-study joint dataset. The first arguments simply define the 
dataset to be used, with key information such as the names of the outcomes and individual 
identification or id variables. The function also contains a range of arguments to control the 
appearance of the plot. 
The argument type allows the user to specify whether just plots of the longitudinal 
trajectories are to be produced (type = "Longitudinal"), whether just Kaplan-Meier plots 
of the time-to-event data are to be returned (type = "Event"), or whether the user wants 
the function to return both plot types (type = "Both"). 
The longitudinal plots produced by the function show the longitudinal trajectories for all 
individuals within a dataset. If the studies include many individuals, the trajectories can 
become heavily overlaid, and so the behaviour of the trajectories can be difficult to distinguish. 
A way to assess the overall behaviour of the trajectories is to add a smoother over the 
trajectories. By setting the argument smoother = TRUE inserts a loess smoother over the 
individual trajectories. 
The  time-to-event plots produced by the function show the Kaplan-Meier [177] plots for each 
study. Various options exist for the time-to-event plots. It is often important to compare the 
curves between different groups. In this case, the name of a categorical grouping variable, such 
as treatment assignment, can be supplied to argument eventby to produce separate curves 
for each group. Another option is to add confidence intervals to the survival curve; this can be 
achieved by setting argument eventconfint = TRUE. 
The function returns an object of class jointplots. If argument type is set to either 
"Longitudinal" or "Both" then the output will contain an element labelled longplots, 
which is a list of ggplot2 objects (see the ggplot2 package [200]) plotting, for each study, 
the individual longitudinal trajectories. If argument type is set to either "Event" or "Both" 
then the output will contain an element labelled eventplots, which is a list of ggplot2 
objects plotting the survival probabilities for each study. Note, in each case if they are 
returned, element longplots and element eventplots are lists of length equal to the 
number of studies in the dataset. 
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The elements of longplots or eventplots are given the labels supplied in argument 
studynames. Individual plots can be extracted either by their placement in the list (e.g. 
longplots[[1]] to extract the longitudinal plot for the first study), or can be extracted by 
name as specified in studynames, e.g. longplots$studyname1. 
As an example, plots of the longitudinal trajectories and survival curves of an example dataset 
can be obtained, using the following code. 
studyplots<-jointmetaplot(dataset = jointdat, study = "study",  
                          longoutcome = "Y", longtime = "time",  
                          survtime = "survtime", cens = "cens", id = "id",  
                          smoother = TRUE,  
                          studynames = c("A", "B", "C", "D", "E"),  
                          type = "Both", eventby = "treat", 
                          eventconfint = FALSE) 
The plots produced can be examined using the following code, noting that plots can be 
extracted by name (first line), or through their placement in the list (second line). 
studyplots$longplots$`studyplot.D` 
studyplots$eventplots[[1]] 
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4.4.3.2 Function to arrange study specific plots in grid 
The jointmetaplot function returns study specific plots, however it is often difficult to 
compare multiple plots at once. As such, a function jointmetaplotall is provided in the 
joineRmeta package to arrange the plots produced by the jointmetaplot function into 
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grid of graphs that can be output as a single image. The function call for this function is shown 
below: 
jointmetaplotall(plotlist, ncol, nrow = NULL, top = NULL, 
  type = c("Longitudinal", "Event", "Both")) 
• plotlist - the output produced by the jointmetaplot function 
• ncol - number of columns in grid to output graphs in (must be specified) 
• nrow - number of rows in grid to output graphs in (optional) 
• top - a title for the grid plots 
• type - as with the jointmetaplot function, types of plots to return 
The output from the jointmetaplot function can be saved to an object in the R workspace, 
e.g. studyplots and supplied to the plotlist argument by plotlist = studyplots. 
The study specific graphs will be arranged in a grid, with common legend where appropriate 
e.g. if survival curves were stratified by a grouping variable. 
An object of class jointplotsall will be returned by the function, which again is a list, the 
elements of which depend on the function argument type. If type is set to "Longitudinal" 
or "Both", then an element "longall" will be present in the returned object, giving the 
study specific longitudinal trajectory graphs arranged in a single grid. If type is set to "Event" 
or "Both", then an element "eventsall" will be present, giving the study specific survival 
curves arranged in a single grid. 
The dimensions of the grid are controlled by arguments ncol and nrow. Argument ncol has 
to be defined in the function call, whilst nrow is optional, and if missing will be calculated 
based on the number of study specific plots supplied to plotlist and the specified value of 
ncol. A common title can be supplied to any grid plots output by the function using argument 
top. 
An example of using the jointmetaplotall function using the plots already generated from 
the simulated dataset simdat is: 
studyplotsall<-jointmetaplotall(plotlist = studyplots, ncol = 2,  
                                top = "Example Data", type = "Both") 
To extract the grid of study specific longitudinal profiles: 
studyplotsall$longall 
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To extract the grid of study specific Kaplan-Meier plots: 
studyplotsall$eventsall 
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4.5 Discussion 
The joineRmeta package contains a range of functions designed for use during the meta-
analysis of multi-study joint longitudinal and time-to-event data. Functions include multi-study 
data simulation functions, data plotting functions, and functions to aid the preparation of data 
into the required format. Functions for analysis of multi-study joint data include a function for 
use in the second stage of a two-stage MA of joint data designed to take joint model fits from 
the two main joint modelling packages in R, and output meta-analyses for each specified 
parameter of interest. A function is also provided to allow users to fit a one-stage model to 
multi-study joint data, which allows users to account for variation between units at different 
levels of the data to be accounted for in a range of ways. As well as individual level (level 2) 
random effects, study level (level 3) random effects can also be included, as well as inclusion of 
fixed interaction terms, and the option to stratify the baseline hazard by study. 
In Chapter 5, the methodology used to implement the functions in the package is described.  
The package is then used when performing an analysis of the INDANA dataset (Chapter 6), and 
also to complete simulation studies investigating both two-stage and one-stage MA methods 
under a variety of scenarios (Chapter 7).  Planned future work to expand the package is 
discussed in Chapter 8. 
Chapter 5 : Methodology Supporting the Implementation of 
the joineRmeta Package 
During this chapter the methodology used in the implementation of the R package 
joineRmeta and its functions, which were described in Chapter 4, is discussed.  Details of 
employing the package’s functions in the R programming environment are not reiterated. The 
chapter begins with a description of the methodology of importance to the two-stage MA and 
the one-stage MA functions respectively, followed by discussion of the methodology used to 
simulate multi-study joint data.   
5.1 Analysis Functions 
This section will cover only the mechanics of how the meta-analytic joint models are fitted. For 
a discussion of proposed methods for the one or two-stage MA of joint data, see Chapter 3. 
5.1.1 Methods for Two-stage Meta-Analyses 
The function jointmeta2 (introduced in Section 4.3.1) takes single study joint model fits from 
packages joineR and JM, extracts the specified parameters of interest and outputs the results 
of fixed and random effects meta-analyses.  Standard meta-analytic techniques are employed; 
inverse variance weightings are used when pooling parameters, with the DerSimonian and 
Laird approach for the random effects MA [10].   
In Section 4.3.1 it was noted that pooling joint model fits from the joineR package gave 
output containing only survMA.direct, whereas pooling fits from the JM results in output 
containing both survMA.direct and survMA.overall.  This is due to difference in 
association structures available in each package.  Consider a joint model of specification in 
equation (17): 
   𝒀𝒌𝒊 = 𝑿𝒌𝒊𝜷𝟏𝒌 + 𝒁𝒌𝒊
(𝟐)𝒃𝒌𝒊
(𝟐) + 𝜺𝒌𝒊 
        𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝑿𝒌𝒊𝜷𝟐𝒌 + 𝑊2𝑘𝑖(𝑡)) 
𝑊2𝑘𝑖(𝑡) ∝ 𝑊1𝑘𝑖(𝑡) = 𝛼𝑘
(2) (𝒁𝒌𝒊
(𝟐)𝒃𝒌𝒊
(𝟐))     
  
(17) 
In the above joint model, the association structure involves only zero mean random effects, no 
fixed effects.  As such, the effect of covariates of interest on the risk of event is fully quantified 
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(directly estimated) by the coefficient of the covariate when included as a time-to-event sub-
model fixed effect, held in vector 𝜷𝟐.  The joineR package fits joint models of this type, with 
association structures that involve only zero mean random effects. 
Alternatively consider a joint model of formulation: 




+ 𝜺𝒌𝒊 = 𝒎𝒌𝒊 + 𝜺𝒌𝒊 
 𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝑿𝒌𝒊𝜷𝟐𝒌 + 𝑊2𝑘𝑖(𝑡))   
𝑊2𝑘𝑖(𝑡) ∝ 𝑊1𝑘𝑖(𝑡) = 𝛼𝑘
(2)
𝑓(𝒎𝒌𝒊)                     
  
(18) 
Equation (18) contains a joint model whose sub-models are linked through an association 
structure that involves some function of the fixed and random effects of the longitudinal sub-
model.  The JM package allows joint models to be fitted that link sub-models using both the 
fixed and random effects.  In cases such as this, if a covariate is present both in the longitudinal 
and the time-to-event sub-model, the overall effect of the covariate on the risk of an event is 
made up of both a direct and indirect effect [87].  As an example, consider the following model: 




𝒕𝒊𝒎𝒆𝒌𝒊 + 𝜺𝒌𝒊    
           𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝛽21𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝛽22𝑘𝑔𝑒𝑛𝑑𝑒𝑟𝑘𝑖 + 𝑊2𝑘𝑖(𝑡))                                      





If the effect of treatment assignment 𝑡𝑟𝑒𝑎𝑡𝑘𝑖 on the risk of an event is considered, a direct 
effect results from the covariate being included in the time-to-event sub-model (𝛽21𝑘), but an 
indirect effect is also present through the association structure (𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡𝛽12𝑘).  The overall 
effect of treatment on this risk of the event is then the sum of the direct and indirect effects 
(𝛽21𝑘 + 𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡𝛽12𝑘).  If a covariate is included in the time-to-event sub-model but not in the 
longitudinal sub-model, regardless of the fact that the association structure involves both fixed 
and random effects, the overall effect will equal the direct effect.  An example of this is the 
inclusion of gender as a covariate in the time-to-event sub-model in equation (19).  As it is not 
present in the longitudinal sub-model, the direct effect (𝛽22𝑘) equals the overall effect. 
The case where a JM fit uses an association structure that involves both the current value and 
current slope of the longitudinal trajectory is more complex: 
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𝒀𝒌𝒊 = 𝛽10𝑘 + 𝛽11𝑘𝒕𝒊𝒎𝒆𝒌𝒊 + 𝛽12𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝛽13𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 ∗ 𝒕𝒊𝒎𝒆𝒌𝒊 + 𝑏𝑘𝑖0
(2)
+ 𝑏𝑘𝑖1
(2)𝒕𝒊𝒎𝒆𝒌𝒊 + 𝜺𝒌𝒊 
𝒀𝒌𝒊 = 𝒎𝒌𝒊 + 𝜺𝒌𝒊  
 𝜆𝑘𝑖(𝑡) = 𝜆0(𝑡) exp(𝛽21𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝑊2𝑘𝑖(𝑡))  
   𝑊2𝑘𝑖(𝑡) = 𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡𝑓(𝒎𝒌𝒊) + 𝛼𝑘_𝑠𝑙𝑜𝑝𝑒𝑓′(𝒎𝒌𝒊)        
  
(20) 
In the above model, (equation (20)), the direct effect of treatment on the risk of an event 
quantified by 𝛽21𝑘.  Indirect effects of treatment on risk of an event are present through the 
association structure equaling 𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡𝛽12𝑘 + 𝛼𝑘_𝑠𝑙𝑜𝑝𝑒𝛽13𝑘, giving an overall effect of 
treatment on risk of an event of 𝛽21𝑘 + 𝛼𝑘_𝑐𝑢𝑟𝑟𝑒𝑛𝑡𝛽12𝑘 + 𝛼𝑘_𝑠𝑙𝑜𝑝𝑒𝛽13𝑘.  As detailed in Chapter 
4, the jointmeta2 function can handle such as case of mixed current value and slope 
association structure. 
As well as estimates of the effects of covariates, to perform a MA, estimates of the variability 
of the effects are required.  For cases where the overall effect consists of both a direct and 
indirect effect this can be estimated using the delta method [201], which approximates the 
standard error of a function of a random variable by expanding the function around its mean 
and (by using a first order Taylor approximation) estimates the variance of the function. An 
example of this calculation for joint models using the Stata software [84], using the nlcom 
function is given by Crowther et al [160]. The same procedure can be implemented in R 
through the msm package, using the deltamethod function. This is automatically completed in 
the jointmeta2 function. 
5.1.2 Methods for One-Stage Meta-Analyses 
This section discusses the methodology used by the one-stage multi-study joint modeling 
function jointmeta1 available in the joineRmeta package and focuses on the mechanics 
behind the model fitting function. 
5.1.2.1 General Likelihood formulation 
Rizopoulos [52] notes that due to the presence of random effects in the joint model, unlike the 
Cox model, estimation cannot be based solely on the partial likelihood, and must instead use 
the full likelihood.  In this section, the likelihood stated for the one study case in Wulfsohn and 
Tsiatis [78] is extended to a multi-study case.   
 138   
 
The nesting of longitudinal measurements within individuals, and individuals within studies 
must be considered.  Extending the single study case, random effects could be included at 
either the study or the individual level. The complete data is defined to be 𝛀, where  𝛀 =




 ), with 𝑇𝑆𝑘𝑖 representing the survival time for individual 𝑖 in 
study 𝑘, Δ𝑘𝑖 is the censoring indicator,  𝒀𝑘𝑖 and  𝒕𝑘𝑖 are the vectors of longitudinal 




 are the study and individual level random 
effects.  Equation (21) shows the complete or full likelihood (referred to as L(𝛀)) of the joint 
model for multiple studies. 
In equation (21), the notation introduced in Chapter 3 is employed. 𝐾 is the total number of 
included studies (with study indicator 𝑘 = 1 … 𝐾).  The total number of individuals in study 𝑘 is 
denoted by 𝑛𝑘.  The total number of longitudinal measurements recorded for individual 𝑖 from 
study 𝑘 is denoted by 𝑚𝑘𝑖.  Definitions for each of the functions that contribute to 𝐿(𝛀) follow: 


















































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   















































































































































5.1.2.1.1 Longitudinal sub-model component   
The probability distribution function of each longitudinal measurement 𝑌𝑘𝑖𝑗  (recorded for 
individual 𝑖 in study 𝑘 at their 𝑗th recorded time-point 𝑡𝑘𝑖𝑗) is given by 





2), see equation (22) for the full specification.  The total 
contribution of the longitudinal portion to the complete likelihood for a particular 
individual is found by the product of this function across all time points recorded for the 







𝑗=1 .  Here, 𝜷1 are the longitudinal 
population fixed effects, 𝒃𝑘𝑖
(2)
 are the individual specific (level 2) random effects, 𝒃𝑘
(3)
 are 
the study specific (level 3) random effects (if present), and 𝜎𝑒
2 is the variance of the 
measurement errors (represented by 𝑘𝑖𝑗).  These longitudinal measurements can occur at 
times unique to each individual.  This vector of measurement times for each individual is 
denoted by 𝒕𝑘𝑖 and is of length 𝑚𝑘𝑖.  It is assumed that the longitudinal measure recorded 
at each time point for an individual can be considered normally distributed.  The mean of 


















), with variance equal to 𝜎𝑒
2.  Note, that in the Maximisation or M-step 
of the Expectation Maximisation (EM) algorithm (the procedure employed in the 
jointmeta1 function to fit the one-stage joint model) the random effects contribute to 
the mean rather than the variance of the longitudinal measurements. This is because in the 
Expectation or E-step, estimates of functions of the random effects are produced.  In the 
M-step, the likelihood of the model is maximized, with functions of the random effects held 
constant at the estimates produced in the E-step (resulting in their contribution to the 
mean rather than the variance of the longitudinal measurement distribution).  The use of 
the EM algorithm in the one-stage joint modelling function is discussed in Section 5.1.2.2. 
In 𝜂𝑘𝑖𝑗, 𝒙𝟏𝒌𝒊𝒋 represents the covariates for the fixed effects at time point 𝑗 for individual 𝑖 in 
study 𝑘.  The covariates over all time points for the individual are held in the design matrix 
𝑿𝟏𝒌𝒊, which will have 𝑚𝑘𝑖  rows and 𝑝1 columns (where 𝑝1 is the number of fixed effects in 
the longitudinal sub-model).   
The covariates for the individual specific (level 2) random effects at time point 𝑗 for 
individual 𝑖 in study 𝑘 are represented by 𝒛𝒌𝒊𝒋
(𝟐)
, and those for the study level random effects 
by 𝒛𝒌𝒊𝒋
(𝟑)











 for the 
individual and study level random effects respectively. If study level random effects are not 
included in the model, terms involving 𝒃𝑘
(3)
 are not present.  The model assumes that the 
covariates assigned random effects have also been assigned fixed effects (i.e. that the 




 are subsets of the columns of design matrix 
𝑿𝟏𝒌𝒊). 
Throughout, only time varying covariates that can be expressed as functions of time (e.g. 
interactions between time and stationary variables, such as treatment group) can be 
assigned random effects in the longitudinal sub-model. Other time varying covariates that 
cannot be stated as some function of time and a stationary covariate are not allowed to be 
assigned random effects (e.g. weight measured at successive time points).  This is due to 
the necessity to know the value of the random effects at 𝑇𝑆𝑘𝑖 (the survival time of 
individual 𝑖 in study 𝑘); currently the value in the association structure for a time-varying 
covariate not calculable from a time variable and a stationary covariate cannot be 
approximated by the package. 
5.1.2.1.2 Time-to-event sub-model component 





, 𝜆0, 𝜶), as specified in equation (23).  The exact structure of this 
component depends on the association structure of the joint model.  Only the random 
effects proportional association structure is currently considered, but extensions to 
available association structures are discussed in Section 8.3.2.2. 
Throughout, 𝑿𝟐 represents the design matrix for the fixed effects in the time-to-event sub-
model, and 𝜷𝟐 the fixed effect coefficients, while 𝜆0 represents the unspecified baseline 
hazard function.  The design matrix 𝑿𝟐 will have number of rows equal to the number of 
individuals in the analysis (total number of individuals across studies for non-stratified 
models (∑ 𝑛𝑘
𝐾
𝑘=1 ), or number of individuals within a study (𝑛𝑘) for models with a stratified 
baseline, in which case the fixed effect design matrix would be denoted 𝑿𝟐𝒌), and will 
always have 𝑝2 columns.  Here 𝑝2 is the number of fixed effects in the time-to-event sub-
model.  It is assumed that 𝑿𝟐  contains no time variable covariates. 
The survival time (𝑇𝑆𝑘𝑖) is the minimum of the true event time (𝑇𝐸𝑘𝑖) and the censoring 
time (𝑇𝐶𝑘𝑖) for individual 𝑖 in study 𝑘.  The event indicator (Δ𝑘𝑖) takes a value of 1 if the 
individual experienced an event at 𝑇𝑆𝑘𝑖, and 0 otherwise.  Terms shared between the sub-
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models (preceded by 𝜶 terms) have the same definitions as in the longitudinal sub-model 
section.  Note that any point where time is used in the shared terms in 




, 𝜆0, 𝜶), 𝑇𝑆𝑘𝑖   (or times from 0 to 𝑇𝑆𝑘𝑖) are used in place of 
longitudinal times 𝑡𝑘𝑖𝑗.  Similarly any time varying covariates in the shared terms take 
values at times relating to the survival data rather than the longitudinal data.  
The association terms (represented by 𝜶 terms) have bracketed superscripts to identify the 
data level they relate to.  Specifically, 𝛼(2) denotes the association parameter for shared 
zero mean individual level (level 2) random effects, and 𝛼(3) represents the association 
parameter for shared zero mean study level (level 3) random effects.  This function can 
currently only fit models that share zero mean random effects between sub-models, with 
common association parameter across random effects at the same level, termed random 
effects only proportional association. 





component is not present. 
5.1.2.1.3 Study specific random effects component 
The probability distribution of the zero mean study specific (level 3) random effects, 
𝑓 (𝒃𝑘
(3)|𝑨), is given in equation (24).  If no study level random effects are included in the 
model, then 𝑓 (𝒃𝑘
(3)|𝑨) is not present in equation (21) (and consequently 𝒃𝑘
(3)
 does not 
require integrating out).  The random effects are considered to follow a zero mean 
multivariate normal distribution with covariance matrix 𝑨 of dimension 𝑟 (the number of 
study level random effects).    
If only one study specific random effect is considered, giving 𝑨 = 𝜎𝐴
2 and 𝑟 = 1, then 











2⁄ }  
 
 
5.1.2.1.4 Individual level random effects component 
The probability distribution function of the zero mean individual specific (level 2) random 
effects is given by 𝑓(𝒃𝑘𝑖
(2)
 𝑫), see equation (25), where 𝑞 represents the number of 
individual specific (level 2) random effects.  As with the study level random effects, the 
individual level random effects are assumed to follow a multivariate normal distribution 
with covariance matrix 𝑫 if 𝑞 > 1: 
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If only one individual level random effect is included in the model, then 𝑫 = 𝜎𝐷
2 and 𝑞 = 1, 











2⁄ }  
 
 
The jointmeta1() function assumes that all models fitted will have at least one 
individual level random effect, and so 𝑓(𝒃𝑘𝑖
(2)
 𝑫) will always be present in the likelihood. 
5.1.2.2 EM algorithm 
For the single study case, the joint model is commonly fitted using the EM algorithm [197];  
this method is also employed in this thesis to fit multi-study joint models.  Discussion of the 
use of the EM algorithm with joint models for longitudinal and time-to-event data is given 
in Wulfsohn and Tsiatis [78] and Rizopoulos [52].  The EM algorithm fits a model by 
iterating between two steps – the Expectation or E-step and the Maximisation or M-step.  
In the E-step, estimates of the value of various functions of random effects included in the 
model are calculated.  These estimates are then used in the M-step to determine the 
estimates of other parameters, for example covariance matrices and baseline hazard 
functions.   
The EM algorithm is simple to implement and applicable to a wide range of problems [197].  
It has already been shown to work for the case of joint models [52, 78].  Here,  the EM 
methods proposed for the single study in Wulfsohn and Tsiatis [78] are extended to the 
case with multilevel data and random effects at more than one level.    
Despite the EM algorithm being a stable, widely applicable and reliable method, issues 
have been identified with the use of the EM algorithm.  One general issue is that whilst the 
EM algorithm is applicable to a wide range of situations, it can be slow to converge [202, 
203]. Slow convergence is a particular issue here due to the large sizes of multi-study 
datasets.  In addition, in order to work well the EM algorithm benefits from a good choice 
of starting values.  These are easily obtained in the joint modelling case from separate 
longitudinal and time-to-event fits calculated before the main joint model fit, using the 
lme4 [204] and survival [195] packages respectively.  
Some alternatives to the EM algorithm in the joint modelling context exist.  For example 
Crowther et al 2012 [159] fit fully parametric joint models, allowing the use of Newton-
Raphson methods to directly maximise model parameters.  Alternatively, Bayesian 
methods such as MCMC can be used to fit joint models, such methods are implemented in 
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the R package JMBayes [82], or EM algorithms with an MC step, as employed in the 
joineRML package [181].  Potential improvements to model fitting are discussed as 
extension work in Chapter 8. 
5.1.2.2.1 Expectation Step 
As mentioned, in the expectation step or E-step, expectations of functions of the random 
effects included in the one-stage joint model are calculated.  These are then used in the M- 
Step to calculate the values of model parameters.   
Gaussian quadrature methods approximate integrals of functions with respect to a given 
distributions kernel, using a weighted average of the integral at certain abscissa or 
locations (denoted by 𝑎, see Stroud and Secrest [205]).  Weights for these abscissa, 
denoted by 𝜋 terms, can be obtained from existing tables (e.g. Abromowitz and Stegun 
[206]) or from algorithms (see Golub [207] and Golub and Welsch [208]).   
Gauss-Hermite quadrature is used is to estimate the functions of random effects needed 
for model fitting.  This method uses a weighting function of 𝑒−𝑥
2
 (see Abromowitz and 
Stegun [206]).  The major joint modelling paper Wulfsohn and Tsiatis [78] used Gauss-
Hermite quadrature to evaluate functions of random effects in their joint model. 
An issue with Gauss-Hermite quadrature is that if the distribution being approximated has 
a peak that lies far from zero, or if the spread of the distribution is different to the kernel 
being used in the quadrature, the quadrature may not give good results unless a large 
number of quadrature points are used [209].   
Adaptive Gauss-Hermite quadrature provides a solution to the issue of the distribution 
being approximated having a different spread and location to the kernel being used in the 
quadrature (see Liu and Pierce [210], and Pinheiro and Bates [209]).  In adaptive Gauss-
Hermite quadrature the locations and spread of the abscissa are adjusted at each iteration 
of the model fitting process so that they more closely reflect the shape of the integral of 
interest.  This method has the benefit of requiring fewer quadrature points, because they 
are placed where they are most needed (see Pinheiro and Bates [209] for simulations).  
However, as the points are rescaled at each iteration, this method comes with a higher 
computational burden.   
An example of use of adaptive Gauss-Hermite quadrature in a joint modelling context is 
given by Crowther et al [159] for flexible parametric joint models.  By using parametric 
models they were able to estimate model parameters using Newton-Raphson rather than 
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EM algorithm methods; however adaptive quadrature was used to estimate random 
effects.  They compared results from non-adaptive Gauss-Hermite quadrature with 5 and 
15 quadrature points to an adaptive method with 5 quadrature points.  The adaptive 
approach was established as superior over the non-adaptive due to the reduced number of 
quadrature points required but the need to evaluate model estimates using different 
numbers of quadrature points to ensure stability was highlighted, a point reiterated by 
Lesaffre and Spiessens [211]. 
Current adaptive Gauss-Hermite quadrature methods for joint longitudinal and time-to-
event models have been applied to data with two levels (longitudinal measurements 
nested within individuals).  However, the data considered here has another level of nesting, 
namely that longitudinal measurements are nested within individuals, who are then nested 
within studies.  Therefore Gauss-Hermite quadrature data with more than two levels must 
be examined. 
A useful paper that describes the process and equations of using adaptive Gaussian 
quadrature for multilevel models is Rabe-Hesketh et al [212] who describe in detail the 
maximum likelihood estimation of limited and discrete dependent variable models which 
contain nested random intercepts and covariates using adaptive Gauss-Hermite 
quadrature.  Other useful papers include Pinheiro and Chao [213], who demonstrate the 
expansion of adaptive Gaussian quadrature for generalized linear models [209] to cases 
with data nested in multiple levels.  They note that by exploiting the structure of the 
integrand in a generalised linear mixed effect model, they can apply a transformation so 
that the quadrature becomes multiple applications of one dimensional quadrature rules.  
Methods for multilevel generalized linear models are also discussed by Rabe-Hesketh [214], 
where adaptive quadrature is again discussed for generalized linear models with more than 
two levels and both random intercepts and random coefficients.  Gibbons and Hedeker 
[215] discuss approaches for three level probit and logistic regression models, and further 
discuss orthogonalisation of model parameters to aid estimation.  Multilevel ordinal 
regression models are described by Hedeker and Gibbons [216], also by Raman and 
Hedeker [217].  The latter describes the modelling of three level ordinal data, with 
commonly distributed (i.e. same distribution across units at the same level) random effects 
at level 2 and level 3.  These random effects were estimated using Gauss-Hermite 
quadrature, estimating random effects at lower levels followed by random effects at higher 
levels.  Gauss-Hermite quadrature was also used by Crowther et al [58] for the modelling of 
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multilevel survival models with random effects in a meta-analytic setting.  They extended 
the methods of Liu and Huang [202] from one to many random effects in a survival model.  
These papers, whilst they do not implement joint longitudinal and time-to-event models, 
demonstrate the methods and required calculations for a range of models that deal with 
data with more than two levels, generally for cases just containing a random intercept at 
each level.  Using these papers, an attempt was made to implement fully adaptive Gauss-
Hermite quadrature for the estimation of random effects allowing for up to three random 
effects per level.  The extension to data with three levels involves methods described in 
Rabe-Hesketh et al [212].  This paper highlighted that adaptive quadrature cannot be 
directly applied to a model with random effects for three level data, because the posterior 
density of a random effect being estimated is conditional on the random effects not yet 
evaluated as well as random effects at higher levels.  They solve this issue through 
transformation of the random effects.  Attempts were made to implement fully adaptive 
quadrature in the joineRmeta package.  However, the methods presented in Rabe-Hesketh 
et al [212] proved difficult to follow, as notation changed several times during the paper, 
and the link between different steps of the transformations were unclear.  As such, 
implementation of this method with joint models resulted in many model fitting issues that 
were difficult to resolve, and convergence of joint models could not be consistently 
achieved.  As such, completion of implementation of fully adaptive quadrature in the 
package has been postponed for future research (see Section 8.3.2.2) 
In a paper in 2012 [196], Rizopoulos suggested pseudo-adaptive Gauss-Hermite Quadrature 
as an alternative to fully adaptive quadrature for the fast fitting of joint models.  In this 
variation, the abscissa were relocated and rescaled only once at the start of the joint model 
fitting process rather than at each iteration.  The paper proposed fitting a standalone 
longitudinal model (already required to find starting points for the EM algorithm when 
fitting a joint model), and used empirical Bayes estimates of the locations of random effects 
of this longitudinal model (the conditional modes of the random effects) to relocate and 
rescale the abscissa to estimate the random effects in the full joint model.  The paper 
tested the pseudo adaptive method against the fully adaptive method, and noted that the 
pseudo adaptive method gave similar results but was much faster than the fully adaptive.  
This pseudo adaptive method is currently implemented as the default quadrature option in 
the R package JM [81]. 
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Whilst issues were encountered implementing fully adaptive quadrature for three level 
joint data, the pseudo adaptive procedure was easily extended.  As such, the joineRmeta 
package currently relies on the pseudo adaptive Gauss-Hermite quadrature methods 
presented in Rizopoulos [196], using estimates of the conditional modes of the random 
effects available from the initial longitudinal model fit necessary to obtain suitable starting 
values for the EM algorithm.  The procedure provides a fast and accurate method of 
estimation without a large computational burden, both important considerations for a one-
stage meta-analysis with potentially large datasets.    
Wulfsohn and Tsiatis [78] described in their paper that during the E-step of the EM 
algorithm it was necessary to find the expected value of the random effects and various 
functions of the random effects.  They showed that for the model presented in their paper, 
with only two levels of nesting in the model (longitudinal measurements nested within 
individuals), the expectation of some function ℎ of the random effects, can be expressed by 
equation (26): 
 
𝔼[ℎ(𝒃𝒊)|𝑇𝑆𝑖, Δ𝑖, 𝒀𝑖 , 𝒕𝑖] =











As some of the models considered here contain random effects across several levels 
(individual level and study level), formulations of the above equation must be considered 
for cases where the model contains both 𝒃𝑘𝑖
(2)
 terms and 𝒃𝑘
(3)
 terms, or only 𝒃𝑘𝑖
(2)
 terms.   
As the EM algorithm fits the model using an iterative process, when using expressions such 
as that shown in equation (26) to estimate functions of the study level random effects, the 
individual level random effects are held constant at their estimated value from the last 
iteration (or their value estimated from the standalone longitudinal model in the first 
iteration).  Similarly when the individual level random effects are estimated in the E-step, 
study level random effects (if included), are held at their estimated value from the last 
iteration.  In the future, implementation of adaptive Gaussian quadrature will allow 
random effects at any level to be estimated simultaneously (see Section 8.3.2.2). 
5.1.2.2.1.1 Estimation of functions of study level random effects 
If the model specified to be fitted contains study level random effects, functions of the 
study level random effects must be estimated during the E-step.  When estimating such 
functions, all data relating to each study level (level 3) unit is considered, which contains 
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data from multiple individuals (level 2 units).  As mentioned, individual level random effects 
are held constant at their current estimate, denoted ?̂?𝑘𝑖
(2)
, when estimating study level 
random effects. 
In order to estimate the function corresponding to the expression in equation (26) for the 
case where the model contains study level random effects, the expression  
𝑓 (𝒃𝑘
(3)
 𝑻𝑆𝑘, 𝚫𝑘, 𝒀𝑘 , 𝒕𝑘 , ?̂?, ?̂?𝑘𝑖
(2)
) must be defined. Using Bayes’ theorem that 𝑃(𝐴|𝐵) =
𝑃(𝐴 ∩ 𝐵)/𝑃(𝐵):  
𝑓 (𝒃𝑘
(3)





, 𝑻𝑺𝒌, 𝚫𝑘  𝒀𝑘 , 𝒕𝑘 , ?̂?, ?̂?𝑘𝑖
(2)
)




Then using 𝑃(𝐵) = ∫ 𝑃(𝐵|𝐴)𝑃(𝐴) 𝑑𝐴 and 𝑃(𝐵 ∩ 𝐴) = 𝑃(𝐵|𝐴)𝑃(𝐴): 
𝑓 (𝒃𝑘
(3)




𝑓 (𝑻𝑆𝑘 , 𝚫𝑘  𝒃𝑘
(3)




 𝒀𝑘, 𝒕𝑘 , ?̂?, ?̂?𝑘𝑖
(2)
)
∫ 𝑓 (𝑻𝑆𝑘 , 𝚫𝑘  𝒃𝑘









Therefore, the expression used to calculate the value of functions of the study level 
random effects is given by: 
 𝔼  ℎ (𝒃𝑘
(3)






)𝑓 (𝑻𝑆𝑘 , 𝚫𝑘  𝒃𝑘
(3)








∫ 𝑓 (𝑻𝑆𝑘 , 𝚫𝑘  𝒃𝑘
(3)












In equation (27), ℎ (𝒃𝑘
(3)) is some function of the study level random effects to be 
estimated.  The specification of 𝑓 (𝑻𝑆𝑘 , 𝚫𝑘  𝒃𝑘
(3)
, 𝒀𝑘 , 𝒕𝑘 , ?̂? , ?̂?𝑘𝑖
(2)
), the time-to-event 
component of the full likelihood, is already known (see equation (23)).   
If adaptive Gaussian quadrature was employed in the E-step, as in Wulfsohn and Tsiatis 
[78], the distribution of the study level random effects given the longitudinal 
measurements would be calculated at each iteration, in order to determine the values of 
the abscissa to employ during the quadrature.  However, as pseudo-adaptive Gaussian 
quadrature is employed, the abscissa are calculated once before beginning the iterative 
149 
 
process, based on the locations of the random effects estimated by the standalone 
longitudinal model.   
The abscissa are rescaled at the start of the iterations to fit the joint model using the 
following expression: 
 𝒂(𝟑)𝒌 = ?̂?𝒌
(𝟑) + √𝟐?̂?𝒌
−𝟏𝒂 (28) 
In equation (19), 𝒂 denotes the vector of standard abscissa locations [205], and ?̂?𝒌
(𝟑) are the 
conditional nodes of the study level random effects produced by the standalone 
longitudinal model fit. The matrix ?̂?𝒌 is the Choleski decomposition of the matrix of the 




, which is the 
covariance matrix of the estimates of the study level random effects from the standalone 
longitudinal model fit.  The expression produces abscissa for the study level or level 3 
random effects, denoted by 𝒂(𝟑)𝒌.  Once values for the abscissa for the study level random 
effects have been calculated, these abscissa values are input in place of any occurrence of 
the study level random effects.  Given these abscissa values, and the definitions of the 
functions that constitute equation (27), estimates of any function ℎ (𝒃𝒌
(𝟑)) of the study 
level random effects can be calculated, which are then used in the M-step to update 
estimates of the model parameters. 
5.1.2.2.1.2 Estimation of functions of individual level random effects 
If the model to be fitted contains individual level random effects, functions of the individual 
level random effects must be estimated during the E-step (these are required to maximize 
estimates of model parameters in the M-step).  When estimating these functions, all data 
relating to each individual level (level 2) unit is considered, and any study level random 
effects are held constant at their current estimate (denoted by ?̂?𝑘
(3)
).  If no study level 
random effects are included in the model, ?̂?𝑘
(3)
 terms are removed from the following 
calculations. 
In order to estimate the function corresponding to the expression in equation (26) for the 
case where the model contains individual level random effects, the expression 
𝑓 (𝒃𝑘𝑖
(2)
 𝑻𝑆𝑘𝑖 , 𝚫𝑘𝑖, 𝒀𝑘𝑖, 𝒕𝑘𝑖, ?̂?, ?̂?𝑘
(3)
) must be defined. Using 𝑃(𝐴|𝐵) = 𝑃(𝐴 ∩ 𝐵)/𝑃(𝐵): 
𝑓 (𝒃𝑘𝑖
(2)




(2), 𝑻𝑆𝑘𝑖, 𝚫𝑘𝑖  𝒀𝑘𝑖, 𝒕𝑘𝑖, ?̂?, ?̂?𝑘
(3)
)






Then using 𝑃(𝐵) = ∫ 𝑃(𝐵|𝐴)𝑃(𝐴) 𝑑𝐴 and 𝑃(𝐵 ∩ 𝐴) = 𝑃(𝐵|𝐴)𝑃(𝐴): 
𝑓 (𝒃𝑘𝑖
(2)




𝑓 (𝑻𝑆𝑘𝑖, 𝚫𝑘𝑖  𝒃𝑘𝑖
(2)




 𝒀𝑘𝑖, 𝒕𝑘𝑖 , ?̂?, ?̂?𝑘
(3)
)
∫ 𝑓 (𝑻𝑆𝑘𝑖, 𝚫𝑘𝑖  𝒃𝑘𝑖









Therefore, the formula needed to estimate functions of the individual level random effects 
is given by: 
 𝔼  ℎ (𝒃𝑘𝑖
(2)) |𝑻𝑆𝑘𝑖 , 𝚫𝑘𝑖, 𝒀𝑘𝑖, 𝒕𝑘𝑖, ?̂?, ?̂?𝑘
(3)




)𝑓 (𝑻𝑆𝑘𝑖, 𝚫𝑘𝑖  𝒃𝑘𝑖
(2)








∫ 𝑓 (𝑻𝑆𝑘𝑖 , 𝚫𝑘𝑖  𝒃𝑘𝑖
(2)











In equation (29), ℎ (𝒃𝑘𝑖
(2)
) is the function of the individual level random effects to be 
estimated.  The specification of 𝑓 (𝑻𝑆𝑘𝑖, 𝚫𝑘𝑖  𝒃𝑘𝑖
(2), 𝒀𝑘𝑖, 𝒕𝑘𝑖, ?̂? , ?̂?𝑘
(3)
), the time-to-event 
component of the full likelihood, is already known (see equation (23)).   
As before, as pseudo-adaptive Gaussian quadrature is employed, the abscissa at which to 
assess the integral are calculated once at the start of the iterative process.  The abscissa 
follow equation (30): 
 𝒂(𝟐)𝒌𝒊 = ?̂?𝒌𝒊
(𝟐) + √𝟐?̂?𝒌𝒊
−𝟏𝒂 (30) 
Here, 𝒂 denotes the vector of standard abscissa locations [205], and ?̂?𝒌𝒊
(𝟐) are the 
conditional nodes of the individual level random effects produced by the standalone 
longitudinal model fit. The matrix ?̂?𝒌𝒊 is the Choleski decomposition of the matrix of the 
negative second derivative of the log-likelihood −𝜕2ℓ(𝛀)/𝜕𝒃𝒌𝒊
(𝟐)𝜕𝒃𝒌𝒊
(𝟐)𝑻, which is the 
covariance matrix of the estimates of the individual level random effects from the 
standalone longitudinal model fit.  The expression produces abscissa for the individual level 
(level 2) random effects, denoted by 𝒂(𝟐)𝒌𝒊.  Once values for the abscissa for the individual 
level random effects have been calculated, these abscissa values are input in place of any 
occurrence of the individual level random effects.  Given these abscissa values, and the 
definitions of the functions that constitute equation (29), estimates of any function 
ℎ (𝒃𝒌𝒊
(𝟐)) of the individual level random effects can be calculated, which are then used in 
the M-step to update estimates of the model parameters. 
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5.1.2.2.2 Maximization Step 
During the Maximization or M-step of the EM algorithm, the estimates of functions of 
random effects (calculated through pseudo-adaptive Gaussian quadrature during the E-
step) are used to maximize the estimates of the model parameters.  Throughout this 
section, the expressions and procedures used to maximize these estimates are stated.  
Much of the work extends either standard likelihood theory [88], or theory of joint model 
parameter estimation already available in the literature [52, 78].   
Throughout, the expressions are stated as they would appear if study level random effects 
were included in the model. However, if study level random effects were not present, any 
components containing them would not appear in the stated expressions. Additionally, any 
components that are expressions involving random effects are stated as expectations of 




)) , highlighting that these components are 
functions of the random effects whose expected values have been calculated in the E-step.  
Finally, as the complete likelihood for models fitted can be complex, where appropriate, 
only the portions of the likelihood that deal with the parameters being maximized are 
stated, e.g. for the measurement error variance 𝜎𝑒
2 only the portion of 𝑳(𝛀) that deals with 
the longitudinal data is shown. 
5.1.2.2.2.1 Estimation of the unspecified baseline hazard 
Wulfsohn and Tsiatis [78] note that the baseline hazard function is only considered to take 
weight at an event time.  This is in line with the discussion that follows the main text in Cox 
[50].  Additionally, the closed form estimate of the baseline hazard function in Wulfsohn 
and Tsiatis [78] takes the form of the Breslow estimator for the baseline hazard (see 
Breslow, part of the discussion of Cox [50]).  The estimators in the models fitted by 
joineRmeta take a similar form, based on the Breslow estimator, but summed across all 
the included studies: 
?̂?0(𝑢𝑔) = ∑ ∑
Δ𝑘𝑖𝕀(𝑇𝑆𝑘𝑖 = 𝑢𝑔)

















In equation (31), 𝑔 represents a particular event (where 𝑔 = 1, … , 𝐺 is used to count 
through the unique event times).  The indicator variable 𝕀(𝑇𝑆𝑘𝑖 = 𝑢𝑔) ensures that the 
baseline hazard function only takes weight at times when there is an event or censoring, 
and multiplying it by the censoring indicator Δ𝑘𝑖 ensures weight is only taken event times. 
The risk set (individuals who have not yet been censored or have not yet experienced an 
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event) at event time 𝑢𝑔 is denoted by 𝑅(𝑢𝑔).  For stratified models the risk set is drawn 
separately from each included study’s population, whereas for un-stratified models the risk 
set is drawn from all individuals in the meta-analysis.  As such, for models with a stratified 
baseline hazard, a separate baseline hazard will be calculated for each study included in the 
meta-analysis.  The expression in equation (31) is given for an un-stratified baseline hazard, 
however the expression can be simply modified to the stratified case by changing those 
who contribute to the risk set. For a discussion of one-stage multi-study joint models with 
or without a stratified baseline hazard see Section 3.3. 
5.1.2.2.2.2 Estimation of the longitudinal fixed effect coefficients 
The longitudinal sub-model fixed effects (𝜷𝟏) were estimated using the Ordinary Least 
Squares (OLS) estimator.  This estimator is based on the residual sum of squares (RSS), 
denoted by:  
 (𝒀 − 𝑿𝟏𝜷𝟏 − 𝔼[𝒁
(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])
𝑇
(𝒀 − 𝑿𝟏𝜷𝟏 − 𝔼[𝒁
(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])      
= ((𝒀 − 𝔼[𝒁(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)]) − 𝑿𝟏𝜷𝟏)
𝑇
((𝒀 − 𝔼[𝒁(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])
− 𝑿𝟏𝜷𝟏) 
= (𝒀 − 𝔼[𝒁(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])
𝑇
(𝒀 − 𝔼[𝒁(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])                     
− 2𝜷𝟏
𝑻𝑿𝟏





As population parameters are being estimated, common across all included studies, the 
estimation procedure involves all data in the dataset. The first derivative of this expression 








Setting this equal to zero, and rearranging, gives the ordinary least squares estimate of the 
longitudinal fixed effects: 
 ?̂?1 = (𝑿
𝑻𝑿)−1 (𝑿𝑻(𝒀 − 𝔼[𝒁(𝟐)𝒃(𝟐)] − 𝔼[𝒁(𝟑)𝒃(𝟑)])) 
 
(34) 
In the future, as the package is expanded, alternative methods to estimate the longitudinal 
fixed effects may be necessary (e.g. when 𝛽1 parameters are present in the association 




5.1.2.2.2.3 Estimation of the time-to-event fixed effect coefficients and association 
parameters 
The fixed effect coefficients (𝜷𝟐) in the time-to-event sub-model and the association 
parameters (𝛼(2) and 𝛼(3)) will be estimated using a one-step Newton Raphson method (as 
is currently used in joineR [80] , and discussed by Rizopoulos [52]).  To update the 
estimates of these parameters, the score vector 𝑺 and the information matrix 𝑰 must be 
calculated.  
It should be highlighted that during model fitting, the association parameters are calculated 
along with the fixed effect parameters.  Therefore the score vector 𝑺 will be of length 𝑝2 
(the number of time-to-event sub-model fixed effect coefficients) plus the number of 
association parameters (one for each level of random effects included in the model).  
Consequently, if the model just contains individual level random effects, 𝑺 will be of length 
𝑝2 + 1, whereas if the model contains both individual and study level random effects 𝑺 will 
have length 𝑝2 + 2.  Note that the software requires at least one individual level random 
effect to be specified in the model (to ensure the presence of parameters to share between 
sub-models).  The first  𝑝2 elements of 𝑺 equal the first differentiate of the expected log-
likelihood with respect to each value in the vector of time-to-event fixed effect coefficients 
𝜷𝟐, given the estimated values of the functions of any random effects.  The remaining 
elements are the first differentiate with respect to each association parameter included in 
the model (ordered with the association parameter for the individual level random effects 
first, followed by that for the study level random effects if included).   
The information matrix 𝑰 is a square matrix that contains the negative of the second order 
differentiates of the expected log-likelihood, giving a matrix with number of rows and 
columns equal to 𝑝2 plus the number of association parameters.   
The estimates of the elements of 𝜷𝟐 can be updated at each iteration using equation (35), 
where 𝜈 is the iteration counter, such that ?̂?
2(𝜈−1) are the estimates of the time-to-event 
sub-model fixed effect coefficients from iteration 𝜈 − 1.  Furthermore, 𝑺(𝜈−1)(?̂?2(𝜈−1)) is 
the score function, and 𝑰(𝜈−1)
−1 (?̂?2(𝜈−1)) the inverse of the information matrix, both based 
on the coefficient estimates ?̂?2(𝜈−1): 






The estimates of the association parameters are updated in a similar way. Below, the 
expressions necessary to calculate the score vector and the information matrix at each step 
are stated.  The expressions are given for a case where both individual level and study level 
random effects have been included in the model (giving the score vector 𝑺 a length of 𝑝2 +
2, and the information matrix 𝑰 row and column dimensions equal to 𝑝2 + 2). 
The first 𝑝2 elements of 𝑺, relate to the coefficients of the fixed effects in the time-to-event 























In the above equation, 𝑔 takes values 1 to 𝑝2.  The remaining elements of the score vector 
relate to the association parameters for the individual level random effects (𝛼(2)), and (if 



































































𝐼(𝛽21) ⋯ 𝐼(𝛽21, 𝛽2𝑝2) 𝐼(𝛽21, 𝛼
(2)) 𝐼(𝛽21, 𝛼
(3))
⋮ ⋱ ⋮ ⋮ ⋮
𝐼(𝛽21, 𝛽2𝑝2) ⋯ 𝐼(𝛽2𝑝2) 𝐼(𝛽2𝑝2 , 𝛼
(2)) 𝐼(𝛽2𝑝2 , 𝛼
(3))
𝐼(𝛽21, 𝛼
(2)) ⋯ 𝐼(𝛽2𝑝2 , 𝛼
(2)) 𝐼(𝛼(2)) 𝐼(𝛼(2), 𝛼(3))
𝐼(𝛽21, 𝛼
(3)) ⋯ 𝐼(𝛽2𝑝2 , 𝛼







Note that any row or column containing the study level association parameter 𝛼(3) will not 
be present if study level random effects are not included in the model. The elements in the 
information matrix correspond to different expressions depending on their location in the 
matrix.  The first 𝑝2 values on the diagonal have form: 
𝐼(𝛽2𝑔)


















Whilst the off-diagonals in the first 𝑝2 rows and columns of the information matrix take 
form: 
𝐼(𝛽2𝑔, 𝛽2𝑓)
















In the above expressions, 𝑔 and 𝑓 take values between 1 and 𝑝2 (with 𝑔 ≠ 𝑓).  The 
remaining on-diagonals take form: 
𝐼(𝛼(2))













































The remaining off diagonal elements take the following forms, depending on their 
placement in the information matrix (see above for matrix structure). 
𝐼(𝛽2𝑔 , 𝛼
(2))





































































Using these expressions that make up the score vector 𝑺 and information matrix 𝑰 along 
with the Newton-Raphson procedure stated in equation (35), the estimates for the time-to-
event sub-model fixed effect coefficients 𝜷𝟐, and the association parameters 𝛼
(2) and 𝛼(3), 
can be updated at each iteration. 
5.1.2.2.2.4 Estimation of the longitudinal measurement error variance  
The maximum likelihood estimator for the measurement error variance 𝜎𝑒
2 in the 
longitudinal sub-model is estimated using standard maximum likelihood theory.  Displaying 
























                            








































𝑘=1   
 
(37) 
Taking the first derivative of equation (37) with respect to 𝜎𝑒
2 and setting equal to zero 
gives: 












𝑘=1   
 
(38) 
















5.1.2.2.2.5 Estimation of the covariance matrix for individual level random effects 
The one-stage function available in joineRmeta requires the existence of at least one 
individual level random effect in the specified model.  The composition of the Maximum 
Likelihood Estimate (MLE) for the variance of these random effects depends on the number 
of random effects included in the model. 
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If multiple individual level random effects are included in the model, they follow a 
multivariate zero mean normal distribution.  Therefore the maximum likelihood estimate 
for the covariance matrix of this distribution, denoted ?̂? is required.  The methods to 
obtain this estimate rely on the methods presented in Wulfsohn and Tsiatis [78] to 
estimate parameters for the joint model, and Anderson and Olkin [218] who discuss 
methods to obtain maximum likelihood estimates for multivariate normal distributions. 
In the complete data likelihood the only component to directly involve the covariance 
matrix 𝐷 for the individual specific random effects is 𝑓(𝒃𝑘𝑖
(2)
 𝑫), (equation (40)).   
 

















The expectation (denoted by 𝔼) is taken over the individual level random effects.  The 
expected values of the required functions of the individual level random effects are 
calculated in the E-step of the EM algorithm. The log-likelihood is then: 
 
























































































































From Anderson and Olkin [218], an expression 𝑓(𝚺, 𝑽) = − log|𝚺| − 𝑡𝑟(𝚺−1𝑽) has 
derivative with respect to elements of 𝚺 (in matrix form) of −𝚺−1 + 𝚺−1𝑽𝚺−1.  Therefore, 





𝑘=1  and 
1
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Equation (46) states the maximum likelihood estimate for the covariance matrix 𝑫, for the 
case where two or more individual level random effects have been included in the model to 
be fitted by the one-stage function.  If the model contained only one individual level 
random effect, then 𝑫 would be a single value, termed 𝜎𝐷
2).  In this case, the relevant 
portion of the likelihood has the form: 
 
𝐿(𝛀) = 𝔼   (2𝜋𝜎𝐷













Then the log-likelihood: 
 









































































5.1.2.2.2.6 Estimation of the covariance matrix for study level random effects 
It has already been noted that when no study specific (level 3) random effects are included 
in the model, the 𝑓(𝑏𝑘
(3)
 𝑨) term is not included in the complete data likelihood.  If only 
one study level random effect is included in the model, then MLE of the variance of the 
study level random effect, denoted 𝜎𝐴
2, can be determined as follows.  The likelihood takes 
the form: 
 
𝐿(𝛀) = 𝔼 [ (2𝜋𝜎𝐴















































If more than one study level random effect is included in the model, the relevant portion of 
the likelihood takes the form: 
 














The MLE for the covariance matrix 𝑨 is derived in a similar way to that for individual level 





































               




(3))  to be the trace of a 1 by 1 matrix. Using this, and 
the fact that 𝑡𝑟(𝑮𝑯) = 𝑡𝑟(𝑮𝑯), allows: 
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(56) 












𝑡𝑟(𝑨−1𝑹  ) 
(57) 
Again, using Anderson and Olkin [218], the first derivative of this expression with respect to 
the elements of 𝐴 can be found. By setting equal to zero and rearranging the MLE for the 































5.1.2.2.2.7 Additional procedures conducted by the function 
Once both the E-step and the M-step in an iteration have been completed, the estimates of 
the model parameters given by the current and the previous iteration are compared.  If the 
largest difference observed between any of the parameter estimates from consecutive 
iterations is less than the value supplied to the tolerance argument tol in the function call, 
then the iterative procedure ends, and the estimated model parameters are returned. 
Once the model parameters have been estimated by the EM algorithm, the function 
calculates the log-likelihood of the model, by inputting the estimated model parameters 
into the log of the likelihood expression shown in equation (21).  Again, the random effects 
are integrated out using a pseudo adaptive Gauss-Hermite procedure, as described in 
Section 5.1.2.2, with number of quadrature points set using the function argument lgpt. 
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5.2 Simulation of multi-study joint data 
The package contains a function to simulate multi-study joint longitudinal and time-to-
event data, namely simjointmeta().  The methodology for simulation of data under a 
proportional hazards model with time varying covariates is described in Bender et al [219] 
and Austin [220]. In the following section, a general overview of the methods used to 
simulate data by the simjointmeta function is given. Details of data simulations 
conducted under specific conditions during later simulation studies are given in Chapter 7. 
During discussion of the data simulation function, expressions are presented with a single 
individual level association parameter 𝛼(2) and a single study level association parameter 
𝛼(3).  If separate association parameters were specified for each random effect (see 
Section 4.4.1) then these common association parameters would simply be replaced with 




.  If separate association parameters are specified for 




 for the case of common 











 for the case of separate association parameters for each random effect 
(similarly for parameters 𝜃0, 𝜃1, and, if supplied, 𝜆, specified using arguments theta0, 
theta1, and censlam respectively). Expressions using common values are given, but note 
that the function allows study specific values for these arguments to be used. 
The data simulation function in the package simulates data under a model that includes a 
fixed treatment assignment term in the time-to-event sub-model, and a fixed intercept, 
time and treatment term in the longitudinal sub-model.  All data within a study is simulated 
at the same time.  Initially, a full design matrix for the fixed effects is generated, so that 
when simulating study 𝑘 (for 𝑘 = 1 … 𝐾 where 𝐾 is the total number of studies) of size 𝑛𝑘 
individuals with 𝑚𝑘 total possible longitudinal measurements, the longitudinal fixed effects 
design matrix for the study 𝑿𝟏𝒌 is (𝑛𝑘 ∗ 𝑚𝑘)  by 3 (the number of fixed effects in the 
longitudinal sub-model), and the time-to-event design matrix 𝑿𝟐𝒌 is 𝑛𝑘 by 1. The treatment 
assignment variable is generated from a binomial 𝐵(𝑛𝑘 , 0.5) distribution, with a long 
version included in 𝑿𝟏𝒌.  The design matrices for the individual level random effects 𝒁𝒌
(𝟐) 
will be a subset of 𝑿𝟏𝒌 containing only the covariates assigned individual level random 
effects, similarly for 𝒁𝒌
(𝟑) if study level random effects are to be included. 
To generate the individual level random effects for individuals in study 𝑘, labelled 𝒃𝒌
(𝟐), 𝑛𝑘 
realizations from a  zero mean multivariate normal distribution of dimension 𝑞 (the number 
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of individual level random effects, equal to 2 if rand_ind is set to “intslope”, or 1 if 
rand_ind is set to “int”) are generated.  If study level random effects, labelled 𝒃(𝟑), are 
specified, 𝐾 realizations (one for each study 𝑘 to be simulated) are generated from a 
multivariate distribution of dimension 𝑟 (the number of study level random effects, equal 
to 2 if rand_stud is set to “inttreat”, and 1 if rand_stud is set to “int” or 
“treat”).   The independent but identically distributed longitudinal measurement errors 
𝜺𝒌 are generated as a vector of realizations from a 𝑁(0, 1) distribution multiplied by the 
square root of the measurement error variance (specified by argument vare), with one 
realization for each simulated longitudinal measurement. 
The longitudinal measurements 𝒀𝒌 for study 𝑘 for all individuals at all time points are then 
calculated using the following equation: 











In equation (59), 𝜷𝟏 are the population coefficients for the longitudinal covariates 
(specified using argument beta1). If study level random effects are not specified, then the 
𝒁𝒌
(𝟑)𝒃𝒌
(𝟑) is not included in the model. At first, a longitudinal measurement for each 
individual within each study at each possible time point is generated. Measurements taken 
after the simulated event time are discarded before the data is returned by the function. 
The distribution the time-to-event data is simulated under depends on the presence of 
time varying covariates in the random effects specification. No time-varying covariates are 
included as fixed effects in the model the time-to-event data is simulated under. However 
the joint data is simulated under a random effects only association structure, meaning that 
if data is simulated under a joint model containing a random time effect, time will be 
present in the time-to-event sub-model through the association structure.  If time is not 
assigned a random effect, all terms in the time-to-event sub-model are time stationary.   
There is no option in the function to include study level random effects for time varying 
covariates (and so during this section the term 𝒁𝑘
(𝟑)𝒃𝑘
(𝟑) is not expanded), however time 
can be assigned an individual level random effect.  
If time is present in the time-to-event sub-model (because rand_ind = “intslope” ) 
then the risk of hazard changes over time.  As such, the function simulates data under a 
distribution that permits the baseline hazard to vary over time, namely the Gompertz 
distribution.  If time is not present in the time-to-event sub-model (because rand_ind = 
“int” ) then the risk of hazard remains constant over time. As such, the function simulates 
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data under a distribution that holds the baseline hazard constant over time, namely the 
exponential distribution.  This approach for simulating multi-study joint data is based on 
the theory for simulating time-to-event information with time varying covariates reported 
by Bender et al [219] and Austin [220], and the single study data simulation function 
contained in joineR [80].  
A discussion of data simulated under a model with a random intercept at the individual 
level is now given, i.e.  rand_ind = “int”.  In this case, time-to-event data is simulated 
for study 𝑘 under the following model: 







In equation (60), the time-to-event sub-model contains a fixed treatment effect (where 
𝒕𝒓𝒆𝒂𝒕𝒌 contains the treatment assignments for all individuals in study 𝑘), a shared 
individual level random intercept with individual level association parameter 𝛼(2), and 
shared time stationary study level random effects with study level association parameter 
𝛼(3).  If study level random effects are not specified, then the 𝛼(3)𝒁𝒌
(𝟑)𝒃𝑘
(𝟑) component will 
not appear in the model.  In this case, as the time-to-event sub-model does not directly 
involve time varying covariates the event times are generated using the expression in 















In the above expression, 𝑻𝑬𝒌 is the vector of estimated event times for study 𝑘,  𝑿𝟐𝒌 is the 
stacked design matrix for the time-to-event sub-model for all 𝑛𝑘 individuals in study 𝑘, and 
𝜷𝟐 is the coefficient for the time-to-event treatment effect as specified to argument 
beta2.  Again, if study level random effects are not specified in the data simulation 
function call, the 𝜶(𝟑)𝒁𝒌
(𝟑)𝒃𝒌
(𝟑) component would not appear. The 𝜃0 parameter is the 
exponential of the 𝜆 parameter for an exponential distribution, specified in the function as 
argument theta0.  The parameter 𝑼𝒌 is a vector of 𝑛𝑘 realisations from 𝑈(0,1). 
In the methods presented in Bender et al [219], and Austin [220], the distribution of the 
baseline hazard that data is simulated under, and the distribution type of the event times, 
is the same. As such, the expression in equation (61) simulates event times under an 
exponential distribution, and the baseline hazard is exponentially distributed.  This is 
because the time-to-event sub-model does not involve time-varying covariates, and as 
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noted in Bender et al [219], the baseline hazard for an exponential distribution is a constant 
value: it does not vary with time. 
Alternatively, if data is simulated under a model with both a random intercept and a 
random time term at the individual level, i.e.  rand_ind = “intslope”, then the time-
to-event sub-model data is simulated under has specification: 









Equation (62), has the same parameters as equation (60), with the addition of an individual 
level random slope 𝒃𝟏𝒌
(𝟐)
𝒕𝒊𝒎𝒆𝒌.  As before,  𝜶
(𝟑)𝒁𝒌
(𝟑)
𝒃(𝟑) will only be included in the model 
if study level random effects are specified in the function call.  Unlike before, data are now 
being simulated under a time-to-event model with a time varying covariate present in the 
time-to-event sub-model through the association structure.  As such, simulating event 
times under an exponential distribution is no longer appropriate, as the baseline hazard will 
not remain constant over time.  Instead, event times are simulated under a Gompertz 
distribution (see [219, 220]), which is often used to represent human lifetimes. The 
Gompertz distribution has a baseline hazard that can vary over time, which is necessary 
given that equation (62) contains a time varying random effect 𝒃𝟏𝒌
(𝟐)
. As such, event times 






















In equation (63), 𝑼𝒌 again represents 𝑛𝑘 realisations from 𝑈(0, 1), 𝛼
(2) and 𝛼(3) are 
respectively the individual level and study level association parameters, 𝒃𝟎𝒌
(𝟐) are the 
individual level random intercepts and 𝒃𝟏𝒌
(𝟐) the individual level random time terms for 
study 𝑘, and 𝒁𝒌
(𝟑)𝒃𝒌
(𝟑) are the study level random effects and their design matrix.  The 
parameters 𝜃0 (the exponential of which is the scale parameter of a Gompertz distribution, 
i.e. 𝜅 = exp 𝜃0) and 𝜃1 (the shape parameter of a Gompertz distribution) are used along 
with the coefficients in the model to control the distribution of the event times.  They are 
specified in the function call through arguments theta0 and theta1. Bender et al [219] 
suggested using the extreme value theory to calculate values to set  theta0 and theta1 
to, given target mean and variance for the event times.   
A Gompertz distribution has increasing hazard for a positive shape parameter, constant 
hazard for a shape parameter equal to 0 (equivalent to an exponential distribution), and a 
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decreasing hazard for negative shape parameters.  Under the above model, the probability 
density function of the event times takes form: 
 
𝑓0(𝑡) = 𝜅 exp(𝜃1𝑡) exp (
𝜅
𝜃1
(1 − exp(𝜃1𝑡))), where 𝜅 = exp 𝜃0 
  
(64) 
However, if the shape parameter is negative, if time is allowed to tend towards infinity, 
there is a non-zero probability of living forever.  As such, in the function, event times when 
the Gompertz distribution is employed are simulated under a two-step process. First, for 
each individual 𝑖 within study 𝑘, the following two conditions are checked (using the 
uniform realizations held in 𝑼𝒌). 
𝐶𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 1: (𝜃1 + 𝛼
(2)𝑏1𝑘𝑖
(2)) < 0 
𝐶𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 2: 𝑈𝑘𝑖 < exp (








If the conditions are both true, the individual is automatically assigned an event time of 
infinity, otherwise their event time is generated under equation (63).  As such, unless it is 
acceptable for individuals to be assigned infinite event times when rand_ind = 
“intslope”, it is important to either allow censoring, or to specify that event times be 
truncated at a certain time (using arguments trunctation and trunctime).   
Regardless of the individual level random effects specification that the data is generated 
under, if the data is specified as censored (i.e. censoring = TRUE), the censoring time is 
generated in the same way.  The censoring times are always exponentially distributed, 
under exp(𝜆), where 𝜆 is specified in the function call using argument censlam.  As such, 







In equation (65), as earlier, 𝑼𝒌 is a vector of length 𝑛𝑘 of realizations from 𝑈(0,1), and 𝜆 is 
the value of censlam as specified in the function call.  If censoring is permitted, then the 
survival time returned by the distribution is the minimum of the generated censoring and 
event times, with, for each individual, the censoring variable taking value 1 if 𝑇𝐸𝑘𝑖 < 𝑇𝐶𝑘𝑖, 0 
otherwise. 
Once both the longitudinal and time-to-event data has been simulated in this manner, the 




During this chapter the methodology which underpins the functions made available in the 
multi-study joint modelling package joineRmeta has been presented and discussed.  The 
theory behind multi-study joint longitudinal and time-to-event data simulation has been 
presented, as well as the background as to why certain association structures cause effects 
on event risks to be decomposable into direct and indirect effects.  The methods used to fit 
one-stage multi-study joint models have been described, and areas of future work to either 




Chapter 6 : Real Data Applications of Joint Meta-Analytic 
Methods 
In this chapter, the one-stage and two-stage meta-analytic methods for joint data 
described in Chapter 3 are applied to a real dataset.  Issues and considerations of the 
methods when used in an applied research example will be discussed, and the results 
motivate the simulation studies conducted in Chapter 7.  The chapter will conclude with a 
discussion of the results of the real world example. 
6.1 Description of the INDANA dataset 
The INDANA dataset produced by the INDANA collaboration [91] is an IPD dataset 
comprising of data for hypertensive (high blood pressure) patients from multiple studies.  It 
was assembled to determine how the efficacy of pharmacological treatment for high blood 
pressure depended on patient characteristics [91].  The investigation included any 
randomised controlled trials that assessed the efficacy of any drug interventions for 
hypertension (denoted by treatment group 1), versus no treatment, placebo or usual care 
(denoted by treatment group 0).  A total of 14 trials were included in the collaboration. 
During this research, a subset of the INDANA dataset was examined, which included any 
studies containing both longitudinal and time-to-event IPD.  The subset analysed 
(henceforward referred to as the INDANA data) consisted of data from 6 trials [221-226]. 
The individual studies in the subset are referred to as EWPHE [221], COOP [222], STOP 
[223], SHEP [224], MRC1 [225] and MRC2 [226] respectively. 
The dataset contained two continuous longitudinal outcomes: systolic and diastolic blood 
pressure (denoted SBP and DBP respectively).  Three time-to-event outcomes are available; 
time to death, time to myocardial infarction (MI,  death of a portion of heart muscle due to 
blood supply disruption resulting in heart attack [227]), and time to stroke (a sudden attack 
of weakness affecting one side of the body caused by interrupted blood supply to the brain 
[227]).  The latter two time-to-event outcomes included both terminal and non-terminal 
events.  These outcomes are all linked to cardiovascular disease (CVD) [228].  As this thesis 
is concerned with univariate joint models, analysis is restricted to three pairs of outcomes, 
namely SBP and time to death, SBP and time to MI, and SBP and time to stroke. SBP was 
analysed rather than DBP as SBP is noted to be a more significant issue as age increases, 
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and elevated DBP is more common in populations below 50 [229].  As such, given the 
demographic of the INDANA dataset (Section 6.1.1), an analysis of SBP is more appropriate. 
For the EWPHE trial an intention to treat analysis is only possible for fatal endpoints, and so 
the study contributed data only to the SBP and time to death analysis.  The final joint 
dataset used in this thesis contained a maximum of 6 studies totalling at most 29837 
individuals.  Exact numbers of individuals contributing to each analysis are available in each 
analysis’ results table. 
During these analyses, the aim was to demonstrate methods developed during this thesis 
rather than to investigate potential treatment modifiers.  As such, although the INDANA 
datasets contained additional patient covariates, models in this investigation only involved 
the treatment assignment and longitudinal measurement time covariates.  In addition, as 
analyses are based on a subset of available studies (containing those that could provide 
both longitudinal and time-to-event IPD), any clinical interpretation should be made with 
caution. 
6.1.1 Comparison of demographics between studies 
Heterogeneity between studies can occur due to differences in the patients’ demographics.  
For example, the observed treatment effect may differ between studies with elderly 
compared to younger populations.  The INDANA dataset contains a range of baseline 
variables measured in some or all the included studies (data in Table 6 and Table 7, levels 
of missing data in Table 8).  Many of these recorded covariates are known to influence CVD 
(Cardiovascular Disease) or blood pressure, for example many of them are included in the 
QRISK model (which produces a CVD risk score), or its update QRISK2 (which includes the 
variables in QRISK, as well as several additional variables such as patient reported ethnicity) 
[230-235].  The demographic characteristics in the INDANA dataset show potential 
differences between the studies, which, for covariates linked to CVD, may cause between 
study heterogeneity.   
The size of the studies included in the INDANA data varies considerably, with the smallest 
study contributing 840 individuals (EWPHE), and the largest containing 17354 individuals 
(MRC1, over half of the IPD). The proportions of individuals assigned to each treatment 
group is similar across studies (close to equal proportions).  Table 6 shows the discrete 
baseline measurements available in the INDANA dataset, from which several areas can be 
identified where the demographics differ between studies. 
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Firstly, for most studies, between 60% and 70% of the study population are female.  
However, the largest study in the meta-analysis, MRC1, had closer to equal gender 
proportions.  Within each study, the proportion of females in each treatment group were 
comparable, as expected due to the randomisation process.  As discussed in Reckelhoff 
[236], age-matched men are generally at higher risk of CVD than premenopausal women, 
and women had lower 24 hour mean blood pressure than men until the age of 70-79 years.  
Additionally, gender is included in the aforementioned QRISK2 model as potentially related 
to CVD [231, 232, 235].  The difference between proportion of females between MRC1 and 
the other studies could result in heterogeneity. 
The proportion of smokers varies at baseline between studies, with only 7.7% of those in 
the STOP trial classed as a smoker at baseline, compared to 28.9% in the MRC1 study.  
Within studies, there were similar proportions of smokers between treatment groups, 
apart from COOP which had 16.8% smokers at baseline in the no treatment, placebo or 
usual care group, and 22.7% in the any drug intervention group.  Smoking is a risk factor for 
CVD [235], with NICE guidelines for hypertension in adults recommending support to help 
patients stop smoking [229].  Consequently, the variation between studies in proportion of 
smokers may lead to between study heterogeneity, and the inconsistency between 
treatment groups in COOP may reduce apparent treatment benefit. 
There was a disparity in proportion of individuals with history of diabetes between studies.  
Some trials (COOP, MRC1, MRC2) contained no, or close to zero, individuals with history of 
diabetes, whereas the remaining studies (EWPHE, SHEP, STOP) involved populations where 
just under 10% had a history of diabetes.  Proportions of individuals with history of 
diabetes were comparable between treatment groups within studies.  Type 2 diabetes is 
included in the QRISK2 model [231, 232, 235] used to predict CVD. Whilst information on 
type of diabetes was not provided in the dataset, variability in proportions of those with 
history of diabetes between study populations could lead to between study heterogeneity. 
History of treatment for high blood pressure is a missing variable for the STOP trial.  
However, where recorded, there is disparity between studies, with COOP, MRC1 and MRC2 
containing no individuals with history of treatment for high blood pressure, whereas 
EWPHE contains 57.7%, and SHEP contains 33.3%. The proportions between treatment 
groups are similar for SHEP, whereas slightly fewer in the any drug intervention group in 
EWPHE have a history of treatment for high blood pressure (55% compared to 60.4%).  
History of high blood pressure was also included in the dataset, but this was only recorded 
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in the MRC1 trial, who recorded that none of patients had a history of high blood pressure.  
The QRISK2 model includes previous treatment for hypertension as a variable, indicating a 
possible link to CVD.  As such, again the treatment response between studies could differ 
due to the differing populations. 
The dataset also includes variables for history of MI (myocardial infarction) and history of 
stroke.  The proportions were low in most cases, with only EWPHE reporting higher 
proportions than 5% for history of stroke in both treatment groups.  In general, proportions 
with history of each event were similar across studies and between treatment groups 
within studies. 
Table 7 contains summaries of the continuous variables included in the dataset.  Again 
many are linked to CVD.  As mentioned earlier, increasing age is linked with increasing risk 
of hypertension [234].  Most studies in the meta-analysis have a mean age around 70 years 
old, apart from MRC1, which has a mean age of 52.1 years. Within each study the mean 
age was similar between treatment groups.  As hypertension depends on age, as evidenced 
by the covariate’s inclusion in the QRISK and QRISK2 models [234, 235], the large difference 
in mean age between MRC1 and the other studies could manifest as between study 
heterogeneity. 
Height and weight are included in the INDANA dataset, and Body Mass Index (BMI, derived 
from these measurements) is known to affect CVD [230, 234, 235].  As such, BMI was 
calculated and compared.  Mean BMI within each study was comparable between 
treatment groups.  Across studies, BMI was again comparable, with largest mean BMI of 
27.6 in SHEP, and lowest of 26.4 in EWPHE. Consequently, BMI, whilst having the potential 
to affect the outcomes of this real example, may not contribute greatly to between study 
heterogeneity in this case. 
Baseline heart rate is also available in the dataset.  The effect of heart rate on hypertension 
has been widely debated [237, 238], and it is not commonly used as a predictor for CVD.  
This value was unmeasured in the EWPHE and MRC1 trials, and showed some variability 
between trials where it was recorded (e.g. mean baseline heart rate in SHEP was 70.8, 
whilst in MRC2 it was 82.2).  Within studies, baseline heart rate was comparable within 
treatment groups.  However, as a link between CVD or hypertension and heart rate has not 




Baseline was included as a time-point in longitudinal analyses, and so baseline SBP 
constituted part of the outcome for the longitudinal models.  Baseline DBP was also 
included in the dataset.  Variability between studies existed for SBP, with MRC2 giving a 
mean baseline SBP of 161.6, whilst the COOP trial reported a mean baseline SBP OF 197.1.  
A diagnosis of hypertension can stem from elevated systolic or diastolic blood pressure, 
although elevated DBP is more common for those under 50, whilst SBP is a greater issue for 
older populations [229].  Baseline DBP varied between studies, with lowest mean value 
76.8 in SHEP, whilst highest in STOP with 101.7.  There was little variability within studies 
between treatment groups.  Such variability at baseline in SBP or DBP is likely to translate 
into variability between studies in treatment estimates. 
Serum cholesterol is a recognised predictor for CVD [234], however mean baseline 
cholesterol was similar between studies and between treatment groups within studies, and 
so was unlikely to cause severe heterogeneity.  The dataset also contained baseline serum 
creatinine, which can be used to measure renal function (important as hypertension is a 
risk factor for chronic kidney disease [239]).  This variable was not recorded in the MRC1 
trial, and was similar for all other trials apart from SHEP, which reported marginally higher 
mean values (within studies mean values were comparable between treatment groups).  
The differences in this variable between studies could lead to heterogeneity, however the 
variable is a measure of the effect of hypertension or its treatment on renal performance, 
and so may not directly affect the outcomes of interest. 
For both the discrete and continuous data, some variables contained missing data (Table 
8).  In most cases where missing data was present, data was available for the covariate for 
over 95% of the population.  However, some variables displayed much higher levels of 
missingness (e.g. baseline heart rate was missing for 62% of the population), and several 
variables were completely unrecorded in some studies (identified by NR=Not Recorded).  
This does not severely affect this investigation as the covariates are not used, but it could 
present an issue for this disease area in the future if covariates with a high level of 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Number missing values (%) 
Study Overall 
COOP EWPHE MRC1 MRC2 SHEP STOP 
Smoking 
Status 
7 (0.8) 0 (0.0) 77  (0.4) 2 (0.0) 2 (0.0) 19 (1.2) 107 (0.4) 
History of 
Diabetes 




























17 (1.9) 0 (0.0) 2 (0.0) 0 (0.0) 59 (1.2) 13 (0.8) 91  (0.3) 
History of 
stroke 
17 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) 32 (0.7) 13 (0.8) 62 (0.2) 
Baseline 
BMI 














































Table 8: Number of missing values (% missing) from baseline variables by study and overall. Unlisted variables 
contained no missing data.  NR = Not Recorded in the study.   
6.1.2 Longitudinal Data 
Possible measurement times for the longitudinal outcomes were baseline, 6 months, 1 year 
and annually thereafter to a maximum of 7 years (giving 9 potential measurement times), 
however measurement schedules differed between studies.  The SHEP study recorded at 
least some individuals at 6 measurement times, and STOP and MRC1 at 7 measurement 
times.  The remaining studies reported measurements at all 9 possible measurement times.  
Only an individual’s longitudinal measurements made before their recorded survival time 
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contributed towards each analysis.  The number of longitudinal measurements at each 
time point are available in Table 9. 
Study 
Time (years) 
0 0.5 1 2 3 4 5 6 7 
SBP and time to death 
COOP 884 760 785 722 514 329 267 200 160 
EWPHE 840 749 653 509 383 297 213 118 63 
MRC1 17354 16525 16343 15308 14611 12584 8353 0 0 
MRC2 4394 4182 4100 3765 3490 3223 2596 655 52 
SHEP 4736 0 4243 4091 3938 2644 1164 0 0 
STOP 1612 1520 1440 798 311 67 29 0 0 
SBP and time to MI 
COOP 884 759 782 713 506 319 260 195 155 
MRC1 17354 16512 16309 15253 14520 12478 8273 0 0 
MRC2 4394 4176 4086 3739 3465 3183 2564 644 52 
SHEP 4728 0 4220 4051 3877 2592 1141 0 0 
STOP 1612 1518 1433 784 299 65 28 0 0 
SBP and time to stroke 
COOP 884 754 777 709 496 316 251 187 153 
MRC1 17354 16521 16325 15282 14572 12542 8318 0 0 
MRC2 4394 4172 4080 3737 3451 3177 2547 642 51 
SHEP 4736 0 4206 4005 3834 2555 1105 0 0 
STOP 1612 1515 1418 767 294 66 29 0 0 
Table 9: Number of longitudinal measurements available at each time point by study for analysis of SBP and 
time to death, SBP and time to MI, and SBP and time to stroke. 
Plotting the longitudinal trajectories for SBP each study indicated a change in mean study 
population trajectory slope at approximately 6 months (Figure 37-Figure 39, Appendix 2).  
To account for this characteristic of the data, a variety of functions of the longitudinal time 
variable 𝑡 were tested for inclusion in joint models fitted to each study and to the multi-
study meta-dataset,  (including 𝑡2 and exp(−𝑔 ∗ 𝑡), where 𝑔 is some constant), and the 
model fits compared using the deviance and the AIC scores.  It was determined that the 
change in the longitudinal trajectory was well represented across the studies by including 
an exp(−3 ∗ 𝑡) term when modelling SBP.  This approach is employed both in the two-
stage and the one-stage investigations shown in this chapter.  
The option to fit a changepoint model to the data was considered, and preliminary code to 
fit such a model developed.  However, there were some issues with model convergence, 
and as the model containing an exp(−3 ∗ 𝑡) term fitted the data adequately, completion of 
the changepoint model code was delayed until a later date. 
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Figure 4-Figure 6 show the longitudinal trajectories panelled by event type (0 = censored, 1 
= experienced the event in question), with longitudinal time adjusted by survival time 
(𝑡𝑘𝑖𝑗 − 𝑇𝑆𝑘𝑖).  This adjustment allows changes in the longitudinal trajectory just before the 
individual is censored or experiences the event to be identified.  In many of the studies, for 
each of the time-to-event outcomes, the SBP values taken by those experiencing an event, 
compared to those censored, tend to be higher.  Additionally, the loess smoother for those 
censored shows an initial decrease followed by a plateau, whilst those experiencing the 
event showed a loess smoother with a more constant linear decline. These differences in 
loess smoothers indicate a potential benefit of jointly modelling SBP and each of the three 
time-to-event outcomes of interest. 
Panelling the graphs further by treatment assignment (Figure 7-Figure 9) additionally 
allows differences between those assigned to any drug intervention for hypertension 
(TREAT = 1) versus those assigned to no treatment, placebo or usual care (TREAT = 0) in SBP 
trajectories to be assessed. The SBP values for those assigned to any drug intervention 
appear marginally lower than those assigned to no treatment, placebo or usual care. The 
shapes of the loess smoothers remained relatively similar between treatment groups for 
those censored and also for those experiencing an event. Consequently, whilst assignment 
to any drug intervention for hypertension is likely to reduce SBP, the association between 





Figure 4: For SBP and time to death, individual longitudinal trajectories (black) panelled by event type for each 
study, with loess smoother (red).  Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) from 





Figure 5: For SBP and time to MI data, individual longitudinal trajectories (black) panelled by event type for each 
study, with loess smoother (red). Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) from 





Figure 6: For SBP and time to stroke data, individual longitudinal trajectories (black) panelled by event type for 
each study, with loess smoother (red).  Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) 





Figure 7: For SBP and time to death, individual longitudinal trajectories (black) panelled by event type and 
treatment group (1=any drug intervention for hypertension, 0= no treatment, placebo or usual care) for each 
study, with loess smoother (red).  Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) from 





Figure 8: For SBP and time to MI data, individual longitudinal trajectories (black) panelled by event type and 
treatment group (1=any drug intervention for hypertension, 0= no treatment, placebo or usual care) for each 
study, with loess smoother (red). Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) from 





Figure 9: For SBP and time to stroke data, individual longitudinal trajectories (black) panelled by event type and 
treatment group (1=any drug intervention for hypertension, 0= no treatment, placebo or usual care) for each 
study, with loess smoother (red). Time is adjusted by subtracting individual specific survival times (𝑇𝑆𝑘𝑖) from 




6.1.3 Time-to-event data 
The event rates for each outcome of death, stroke and MI in the included studies are given 
in Table 10.  The percentage of participants experiencing death varies considerably 
between the included studies, with the lowest occurring in the MRC1 study (2.9%) and the 
highest in the EWPHE dataset (33.8%).  However, the percentages of participants 
experiencing the other time-to-event outcomes (stroke and MI) seem more comparable 






myocardial infarction event 
(%) 
Number experiencing 
stroke event (%) 
COOP 130 (14.7) 73 (8.3)  59 (6.7)  
EWPHE 284 (33.8) NR NR 
MRC1 501 (2.9)   456 (2.6)  169 (1.0)  
MRC2 616 (14.0)  287 (6.5)  235 (5.3) 
SHEP 455 (9.6)  245 (5.2)  262 (5.5)  
STOP 99 (6.1)  66 (4.1)  83 (5.1)  
Overall 2085 (7.0) 1127 (3.8) 808 (2.7)  
Table 10: Event rates for included studies in INDANA dataset.  Missing data: 840 missing stroke event indicators 
(all from EWPHE), 848 missing myocardial infarction event indicators (840 missing from EWPHE, 8 missing from 
SHEP).  Note that no information was recorded (NR = Not Recorded) for time to MI or time to stroke for study 
EWPHE. 
Kaplan-Meier plots with number at risk tables are provided for the time-to-event outcomes 
death, MI, and stroke in Figure 10 to Figure 12. Examination of these plots identifies several 
points for discussion. 
Firstly, for the outcome time to death (Figure 10), for studies COOP, MRC1, MRC2, and 
SHEP, there is little difference in the survival curves for those assigned to no treatment, 
placebo or usual care (red) to those assigned to any drug intervention for hypertension 
(blue).  However, for studies EWPHE and STOP there is a greater difference between the 
curves.  For EWPHE the curve for those assigned to placebo, no treatment or usual care is 
initially below that of those assigned to any drug intervention, although the curves cross at 
later time points.  Similarly, the curve for those assigned to no treatment, placebo or usual 
care in the STOP trial lies below that of those assigned to any drug intervention, again 
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indicating worse survival for those assigned to no treatment, placebo or usual care versus 
any drug intervention for hypertension.   
For the outcome time to MI (Figure 11), the survival curves across all studies for those 
assigned to any drug intervention for hypertension (blue) versus those assigned to no 
treatment, placebo or usual care (red) are similar.  The curves are slightly more distinct for 
the COOP trial, especially at later time points, however still could not be described as 
separated from each other. 
For the outcome time to stroke (Figure 12) a clearer distinction between the survival curves 
for those assigned to no treatment, placebo or usual care (red) versus those assigned to 
any drug intervention (blue) is seen.  Apart from the MRC1 trial (where the survival curves 
are not distinct), the remaining studies all display survival curves where the curve for those 
assigned to no treatment, placebo or usual care falls below the curve for those assigned to 
treatment (indicating better survival in the any drug intervention group).  In some studies 
(MRC2, COOP, to a point SHEP) the separation of the curves is more noticeable only after a 
certain time point.   
Overall, for the three time-to-event outcomes, the assumption of proportional hazards 
appears acceptable, and time-to-event sub-model of any joint models fitted as well as any 
separate time-to-event analyses will follow a PH model.  In the future, alternatives to the 
PH model will be included in the joineRmeta package, allowing more flexibility in model 






Figure 10: Kaplan-Meier curves for time to death outcome for analysis of SBP and time to death.  Number at risk 
tables are shown under the plot for each study.  The any drug intervention for hypertension group is represented 





Figure 11: Kaplan-Meier curves for time to MI outcome for analysis of SBP and time to MI. Number at risk tables 
are shown under the plot for each study.  The any drug intervention for hypertension group is represented by 





Figure 12: Kaplan-Meier curves for time to stroke outcome for analysis of SBP and time to stroke. Number at risk 
tables are shown under the plot for each study.  The any drug intervention for hypertension group is represented 






6.2 Two-stage Meta-Analysis of INDANA dataset 
This two-stage meta-analytic analysis of the INDANA dataset was presented as a real data 
application in Sudell et al [176]. 
As discussed in Chapter 1, in single study cases, where an association exists between a 
longitudinal and a time-to-event outcome, joint models can provide more efficient, less 
biased results than separate analyses [158].  To determine whether this behaviour persists 
in a multi-study analysis, the investigation aimed to examine for a real dataset whether use 
of joint longitudinal and time-to-event models in the first stage of the MA was preferable 
to use of separate longitudinal or time-to-event models. 
6.2.1 Methods  
The methods and guidelines proposed in Section 3.2 for the two-stage MA of joint data are 
applied to the INDANA dataset.  Throughout, study specific coefficient estimates include a 
𝑘 in their subscript e.g. ?̂?12𝑘 whilst the pooled estimates produced by the meta-analyses 
are denoted e.g. ?̂?12. 
6.2.1.1 Preliminary work 
Plots of the longitudinal trajectories for each study panelled by event type were presented 
in Figure 4 to Figure 6 for those individuals contributing to the analysis of SBP and time to 
death, time to MI and time to stroke respectively.  From these longitudinal trajectory plots 
several points were noted. 
Firstly (using Figure 37 to Figure 39 in Appendix 2, which do not adjust time by survival 
time), the longitudinal trajectories showed a change in trajectory at approximately 6 
months in each study across all time-to-event outcome groups (identifiable from the 
smoother applied to the trajectory plots).  As discussed earlier this behaviour is accounted 
for through inclusion of an exp(−3 ∗ 𝑡) term in the longitudinal sub-model.  Otherwise, it 
appears that the trajectories might be reasonably represented through a linear mixed 
effects model. 
Secondly, there appears to be considerable variation between individuals in their 
longitudinal intercept, and the slope shown in the longitudinal trajectories.  As such, a 
longitudinal sub-model that allows for both a random intercept and a random slope may be 
preferred. 
Thirdly, the potential link or association between the longitudinal and the time-to-event 
outcomes needs to be considered.  There was some evidence in Figure 4 to Figure 9 to 
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suggest associations between SBP and the time-to-event outcomes.  The NICE guidelines 
“Hypertension in adults: diagnosis and management” [229] identifies firstly that for each 2 
mmHg rise in SBP, there is an associated 7% increased risk of mortality from ischaemic 
heart disease, and 10% increased risk of mortality from stroke, and secondly that 
hypertension is a major risk for haemorrhagic stroke, myocardial infarction, and premature 
death.  As such, clinical evidence exists for a link between SBP and each of time to death, 
time to myocardial infarction (MI) and time to stroke.  As this investigation aims to 
investigate methods rather than change clinical practice, the random effects only 
proportional association structure is employed, although other association structures may 
have relevant clinical interpretations. 
Kaplan-Meier curves plotted by treatment group (any drug intervention in blue, and no 
treatment, placebo or usual care in red) are given in Figure 10-Figure 12.  As noted earlier 
(Section 6.1.3), the curves for each of time to death, time to MI and time to stroke indicate 
that a PH model might be generally acceptable. 
From examination of both the plots, and consideration of the clinical background of the 
data, it is considered appropriate to analyse the data using a joint model consisting of a 
mixed effects model for the longitudinal sub-model, a proportional hazards model for the 
time-to-event sub-model, and a random effects only proportional association structure. 
6.2.1.2 First Stage 
In the first stage of the two-stage MA of the INDANA dataset, joint models and separate 
longitudinal and time-to-event models, were fitted to each study.  As the same joint model 
specification was believed appropriate across the included studies, the joint models fitted 
to each study 𝑘 all had the following format: 
𝑆𝐵𝑃𝑘𝑖𝑗 = 𝛽10𝑘 + 𝛽11𝑘𝑡𝑘𝑖𝑗 + 𝛽12𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝛽13𝑘 exp(−3 ∗ 𝑡𝑘𝑖𝑗) + 𝑏0𝑘𝑖
(2) + 𝑏1𝑘𝑖
(2)𝑡𝑘𝑖𝑗 + 𝑘𝑖𝑗  










Here, 𝑡𝑘𝑖𝑗 is longitudinal time, and terms 𝛽10𝑘 through 𝛽13𝑘 are the coefficients for 
longitudinal fixed effects estimated for each study 𝑘.  The individual level random effects 
𝑏0𝑘𝑖
(2)  and 𝑏1𝑘𝑖
(2) follow 𝒃𝒌𝒊
(𝟐)~𝑁(0, 𝑫𝒌), while the error term 𝑘𝑖𝑗 is distributed 𝑁(0, 𝜎𝑒𝑘
2 ). The 
time-to-event sub-model consists of an unspecified baseline hazard 𝜆0(𝑡), as well as a 
study specific fixed treatment effect with associated coefficient 𝛽21𝑘. 
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The association structure takes the zero mean individual level random effects from the 
longitudinal sub-model and inserts them with study specific common coefficient 𝛼𝑘
(2)
 (the 
association parameter) into the time-to-event sub-model giving term 𝑊2𝑘𝑖(𝑡).   
As noted earlier, as well as the joint models, standalone longitudinal and time-to-event 
models were fitted to the INDANA datasets.  These standalone models had the same 
specifications as the corresponding sub-models of the joint model shown in equation (66), 
apart from that the 𝑊2𝑘𝑖(𝑡) term was not present in the standalone time-to-event model. 
6.2.1.3 Second stage 
The second stage of the MA involved extracting parameters of interest from the study 
specific model fits and pooling them using standard meta-analytic techniques. During the 
second stage of the meta-analysis, interest focussed on the fixed treatment assignment 
coefficient from both sub-models (namely coefficients 𝛽12 and 𝛽21) as well as the 
association parameter 𝛼(2).  These coefficient estimates were extracted from the models 
for each study for each analysis, as well as the standard error estimate and the sample size.   
These results were then pooled in both a fixed and a random effects MA, using the inverse 
variance approach [2, 184], with the DerSimonian and Laird [10] approach for the random 
MA (methods discussed in Section 3.2.3). All studies with available data contribute to the 
analysis. The same model specification was utilised for each study, for each outcome pair 
(SBP and time to death, SBP and time to MI, and SBP and time to stroke). Separate MA 
were performed for each parameter of interest (namely the longitudinal treatment effect 
estimate ?̂?12, the time-to-event treatment effect estimate ?̂?21, and the association 
parameter estimate ?̂?(2)). 
6.2.1.4 Software 
Joint models, and separate longitudinal and time-to-event models were fitted using 
functions in the R package joineRmeta (available through GitHub: 
https://github.com/mesudell/joineRmeta).  The functions available in this packages were 
developed during this thesis, and are fully described in Chapter 4.  During the second stage 
of the two-stage MA, the R package meta [182] was used. 
To obtain standard errors in the joineRmeta package it is necessary to perform a 
bootstrapping procedure; Hsieh et al [89] emphasised that use of the profile likelihood to 
estimate the standard errors in joint models could lead to underestimation of the standard 
errors when an unspecified baseline hazard is employed.  Consequently the time taken to 
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obtain precision estimates from the joint models was considerably longer than for the 
separate meta-analyses given some of the larger sample sizes in the included studies.  This 
is further discussed in the simulation studies in Chapter 7. 
6.2.2 Results 
During the two-stage MA, a statistically significant negative time-to-event treatment 
assignment coefficient (𝛽21) would indicate that assignment to any drug intervention for 
hypertension versus no treatment, placebo or usual care significantly reduced the risk of 
the event in question.  A statistically significant negative longitudinal treatment assignment 
coefficient (𝛽12) would indicate that assignment to any drug intervention for hypertension 
significantly decreased SBP.  A statistically significant positive association parameter (𝛼(2)) 
would indicate that individuals with a positive deviation above the population mean 
longitudinal value in their recorded longitudinal values at a given time point are at higher 
risk of the event.   
Table 11 to Table 13 present the results of the analysis of the INDANA dataset in a two-
stage MA employing separate longitudinal models, separate time-to-event models or joint 
models in the first stage of the analysis, for the investigation of SBP and each of time to 
death (Table 11), time to MI (Table 12) and time to stroke (Table 13).   
6.2.2.1 Longitudinal component  
There is little difference between the estimates of the longitudinal treatment effect 
coefficient from the separate longitudinal analysis compared to the joint analysis (Table 11 
to Table 13). Assignment to treatment for hypertension versus no treatment, placebo or 
usual care is estimated to significantly reduce SBP for each analysis conducted.  There is 
heterogeneity between study specific estimates (the 𝜏2 statistic varied between 2.92 and 
3.21, whilst the 𝐼2 statistic was greater than 95% in all cases).  However, both the fixed and 
random effects MA agreed in the significance and direction of the pooled results. 
6.2.2.2 Time-to-event component 
Again, there was similarity for this real data example between the time-to-event treatment 
effect coefficient estimated within each study between the separate and the joint model 
analyses for each set of outcomes (Table 11 to Table 13).  Additionally, there was little 
evidence of heterogeneity between studies across any of the meta-analyses for either 
method for the time-to-event treatment coefficient for any of time to death, MI or stroke.  
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For time to death (Table 11), for both the separate and the joint analysis, a significant 
negative time-to-event treatment effect coefficient was observed in the STOP trial, 
however no significant effect of treatment assignment was observed in any other study for 
SBP and time to death, or in the pooled results from either the fixed or random MA. 
For time to MI (Table 12), a significant negative time-to-event treatment effect (indicating 
assignment to any drug intervention for hypertension significantly reducing the risk of MI) 
was observed for both the separate and the joint analysis in the SHEP trial.  However, 
again, none of the remaining trials observed a significant treatment effect.  Interestingly, 
the pooled results from both the fixed and the random effects MA for the separate time-to-
event analysis showed a significant negative pooled treatment effect coefficient.  However, 
neither of the pooled results from the joint analysis for the fixed or the random MA were 
significant.  As such, simultaneously modelling both the longitudinal and the time-to-event 
outcome resulted in a shift in the estimated pooled treatment effect coefficient for the 
time-to-event outcome towards zero. 
For time to stroke (Table 13), all studies for the separate time-to-event analysis, and all 
studies apart from MRC2 for the joint analysis, reported a significant negative treatment 
effect coefficient (meaning that most cases observed that assignment to treatment was 
linked to a significant reduction in risk of stroke).  The pooled results for both the separate 
and the joint analyses were similar, with both the fixed and random MA displaying 
significant negative pooled treatment effect coefficients.  This indicated that both separate 
and joint methods estimated that assignment to any hypertensive treatment version no 
treatment, placebo or usual care decreased the risk of stroke. 
6.2.2.3 Association  
The estimated association parameters from each study for each outcome combination (SBP 
and each of time to death, time to MI and time to stroke, Table 11 to Table 13) were small 
in magnitude.  Additionally, for each combination of outcomes, there was evidence of 
heterogeneity between studies in the estimated association parameters (𝐼2 ranging from 
83.20% to 90.30%, p value for chi squared test for heterogeneity <0.001 in all cases).  In all 
three cases 𝜏2 was small in magnitude, however the magnitudes of the association 
parameters were in themselves small.  For SBP and time to death, and SBP and time to MI 
(Table 11 and Table 12) a significant positive association parameter was estimated in the 
largest included trial, MRC1, suggesting that an individual with SBP values above the 
population average at a given time has an associated higher risk of an event at that time.  
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The pooled association parameter estimate was significant for both these analyses for the 
fixed MA, however in both cases the pooled estimate from the random MA was not 
significant.  For time to stroke (Table 13), a significant positive association parameter was 
estimated for studies COOP, MRC1 and SHEP.  Again, the fixed MA produced a significant 
positive pooled association parameter, however the result from the random MA was not 
significant.  Throughout, the wider confidence intervals produced by the random MA 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3 One-stage Meta-Analysis of INDANA dataset 
In this section the one-stage meta-analysis of the INDANA dataset is presented.  This 
section commences with statements of the exact models fitted to the data, followed by 
presentation of the results of the one-stage model.   
6.3.1 Methods 
6.3.1.1 Model specifications 
As in the two-stage analysis (Section 6.2), each pairwise combination of longitudinal 
outcome SBP and time to death, time to MI, and time to stroke have been analysed.  The 
models discussed in Section 3.3 have been employed, which take format as in Table 14 
when applied to this dataset.  Models are grouped to demonstrate different methods to 
account for between study heterogeneity.  Group 0 ignores between study differences and 
Group 1 includes fixed interaction terms (in both sub-models) between the study 
membership variable and treatment assignment.  Groups 2 and 3 introduce study level 
random effects (with random intercept, or random intercept and treatment term 
respectively).  Groups 4 and 5 stratify the baseline hazard of the time-to-event sub-model 
by study, with Group 5 additionally containing a study level random treatment term.  
Again, the exp(−3 ∗ 𝑡𝑘𝑖𝑗) term is present in the longitudinal sub-model, to model the 
change in trajectory noted earlier.  
Once models were fitted, estimates of the coefficients of interest were extracted from the 
models (treatment effects 𝛽12 and 𝛽21 from each sub-model , and any association 
parameters available) along with their 95% confidence intervals, and the number of 
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Models were fitted using the joineRmeta package (described in Chapter 4 and Chapter 5).  
Joint models in a single study setting can be time-consuming to fit.  In the models examined 
here this issue persists through the need to bootstrap to gain standard error estimates.  
Both model fitting, and so bootstrapping, was time intensive due to the large size of the 
meta-dataset.  As such, the Chadwick supercomputer (owned by the University of 
Liverpool), was used to fit the models, and run each separate bootstrap, which were then 
compiled on a standalone laptop.  One-stage methods may be difficult for researchers to 
apply without access to such resources, dependent on the size of the meta-dataset. 
6.3.2 Results 
The results for the one-stage analysis of the INDANA dataset are shown in Table 15-Table 
17 and Figure 13-Figure 21.  Results are displayed for each of the six model groups (Table 
14) for both the joint and separate analyses for each pair of outcomes.  As noted earlier, 
the separate models have the same structure (excepting association terms) as the 
corresponding sub-model of the joint model. 
6.3.2.1 SBP and time to death 
For the analysis of SBP and time to death, across all groups of models fitted for both the 
separate and joint analyses, all estimates of longitudinal treatment effect were significant 
and negative. This indicated that allocation to any drug intervention for hypertension 
versus no treatment, placebo or usual care significantly reduced SBP (Table 15).  All groups 
of joint models tested gave similar results apart from group 3, which accounted for 
between study heterogeneity solely through use of study level random effects.  This 
estimate, whilst still being significant and negative, was much closer to zero than the joint 
model longitudinal treatment coefficient estimate from other groups.   The estimates 
within each model group were similar between the joint and the separate methods (apart 
from group 3, where the separate model gave an estimate comparable to the other 
groups).  However, the confidence intervals were wider in many cases for the separate 
than the joint models (Figure 13). 
The majority of time-to-event treatment effect estimates for SBP and time to death (Table 
15) were not statistically significant (apart from the treatment effect estimate from the 
STOP trial for the joint and separate models in model group 1). Again, there was similarity 
between the estimates between the joint and separate analyses, although the results from 
the joint model were closer to zero, and variation existed in the confidence for models 
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belonging to group 1 (Figure 14).  Overall, there was little evidence from any model group, 
from either the separate or joint analyses indicating any difference in risk of death between 
the any drug intervention for hypertension group versus no treatment, placebo or usual 
care. 
For all model groups, the estimated individual level association parameters for the SBP and 
time to death analysis were positive and significant, although small in magnitude (Table 15, 
Figure 15).  Estimates were similar across all the model groups, with interpretation that 
individuals with higher SBP values than the population average were at higher risk of death.   
The estimates of the study level association parameter (Table 15, Figure 15) were 
insignificant for groups 2 and 5 (model groups involving just a study level random 
intercept), and significant and positive for group 3 (the model group involving a study level 
random intercept and random treatment effect).  This significant study level association 
parameter would be interpreted that study populations with a study average SBP higher 
than the overall population average are at higher risk of death. The association estimate for 
the group 3 model differed significantly in value from those from model groups 2 or 5, and 
had a narrower confidence interval.  The variation in study level association parameter 
estimates may be due to the estimation of study level random effects being based on 6 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.2.2 SBP and time to MI 
For SBP and time to MI, all estimates of longitudinal treatment effect produced by either 
the joint model or the separate analyses from any model group were significant and 
negative (Table 16).  As such, the analyses indicated that assignment to any drug 
intervention for hypertension versus no treatment, placebo or usual care significantly 
reduced SBP. The estimate produced by the joint model for model group 3 (which 
accounted for between study heterogeneity using study level random intercept and 
treatment terms) was different in magnitude to the other joint model estimates.  Except 
for model group 3, treatment effect estimates from separate and joint models were 
comparable.  However, confidence intervals (Figure 16) were wider for the separate 
analyses for model groups 2, 3 and 5 (which each contained study level random effects), 
and differed between the joint and separate analyses for groups 1 and 4 (which contained 
fixed between study membership and treatment group in the longitudinal sub-model). 
The time-to-event treatment effect coefficient for SBP and time to MI showed evidence of 
a significant reduction in risk of MI for those assigned to any drug intervention for 
hypertension versus no treatment, placebo or usual care for the joint and separate 
analyses from model groups 0, 2, 3, 4, 5 (Table 16).  However, for model group 1 (which 
included fixed study membership and interaction between study membership and 
treatment assignment), only the estimate from SHEP for the joint model was significant.  
Overall, there was agreement between the treatment effect estimates from the joint and 
separate analyses across the model groups (Figure 17), although the results for the joint 
models were closer to zero, and there was variation in the confidence intervals between 
the joint and separate results for group 1 models. 
All estimates of the individual level association parameter for the SBP and time to MI across 
all model groups were significant and positive (Table 16, Figure 18), indicating that 
individuals with higher than average values of SBP were at greater risk of MI. However, the 
estimates were small in magnitude.   
The study level association parameters (Table 16, Figure 19), were non-significant for the 
model groups that just contained a study level intercept (groups 2 and 5), however group 3 
(which contained a study level random intercept and treatment effect) reported a 
significant positive association parameter.  This would be interpreted that study 
populations with a study average SBP higher than the overall population average are at 
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higher risk of MI.  However, again due to the number of studies included in the meta-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.2.3 SBP and time to stroke 
All estimates of the longitudinal treatment effect for SBP and time to stroke across all 
model groups for both the joint and separate analyses were significant and negative (Table 
17).  As such there was evidence that assignment to any drug intervention for hypertension 
versus no treatment, placebo or usual care significantly reduced SBP.  Effect estimates 
between the joint and separate methods and across model groups were similar, apart from 
the joint model results from group 3 (which accounted for between study heterogeneity 
solely using study level random effects).  The joint model group 3 longitudinal treatment 
effect was significant and negative but smaller in magnitude than the other results.  The 
group 3 results for the separate model were comparable to the other model groups.  Again, 
there was variation in the size of confidence intervals between the joint and separate 
models (Figure 19). 
The time-to-event treatment effect coefficient for SBP and time to stroke showed evidence 
of a significant reduction in risk of stroke for those assigned to any drug intervention for 
hypertension versus no treatment, placebo or usual care for the joint and separate 
analyses from model groups 0, 2, 3, 4, 5 (Table 17).  In addition, for model group 1, a 
significant negative treatment effect was estimated in studies COOP, MRC1, SHEP and STOP 
from the joint model, and for studies COOP and MRC1 from the separate model.  Effect 
estimates were similar across model groups, and between joint and separate models.  From 
Figure 20, it can be seen that confidence intervals for model groups 0 and 2 through 5 are 
comparable between the joint and separate methods, although there are noticeable 
differences between the intervals for model group 1. 
As with the other analyses, across all model groups, all the individual level association 
parameters were statistically significant and positive, although small in magnitude (Table 
17, Figure 21).  This indicated evidence that individuals with greater than average SBP were 
at higher risk of a stroke. 
Again, for the study level association parameters calculated for groups 2, 3, and 5, the 
groups containing just a study level random intercept (2 and 5) returned an insignificant 
negative study level association parameter (Table 17, Figure 21).  However, group 3 (which 
contained a study level random intercept and treatment effect) returned a significant 
positive study level association parameter, interpreted that studies with a study population 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.4 Discussion of Joint Meta-Analysis of Real Data 
During this chapter a demonstration of the methods discussed in this thesis applied to the 
INDANA has been presented.  Both a two-stage and a one-stage meta-analysis of the 
dataset have been conducted. 
6.4.1 Discussion of Two-Stage joint MA of INDANA data 
In the two-stage analysis of the INDANA dataset, based on the joint modelling analysis, 
assignment to any treatment for hypertension versus no treatment, placebo or usual care 
significantly reduced SBP across all studies examined (heterogeneity across studies was 
present in the magnitude of the effect, but the direction and significance of estimates is 
consistent across studies).  Assignment to any treatment for hypertension, versus no 
treatment, placebo or usual care, had no significant effect on risk of an event (based on 
random effects MA given the heterogeneity of estimates, although assignment to any 
treatment for hypertension appears to have a greater (but still insignificant) effect on risk 
of stroke, than on MI or death.   
Evidence of heterogeneity was noted between studies for several of the parameters, such 
as the association parameter (where the estimate from MRC1 often differed from the 
remaining studies), and longitudinal treatment effect estimate.  This could be attributable 
to the fact that the studies differed in demographics known to be linked to the disease area 
(Section 6.1.1).  The Cochrane handbook [184] (section 9.5.3) details seven approaches to 
dealing with heterogeneous parameter estimates in the second stage of two stage MA (or 
AD-MA), namely checking the data is correct, not pooling results in a MA, exploring 
heterogeneity (through a subgroup analysis or meta-regression), ignoring the 
heterogeneity (as the p value from a fixed effect MA is a valid test of the null hypothesis of 
no effect in every study, although ideally heterogeneity should be explained and accounted 
for), performing random effects MA in place of fixed effects MA, changing the effect 
measure (such as using standardized results), or finally by excluding studies. Alternatively, 
given the availability of IPD, two or one-stage analyses could be conducted, including of 
demographic characteristics thought to influence the effect measure in the sub-models, or 
even employing more complex association structures such as ones that allow interaction 
between association and certain covariates. 
Various tests and procedures exists for assessing the level of heterogeneity when pooling 
parameters including the p value for the 𝜒2 test for presence of heterogeneity in treatment 
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effects (which is low powered where included studies are few or small in size), the estimate 
of between study heterogeneity 𝜏2 (which takes larger values for analyses with greater 
heterogeneity, but is not a test statistic that can be compared to certain criteria) or the 𝐼2 
statistic, which states the percentage of variability in effect estimates due to heterogeneity 
rather than chance [184]. The values for 𝐼2 have been grouped into four overlapping 
categories, namely values of 0% to 40% represent potentially unimportant heterogeneity, 
30% to 60% moderate heterogeneity, 50% to 90% substantial heterogeneity, and 75% to 
100% considerable heterogeneity.  Overall, presence of heterogeneity is often a diagnosis 
made by the researcher, based on the combination of evidence from the p value, 𝜏2, 𝐼2, 
and visual assessment of the forest plot (e.g. non-overlap of confidence intervals between 
studies could indicate heterogeneity), rather than based on the result of a statistical test.As 
this investigation aimed to demonstrate methods, rather than conduct an in-depth 
assessment of potential treatment modifiers, covariates such as age, gender etc. have not 
been included in the examined models.   
In this real example of two-stage meta-analysis of joint data, there was mostly little 
difference between the estimates obtained using separate longitudinal or time-to-event 
models in the first stage compared to using joint models (apart from the difference in 
statistical significance between the pooled estimates for the time-to-event treatment 
effect coefficient between separate and joint models).  This agreement between separate 
and joint models is expected, as the association parameters from the random effects MA 
(examined due to presence of heterogeneity) were not statistically significant, and all 
association parameter estimates were small in magnitude.   
In single study cases, evidence has been presented indicating that less biased results are 
obtained by using joint models rather than separate models in cases where the longitudinal 
and the time-to-event outcomes are correlated [158].  To investigate further whether this 
behaviour persists in the multi-study case, a two-stage MA simulation study was performed 
examining scenarios with a range of magnitudes of association parameter (presented in 
Chapter 7). 
6.4.2 Discussion of One-Stage joint MA of INDANA data 
Throughout the one-stage real data investigation, all analyses from all model groups for 
both joint and separate models estimated significant negative longitudinal treatment 
effect.  This is interpreted that assignment to any drug intervention for hypertension versus 
no treatment, placebo or usual care significantly reduces SBP.  It was expected that the 
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longitudinal estimates across all pairwise combinations of outcomes (SBP and time to 
death, SBP and time to MI, and SBP and time to stroke) are similar, as the longitudinal 
outcome is the same. 
The estimates of the longitudinal treatment effect produced by the joint models fitted 
under the group 3 specification (see Table 15-Table 17) differed significantly from those 
produced by the other groups.  This may be attributable to the fact that the group 3 models 
accounted for between study heterogeneity solely through study level random effects, 
whose distribution is based effectively on a number of data points equal to the number of 
studies involved in the analysis.  As this was small (5 or 6) in all the analyses conducted, the 
distribution may be badly estimated.  The other groups that employed study level random 
effects (groups 2 and 5) only included one study level random effect, and employed other 
additional methods such as fixed terms or stratified baseline hazard to account for 
between study heterogeneity.  The estimates of longitudinal treatment effect from these 
groups were more similar to the groups that involved no study level random effects.  This 
may be due to a variety of reasons e.g. a simpler study level random effects distribution to 
estimate.  It is important to determine whether the estimates provided by joint models of a 
group 3 type specification become more reliable as the number of studies contributing to 
the meta-analysis increases.  This hypothesis is investigated in the one-stage simulation 
study described in Section 7.2.  
It is interesting to note that the longitudinal treatment effect estimate from group 3 for the 
separate model was similar to the results from the remaining groups for both the separate 
and joint models.  This may be attributable to the fact that in the separate model, the study 
level random effects in group 3 solely model the between study variation in longitudinal 
intercept and treatment effect.  However, in the joint model, they are additionally involved 
in modelling the link between the longitudinal and time-to-event outcomes, and 
accounting for between study heterogeneity in the time-to-event sub-model.  The 
simulations in Section 7.2 will investigate whether this disparity in group 3 models between 
separate and joint analyses persists under a range of conditions. 
Throughout, the results from separate and joint models have been similar, although in 
several cases for the time-to-event treatment effect estimate, the joint model estimate has 
been closer to zero.  The similarity between the methods may be due to the fact that whilst 
the association parameters are generally significant, they are small in magnitude.  
Differences between separate and joint models may be observed with significant 
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association parameters, a scenario investigated in the one-stage simulation study (Section 
7.2). However, effect of the link between the longitudinal and time-to-event outcomes 













) removed if study level random 
effects are not included in the model).  As such, the value of 𝑊2𝑘𝑖(𝑡) was output for each 
individual, for each study in the one-stage analysis as well as overall across all studies, for 
each of SBP and time to death, SBP and time to MI, and SBP and time to stroke.  These 
results are available in Appendix 5. The median, lower and upper quartiles, and minimum 
and maximum observed values have been reported in Table 29, and the densities of the 
𝑊2𝑘𝑖(𝑡) terms summarised graphically in Figures 60-62.  From these results, several points 
can be noted. Firstly, there is often a noticeable difference between results from model 
group 0 (which ignores between study heterogeneity) and the remaining model groups, 
highlighting the importance of accounting for between study heterogeneity when it is 
known or suspected.  Secondly, the results from model group 3 are often different to those 
from model groups 1, 2, 4 or 5 (as observed with the parameter estimates already reported 
in this chapter).  However the behaviour of the 𝑊2𝑘𝑖(𝑡) produced by model group 3 differs 
between studies.  For studies COOP and STOP the model group 3 𝑊2𝑘𝑖(𝑡) are higher in 
magnitude than those from model groups 1, 2, 4 or 5, whereas for MRC1 and SHEP they are 
lower.  For MRC2, and (for SBP and time to death) EWPHE, the 𝑊2𝑘𝑖(𝑡) estimates are 
similar between model groups 3 and model groups 1, 2, 4 and 5.  This variability might 
suggest that a model that allows for heterogeneity in the association parameter might be 
beneficial (this is mentioned as planned future extension in Chapter 8). 
The estimates of 𝑊2𝑘𝑖(𝑡) across all three sets of analyses (time to death, MI or stroke) 
show densities that include 0, although the estimates from SBP and time to stroke are not 
as closely centred about zero as for SBP and time to death, or SBP and time to MI.  As such, 
this examination of 𝑊2𝑘𝑖(𝑡) reinforces the conclusion that these analyses do not show a 
strong, consistent relationship between SBP and the events of interest.   
Figures 15, 18 and 21, which display the association parameter estimates and 95% CIs for 
the analyses of SBP and each of time to death, time to MI and time to stroke, display a 
pattern in the estimate of the study level association parameter 𝛼(3) for model groups 2, 5 
and 3.  The estimates produced by model groups 2 and 5 are in agreement; close to zero, 
non-significant, with wide confidence intervals.  However the result produced by model 
group 3 is significant and positive, with narrow confidence intervals.  This estimate of 𝛼(3) 
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produced by model group 3 should be treated with caution, as it is inconsistent with the 
results produced by model groups 2 and 5 (this behaviour holds for other parameter 
estimates; for example, model groups 2 and 5 produce longitudinal treatment effect 
estimates similar to those produced by the other model groups, whereas model group 3 
produces estimates inconsistent with those produced by the other model groups). As such, 
there is some suggestion that model group 3 does not reliably estimate model parameter 
estimates from the sub-models or association structure. As mentioned before, this may be 
due to the study level random effects being poorly estimated.   
Issues with estimation of study level random effects have been stated as a potential reason 
for the differing performance of model group 3. The study level random effects quantify 
the difference between study populations in the dataset.  A large number of level 2 units 
(total individuals included in the meta-analysis) aids with the estimation of the distribution 
of individual level random effects.  A large study population helps to establish the 
behaviour and demographic of that single study.  However, the level of variability between 
studies is assessed by comparison between different study populations, and so is 
influenced by the number of studies included, rather than the sample size contained within 
each study.  The narrow confidence intervals displayed for e.g. the 𝛼(3) parameter from 
model group three could be attributable to the large number of level 2 units (individuals in 
the meta-analysis), but the small number of level 3 units (studies in the meta-analysis) 
could lead to the point estimates themselves being incorrect (potentially explaining the 
difference in parameter estimates reported by model groups 3 compared to the other 
model groups). 
In this demonstration of the methodology developed in Chapter 3, we have fitted examples 
from a range of approaches to account for between study heterogeneity.  Fitting a range of 
models has allowed us to highlight the inconsistency between model group 3 (which solely 
accounts for between study heterogeneity using study level random effects) and the 
remaining model groups.  In practice, a one-stage meta-analysis may not employ several 
approaches to account for between study heterogeneity.  However, it might be 
recommended that, in complex MA such as those for joint data, in a secondary analysis, the 
primary analysis be repeated using an alternative method to account for between study 
heterogeneity, as if the results produced by the secondary analysis are consistent with the 
main analysis, confidence in the reliability of the main analysis would be increased. 
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6.4.3 Comparison of one and two-stage approaches 
There were similarities between the results of two and the one-stage analyses.  The 
longitudinal treatment effect was consistently statistically significant and negative across all 
analyses regardless of the methods used.  As such, there is clear evidence that allocation to 
any hypertensive medication versus no treatment, placebo or usual care significantly 
reduces SBP.   
The time-to-event treatment effect estimates were also similar between the one and two-
stage analyses, however there were differences in significance of results.  The two-stage 
analysis showed a significant reduction in risk of an event for SBP and time to stroke based 
on the joint analysis, whereas the one-stage analysis showed an additional significant 
reductions in risk of an event for SBP and time to MI.  Furthermore, in the two-stage 
analysis, the individual level association parameters showed evidence of heterogeneity, 
with pooled non-significant estimate from the random MA.  Conversely, the one-stage 
analysis produced significant positive (small magnitude) individual level association 
parameters across all analyses conducted.  Overall, whilst the point estimates obtained 
from the two-stage and one-stage analyses were similar, there were differences in 
significance of results.  
Recently Burke et al [189] described the common reasons that results from one and two-
stage analyses based on the same data may differ.  In our case, the discrepancy might be 
attributable to the fact that one-stage methods used exact likelihood methods versus, the 
two-stage which used approximate likelihood methods (which Burke et al note could be 
unreliable for time-to-event outcomes when the outcome is rare).  Another potential 
reason for the discrepancy may be that whilst the one-stage approach accounts for 
correlation between parameters, standard MA methods in a two-stage MA do not.  A 
solution to this could be to utilise multivariate meta-analytic methods in the second stage 
of a two stage MA, discussed in Section 8.3.2.1. 
6.4.4 Limitations of conducted analyses 
These investigations focused only on demonstrating the methods contained in this thesis, 
and did not include some variables known to be linked to CVD.  Inclusion of these variables 
may reduce some of the heterogeneity seen. Future analyses aiming to influence 
healthcare should investigate in detail the covariates known to effect hypertension or CVD. 
The analyses conducted in this chapter were restricted to joint models that employed a 
linear mixed effects model for the longitudinal sub-model, with a PH model for the time-to-
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event sub-model, with zero mean random effects with level specific association parameters 
forming the association structure.  However, other joint modelling specifications may be 
preferable, such as use of splines in the longitudinal sub-model to account for the 
mentioned change in trajectory at around 6 months.  In addition, given that the Kaplan-
Meier curves cross for some outcomes for some studies investigation of other time-to-
event sub-model types (such as AFT or parametric models) may prove beneficial.  Finally, 
clinically, it may make sense to investigate alternative association structures, e.g. current 
value structure that would model how the true recorded value of the longitudinal outcome 
affects the risk of an event.  The analyses were restricted to the presented model 
specifications by the choice of software used, however there are plans in the future to 
expand the joineRmeta package to allow for greater flexibility in model structure (see 
Section 8.3.2.2). 
In addition, to account for the change in slope in the longitudinal trajectories, an 
exp(−3 ∗ 𝑡) term was included in both the one and two-stage analyses.  However a 
random effect was only included for the linear time term (whose interpretation may be 
complicated if the effect of the exp(−3 ∗ 𝑡) differs across individuals).  As such, the 
analysis may be improved by investigation of more complex random effects structures, 
such as assignment of an individual level random effect to exp(−3 ∗ 𝑡). This analysis aimed 
only to demonstrate the methodology produced in this research.  In an analysis aiming to 
influence healthcare, an in depth investigation of potential fixed and random effect 
specifications would be undertaken. The results in the real data analysis display some 
heterogeneity between studies. Here, the heterogeneity is likely to be due to the 
differences in demographics between studies included in the meta-analysis, as the included 
studies differ in parameters known to be linked to the outcomes, such as age (see Section 
6.1).  An adjusted analysis may display reduced heterogeneity.  This is reinforced by the 
fact that the simulation studies displayed less heterogeneous results (see Chapter 7, 
although it should be noted that simulated data is generally less heterogeneous than real 
data, for example due to the lack of measurement error). 
6.4.5 Concluding remarks 
Overall, this chapter has demonstrated the application of methods developed in this thesis 
to a real dataset. The analyses shown here motivated both the one and two-stage 
simulation studies described in Chapter 7, and the proposed further work to be conducted, 
discussed in Chapter 8. 
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Chapter 7 : Simulation investigation of joint meta-analytic 
methods 
In this Chapter the simulation investigations undertaken both for the two-stage and the 
one-stage MA of joint longitudinal and time-to-event data are described.   
The INDANA dataset displayed small magnitude associations between the longitudinal and 
time-to-event outcomes, resulting in little difference between joint and separate MA 
(Chapter 6).  However, joint models have shown benefits (such as reduced bias and 
increased efficiency) over separate analyses for single study cases [158].  As such, it is 
necessary to establish if joint models show benefit over separate models in MA under a 
range of association magnitudes.  Simulations to investigate this for one and two-stage MA 
approaches are shown in Sections 7.1 and 7.2. 
Additionally, the one-stage INDANA analyses highlighted potential issues with the proposed 
one-stage models that involved study level random effects.  Consequently, to determine 
what conditions are required for estimation of study level random effects to be reliable, 
additional one-stage simulation studies were conducted that varied the number of studies 
included in the MA, and varied the level of between study heterogeneity (see Section 7.2). 
During the simulation studies, the University of Liverpool’s HTCondor system was used, see 
[240], https://research.cs.wisc.edu/htcondor/ , and http://condor.liv.ac.uk/ .  The condor 
system at the university makes use of over 500 computers across the university campus, 
and allows “jobs” such as R analyses to be run on any idle computers.  Such systems allow 
analyses that require the same procedure to be carried out multiple times, such as in 
simulation studies, to be completed sooner by running the analyses in parallel on different 
machines.  The system has restrictions, for example analyses cannot run for over 24 hours 
as the system resets daily, and partially completed analyses can be forced to restart if the 
computer they are running on becomes unavailable.  However, the system is a powerful 
tool to allow in depth simulations studies to take place. 
7.1 Simulations investigating two-stage methods 
The two-stage MA simulation investigation described here was reported as part of Sudell et 
al [176]. In the following sections, the background methodology of the data simulation is 
described.  Analysis of the simulated data follows the method described in Section 3.2.  The 
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models fitted to the simulated data are defined, and the results of the simulation study 
presented and discussed. 
7.1.1 Simulation of joint data for two-stage simulations 
During the simulation study, joint data containing a single continuous normally distributed 
longitudinal outcome and a single censored time-to-event outcome was simulated, using 
the simjoint data simulation function in the joineR package [80].  Each dataset 
contained 5 studies, each with 500 individuals randomised equally to two treatment 
groups.  A maximum of 5 longitudinal measurements at times 0, 1, 2, 3, 4 were permitted, 
with measurements retained only up to the individual’s survival time.  Data for each study 
was simulated separately, and then pooled to form a meta-dataset.  The joint data was 
simulated under the model shown in equation (67). 
 𝑌𝑘𝑖𝑗 = 𝛽10𝑘 + 𝛽11𝑘𝑡𝑘𝑖𝑗 + 𝛽12𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝑏0𝑘𝑖
(2) + 𝑏1𝑘𝑖
(2)𝑡𝑘𝑖𝑗 + ε𝑘𝑖𝑗  








In equation (67), the longitudinal outcome 𝑌𝑘𝑖𝑗  is simulated under a model that contains 
fixed intercept, time and treatment terms (with corresponding coefficients 𝛽10𝑘, 𝛽11𝑘 and 




 respectively), and an 
error term 𝑘𝑖𝑗.  The individual level random effects follow a multivariate normal 
distribution  𝒃𝑘𝑖
(2) ~𝑁(0, 𝑫𝒌) and are considered independent of the errors, which are 
considered IID and follow a 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2) distribution.  The longitudinal and time-to-event 
outcomes were linked through a proportional random effects only association structure, 
where the individual level random effects were inserted with common coefficient 𝛼𝑘
(2) 
(with event times 𝑇𝑆𝑘𝑖 replacing longitudinal times 𝑡𝑘𝑖𝑗) into the time-to-event sub-model, 
giving term 𝑊2𝑘𝑖(𝑡).  The coefficients for the fixed effects in both the longitudinal and 
time-to-event sub-models were common across simulated studies. 
The time-to-event outcome was simulated using the methodology described by Bender et 
al [219] and Austin [220], an overview of the implementation of their methods for this 
simulation study follows.  Event times were considered to be Gompertz distributed, with 
scale parameter 𝜅 = exp (𝜃0 + 𝛼𝑘
(2)𝑏0𝑘𝑖
(2)), 𝜅 > 0, and shape parameter 𝜔 = 𝜃1 + 𝛼𝑘
(2)𝑏1𝑘𝑖
(2), 
−∞ < 𝜔 < ∞.  In the shape and scale parameter definitions,  𝛼𝑘
(2) is the common 
association parameter for the individual level random effects, 𝜃0 and 𝜃1 are parameters 
used to control the distribution of the event time (which are specified by the user in the 
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 are respectively the 
individual specific random intercept and time terms.  The extreme value distribution was 
used to calculate the values to assign to 𝜃0 and 𝜃1. Using that the random effects 𝒃𝑘𝑖
(2)
 had 
expectation of zero, for a Gompertz distribution:  












In the above equations, 𝜋 ≈ 3.142,the mathematical constant pi, and 𝛾 ≈ 0.5772 is Euler’s 
constant.  A mean event time of 𝜇0 = 3 with standard deviation 𝜎0 = 1 was specified.  
Given that longitudinal time points were simulated as 0, 1, 2, 3, 4, through testing 10,000 
realisations from a Gompertz distribution with these specifications, it was confirmed that 
this distribution would produce individuals with varying numbers of recorded longitudinal 















As such, given the definitions of the shape and scale parameter: 












These values were then supplied as 𝜃0 and 𝜃1 to the data simulation code.   
The event rate (proportion of individuals in the data in each study that experienced an 
event) was controlled through the censoring times (which followed an exponential 
distribution, with parameter 𝜑).  Two sets of data were produced, one with a “high” event 
rate (~75%) and one with a “low” event rate (~25%).  A range of 𝜑 parameters for the 
censoring distribution were tested given the distribution of the event times, resulting in 
𝜑 = exp (−3.08) and 𝜑 = exp (−0.58) for the high and low event rate data respectively.  
As the longitudinal data being simulated contained both a random intercept and slope, to 
ensure presence of censorings, individual’s event times were generated in a two-stage 
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process.  Firstly a random number 𝑈𝑘𝑖 was generated from a uniform 𝑈(0,1) distribution 
for each individual 𝑖 in the dataset for study 𝑘.  An indicator variable took value true if both 
the following conditions were satisfied, false otherwise. 




) < 0 
𝐶𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 2: 𝑈𝑘𝑖 < exp (









If the indicator was set to true, the individual’s event time was set to infinite (guaranteeing 























In equation (68), 𝑇𝐸𝑘𝑖 represents the event time of the 𝑖th individual in the 𝑘th study, 𝑥21𝑘𝑖 
represents their treatment assignment covariate, and 𝛽21𝑘 the fixed treatment assignment 
coefficient in the time-to-event sub-model.  The other parameters have been defined 
earlier.  If time-stationary parameters additional to treatment assignment were included in 
the model, these would be included in a linear combination with 𝛽21𝑘𝑥21𝑘𝑖 e.g. 
𝛽21𝑘𝑥21𝑘𝑖 + 𝛽22𝑘𝑥22𝑘𝑖 + ⋯. 
As mentioned, each individual’s censoring time was generated under an exponential 
distribution with parameter 𝜑 (see Bender et al [219]): 






In equation (69), 𝑇𝐶𝑘𝑖 is the censoring time for individual 𝑖 in study 𝑘.  The final event time 
for each individual is then 𝑇𝑆𝑘𝑖 = min(𝑇𝐸𝑘𝑖, 𝑇𝐶𝑘𝑖), with censoring variable set to 1 if 𝑇𝑆𝑘𝑖 =
𝑇𝐸𝑘𝑖, 0 otherwise.   
The parameters for the models the data were simulated under were chosen to represent 
large differences between treatment groups, in order that deviations of different methods 
from the true parameter values could be clearly identified.  In the longitudinal sub-model 
for each study 𝑘, the population intercept 𝛽10𝑘 was set to 1, the time coefficient 𝛽11𝑘 set 
to 3 and the treatment assignment coefficient 𝛽12𝑘 was set to 2.  The individual level 
random effects were generated under the following distribution (with the same covariance 












The IID measurement errors 𝑘𝑖𝑗 were generated under a 𝑁(0, 0.01) distribution.  The 
time-to-event treatment assignment coefficient 𝛽21𝑘 for each study 𝑘 was set to 3.   
In order to compare joint models to separate longitudinal or time-to-event models in a 
range of settings, 5 association levels were investigated by setting the association 
parameter 𝛼𝑘
(2)
 for each study 𝑘 to 0, 0.25, 0.5, 0.75 and 1.  Only positive associations were 
examined, as behaviour for negative associations was expected to be similar, but opposite, 
in direction. 
For each scenario, datasets with homogenous treatment effects between studies and 
datasets with heterogeneous treatment effects between studies were generated.  This was 
achieved by setting the longitudinal treatment effect coefficient 𝛽12𝑘 to 2 and the time-to-
event treatment effect coefficient 𝛽21𝑘 to 3 for the homogenous scenarios for each study 
𝑘, and instead using study specific realisations from an 𝑁(2, 0.5) and a 𝑁(3, 0.5) 
distribution for the heterogeneous scenarios. There was greater variation in event rates 
between simulated data for different levels of association in the high event rate group 
compared to the low event rate group (observed event rates available in Table 28, 
Appendix 3). 
For each scenario (combination of association level, homogenous or heterogeneous 
treatment effect between studies, low or high event rate) 1000 datasets were simulated.   
7.1.2 Two-stage models fitted to simulated joint data 
Following methods introduced in Chapter 3, a joint model of specification shown in 
equation (70) was fitted to each study’s data within each dataset within each scenario: 
 𝑌𝑘𝑖𝑗 = 𝛽10𝑘 + 𝛽11𝑘𝑡𝑘𝑖𝑗 + 𝛽12𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝑏0𝑘𝑖
(2) + 𝑏1𝑘𝑖
(2)𝑡𝑘𝑖𝑗 + 𝑘𝑖𝑗  
𝜆𝑘𝑖(𝑡) =  𝜆0(𝑡) exp(𝛽21𝑘𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + 𝑊2𝑘𝑖(𝑡)) 
𝑊2𝑘𝑖(𝑡) = 𝛼𝑘






This model employed a linear mixed effects model for the longitudinal sub-model 
containing a fixed intercept, time and treatment assignment term, and individual specific 
random intercept and time term as well as an error term.  The individual random effects in 
each study are assumed to follow a multivariate normal distribution with zero mean, and 
are considered independent of the error terms.  The error terms are considered to be IID 
across time points and follow a zero mean normal distribution.  The time-to-event sub-
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model uses an unspecified baseline hazard, and contains only a fixed treatment assignment 
term.  The association structure linking the sub-models is a proportional random effects 
only structure, which shares the zero mean individual level random effects between the 
sub-models with common association parameter 𝛼𝑘
(2).  Instances of longitudinal time 𝑡𝑘𝑖𝑗 in 
the association structure are replaced with the survival time 𝑇𝑆𝑘𝑖.  As well as joint models, 
separate longitudinal and time-to-event models were fitted to each dataset.  The 
longitudinal models had the same specification as the longitudinal sub-model of the joint 
model.  The time-to-event models had the same specification as the time-to-event sub-
model, except the 𝑊2𝑘𝑖(𝑡) term was not present. 
Once the models were fitted, study specific model parameter estimates for the treatment 
effects from each sub-model (𝛽12𝑘, 𝛽21𝑘) and the association parameter (𝛼𝑘
(2)) were 
extracted along with estimates of their standard errors, and the sample size of each study.  
Separate meta-analyses were performed for each parameter of interest (using the meta-
analytic techniques discussed in Section 3.2.3), to produce pooled estimates ?̂?12,  ?̂?21, and 
?̂?(2). Both fixed and random effects meta-analyses were conducted, and the pooled point 
estimates and 95% confidence intervals for the parameters extracted from each, along with 
heterogeneity measure 𝜏2.  The mean pooled estimates for each parameter, along with 
their standard error (the standard deviation of the pooled estimates produced by the 
simulation study) were recorded. During the simulation study the number of failed fits 
(where the model failed for fit for at least one study in the simulation run) per scenario 
were recorded. Coverage was also calculated for each set of simulations, as the percentage 
of simulation runs where the confidence interval for the pooled parameter estimates 
contained the “true” value the parameter was simulated under. 
7.1.3 Two-stage simulation study results 
Results for the simulation study for two-stage MA of joint data are presented in Table 18-
Table 21. Plots for these results are given in Figure 22-Figure 24, with the dotted line in the 
mean pooled estimate column identifying the “true” value of the parameter, and in the 
coverage column identifying 95% coverage.   
Throughout the scenarios investigated, the fixed and random effect MA results were similar 
for the homogenous datasets, while the random effect MA showed better coverage for the 
heterogeneous datasets.  Consequently, the plots show only the results from the random 
MA, with results from both the fixed and random MA available in Tables 2-5.  Additionally, 
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the estimates of 𝜏2 were larger (as expected) for the heterogeneous than the homogenous 
data.   
Across scenarios, regardless of the level of association between the longitudinal and the 
time-to-event outcomes, the mean pooled estimates of the longitudinal treatment effect 
coefficient (?̂?12) based on joint model fits and those based on the separate longitudinal 
models agreed well (Table 18-Table 21, Figure 22).   
The mean pooled estimates for the treatment effect coefficient for the time-to-event 
outcome (?̂?21) based on use of joint models in the first stage of the two-stage MA are close 
to the true values of the coefficients across all tested association levels (Table 18-Table 21, 
Figure 23). 
Conversely, different behaviour is observed for the mean pooled estimates of ?̂?21 from 
analyses that use a separate time-to-event model in the first stage of the MA (Table 18-
Table 21, Figure 23). The results agree with those based on the joint model when 
association is 0, across all scenarios tested.  However, once association is non-zero, the 
mean pooled estimate from the separate model increasingly underestimates the true 
parameter value as the magnitude of individual level association increases, with coverage 
dropping to zero.  Also the empirical standard errors of the pooled ?̂?21 estimates from the 
joint models appear relatively constant, with some increase with increasing association.  
However, as association increases in magnitude, the empirical standard errors of the 
pooled ?̂?21 estimates from the separate time-to-event approach decreases. 
The association parameter is only produced by the joint model approach.  Across all 
simulation scenarios, the mean pooled ?̂?(2) estimates were close to the true value (to be 
expected given that the joint models utilise the same association structure that the data 
was generated under).  The empirical standard error of the pooled estimate increased 
slightly as association increases.  The coverage also decreased slightly for larger magnitudes 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 22: Plot for two-stage meta-analysis simulation study for longitudinal treatment effect parameter 𝛽12. 
The dotted line in the mean estimate column identifies the “true” value the parameter was simulated under.  






Figure 23: Plot for two-stage meta-analysis simulation study for time-to-event treatment effect parameter 𝛽21. 
The dotted line in the mean estimate column identifies the “true” value the parameter was simulated under.  





Figure 24: Plot for two-stage meta-analysis simulation study for association parameter 𝛼(2). The dotted line in 
the mean estimate column identifies the “true” value the parameter was simulated under.  The dotted line in the 




7.2 Simulations investigating one-stage methods 
A variety of ways exist to account for between study heterogeneity in one-stage meta-
analytic models, including fixed interaction terms with study membership variables, study 
level random effects and stratification of baseline hazard by study.  However, the reliability 
of these methods may depend a range of factors such as the number of studies included in 
the meta-analysis, the level of between study heterogeneity, or the level of association 
between the longitudinal and time-to-event outcomes.   
Consequently, three sets of simulation scenarios were investigated to test the behaviour of 
the methods developed in Section 3.3.  The first varied levels of association at both the 
individual and the study level, the second varied the numbers of included studies in the 
meta-analysis, and the third varied the level of between study heterogeneity. 
As with the two-stage simulation study, it is interesting to compare the performance of 
one-stage joint meta-analytic models, with one-stage separate longitudinal or time-to-
event meta-analytic models.  As such, both approaches (separate and joint) have been 
conducted and compared. 
In the two-stage simulation study, heterogeneity was induced between studies by 
generating treatment effect as realisations from a distribution.  However, it was necessary 
during the one-stage simulations to exactly specify the distribution of the study level 
random effects, to allow the between study heterogeneity to be more accurately 
controlled.  As such, I wrote and implemented a function to simulate multi-study joint 
longitudinal and time-to-event data (see Sections 4.4.1 and 5.2).   
7.2.1 Simulation of joint data for one-stage simulations 
Across the sets of scenarios investigated in the simulation study, multi-study joint data was 
generated under the same process using the methodology described previously in Sections 
4.4.1 and 5.2.  This methodology extends the work of Bender et al [219] and Austin [220].  
In this section, this process is described, and details of parameters for each set of 
simulations are given. For each set of simulations, for each scenario, 1000 datasets were 
simulated. 
The number of included studies varies between scenarios, however each simulated study 
contained 500 individuals randomised equally to two treatment groups.   A maximum of 10 
longitudinal measurements at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4 were permitted, 
with measurements recorded only up to the individual’s survival time.  Data for all studies 
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was simulated simultaneously, with any between study heterogeneity generated through 
specification of the study level random effects distribution.  The joint data was simulated 
under the following model: 




(3)𝑡𝑟𝑒𝑎𝑡𝑘𝑖 + kij 











In equation (71), the longitudinal outcome 𝑌𝑘𝑖𝑗 follows a linear mixed effects model 
containing fixed intercept, time and treatment terms (with coefficients 𝛽10, 𝛽11 and 𝛽12), 




), study level random 




) and an error term 𝑘𝑖𝑗.  The random 
effects follow multivariate normal distributions, with the indivdiual level random effects 
distributed 𝒃𝑘𝑖
(2)
~𝑁(0, 𝑫), and the study level random effects distributed 𝒃𝑘
(3)
~𝑁(0, 𝑨).  
The random effects are independent of each other, and of the error terms, which are 
considered to be IID following 𝑘𝑖𝑗~𝑁(0, 𝜎𝑒
2). 
The event times are modelled using a Cox PH model with unspecified baseline hazard 
𝜆0(𝑡), with a single fixed effect of treatment group (coefficient 𝛽21). The longitudinal and 
time-to-event sub-models are linked through shared zero mean random effects 
(represented by term 𝑊2𝑘𝑖(𝑡)), with common association parameters at each level of the 
random effects. 
The event times 𝑻𝑬 were specified to be Gompertz distributed with mean 3 and standard 
deviation 0.5.  Using the extreme value distribution (with 𝛾 ≈ 0.5772  representing Euler’s 
constant, and 𝜋 ≈ 3.142 the mathematical constant pi), this lead to the parameters 







 ≈  2.5651 
𝜃0 = log(𝜃1 exp(−𝛾 − 𝜇0𝜃1)) = log(𝜃1 exp(−𝛾 − 3𝜃1)) ≈  −7.330517 
Due to the volume of planned simulations, only datasets with a “low” (~25%) event rate 
were generated.  A range of censoring parameters were tested in the multi-study data 
simulation function to obtain datasets with mean event rate at 25%.  As such, the censoring 
times 𝑻𝑪 followed an exponential distribution with parameter 𝜑 = exp(−0.426). As 
before, the survival time for each individual 𝑖 was the minimum of their censoring and 
event times (𝑇𝑆𝑘𝑖 = min (𝑇𝐸𝑘𝑖, 𝑇𝐶𝑘𝑖)). 
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As mentioned, when the simulation studies were designed, parameter values were chosen 
such that deviations of different methods from the true parameters values would be clearly 
discernible.   A summary of the values used for the different groups of simulations is given 
in Table 22. 
Briefly, all sets of simulations utilised the same fixed effect and error term variance values 
(𝛽10 = 1, 𝛽11 = 3, 𝛽12 = 2, 𝛽21 = 3, 𝜎𝑒
2 = 0.01).  Additionally, the individual level random 
effects covariance matrix 𝑫 remained constant (defined in Table 22).  However, the 
remaining aspects of the datasets (association parameters, number of included studies, 
level of between study heterogeneity) varied between simulation groups.  These aspects 
are stated in Table 22 for each simulation group, and are briefly discussed in the following 
section. 
7.2.1.1 Set 1: Varying levels of association 
The individual level association parameter 𝛼(2) and the study level association parameter 
𝛼(3) are permitted to take values 0, 0.5 and 1, giving a total of 9 unique scenarios (all 
combinations of possible association parameters at each level). Only positive associations 
were examined as situations with negative associations were expected to have similar 
behaviour, but in the opposite direction.  The number of included studies in each dataset 
was set to 5, whilst the study level random effects covariance matrix 𝑨 (defined in Table 
22) remained constant across scenarios. 
7.2.1.2 Set 2: Varying numbers of studies included in the meta-analysis 
During this set of simulations, meta-analyses containing 5, 10 or 15 studies were 
generated.  These values were selected to give a sense of the effect a range of different 
numbers of included studies on the behaviour of the developed methods. The association 
parameters were held constant across scenarios (with 𝛼(2) = 𝛼(3) = 0.5).  Additionally, 
the study level random effects covariance matrix 𝑨 (defined in Table 22) remained constant 
across scenarios. 
7.2.1.3 Set 3: Varying levels of between study heterogeneity 
Between study heterogeneity was controlled through the study level random effects 
covariance matrix 𝑨. Values taken for 𝑨, labelled 𝑨𝟏, 𝑨𝟐 and 𝑨𝟑 are specified in Table 22, 
representing cases for no between study heterogeneity, and then two increasing levels of 
between  study  heterogeneity. 
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During this simulation set, across all scenarios, 5 studies were simulated for each dataset, 
with association parameters were held constant across scenarios at 𝛼(2) = 𝛼(3) = 0.5. 
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7.2.2 One-stage models fitted to simulated joint data 
The models fitted to each set of simulations in the one-stage simulation study were 
described in Section 3.3.2.  Exact specifications of the joint models are given in Table 23.    
 Briefly, the examined models fall into 6 unique groups (identified in Table 23).  Group 0 is a 
naïve model which ignores between study heterogeneity.  Group 1 accounts for between 
study heterogeneity using interaction terms between the study membership and treatment 
group variables in both the longitudinal and time-to-event sub-models.  Group 2 introduces 
a study level random treatment effect which is shared alongside the individual level 
random effects between sub-models, but the sub-models still contain a fixed study 
membership term.   Group 3 solely accounts for between study heterogeneity using a study 
level random intercept and treatment effect, which are shared between sub-models 
through the association structure.  Group 4 includes fixed interaction terms between study 
membership and treatment group variables in the longitudinal sub-model, and a baseline 
hazard stratified by study in the time-to-event sub-model.  Group 5 includes a study 
membership fixed effect in the longitudinal sub-model, a baseline hazard stratified by study 
in the time-to-event sub-model, and a study level random treatment effect present in both 
sub-models through the association structure. 
As well as one-stage joint models, separate longitudinal and time-to-event one-stage 
models were also fitted to each dataset in each scenario in each simulation group.  The 
longitudinal separate models had the same specification as the corresponding joint model 
longitudinal sub-model within each model group.  The time-to-event separate models had 
the same specification as the corresponding joint model time-to-event sub-model within 
each model group, apart from the absence of the  𝑊2𝑘𝑖(𝑡) term. 
Once each model had been fitted, a record was made of whether there was an error with 
the model fit, and whether the model had converged.  Separate models were fitted 
automatically during the joint modelling process, to obtain starting values for the EM 
algorithm (Section 4.3.2.1); consequently the number of failed fits was equal between the 
separate and joint approaches.  If the model had successfully fitted and converged, any 
parameters of interest were extracted along with their 95% confidence intervals.  These 
included any longitudinal or time-to-event treatment parameters (𝛽12 and 𝛽21 terms), and 
association parameters (𝛼(2) and if present 𝛼(3)).   
For models groups that involved interaction terms between study membership and 
treatment group (groups 1 and 4), study specific treatment effects could be extracted.  In 
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order to be able to compare across studies, these study specific treatment effects were 
pooled using methods identical to a random effects meta-analysis (described in Section 
3.2.3) to produce a single estimate for treatment effect. 
When the information from each model fit was extracted, a record was made of the 
number of successful model fits for each scenario within each simulation group.  
Additionally, for each of the joint and separate models, for each parameter of interest, the 
mean parameter estimate and it’s standard error (standard deviation of the parameter 
estimates) were calculated.  In addition, the coverage was estimated (the proportion of the 
1000 model fits whose estimated 95% confidence interval for the parameter in question 
















𝒕𝒌𝒊𝒋 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 







𝒀𝒌𝒊𝒋 = 𝜷𝟏𝟎 + 𝜷𝟏𝟏𝒕𝒌𝒊𝒋 + 𝜷𝟏𝟐𝒕𝒓𝒆𝒂𝒕𝒌𝒊 





𝒕𝒌𝒊𝒋 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝜷𝟐𝟐𝒔𝒕𝒖𝒅𝒚𝒌𝒊
+ 𝜷𝟐𝟑𝒕𝒓𝒆𝒂𝒕𝒌𝒊 ∗ 𝒔𝒕𝒖𝒅𝒚𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 














𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝜷𝟐𝟐𝒔𝒕𝒖𝒅𝒚𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 
Association Structure 𝑾𝟐𝒌𝒊(𝒕) = 𝜶
(𝟐)(𝒃𝟎𝒌𝒊
(𝟐) + 𝒃𝟏𝒌𝒊













𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 










𝒀𝒌𝒊𝒋 = 𝜷𝟏𝟎 + 𝜷𝟏𝟏𝒕𝒌𝒊𝒋 + 𝜷𝟏𝟐𝒕𝒓𝒆𝒂𝒕𝒌𝒊 





𝒕𝒌𝒊𝒋 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎𝒌(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 














𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝜺𝒌𝒊𝒋 
Time-to-event Sub-
Model 
𝝀𝒌𝒊(𝒕) =  𝝀𝟎𝒌(𝒕) 𝐞𝐱𝐩(𝜷𝟐𝟏𝒕𝒓𝒆𝒂𝒕𝒌𝒊 + 𝑾𝟐𝒌𝒊(𝒕)) 
Association Structure 𝑾𝟐𝒌𝒊(𝒕) = 𝜶
(𝟐)(𝒃𝟎𝒌𝒊
(𝟐) + 𝒃𝟏𝒌𝒊
(𝟐) 𝑻𝑺𝒌𝒊) + 𝜶
(𝟑)(𝒃𝟏𝒌
(𝟑)𝒕𝒓𝒆𝒂𝒕𝒌𝒊) 
Table 23: Model group specifications for one-stage simulation studies
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7.2.3 One-stage simulation study results 
Throughout, mean parameter estimates along with their standard errors and coverage 
values are presented in tables.  Two sets of figures were produced for each simulation 
group,  the first is simply a graphical representation of the mean parameter estimate with 
95% confidence intervals calculated based on the SE of the parameter estimates within 
each scenario (included in the main text).  The second set plots the parameter point 
estimates and confidence intervals for each successful model fit within each scenario, 
allowing an examination of the widths of confidence intervals, and the positioning of 
estimates compared to the true value of the parameter.  These graphs are numerous, and 
so are presented in Appendix 4.   
7.2.3.1 Simulation Set 1: Varying levels of association 
For the first set of simulations (Table 24 and Table 25, and Figure 25-Figure 28), the lowest 
proportion of successfully completed model fits was 94.2% (for model group 1 fitted to the 
scenario where 𝛼(2) = 0 and 𝛼(3) = 1).   
The mean estimate for the longitudinal treatment effect parameter 𝛽12 is close to the true 
value of 2 for both the separate and the joint analyses across all model groups and 
scenarios (Table 24 and Table 25, Figure 25).  Additionally the SE of the point estimates for 
the treatment effect produced by the simulations is similar for both the separate and joint 
analyses.  However, there are noticeable differences in coverage.  For both the separate 
and joint analyses, for model group 0 (the naïve model that ignores between study 
heterogeneity), coverage is under 20% for all scenarios investigated (Table 24, Figure 25).  
However, for the remaining model groups (which all account for between study 
heterogeneity in various ways), the coverage for the separate longitudinal model is higher, 
between 85 and 90% across all scenarios.  Whilst this holds for the joint model results for 
model groups 1 and 4, the same cannot be said for the joint model results from any model 
group involving study level random effects (model groups 2, 3 and 5).  Here, although the 
mean parameter estimate is close to the true value, the coverage is low (between 9 and 
14%).  An explanation for this can be found by examining the plots showing the point 
estimate and confidence interval for each dataset for each model group and scenario 
(Appendix 4, Figure 40-Figure 42).   For any model group containing study level random 
effects, the confidence intervals for the joint model estimates of longitudinal treatment 
effect are narrow.  Consequently, although the estimates are clustered around the true 
parameter value, coverage is low.   
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For the time-to-event treatment effect parameter 𝛽21 (Table 24 and Table 25, Figure 26), 
as study level association (𝛼(3)) increases, for both separate and joint approaches, the 
variability between estimates increases (represented by larger confidence bands about the 
mean estimates).  Additionally, as 𝛼(3) increases, the estimates from model groups 0 and 3 
become increasingly different from the estimates from the other model groups.  As 
individual level association (𝛼(2)) increases, the separate time-to-event approach 
increasingly underestimates the treatment effect, whilst the estimates from the joint 
approach remain close to the true value.  The coverage of the results from the joint models 
is comparable to that of the separate models when the individual level association 𝛼(2) =
0, however the joint modelling results show better (although not ideal) coverage for non-
zero individual level associations (Table 24 and Table 25, and Figure 43-Figure 45 in 
Appendix 4).  Non-zero study level association appears to increase the variability between 
simulations in estimated mean time-to-event treatment effect, rather than increase the 
discrepancy between the separate and joint modelling results.  Throughout, with non-zero 
association at any level, naïve model group 0 performs badly, for both separate and joint 
approaches. 
All fitted joint models contain individual level random effects, and so all estimated the 
individual level association parameter 𝛼(2) (note: no separate analyses produce estimates 
of either association parameter).  The estimates of 𝛼(2) appear poor for model group 0 
(which ignores between study heterogeneity).  However, for the remaining model groups, 
across all investigated scenarios, the mean association parameter estimates are close to 
the true values (Table 24 and Table 25, Figure 27).  The coverage appears constant and high 
for model groups 1, 2, 4 and 5, however there are some instances of lower coverage for 
model group 3 (which solely relies on study level random effects to quantify between study 
heterogeneity).    Examination of Figure 46-Figure 48 in Appendix 4 (that show the results 
of the individual simulations), shows a tendency of underestimation of the individual level 
association parameter in model group 3 for combined higher levels of individual and study 
level association. 
The study level association parameter 𝛼(3) is only estimated for model groups that contain 
study level random effects (namely model groups 2 and 5 which contain study level random 
treatment effect, and model group 3 which contains study level random intercept and 
treatment effect).  The mean estimates of 𝛼(3) are closest to the true values for model 
group 3, although they are still biased (Table 24 and Table 25, Figure 28).  However, the 
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estimates for model groups 2 and 5 are not close to the true values. The coverage appears 
varied for the study level association parameter across all model groups, with coverage 
higher for model group 3.  From Figure 49-Figure 51 in Appendix 4, the confidence intervals 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 25: Graphical representation of the mean longitudinal treatment effect (𝛽12) estimates from Table 24 and 
Table 25 for separate and joint models for simulation set 1,investigating varying association parameters.  The 





Figure 26: Graphical representation of the mean time-to-event treatment effect (𝛽21) estimates from Table 24 
and Table 25 for separate and joint models for simulation set 1, investigating varying association parameters. 





Figure 27: Graphical representation of the mean individual level association parameter (𝛼(2)) estimates from 
Table 24 and Table 25 for separate and joint models for simulation set 1, investigating varying association 




Figure 28: Graphical representation of the mean study level association parameter (𝛼(3)) estimates from Table 
24 and Table 25 for separate and joint models for simulation set 1, investigating varying association 




7.2.3.2 Simulation Set 2: Varying numbers of studies included in the meta-analysis 
For this second set of simulations (Table 26 and Figure 29-Figure 32), the lowest proportion 
of successfully completed model fits was 99.9% (one failed fit for each of model groups 3 
and 5).   
Across all scenarios and model groups, for both the separate and joint analyses, the mean 
estimate of the longitudinal treatment effect 𝛽12 was close to the “true” value of 2 (Table 
26, Figure 29).  The SE were comparable across model groups and scenarios between the 
separate and joint analyses, with SE of the simulation estimates decreasing as the number 
of included studies increased (Figure 29). Coverage was poor for both the separate and 
joint analyses across scenarios for the naïve model group (group 0).    For the remaining 
model groups, again the separate models showed good coverage (between 86 and 94%) 
across investigated scenarios.  However, joint model results from model groups involving 
study level random effects again showed poor coverage (between 9 and 20%), whilst those 
from model groups not involving study level random effects showed  coverage between 87 
and 94%.  Again the reason for this can be seen through examination of Figure 52, 
Appendix 4; again whilst the point estimates for 𝛽12 from model groups 2, 3 and 5 are 
clustered around the true parameter value, the confidence intervals are narrow. 
For all scenarios for all model groups investigated, the separate analyses underestimated 
the true value of the time-to-event treatment effect  𝛽21, whereas the mean estimate from 
the joint models was closer to the true value of 3 (Table 26, Figure 30).  The SE of the 
estimates decreased as the number of included studies increased for both the separate and 
joint analyses (Table 26, Figure 30), although the SE for the separate analyses was often 
smaller than that of the joint analyses.  Coverage for the estimates from the separate 
analyses were low for all model groups and scenarios (6% or less).  Coverage for the joint 
model analyses was higher across all model groups, although still much lower than the 
ideal level of 95% (Table 26).  Examination of Figure 53, Appendix 4, indicates that despite 
the reduced coverage due to narrow confidence intervals, for model groups involving study 
level random effects, the estimates from joint models were clustered about the true value. 
The individual level association parameter  𝛼(2) was estimated in every fitted joint model 
due to the presence of individual level random effects in each model.  For any model group 
that accounted for between study heterogeneity, the estimates of 𝛼(2) were close to the 
true value of 0.5 with low SE (Table 26, Figure 31).  Coverage was good (between 86 and 
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95%) for model groups  1, 2, 4 and 5.  However, model group 3 (which accounted for 
between study heterogeneity solely though study level random effects) had coverages that 
decreased as the number of included studies increased.  In addition the naïve model group 
(group 0) had coverage of less than 50% for all scenarios investigated.  Examination of the 
simulation specific confidence intervals in Figure 54, Appendix 4, shows that for model 
groups 0 and 3, as the number of included studies increased, the area covered by the 
confidence intervals of the estimates narrowed, leading to poorer coverage. 
The study level association parameter 𝛼(3) was poorly estimated in all model groups it 
appeared in (2, 3 and 5), across all scenarios. The estimates in model groups 2 and 5 (which 
included a study level random treatment effect) were close to zero, with SE and coverage 
decreasing as the number of included studies increased (Table 26, Figure 32).  The 
estimates for model group 3 were closer to the true value of 0.5, however the coverage 
was still poor (between 29 and 43% for all scenarios).  Examination Figure 55, Appendix 4, 
shows confidence intervals decreasing in width for all model groups as the number of 
studies increases, with wider confidence intervals for model groups 2 and 5.  However, only 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 29: Graphical representation of longitudinal treatment effect (𝛽12) estimates shown in Table 26 for 
simulation set 2: investigation of varying numbers of included studies. The dashed line indicates the “true” value 
of 𝛽12 that the data was simulated under  
 
Figure 30: Graphical representation of time-to-event treatment effect (𝛽21) estimates shown in Table 26 for 
simulation set 2: investigation of varying numbers of included studies. The dashed line indicates the “true” value 





Figure 31: Graphical representation of individual level association parameter (𝛼(2)) estimates shown in Table 26 
for simulation set 2: investigation of varying numbers of included studies. The dashed line indicates the “true” 
value of 𝛼(2) that the data was simulated under 
 
Figure 32: Graphical representation of study level association parameter (𝛼(3)) estimates shown in Table 26 for 
simulation set 2: investigation of varying numbers of included studies. The dashed line indicates the “true” value 
of 𝛼(3) that the data was simulated under 
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7.2.3.3 Simulation Set 3: Varying levels of between study heterogeneity 
For this third set of simulations (Table 27 and Figure 33-Figure 36), the proportions of 
successful model fits were low for model groups involving study level random effects (2, 3 
and 5) where there was no between study heterogeneity (𝑨 = 𝑨𝟏 = 𝟎).  Otherwise, the 
proportion of successful model fits was at least 99.8%.   
The estimates from the separate and joint analyses for all model groups for all scenarios 
were close to the “true” value of 2 for the longitudinal treatment effect 𝛽12 (Table 27, 
Figure 33).  SE was similar in all cases between the separate and joint analyses, however 
the coverage differed noticeably.  For any model group that accounted for between study 
heterogeneity, coverage was above 85% for the separate analyses.  However, for the joint 
models, whilst model groups 1 and 4 showed coverage above 88% across all scenarios, any 
model group involving study level random effects, coverage dropped sharply for non-zero 
between study heterogeneity. Examining Figure 56, Appendix 4, the point estimates from 
the joint analyses can be seen to be clustered around the true value, however the 
confidence intervals are narrow leading to low coverage. 
The mean estimates from the joint analyses of the time-to-event treatment effect  𝛽21 are 
close to the “true” value of 3, however fall below the “true” value for the separate analyses 
(Table 27, Figure 34).  The SE are higher for the joint analyses, with SE increasing as 
between study heterogeneity increases. Coverage for the separate analyses is poor (below 
14% for all model groups for all scenarios, with most coverages at 0%).  For the joint 
analyses, coverage for model group 1 is constant at around 86%.  For model group 3, the 
coverage is lower (below 63% for all scenarios).  For the remaining model groups for the 
joint analyses, the coverage is high (above 93%) for cases with no between study 
heterogeneity, but coverage decreases as the level of between study heterogeneity 
increases.  From Figure 57, Appendix 4, the width of the band in which the point estimates 
and their confidence intervals falls in widens (most noticeably for model group 1) as 
between study heterogeneity increases.  Given the increase in the SE of the point 
estimates, the coverage may be dropping due to more variable point estimates, rather than 
changes in confidence interval width. 
The mean estimates for the individual level association parameter 𝛼(2) are close to the 
“true” value of 0.5, with low SE, across all model groups and scenarios (Table 27, Figure 35).  
However, the coverage for model group 0 decreases as the between study heterogeneity 
increases.  Otherwise, for the remaining model groups (except group 3) coverage remains 
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high (above 90%) regardless of the level of between study heterogeneity (although in 
several cases it decreases slightly as between study heterogeneity increases).  For model 
group 3, the coverage is variable, but does not appear to follow a trend as between study 
heterogeneity increases. Examination of Figure 58, Appendix 4, shows the estimates from 
the model groups that account for between study heterogeneity clustered around the true 
value of the estimate, regardless of coverage level. 
The study level association parameter 𝛼(3) is estimated poorly in model groups 2 and 5, 
with estimates negative or close to zero (Table 27, Figure 36).  The estimates from model 
group 3 are closer to the “true” value, but are still underestimated. The SE of the estimates 
is large when there is no between study heterogeneity, and decrease as the level of 
between study heterogeneity increases.  The coverage decreases as the between study 
heterogeneity increases.  Figure 59, Appendix 4, clearly shows the poor parameter 
estimation for no between study heterogeneity, and shows the point estimates for model 
group 3 clustered about the true value, however those for model groups 2 and 5 clustered 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 33: Graphical representation of longitudinal treatment effect (𝛽12) estimates shown in Table 27 for 
simulation set 3: investigation of varying between study heterogeneity.  The dashed line identifies the “true” 
value 𝛽12 that the data was simulated under  
 
Figure 34: Graphical representation of time-to-event treatment effect (𝛽21) estimates shown in Table 27 for 
simulation set 3: investigation of varying between study heterogeneity.  The dashed line identifies the “true” 





Figure 35: Graphical representation of individual level association parameter (𝛼(2)) estimates shown in Table 27 
for simulation set 3: investigation of varying between study heterogeneity.  The dashed line identifies the "true” 
value of 𝛼(2)that the data was simulated under 
 
Figure 36: Graphical representation of study level association parameter (𝛼(3)) estimates shown in Table 27 for 
simulation set 3: investigation of varying between study heterogeneity.  The dashed line identifies the “true” 
value of 𝛼(3)that the data was simulated under 
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7.3 Discussion of simulation studies 
During this chapter, simulation studies investigating the methods presented in Chapter 3 
have been presented.  A range of scenarios, for both one and two-stage methods, have 
been explored. 
7.3.1 Discussion of the Two-Stage Simulation Investigation 
The real data two-stage MA reported in Section 6.2 did not show sizeable differences 
between MA that employed separate methods and MA that employed joint methods in the 
first stage of the MA.  However, the simulation studies involving larger magnitude 
associations (Section 7.1) showed more apparent differences between pooled results from 
separate time-to-event analyses, and joint analyses. 
The fixed and random MA approaches generally gave similar results for the homogenous 
simulated datasets, but the results differed more for the heterogeneous treatment 
simulated datasets. This suggests that researchers conducting a two-stage MA using joint 
longitudinal and time-to-event data should, as with other MA, ensure that random effects 
methods are used if it is known or suspected that heterogeneity exists between the trials 
included in the meta-analysis.  This can be achieved through examination of forest plots, 
and exploring estimates of the 𝜏2 parameter and 𝐼2 statistic. 
Throughout the two-stage simulations, the coverage for the joint modelling approach 
appeared consistently high across different scenarios and association levels.  Examination 
of the estimates from the model fits in the simulation study highlighted that the joint 
approach consistently gave pooled estimates close to the true values for association 
parameters or treatment effects from either sub-model.  
The simulation study also identified that the separate longitudinal approach appeared 
adequate across scenarios investigated, for any association level examined.  However, 
whilst the separate time-to-event approach displayed little bias for pooled treatment effect 
where association between the time-to-event and longitudinal outcomes was insignificant, 
where a positive association was present, the treatment effect was underestimated, with 
bias increasing as the strength of association increases.  This underestimation was 
observed only in the separate time-to-event analyses, not in the joint analyses, and was not 
restricted to the two-stage approach.  This is discussed further below. 
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7.3.2 Discussion of the One-Stage Simulation Investigation 
As with the two-stage simulation study, similarities existed between the estimates of 
longitudinal treatment effect between the separate and joint one-stage MA models across 
the scenarios investigated (Section 7.2).  However, where non-zero positive association 
existed at the individual level, separate time-to-event one-stage MA models 
underestimated the true treatment effect by an increasing amount as individual level 
association increased.  In comparison, the one-stage joint MA models that accounted for 
between study heterogeneity estimated the time-to-event treatment effect satisfactorily 
across all association levels tested. The naïve one-stage MA models (joint or separate) that 
ignored between study heterogeneity behaved poorly across the scenarios examined 
where association was present between the longitudinal and time-to-event outcomes.   
Joint models that shared study level random effects between sub-models through the 
association structure (model groups 2, 3 and 5) displayed issues.  These three model groups 
produced longitudinal treatment effect estimates that clustered about the “true” 
parameter value, but displayed poor coverage.  However, separate longitudinal models 
with the same specification displayed similar treatment effect estimates, with improved 
coverage.  Estimation of the study level association parameter (𝛼(3)) was poor for model 
groups 2 and 5, and slightly better for model group 3 (which accounted for between study 
heterogeneity solely through study level random effects).  However, model group 3 
displayed issues in the estimation of other parameters, e.g. the time-to-event treatment 
effect 𝛽21 and the individual level association parameter 𝛼
(2)).  The behaviour of joint 
model groups involving study level random effects was not improved for differing levels of 
between study heterogeneity, or different numbers of included studies.   
Consequently, I recommend, for scenarios similar to those investigated here, when one-
stage joint MA models are being employed, not to employ methods that share study level 
random effects between sub-models.  However, the separate longitudinal models that 
involved study level random effects appeared to avoid some of the problems encountered 
with the joint approach.  It may be that study level random effects could be employed in 
the longitudinal sub-model, with between study heterogeneity accounted for in the time-
to-event sub-model through stratification of the baseline hazard, fixed interaction terms 
with the study membership variable, or by a frailty term, without any sharing of study level 




From the currently investigated one-stage joint MA model specifications, unless the 
number of included studies renders such an analysis unwieldy, the simulation studies 
indicate model group 1 (which includes fixed interaction terms with the study membership 
in both the longitudinal and time-to-event sub-models) to have the best overall coverage, 
followed by model group 4 (which involves fixed interaction terms with the study 
membership variable in the longitudinal sub-model, and baseline hazard stratified by study 
with study membership as a fixed effect in the time-to-event sub-model).  Time-to-event 
parameters were better estimated in model group 1 than 4 where there was non-zero 
study level association, however model group 4 had marginally faster fitting times (as it 
involved a stratified baseline hazard, meaning that model fitting involved matrices of 
smaller dimensions than unstratified approaches). 
7.3.3 Comparison of one and two-stage simulations 
As noted in Sections 3.4 and 6.4.3, one-stage methods are beneficial compared to two-
stage methods in that their likelihood specification is more accurate [189-191], however 
they are noted to be more computationally intensive to conduct [63, 189, 191].  An 
example of this in the simulation studies was in the estimation of the baseline hazard. In 
the study specific model fits involved in the two-stage analyses, estimation of the baseline 
hazard involved only the event times observed in that study’s population.  One-stage fits 
that did not stratify the baseline hazard by study used event times across all studies, 
resulting calculations using larger matrices and vectors, which were more computationally 
intensive.   
It is important to note the differences in the simulation of multi-study joint datasets 
between the one and two-stage simulation studies, which could cause differences in the 
results from the two approaches.  During the two-stage simulations, homogenous datasets 
were created by simulating data for each study under the same model parameters (with 
minor variability between the dataset for each study stemming from the use of probability 
distributions to generate error terms and individual level random effects).  The between 
study heterogeneity in the two-stage simulation heterogeneous datasets was created by 
generating model parameters from normal distributions, whose mean value equalled the 
“true” parameter value.   
Conversely, during the one-stage simulations, between study heterogeneity was controlled 
using the distribution of the study level random effects; larger values in their covariance 
matrix causes greater between study variability in both the longitudinal and time-to-event 
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outcomes.  However, scenarios that varied the study level association parameter (𝛼(3)) also 
inherently varied the level of between study heterogeneity. Larger magnitudes of 𝛼(3) 
increased the effect of the study level random effects on risk of the event, magnifying the 
between study heterogeneity in the time-to-event outcome. 
In addition, the time points at which longitudinal measurements were recorded differed 
between the datasets simulated for the one and the two-stage investigations.  This 
difference stemmed from early issues with the one-stage modelling code: initially it was 
thought that convergence issues may be attributable to insufficient data, leading to 
inflation of the number of longitudinal time-points in datasets simulated for use during 
development of the jointmeta1 function, however introduction of pseudo-adaptive 
quadrature methods resolved the convergence issues (see Section 5.1.2.2.1). 
Despite the mentioned differences in multi-study joint data simulation, the one and two-
stage simulations agree on several points.  Firstly, the longitudinal effect estimates 
produced by meta-analytic joint methods and the meta-analytic separate longitudinal 
methods are similar (although one-stage joint models that involved study level random 
effects reported poor coverage).  Secondly, where non-zero individual level association is 
present between the longitudinal and time-to-event outcomes, separate time-to-event 
meta-analytic models produce biased estimates of parameters, whereas the estimates 
produced by joint meta-analytic models are closer to the “true” parameter values. 
This behaviour may be linked to the known case where omission of covariates from Cox 
models leads to bias in estimated effect parameters [241-243]. Compared to the joint time-
to-event sub-model (equation (70) and Table 23), the separate time-to-event models do 
not include the 𝑊2𝑘𝑖(𝑡) term.  Where association is present (i.e. when 𝛼𝑘
(2) ≠ 0 for the 
two-stage, or when 𝛼(2) or 𝛼(3) ≠ 0 for the one-stage) the joint approach models risk of an 
event associated with the longitudinal outcome via 𝑊2𝑘𝑖(𝑡).  This term (which has an effect 
on the event risk) is not included in the separate time-to-event model, potentially 
explaining the observed biased treatment effect estimates.  This disparity in parameter 
point estimates was not observed between the separate and joint longitudinal analyses as 
the model specifications for the longitudinal trajectory are identical in both models. 
As noted, at the start of this research, there was a gap in the literature concerning joint 
modelling of multi-study data.  However, Guo and Carlin [158] analysed a single-study 
dataset using separate and joint models.  The joint model association parameter was 
significant and negative.  The differences observed between the estimated survival times 
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produced by the separate and the joint models was attributed to the fact that the joint 
models accounted for correlation between the longitudinal and time-to-event outcomes, 
whereas the separate time-to-event model did not.   
In the simulations reported in Chapter 7, the parameter estimates produced by the 
standalone time-to-event model differ to those produced by the joint model (potential 
reasons for this have been discussed in previous paragraphs).  However the results from 
standalone longitudinal models and the joint model were similar.  There may be cases 
where results from standalone longitudinal models and joint models are significantly 
different.  An example of this could be the case of longitudinal data where patients who do 
not respond as well to treatment as others in the population are more likely to drop out. In 
this case, if dropout if not accounted for in the model (i.e. a standalone longitudinal model 
is fitted) estimates of treatment effectiveness on the longitudinal outcome are based only 
on the healthier patients, and so may be biased.  A joint analysis that accounts for outcome 
related dropout may produce different effect estimates.  Future research specifically into 
longitudinal data complicated by outcome related dropout would be beneficial. 
Whilst no multi-study joint data simulation studies were identified, many single study 
investigations employed simulation approaches to test joint modelling methodology. For 
example, Sweeting and Thompson [244] performed simulation studies to compare three 
methods to model patients with abdominal aortic aneurysms: time-to-event models with 
time-varying covariates, a two-stage approach (where a longitudinal model was fitted, and 
the longitudinal fitted values then included in a time-to-event model), and joint modelling 
methods.  Although the data was multi-centre, this does not appear to have been 
accounted for in their models, and so the simulations reflect a single study case.  Their 
simulation study concluded that the joint modeling approach was preferred, regardless of 
the higher computational burden. 
In this simulation investigation a similar result was observed for the multi-study case for 
both one and two-stage approaches – where an individual level association between the 
longitudinal and time-to-event outcomes existed, the pooled estimates from the separate 
time-to-event model underestimated the true simulated time-to-event treatment effect 
compared to the pooled estimates from the joint model. However, where this association 
was insignificant, the separate and joint analyses produced similar results.  Therefore, as 
with single study cases, in one or two-stage meta-analytic case there is evidence of benefit 
of joint methods over separate methods for estimation of time-to-event coefficients where 
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an association between the longitudinal and time-to-event outcomes is known or 
suspected. As discussed in Section 3.2.1, plotting the longitudinal outcome against time 
(𝑡𝑘𝑖𝑗) minus survival time (𝑇𝑆𝑘𝑖) for each individual, panelled by event type (censored or 
experienced the event), highlights changes immediately before the individual experiences 
the event in question, or is censored.  This is beneficial, as differences in the shape of 
trajectories immediately before 𝑡𝑘𝑖𝑗 − 𝑇𝑆𝑘𝑖 = 0 for those censored and those experiencing 
an event suggests that the longitudinal and time-to-event outcomes are related, that an 
association exists between them.  Alternatively, their might be suggestion from healthcare 
professionals with experience of a given disease area that a particular longitudinal outcome 
and event are linked, again motivating an analysis exploring the association between the 
two outcomes.  Apart from such methods, the most straightforward way to test for an 
association would be to fit a joint model, and assess the significance of the association 
parameter.  In the case of assessing the relationship between a longitudinal outcome 
repeatedly measured over time, and the time until some event, basic assessments of 
correlation become difficult (for example the multiple measurements per individual over 
time need to be accounted for).  Fitting a joint model provides methods to account for the 
complex structure of the data, whilst providing an assessment of the relationship between 
the two outcomes. 
As noted in Section 1.6.4, as the joint models investigated involved an unspecified baseline 
hazard, bootstrap procedures were used to obtain standard errors for parameter estimates 
[89]. The necessity of bootstrapping increases the time taken to perform a joint analysis, 
although bootstrapping to obtain standard errors is not unique to joint modelling: for 
example, using bootstrapping to calculate confidence intervals for longitudinal fits in the 
lme4 package [204] can be time intensive.  
It was difficult to extract exact model fitting and bootstrapping times for the simulation 
studies, due to use of the aforementioned condor system.  In this system, analyses often 
restarted when computers became unavailable, however only a total run time (time 
analysis first started until time analysis finally completed) was reported.  Consequently, 
samples of 100 models were rerun on a standalone laptop, and the results timed.  
Bootstrapping procedures were not timed, but a rough calculation of the time they would 
take to complete can be made by multiplying the time to fit a single model by the number 
of bootstraps to complete.    
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For the two-stage MA simulation study, models fitted to low event rate scenarios with 
association set to 0.5 for homogenous treatment effect data had a mean model fitting time 
of 6.51 seconds, whilst those with heterogeneous treatment effect had mean fitting time of 
6.47 seconds.  Models fitted to the high event rate data (for the same level of association) 
took a mean time of 31.02 seconds for the homogenous treatment effect data, and 31.06 
seconds for the heterogeneous treatment effect data.  The model fitting times for high 
event rate data were likely to be larger as the baseline hazard vector will be longer (as it 
takes weight at each event time [78], it is likely there will be more unique event times in 
high event rate than low event rate data).  Consequently the matrices involved in the 
model fitting process would be larger, resulting in a slightly higher computational burden to 
fit the models. 
For the one-stage MA simulation study, for scenarios from simulation set 1, (5 studies, a 
range of association levels), for a sample of 100 of the simulated datasets, mean fitting 
times were reported at around 40 seconds for model group 1 across the nine scenarios 
(with slightly faster fitting times for larger association magnitudes).  However, model fits 
for group 4 were much faster at between 10 seconds for scenarios with 𝛼(3) = 0 or around 
20 seconds for scenarios with 𝛼(3) > 0.  With increasing number of included studies, or 
increasing numbers of individuals within studies, model fitting times should be expected to 
increase due to the increased size of the supplied dataset.    
This simulation study demonstrated that the time required to fit joint meta-analytic models 
rather than separate time-to-event meta-analytic models is justified where an individual 
level association exists between the longitudinal and time-to-event outcomes, in order to 
prevent time-to-event parameter estimates being biased.  However, it would be beneficial 
to accelerate the model fitting process, or the estimation of standard errors, to reduce the 
time burden of utilising these methods (see Section 8.3.2.2).  
7.3.4 Concluding Remarks 
The benefit of utilising joint models over standalone time-to-event models has been 
demonstrated when non-zero association individual level exists between the longitudinal 
and time-to-event outcomes for both one and two-stage approaches.  Increasing study 
level association was noted to increase the variability in estimates.  For the one-stage 
approach, issues have been identified with models involving study level random effects, 
and future research has been proposed into models that share only individual level random 
effects, and contain (but do not share) study level random effects or frailties. Further 
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details about proposed future research are given in Section 8.3.  Overall, these simulation 
studies have provided in depth investigations of the behaviour of both one and two-stage 
approaches to meta-analysis of joint longitudinal and time-to-event data.   
In the future, I recommend that in a two-stage MA, researchers employ joint models in 
place of separate longitudinal or time-to-event models to analyse multi-study joint 
longitudinal and time-to-event data, where evidence of an association between the 
longitudinal and time-to-event outcomes exists. Association between the outcomes can be 
evaluated by producing plots of the longitudinal trajectories, stratified by event type 
(Section 3.2). Similarly, in a one-stage MA, where evidence of association between the 
longitudinal and time-to-event outcomes exists, a joint modelling approach is employed.  
This approach should account for between study heterogeneity through fixed interaction 
terms with study membership, and stratification of baseline hazard.  In scenarios similar to 
those investigated in the simulation studies, joint models that share study level random 
effects between sub-models should be avoided.  However, as separate and joint methods 
gave similar MA results in simulations and real data analyses when association is 
insignificant, to minimise resources used separate methods could be justified.  The choice 
of model (association structure, baseline hazard, random effect specification, time-to-event 
and longitudinal sub-model etc.) should be made based on the requirements of each 
individual investigation, as one association structure could prove to be more appropriate 
than others.   
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Chapter 8 : Conclusions and Further Work 
8.1 Overview of Thesis and Key Messages 
The work presented in this thesis focussed on the development, application and 
assessment of methods for the meta-analysis of joint longitudinal and time-to-event data.  
Initial examination of the literature suggested there was little existing research into 
modelling multi-study joint data.  A review of single study joint analyses of medical or 
biostatistical data (Chapter 2, Sudell et al [93]) suggested that current reporting standards 
of such analyses could be improved (e.g. by clear specification of the joint model used).  
This is essential both for the current understanding of the published analysis, but also to 
ensure that the work could contribute to future AD-MA of joint data.   The review 
suggested that sufficient information to conduct AD-MA were available for the majority of 
studies reviewed, but that the availability of estimates from each sub-model, and for the 
association structure, appeared linked to the reason stated for using joint modelling 
methodology. 
Novel methodologies for one and two-stage IPD-MA of joint data were developed (Chapter 
3).  Given that coefficients from different joint model specifications can have varying 
interpretations, guidelines were presented and discussed to help to ensure that only 
parameters with comparable interpretations are quantitively pooled.  The guidelines were 
designed to provide a structure for two-stage IPD-MA that researchers could follow to 
produce good quality analyses. A range of methods to account for between study 
heterogeneity in a one-stage IPD-MA were presented and discussed.  Model groups 
accounted for between study heterogeneity using a mix of fixed interaction terms between 
covariates of interest and the study membership variable, study level random effects, and 
stratification of the baseline hazard by study. 
The joineRmeta package in R was developed during this thesis to provide software to aid 
researchers analysing multi-study joint data (Chapter 4 and Chapter 5).  The package 
contained functions to extract and meta-analyse coefficients of interest from single study 
joint model fits, and functions to fit one-stage models to multi-study joint data (with 
options for interaction terms, study level random effects and stratified baseline hazard).  
Functionality was also included to simulate and plot multi-study joint data, as well as 
prepare it in the correct format for analysis. The developmental version of the package is 
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currently available for download from GitHub, and the fully tested version is available on 
R’s CRAN mirror. 
The INDANA dataset [91] was employed to provide a real world example of the application 
of one and two-stage multi-study joint modelling methodology (Chapter 6).  Hypertensive 
patients were randomised to any drug intervention for hypertension, versus no treatment, 
placebo or usual care.  Pairwise combinations of SBP and each of time to death, time to MI 
and time to stroke were analysed through univariate joint models. For both the one and 
two-stage analyses there was little difference between the results from joint or separate 
models, potentially due to the estimated values of any significant associations being small 
in magnitude for this particular clinical example.  Both one and two-stage analyses 
consistently estimated that assignment to any drug intervention for hypertension resulted 
in a significant reduction in SBP.  However, in the two-stage analysis few studies displayed 
significant effect of treatment assignment on risk of MI or death, although more studies 
observed a significant effect on risk of stroke.  In the one-stage analyses, assignment to any 
drug intervention for hypertension significantly reduced risk of stroke or MI for most 
analyses conducted (some study specific treatment effects were not statistically 
significant).  However, apart from the STOP [223] trial, no significant effect of treatment 
assignment on risk of death was observed.  It was noted that as these analyses 
demonstrated methodology rather than identifying covariates linked to the outcome, 
heterogeneity between included studies in variables known to be linked to cardiovascular 
disease could lead to heterogeneity in treatment effect and association parameters. 
Extensive simulation studies were conducted to assess the performance of the one and 
two-stage meta-analytic methods (Chapter 7).  The two-stage simulation studies compared 
use of joint models and separate longitudinal or time-to-event models in the first stage of a 
two-stage MA under a range of scenarios.  These included low or high event rates, 
homogenous or heterogeneous treatment effect between studies, and a range of 
association parameters.  The separate longitudinal and joint approaches produced similar 
treatment effect estimates across scenarios.  However, when non-zero positive association 
was present, the separate time-to-event analyses underestimated the true treatment 
effect by an amount that increased as the magnitude of association increased.  However, 




The one-stage simulation study applied the models proposed in Chapter 3 to a range of 
scenarios, including varying individual level and study level association, varying numbers of 
included studies, and varying between study heterogeneity.  Model groups that included 
study level random effects displayed some issues, especially the group which solely 
accounted for between study heterogeneity through study level random effects.  It was 
proposed that differing association structures, including those that do not share study level 
random effects between models, might be more appropriate.  The most reliable model of 
those tested accounted for between study heterogeneity in each sub-model through fixed 
interaction terms between study membership and covariates of interest, followed by that 
which included fixed interaction terms in the longitudinal sub-model, and a baseline hazard 
stratified by study in the time-to-event sub-model. 
8.2 Implications for research 
The research presented in this thesis identifies several points that have implications for 
future research.  Firstly, the use of joint models is increasing, but in single study 
biostatistical or medical investigations, the reporting of the structure of the joint model 
used, and of estimates of model parameters of interest, could be improved.  This is 
important, as future AD-MA would be affected by the standard of reporting of joint models 
in the literature.  It is hoped that the research published in Sudell et al [93] will draw 
attention to, and so improve, this issue. 
A range of models for the one-stage analysis of joint longitudinal and time-to-event data 
were proposed and examined.  Several issues with the models were highlighted.  The study 
level association parameter was poorly estimated in model groups involving study level 
random effects apart from the group that solely represented between study heterogeneity 
through study level random effects.  However, in this group, the remaining model 
parameters were badly estimated.  The best performance came from the model that 
accounted for between study heterogeneity using fixed interaction terms between the 
study membership variable and covariates of interest, however this model could become 
unwieldy as the number of studies included in the meta-analysis increases.  It was noted 
that models that included study level random effects or frailty terms in the longitudinal or 
time-to-event sub-models may perform better if the study level random effects were not 
shared between the sub-models, an area noted for future research.  As such, this research 
recommends that, until additional joint meta-analytic models can be examined, multi-study 
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joint data is modelled using structures that do not share study level random effects 
between sub-models. 
The joint MA models investigated during this thesis present a larger time commitment than 
standalone longitudinal or time-to-event MA analyses, due to their necessity to bootstrap 
to obtain standard errors caused by the use of an unspecified baseline hazard in the time-
to-event sub-model [89].  However, it has been shown through the one and two-stage 
simulation studies that this additional time investment is justified when there is a 
significant association between the longitudinal and time-to-event outcomes.  When this 
occurs, standalone time-to-event MA model underestimate the true time-to-event 
parameters for non-zero positive associations, whereas joint MA models give estimates 
closer to the true value.  Differences between separate and joint approaches has been 
shown previously in single study cases [158, 172, 244]; the research in this thesis has 
demonstrated similar issues for multi-study analyses.  Therefore, despite the increased 
model fitting times caused by multiple included studies, in the presence of association 
between the longitudinal and time-to-event outcomes, the joint modelling approach 
remains justified in a meta-analytic setting.  The presence of an association can be 
established by plotting longitudinal trajectories panelled by event type – differences in the 
trajectories between those experiencing an event and those censored could suggest the 
presence of an association.  The joineRmeta package developed during this thesis 
contains plotting functions to accomplish this (Chapter 4). 
Both one and two-stage approaches were examined during this thesis.  Burke et al [189] 
have conducted research to identify reasons why the approaches may produce differing 
results.  In this research, a two-stage approach was faster to implement than the one-stage 
approach for both the real analyses and simulation studies.  Bootstrapping to obtain SE was 
completed with a smaller sample size of 𝑛𝑘 in the two-stage approach (the number of 
individuals within each study) rather than of ∑ 𝑛𝑘
𝐾
𝑘=1   in the one-stage approach (the total 
number of individuals in the meta-dataset), although in the two-stage approach 𝐾 separate 
bootstrap procedures had to complete rather than just one.   
A two-stage MA is often sufficient if interest lies solely in estimating treatment effects.  
Two-methods additionally remove the issue of ecological bias, as they only pool within 
study information [63, 180, 192].  However, this approach assumes that study estimates 
can be considered normally distributed, and that their variances are known (an issue for 
small sample sizes or rare events) [191, 193]. 
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Alternatively, a one-stage approach may be preferred if patient level covariates are to be 
included in the model.  One-stage methods have more exact likelihood specification than 
two-stage models, and so they circumvent the assumption of normality within studies [190, 
191].  However, care must be taken in a one-stage MA to separate within and between 
study effects [180].  Additionally, as we have also noted during this thesis, one-stage 
methods tend to be more computationally intensive than two-stage approaches [63, 190]. 
The choice between one and two-stage approaches is often difficult.  Debray et al [194] 
recommends that, where doubt exists as to the best approach, to plan, conduct, and report 
the results of both a one and two-stage analysis (a recommendation echoed by Burke et al 
[189]).   It is hoped that the research provided in this thesis will provide methodology, 
software and guidance for researchers performing meta-analyses of joint longitudinal and 
time-to-event data in the future. 
8.3 Planned future work 
Research into single study joint models continues to expand.  Consequently, a range of 
meta-analytic joint longitudinal and time-to-event datasets may be available in the future.  
It is vital that appropriate methods to analyse a range of different scenarios are available, 
including multivariate multi-study joint models, joint models in a network meta-analytic 
setting, and incorporation of competing risks options.  In addition, developments to the 
joineRmeta package would be valuable, including reduction of model fitting times, and 
expanding the modelling options.   
8.3.1 Planned future methodological research 
The methodology presented in this thesis are restricted to a univariate joint model with a 
single longitudinal outcome modelled using a linear mixed effects model, with a  single 
time-to-event outcome modelled using a Cox PH model (which has an unspecified baseline 
hazard), linked through shared zero mean random effects.   
Additionally, examination of the 𝑊2𝑘𝑖(𝑡) in the one-stage INDANA analyses reported in 
Chapter 6 suggests that it may be beneficial to develop methods to allow the association 
parameter to vary across studies included in the meta-analysis.  Whilst beyond the scope of 
this thesis, it would increase the flexibility of the joint MA modelling methodology 
developed here. 
Also, it has been noted that the estimates from standalone longitudinal models and joint 
models have been similar during the real data and simulation study analyses conducted in 
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this thesis.  However, this may not be the case for joint data specifically generated by 
outcome related dropout in longitudinal studies.  Further real data and simulation studies 
into such dropout data would be beneficial, as it may highlight cases where multi-study 
longitudinal and joint analyses differ. 
However, in reality, many datasets (including the INDANA [91] dataset) contain multiple 
longitudinal and time-to-event outcomes of interest.  Recently, methodology has expanded 
to allow multiple longitudinal or time-to-event outcomes to be simultaneously modelled in 
a single study (e.g. Lin et al [245], with software in joineRML[181] package).  Expanding 
meta-analytic joint models to allow for multiple longitudinal or time-to-event outcomes 
would allow a more overall investigation of available data to take place.  However, such 
models would have to link between multiple outcomes, as well as modelling the clustering 
of individuals within studies.  Consequently, it is likely that there will be challenges with 
model specification and fitting to be reconciled. 
Allowing competing risks in the time-to-event outcome to be accounted for in a multi-study 
joint model would also be beneficial.  An event such as death may occur for several 
reasons.  Competing risks models allows the risk of the event due to each reason to be 
modelled.  Joint models allowing for competing risks in single study cases exists in the 
literature (e.g. [246]).  However, work to expand this methodology to allow for datasets 
containing additional levels of clustering has not been undertaken. 
Network meta-analyses expand standard meta-analyses by allowing a group of studies 
examining the same disease area, but comparing different combinations of possible 
treatments, to collectively assess and compare different treatment combinations.  A recent 
example of a network MA of time-to-event epilepsy data is given in Nevitt et al [247].  
Information comparing treatment options can stem from direct comparisons within 
studies, or from indirect information supplied through the network (e.g. an assessment of 
treatment A versus C can be made using studies comparing treatment A versus treatment 
B, and treatment B versus treatment C).  Utilisation of joint models in this area would be 
intriguing, as the network of information must allow for the structure (sub-models linked 
through an association structure) of the joint model, resulting in linked networks for 
longitudinal, time-to-event and association coefficients.  
An additional area of interest would be to examine the feasibility of combining estimates 
from separate longitudinal or time-to-event models, and joint models in the second stage 
of a two-stage IPD-MA, or in an AD-MA.  This question requires careful consideration, as 
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the requirement of availability of both longitudinal and time-to-event data in a joint MA 
may restrict the studies able to contribute to the meta-analysis.  However, this thesis has 
demonstrated that in a meta-analysis, using estimates from separate time-to-event models 
results in a pooled value that underestimates the true value when significant association 
exists between the longitudinal and time-to-event outcomes.   Conversely, the estimates 
from joint and separate longitudinal models were similar regardless of the significance or 
magnitude of association.  Investigation of the benefit of using both separate and joint 
model results may allow expansion of the data that can contribute to meta-analyses. 
Dynamic prediction has been an area of increasing research within joint modelling [134, 
163, 248-250], where predictions about an individual’s future risk of an event can be 
updated as they provide additional longitudinal measurements.  It would be beneficial to 
investigate dynamic prediction from a one-stage IPD-MA joint model, as such a prediction 
model would take into account all available information on a disease area, rather than just 
that proceeding from a single study.  Such research would help to maximise the benefit of 
IPD-MA joint investigations, whilst providing patients with more accurate risk predictions. 
8.3.2 Planned developments to the joineRmeta package 
The joineRmeta package has been submitted to CRAN in order that it can be downloaded 
directly from R rather than through GitHub. This should increase uptake of use of the 
provided code. As well as ensuring the package is easily accessible, there are a range of 
areas for which extension of the joineRmeta package would be beneficial.  
8.3.2.1 Extensions to functions for two-stage MA 
Firstly, for the jointmeta2 function, it would be beneficial to extend the code to allow 
joint modelling fits from other packages to be supplied.  Whilst the one-stage function 
jointmeta1 in the joineRmeta package is designed to handle multi-study data, it can 
handle single study data providing the data contains a study membership variable (which 
would take a common value across all individuals).  As such, it would be useful to allow the 
jointmeta2 function to accept single study joint model fits fitted using jointmeta1.  In 
addition, the recent joineRML package allows multivariate (multiple longitudinal 
outcome) as well as univariate (single longitudinal outcome) joint models to be fitted.  
Expanding jointmeta2 to take model fits from a wider range of packages would be 
beneficial, as it would increase the applicability of the package. 
In addition, in Section 3.4.1 it was noted that performing multivariate meta-analyses of 
joint model fits, rather than separate meta-analyses for each parameter of interest could 
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be beneficial in that it will model the correlation between parameters [35, 38, 40].  In the 
future, it may be beneficial to include the option to perform multivariate MA in the 
jointmeta2 function.  This would rely on the covariance between parameters to be 
obtainable from the joint model fits.  With this extension in mind, the covariance matrix for 
model parameters is returned from the bootstrapping process in jointmeta1 fits.  In 
addition, the Hessian can be extracted from fits from the JM package. This extension would 
improve the quality of two-stage MA conducted using joineRmeta. 
8.3.2.2 Extensions to functions for one-stage MA 
Currently, the one-stage function jointmeta1 employs a pseudo-adaptive Gaussian 
quadrature procedure to integrate over random effects included in the model [196].  
Although more computationally intensive, a fully adaptive procedure has the potential 
(through relocation of the quadrature points at each iteration) to reduce model fitting 
times.  Adaptive Gaussian quadrature procedures for three level structures with multi-level 
random effects were discussed by Rabe-Hesketh et al [212].  They note that it is necessary 
to rescale multi-level random effects during the estimation procedure.  Some initial work 
was undertaken during this thesis to implement this procedure, however further time was 
needed to interpret and implement the procedure provided in the paper.  In the future, 
implementation of this procedure as an alternative to the pseudo-adaptive procedure for 
the jointmeta1 function is planned. 
Additionally, the function currently employs the EM algorithm [197] to fit the model.  
Various modifications to this method (which could improve model fitting times) could be 
made. Vermunt [251] noted that the computation time of the EM algorithm increases 
exponentially with the number of level 2 units within each level 3 unit. This was not 
experienced during our research, as the iterative process was exploited to hold estimates 
at one level constant when estimating functions of random effects at the other level, 
however with implementation of fully adaptive Gaussian quadrature, this will be an issue. 
Vermunt [251] demonstrates implementation of an edited EM algorithm designed for use 
with parametric or non-parametric hierarchical non-linear models with more than two 
levels, which could be implemented to solve this issue.  Another alternative is to employ an 
EM algorithm with a Monte-Carlo step as in the joineRML package [181]. 
Currently, bootstrapping to obtain standard errors is time consuming.  Lin et al [245] have 
suggested that the underestimation noted by Hsieh et al [89] may not be so severe as to 
prevent use of an approximate standard error estimation procedure during model fitting, 
although bootstrapping to estimate final standard errors may be advisable.  Some initial 
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work was performed when writing the joineRmeta package to calculate such 
approximate standard errors for joint MA models, however the results for study level 
random effects appeared unreliable. It may be that the approximate standard error 
procedure provides better estimations when study level random effects are not involved in 
the association structure.  In the future, the approximate standard errors approach for joint 
models employing an unspecified baseline hazard will be re-examined and implemented in 
the jointmeta1 function. 
The jointmeta1 function could be extended to fit joint models with varying association 
structures. Association structures each have different interpretations, and their selection 
should be driven by the research question, not the availability of software.   Expansions 
could include the current value sharing structure (which inserts the entire longitudinal 
trajectory without the error term into the time-to-event sub-model) or the current slope 
structure (first derivative of the longitudinal trajectory with respect to time).  Additionally, 
options to just share the zero mean random effects at one level rather than both may be 
beneficial, as discussed in Chapter 7.  Additionally, allowing separate association 
parameters for each shared random effect would allow more in-depth assessment of the 
effect of each random effect on the risk of an event.  Allowing structures that link the 
history of the longitudinal outcome to the time-to-event outcome would also be useful [52, 
75].   
Allowing alternative baseline hazard specifications could also be beneficial. Permitting 
parametric baseline hazards or spline based baseline hazards (such as in the single study 
joint modelling package JM [81]) could result in fewer coefficients being estimated, and 
would remove the necessity to bootstrap to determine SE, thus reducing model fitting 
times. 
Expanding the types of sub-models permitted in the package would also be useful.  Many 
continuous longitudinal outcomes are non-linear, and so including longitudinal sub-model 
options such as use of splines would improve the applicability of the package.  In addition, 
permitting alternative covariance structures for the error term (e.g. auto-regressive or 
completely unspecified rather than independently and identically distributed) may allow 
more appropriate models to be fitted.   
In cases where a PH model is not appropriate for the time-to-event outcome, an alternative 
such as the AFT model might be preferred.  A range of modelling options have been used 
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for the MA of time-to-event data [58, 59], which could be incorporated into the time-to-
event sub-model of a multi-study joint model in the jointmeta1 function. 
8.3.2.3 Other extensions to the package 
Additionally, extensions to the functions to produce plots of the study specific data would 
be beneficial.  For example, adjusting the plotting function such that confidence bands 
around the survival curves can be easily included may increase the clarity of the study 
specific Kaplan-Meier plots.  It would also be beneficial to include a function to easily 
produce visualisations of the baseline hazards of analyses.   
8.3.3 Planned future applied investigations 
During this thesis the methods developed were applied to the INDANA dataset of 
hypertensive patients [91].  This analysis was beneficial to test the methods in a real world 
setting, and to motivate subsequent simulation investigations.  However, application of the 
methods to data from other clinical areas may identify additional avenues of research, as 
well as informing clinical practice.  For example, other disease areas could present data 
with different event rates, number of longitudinal measurements, levels of between study 
or between individual heterogeneity, or levels of association, or other characteristics, 
which that could prompt development of new methodology.  As the review of reporting 
quality in single study joint analyses reported (Chapter 2, Sudell et al [93]), joint models 
have been applied in a wide range of clinical areas, including cancer, HIV/AIDS, transplants, 
and cognitive decline.  As such, it is conceivable that a wider range of joint multi-study 
datasets will be established in the future.   
8.4 Conclusion 
In conclusion, the research presented in this thesis has examined the meta-analysis of 
multi-study joint longitudinal and time-to-event data in a frequentist setting.  A range of 
topics have been investigated, including current reporting standards of single study joint 
models with a view to future meta-analyses, one and two-stage methods for meta-analysis 
of joint data and their behaviour under different scenarios, and an R package containing 
code useful when implementing a joint data meta-analysis.  It has been shown that joint 
approaches are preferable to separate approaches to avoid underestimation of time-to-
event coefficients for both one and two-stage joint data MA where association is present 
between the longitudinal and time-to-event outcomes.  There remain a wide range of areas 
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Appendix 1: Search Strategies used in Review of Current Reporting 
Standards of Joint Models in the Literature 
Database : Scopus 
( TITLE-ABS-KEY ( joint W/3 model* ) ) AND ( ( TITLE-ABS-KEY ( longitudinal W/4 survival ) ) 
OR ( TITLE-ABS-KEY ( longitudinal W/4 "time-to-event" ) ) OR ( TITLE-ABS-KEY ( longitudinal 
W/4 ( time W/3 event ) ) ) OR ( TITLE-ABS-KEY ( "repeat* measure*" W/4 survival ) ) OR ( 
TITLE-ABS-KEY ( "repeat* measure*" W/4 "time-to-event" ) ) OR ( TITLE-ABS-KEY ( "repeat* 
measure*" W/4 ( time W/3 event ) ) ) )  
Database : PubMed 
(joint model*) AND (((((((((longitudinal and survival)) OR (longitudinal and "time-to-event")) 
OR (longitudinal and "time to event")) OR (longitudinal and "event time")) OR ((repeat* 
measure*) and survival)) OR ((repeat* measure*) and "time-to-event")) OR ((repeat* 
measure*) and "time to event")) OR ((repeat* measure*) and "event time")) 
Database: Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to Present with Daily Update> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (joint adj3 model*).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] (2329) 
2     (longitudinal adj4 survival).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] (283) 
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3     (longitudinal adj4 time-to-event).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier] (39) 
4     (longitudinal adj4 (time adj3 event)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (54) 
5     ("repeat* measure*" adj4 survival).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (37) 
6     ("repeat* measure*" adj4 time-to-event).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (10) 
7     ("repeat* measure*" adj4 (time adj3 event)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (15) 
8     2 or 3 or 4 or 5 or 6 or 7 (367) 




Appendix 2: Additional longitudinal SBP trajectory plots for INDANA 
dataset 
SBP and time to Death 
 
 
Figure 37: Longitudinal trajectory plots with mean trajectory smoother (red line) for SBP and time to death data, 
with 0 indicating a censoring and 1 indicating an event was experienced. 
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SBP and time to MI 
 
Figure 38: Longitudinal trajectory plots with mean trajectory smoother (red line) for SBP and time to myocardial 




SBP and time to stroke 
 
Figure 39: Longitudinal trajectory plots with mean trajectory smoother (red line) for SBP and time to stroke data, 




Appendix 3: Event Rates for Two-Stage Simulation Studies 
Scenario 



















Mean (sd) 24 (0.8) 24 (1.9) 24 (1.9) 24.1 (1.9) 24 (1.8) 24 (1.9) 
Median (LQ,UQ) 24 (23.4,24.6) 24 (22.8,25.2) 24 (22.8,25.2) 24.2 (22.9,25.6) 24 (22.8,25.2) 24 (22.8,25.4) 
0.25 
Mean (sd) 23.9 (0.8) 23.9 (1.8) 23.9 (1.9) 24 (1.9) 23.9 (1.9) 23.9 (1.9) 
Median (LQ,UQ) 23.9 (23.4,24.5) 23.8 (22.8,25.2) 24 (22.6,25.2) 24 (22.6,25.2) 23.8 (22.6,25.2) 24 (22.8,25.2) 
0.5 
Mean (sd) 24 (0.9) 24 (1.9) 23.9 (1.9) 23.9 (1.9) 24 (1.9) 24 (2) 
Median (LQ,UQ) 24 (23.4,24.5) 24 (22.8,25.4) 23.8 (22.6,25.2) 24 (22.8,25.2) 23.8 (22.8,25.2) 24 (22.6,25.4) 
0.75 
Mean (sd) 24.3 (0.9) 24.3 (2) 24.3 (1.8) 24.4 (1.9) 24.4 (2) 24.2 (1.9) 
Median (LQ,UQ) 24.3 (23.7,25) 24.4 (23,25.6) 24.2 (23.2,25.6) 24.3 (23,25.8) 24.4 (23,25.8) 24.2 (23,25.4) 
1 
Mean (sd) 24 (0.9) 24 (1.9) 23.9 (1.9) 23.9 (1.9) 24 (1.9) 24 (2) 


















Mean (sd) 87 (0.7) 87 (1.6) 87 (1.5) 87 (1.5) 86.9 (1.6) 87 (1.5) 
Median (LQ,UQ) 87 (86.5,87.4) 87 (86,88) 87 (86,88) 87 (86,88.2) 87 (85.8,88) 87 (86,88) 
0.25 
Mean (sd) 86.6 (0.7) 86.6 (1.5) 86.6 (1.5) 86.6 (1.5) 86.6 (1.5) 86.5 (1.5) 
Median (LQ,UQ) 86.6 (86.1,87) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 
0.5 
Mean (sd) 84.3 (0.7) 84.3 (1.7) 84.4 (1.7) 84.3 (1.5) 84.3 (1.6) 84.3 (1.7) 
Median (LQ,UQ) 84.3 (83.8,84.8) 84.4 (83.2,85.4) 84.4 (83.2,85.4) 84.2 (83.2,85.4) 84.4 (83.2,85.4) 84.4 (83.2,85.6) 
0.75 
Mean (sd) 79.6 (0.8) 79.6 (1.8) 79.6 (1.8) 79.6 (1.8) 79.6 (1.8) 79.7 (1.8) 
Median (LQ,UQ) 79.7 (79.1,80.2) 79.6 (78.4,80.8) 79.6 (78.4,81) 79.6 (78.4,80.8) 79.6 (78.4,80.8) 79.8 (78.6,81) 
1 
Mean (sd) 75 (0.9) 75 (1.9) 75 (2) 74.9 (2.1) 75.1 (1.9) 74.9 (1.9) 

















Mean (sd) 24.1 (1) 24.1 (2.1) 24.1 (2.2) 24.2 (2.1) 24.2 (2.1) 24.1 (2.1) 
Median (LQ,UQ) 24.1 (23.5,24.8) 24.1 (22.6,25.6) 24.2 (22.6,25.6) 24.2 (22.8,25.6) 24.2 (22.8,25.6) 24 (22.6,25.6) 
0.25 
Mean (sd) 24 (0.9) 23.9 (2.2) 24 (2.2) 24 (2.1) 24 (2.2) 24.1 (2.1) 
Median (LQ,UQ) 24 (23.4,24.6) 23.8 (22.4,25.4) 24 (22.6,25.6) 24 (22.6,25.4) 24 (22.6,25.4) 24 (22.6,25.6) 
0.5 
Mean (sd) 24.1 (0.9) 24.1 (2.2) 24.1 (2) 24.2 (2.1) 24.1 (2.2) 24.1 (2.1) 
Median (LQ,UQ) 24.1 (23.5,24.8) 24 (22.6,25.6) 24 (22.6,25.6) 24.2 (22.8,25.6) 24 (22.6,25.6) 24 (22.8,25.6) 
0.75 
Mean (sd) 24.4 (0.9) 24.5 (2.2) 24.4 (2.1) 24.4 (2) 24.4 (2.1) 24.3 (2.2) 
Median (LQ,UQ) 24.4 (23.8,25) 24.6 (23.1,26) 24.4 (23,25.8) 24.4 (23,25.8) 24.4 (23,25.8) 24.2 (22.8,25.8) 
1 
Mean (sd) 25 (0.9) 25 (2.1) 25.1 (2.1) 25.1 (2.2) 25.2 (2.1) 24.9 (2.1) 





















Mean (sd) 87 (0.7) 87 (1.5) 87 (1.5) 87 (1.5) 87 (1.4) 87 (1.5) 
Median (LQ,UQ) 87 (86.6,87.5) 87 (86,88) 87 (86,88) 87 (86,88.2) 87 (86.2,88) 87 (86,88) 
0.25 
Mean (sd) 86.6 (0.7) 86.6 (1.5) 86.6 (1.5) 86.6 (1.5) 86.6 (1.5) 86.6 (1.5) 
Median (LQ,UQ) 86.6 (86.1,87) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 86.6 (85.6,87.6) 86.6 (85.6,87.8) 86.6 (85.6,87.6) 
0.5 
Mean (sd) 84.3 (0.7) 84.3 (1.6) 84.4 (1.6) 84.5 (1.6) 84.3 (1.6) 84.3 (1.5) 
Median (LQ,UQ) 84.4 (83.9,84.8) 84.2 (83.4,85.4) 84.4 (83.4,85.4) 84.4 (83.4,85.6) 84.2 (83.2,85.6) 84.4 (83.2,85.4) 
0.75 
Mean (sd) 79.7 (0.8) 79.7 (1.8) 79.6 (1.8) 79.6 (1.8) 79.6 (1.8) 79.8 (1.7) 
Median (LQ UQ) 79.7 (79.2,80.2) 79.6 (78.6,80.8) 79.6 (78.4,80.8) 79.6 (78.4,80.8) 79.6 (78.4,80.8) 79.8 (78.6,81) 
1 
Mean (sd) 75 (0.9) 74.9 (2) 75 (1.9) 75 (1.9) 74.9 (2) 75.1 (1.9) 
Median (LQ,UQ) 74.9 (74.4,75.6) 75 (73.6,76.2) 75 (73.6,76.2) 75 (73.8,76.4) 74.8 (73.4,76.2) 75.2 (73.8,76.4) 
Table 28: Mean and median event rates for data simulated for two stage analysis grouped by target event rate, 
whether treatment effect was simulated as homogenous or heterogeneous across studies, and by level of 
association (given by true association parameter 𝛼(2)) 
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Appendix 4: One stage simulation graphs showing point estimates and 
confidence intervals 
Simulation Set 1: Varying levels of association 
 
Figure 40: Point estimates and confidence intervals for longitudinal treatment effect parameter (𝛽12) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽12 that the data 





Figure 41: Point estimates and confidence intervals for longitudinal treatment effect parameter (𝛽12) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽12 that the data 





Figure 42: Point estimates and confidence intervals for longitudinal treatment effect parameter (𝛽12) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽12 that the data 





Figure 43: Point estimates and confidence intervals for time-to-event treatment effect parameter (𝛽21) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽21 that the data 





Figure 44: Point estimates and confidence intervals for time-to-event treatment effect parameter (𝛽21) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽21 that the data 





Figure 45: Point estimates and confidence intervals for time-to-event treatment effect parameter (𝛽21) for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛽21 that the data 





Figure 46: Point estimates and confidence intervals for individual level association parameter 𝛼(2)  for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛼(2) that the data 





Figure 47: Point estimates and confidence intervals for individual level association parameter 𝛼(2)  for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛼(2) that the data 





Figure 48: Point estimates and confidence intervals for individual level association parameter 𝛼(2)  for 
simulation set 1 investigating varying association parameters (values of association parameters that the data 
was simulated under are stated under each column).  The dashed line indicates the value of 𝛼(2) that the data 





Figure 49: Point estimates and confidence intervals for study level association parameter 𝛼(3)  for simulation set 
1 investigating varying association parameters (values of association parameters that the data was simulated 






Figure 50: Point estimates and confidence intervals for study level association parameter 𝛼(3)  for simulation set 
1 investigating varying association parameters (values of association parameters that the data was simulated 







Figure 51: Point estimates and confidence intervals for study level association parameter 𝛼(3)  for simulation set 
1 investigating varying association parameters (values of association parameters that the data was simulated 





Simulation Set 2: Varying number of included studies 
 
 
Figure 52: Point estimates and confidence intervals for longitudinal treatment effect (𝛽12) for simulation set 2 






Figure 53: Point estimates and confidence intervals for time-to-event treatment effect (𝛽21) for simulation set 2 






Figure 54: Point estimates and confidence intervals for individual level association (𝛼(2)) for simulation set 2 






Figure 55: Point estimates and confidence intervals for study level association (𝛼(3)) for simulation set 2 






Simulation Set 3: Varying levels of between study heterogeneity 
 
Figure 56: Point estimates and confidence intervals for longitudinal treatment effect (𝛽12) parameter for 
simulation set 3 investigating varying between study heterogeneity.  The dashed line identifies the value of 𝛽12 






Figure 57: Point estimates and confidence intervals for time-to-event treatment effect (𝛽21) parameter for 
simulation set 3 investigating varying between study heterogeneity.  The dashed line identifies the value of 𝛽21 






Figure 58: Point estimates and confidence intervals for individual level association parameter (𝛼(2)) parameter 
for simulation set 3 investigating varying between study heterogeneity.  The dashed line identifies the value of 





Figure 59: Point estimates and confidence intervals for study level association parameter (𝛼(3)) parameter for 
simulation set 3 investigating varying between study heterogeneity.  The dashed line identifies that value of 𝛼(3) 
































































   




















   





















   





















   





















   
   





















   
   





















   






















   




















   





















   





















   





















   



















   




















   






















   




















   




















   





















   





















   
















   




















   























   




















   






















   





















   





















   





















   






















   





















   




















   





















   





















   



















   





















   




















   





















   




















   





















   



















   





















   




















   























   






















   





















   




















   



















   




















   























   






















   





















   




















   




















   





















   























   





















   





















   





















   



















   


















   























   






















   




















   






















   





















   






















   






















   






















   





















   





















   





















   





















   























   





















   



















   





















   




















   




















   























   





















   





















   





















   





















   




















   























   






















   





















   





















   





















   




















   























   





















   




















   




















   





















   


















   






















   























   




















   






















   


















   





















   























   






















   





















   





















   





















   




















   























   





















   




















   




















   





















   



















   































































































































































































Figure 60: Plot of densities of estimated 𝑊2𝑘𝑖(𝑡) for each fitted model group, for analysis of SBP and time to 




Figure 61: Plot of densities of estimated 𝑊2𝑘𝑖(𝑡) for each fitted model group, for analysis of SBP and time to 




Figure 62: Plot of densities of estimated 𝑊2𝑘𝑖(𝑡) for each fitted model group, for analysis of SBP and time to 
stroke (ST), for each study separately and overall for the meta-dataset 
